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Abstract 
The interaction of E-, P- and L-selectin with their natural carbohydrate ligands has been shown 
to mediate the initial step of the recruitment of leukocytes and to play a crucial role in many 
physiological processes and disease states. Therefore, control of the leukocyte-endothelial cell 
adhesion process may be useful in cases where excessive recruitment of leukocytes can 
contribute to acute or chronic diseases such as stroke, reperfusion injury, psoriasis or 
rheumatoid arthritis.  
The tetrasaccharide mimetic CGP69669 (41) was early recognized as a lead structure for the 
inhibition of E-selectin. In order to improve the lead compound’s pharmacodynamic profile, two 
different optimization strategies were envisaged. On the one hand, an unoccupied hydrophobic 
patch on the lectin’s surface was targeted with hydrophobic fragments, attached to the galactose 
moiety of the lead compound (193, 194, 195/196, 197/198). On the other hand, the ligand’s 
entropic costs upon binding were minimized by modifying the cyclohexane moiety (226a-c, 
226e-h, 244, 255).  
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193: R = biphenyl-4-carbonyl 
194: R = 5-benzoyl-1H-indole-3-carbonyl 
195/196: R = Bz/c-hexanecarbonyl  (2:1 mixture) 
197/198: R =  
 
 
 
 
  (7:3 mixture) 
41: R1 = H,  R2 = H, R3 = H 
226a: R1 = Me,  R2 = H, R3 = Bz 
226e: R1 = Et, R2 = H, R3 = Bz 
226c: R1 = cPr, R2 = H, R3 = Bz 
226b: R1 = nBu, R2 = H, R3 = Bz 
226f: R1 = (CH2)2CO2Me, R2 = H, R3 = Bz 
226g: R1 = Me, R2 = H, R3 = H 
226h: R1 = Et, R2 = H, R3 = H 
244: R1 = Me, R2 = CO2Me, R3 = Bz 
255: R1 = H, R2 = tBu, R3 = Bz 
 
 
Whereas the first strategy led to inactive compounds, the second resulted in potent antagonists, 
by supporting the pre-organization of the pseudotrisaccharide core in the bioactive conformation. 
The pre-organization and conformational flexibility of the antagonists were evaluated by NMR 
studies. 
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Abbreviations 
Ac   Acetyl 
AcOH  Acetic acid 
AcOOH Peracetic acid 
AIBN  Azodiisobutyrodinitrile 
aq.  Aqueous 
Ar   Aryl 
ax  Axial 
bb  Backbone 
BDEA  Borane N,N-diethylaniline 
complex 
BMS  Borane dimethylsulfide complex 
Bn  Benzyl 
BnBr  Benzylbromide 
BSA  Bovine serum albumine 
Bz   Benzoyl 
cat. catalyst/catalytic amount 
CD34 Cell differentiation antigen 34, 
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CDI  Carbonyl diimidazole 
CR  Complement regulatory-like 
domains 
CRD Carbohydrate recognition 
domain 
Cy  Cyclohexyl 
d Days 
dba 1,5-Diphenyl-1,4-pentadien-3-
one  
DBU 1,8-Diazabicyclo[5.4.0]undec-7-
ene 
DEAD  Diethyl azodicarboxylate 
DMAP  4-Dimethylaminopyridine 
DME   Dimethoxyethane 
DMF  Dimethylformamide 
DMSO  Dimethylsulfoxide 
DMTST  Dimethyl(methylthio)sulfonium 
triflate 
DTBMP 2,6-Di-tert-butyl-4-methylpyridine 
DTBP  2,6-Di-tert-butylpyridine 
e.g.  For example 
ee  Enantiomeric excess 
EGF  Epidermal growth factor 
eq  Equivalent 
ESL-1  E-selectin ligand 1 
Fuc  Fucose 
Gal  Galactose 
GC  Gas chromatography 
GlcNAc N-Acetylglucosamine 
Glc  Glucose 
Gly-CAM-1 Glycosylated cell adhesion 
molecule-1 
GvHD  Graft vs host disease 
h   Hour(s) 
H  Hydrogen 
Hep   Heptose 
IC50  Inhibitory concentration 50% 
ICAM-1 Intercellular cell adhesion 
molecule 1 
IL-1  Interleukine-1 
IL-8  Interleukine-8 
Ind   Indole 
IR   Infrared spectroscopy 
JBW  Jumping between wells 
kDa   Kilo Dalton 
Lac   Lactic acid  
LAD Leukocyte adhesion 
deficiency 
Lea  Lewisa 
Lex  Lewisx 
LPS  Lipopolysaccharide 
mAb   Monoclonal antibody 
MadCAM-1 Mucosal vascular addressin 
cell adhesion molecule 
Man  Mannose 
MBP  Mannose binding protein 
MC  Monte-Carlo 
MD  Molecular dynamics 
Me  Methyl 
min  Minute(s) 
MPLC Medium pressure liquid 
chromatography 
MS   Molecular sieves 
MTPA -Methoxy--(trifluoromethyl)-
phenylacetyl 
MTPA-Cl -Methoxy--(trifluoromethyl)-
phenylacetyl chloride 
NaOMe  Sodium methoxide 
Neu   Neuraminic acid  
Neu5Ac N-Acetyl neuraminic acid, 
sialic acid  
NMM  N-Methylmorpholine 
NMO  4-Methylmorpholine N-oxide 
NMR  Nuclear magnetic resonance  
NOE  Nuclear Overhauser effect 
ODI  Oxalyl diimidazole 
OH  Hydroxyl 
Ph  Phenyl 
Pip  Piperazine 
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PLE  Pig liver esterase 
PMB  p-Methoxybenzyl 
PSGL-1 P-selectin glycoprotein ligand 1 
p-TsOH p-Toluenesulfonic acid 
pyr  Pyridine 
rac  Racemic 
RCM  Ring-closing metathesis 
rIC50  Relative IC50 
rot  Optical rotation 
r.t.  Room temperature 
SAR  Structure-activity relationship 
satd.  Saturated 
SCR   Short consensus repeats 
SD  Stochastic dynamics 
Seph  Sephadex 
Sia  Sialic acid  
sLea  Sialyl Lewisa 
sLex  Sialyl LewisX 
S-Phos 2-Dicyclohexylphosphino-2,6-
dimethoxybiphenyl 
ss Sidechain 
TBAB  Tetrabutylammonium bromide 
TBAF  Tetrabutylammonium fluoride 
TBDMS tert-Butyldiphenylsilyl 
TBDPS tert-Butyldimethylsilyl 
TBME  tert-Butyl methyl ether 
TBS  tert-Butyldimethylsilyl 
TEAB Tetraethylammonium 
bromide 
Temp  Temperature 
TES  Triethylsilane 
Tf  Triflate, 
(triflouromethanesulfonate) 
TFA  Trifluoroacetic acid 
THF  Tetrahydrofuran 
TIS  Triisopropylsilane 
TLC  Thin-layer chromatography 
TMSOTf Trimethylsilyl triflate 
TMSSEt (Ethylthio)trimethylsilane 
TNF−  Tissue necrosis factor  
Tr  Triphenylmethyl 
Ts  Tosyl 
TsCl  Tosyl chloride 
VCAM-1 Endothelial vascular cell-
adhesion molecule-1 
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1.  Introduction 
The interaction of E-, P- and L-selectins with their natural carbohydrate ligands has been shown 
to mediate the initial step of the recruitment of leukocytes and to play a crucial role in many 
physiological processes and disease states. More specifically, selectins are a family of 
carbohydrate-binding proteins expressed at the site of inflammation in response to inflammatory 
stimuli liberated by the injured tissue. Their key role, early in the inflammatory cascade, is to 
promote the tethering and the rolling of leukocytes along the endothelial surface. These steps 
are then followed by the integrin-mediated firm adhesion and the final transendothelial 
migration.1-4 
Therefore, control of the leukocyte-endothelial cell adhesion process may be useful in cases 
where excessive recruitment of leukocytes is contributing to acute or chronic diseases such as 
stroke, reperfusion injury, psoriasis or rheumatoid arthritis.5, 6 In addition, it has been suggested 
that cancer may exploit the selectin-mediated adhesion process to metastasize after entering 
the bloodstream.7, 8 
These therapeutic opportunities let the development of selectin antagonists become an 
attractive pharmacological target for the pharmaceutical industry as well as for academic 
research. 
 
1.1. The selectins and their natural ligands 
1.1.1. The selectin family 
Lectins are proteins that recognize and bind to specific carbohydrate structures of 
glycoconjugates and are usually divided into four groups:9 
 
• C-type lectins  Ca2+-dependent lectins10 
• P-type lectins  recognize phosphorylated mannose residues11 
• Galectins   contain free thiol groups, former S-type lectins9 
• other lectins not fitting in one of the above mentioned categories 
 
The selectins as a Ca2+-dependent C-type lectin family include the three members E-, P- and L-
selectin. They are transmembrane glycoproteins and share common structural motifs like a N-
terminal lectin domain (CRD), an epidermal growth factor (EGF)-like domain, a variable number 
of complement regulatory-like repeats (CR domains), a transmembrane segment and a short C-
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terminal cytoplasmic tail (figure 1).12 The overall homology within the three members of the 
selectin family is approximately 50% at the nucleic acid as well as at the protein level, with the 
lectin and the EGF-like domains showing the highest degree of conservation. The N-terminal, 
120-130 amino acid long lectin domain (CRD) shows typical features of C-type animal lectins.13 
It bears the carbohydrate binding-site which is conformationally stabilized by a calcium ion.12 
The following sequence of 35-40 amino acids, the so-called EGF-like domain contains six 
conserved cystein residues forming three intramolecular disulfide bonds. Unlike the lectin 
domain, the EGF-like domain is less understood in its functional role. Although the carbohydrate 
binding-site is localized on the CRD for all three selectins, the EGF-like domain is also involved 
in ligand binding, either by stabilizing the conformation of CRD or by directly interacting with the 
ligand.14, 15   
 
 
 
Figure 1: Common domains of the selectin family.16  
 
The EGF-like domain is followed by a series of short consensus repeats (SCR), also named 
complement binding proteins (CB). The SCR are sixty amino acids long and contain each 3 
disulfide bridges. The number of SCR differs throughout the selectin family and different species. 
In human, E-selectin contains six, P-selectin contains nine, and L-selectin two SCR. Among 
other species the number of SCR for E-selectin varies from four to six, for P-selectin from six to 
eight, whereas for L-selectin the same number of SCR are found in mouse and rat as in 
humans. Deleting various numbers of SCR in a membrane-anchored P-selectin construct 
resulted in impairment of P-selectin to contribute to leukocyte rolling. These findings suggest that 
the SCR facilitate the interaction of P-selectin with leukocyte and increase the intermembrane 
distance, minimizing the contact with the glycocalyx.17-19 After the transmembrane domain, a 
rather small cytoplasmic tail follows, consisting of 17 amino acids in L-selectin, 32 amino acids in 
E-selectin and 35 amino acids in P-selectin. It probably plays a functional role in the signal 
transduction which is not yet fully understood.20  
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The prefixes of the three members of the selectin family were chosen according to the cell type 
where the molecules were first identified.14 E-selectin, previously known as ELAM-1, was 
originally discovered on the surface of activated endothelial cells, P-selectin on activated 
platelets and activated endothelial cells and L-selectin is constitutively expressed on most types 
of leukocytes.   
 
1.1.2. Natural glycoprotein ligands of the selectins 
As selectins are carbohydrate binding proteins, their natural ligands are glycoproteins and 
glycolipids presenting oligosaccharide or sulfopolysaccharide structures as binding motifs. The 
common carbohydrate epitopes recognized by all three members of the selectin family were 
found to be the trisaccharides Lewisx (Lex, 1) and Lewisa (Lea, 2) and their sialylated derivatives 
sialyl Lewisx (sLex, 3) and sialyl Lewisa (sLea, 4) (figure 2).21-23 
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Figure 2: The common carbohydrate epitopes recognized by all three selectins.  
 
Soluble recombinant forms of the selectins and selectin-IgG fusion proteins have been used for 
affinity isolation and identification of natural glycoprotein ligands for selectin.  
 
For L-selectin seven glycoproteins were identified as ligands so far:24 Gly-CAM-1,25 CD34,26 
MAdCAM-1,27, 28 podocalyxin-like protein,29 endomucin,30 endoglycan31 and PSGL-1.32 
Glycosylation-dependent cell adhesion molecule-1 (Gly-CAM-1), a secreted glycoprotein usually 
stored in cytoplasmic granula, is the best characterized L-selectin ligand so far.25, 33-37 Its 
functional role is supposed to be a secreted regulator, participating in the recruitment of 
lymphocytes into peripheral lymphnodes.38, 39 Sialic acid, fucose and oligosaccharide sulfation 
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were found to be critical for the binding of Gly-CAM-1 to L-selectin. CD34 is a transmembrane 
type I sialomucin, presenting large clusters of O- and N-glycans with 6-sulfo sLex as capping 
structure.40 Both proteins, Gly-CAM-1 and CD34 are also expressed in other tissues than the 
lymph nodes, but there they lack the correct carbohydrate modifications essential for binding.26 
MAdCAM-1 belongs to the Ig superfamily but also contains a short mucin domain. It serves as 
counter-receptor for α4β7 in the integrin-mediated adhesion and arrest of lymphocytes, but one 
of its subpopulation also serves in the selectin mediated rolling. The podocalyxin-like protein 
(PCLP) is a transmembrane sialomucin similar in structure to CD34, and it is able to support the 
tethering and rolling of lymphocytes under physiological flow conditions in vitro.29 Endoglycan 
(EG) belongs to the CD34 family like CD34 and podocalyxin, but shows a different binding 
mechanism as other L-selectin ligands. Instead of sulfopolysaccharides, endoglycan interacts 
with sulfation on two tyrosine residues and sLex structures similar to PSGL-1. 
 
 
Figure 3:  Major selectin and integrin ligands that have been identified so far by affinity isolation with the respective 
selectin as affinity probe.38 
 
PSGL-1 has been identified as the major natural occurring P-selectin ligand, as well as ligand 
for L- and E-selectin.41-43 It is a 250 kDa homodimeric type-I transmembrane protein linked by 
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two disulfide bridges.44 The binding to the selectins takes place at the N-terminal region of 
PSGL-1 for P- and L-selectin, whereas E-selectin binds to one or more additional sites on the 
highly O-glycosylated PSGL-1. Beside a single O-glycan capped with sLex (Thr57), additional 
sulfation at two of the three N-terminal tyrosin residues (Tyr46, Tyr48 or Tyr51) is required for 
the binding of P- and L-selectin. Both sialidation and fucosylation of the O-glycan is essential for 
binding.41, 45-56 
 
Compared to L- and P-selectin, E-selectin has different structural requirements for its ligands. 
Sulfation of the ligands was found to be dispensable for E-selectin, whereas it is essential for 
ligands binding to L- and P-selectin.23, 50, 57 Two glycoprotein ligands were identified by affinity-
isolation with E-selectin-Ig fusion proteins so far.50, 57-60 E-selectin ligand-1 (ESL-1) is a 150 kDa 
glycoprotein containing five putative N-glycosylation sites and 16 cystein rich sites.61 ESL-1 
binds selectively to E-selectin, but not to P-selectin. By comparative analysis of cell lines binding 
to E-selectin and by the use of recombinant soluble E-selectin-agarose affinity chromatography, 
three unusual carbohydrate structures binding selectively to E-selectin were identified.62 All of 
these structures bear a 3-sialyl di-Lewisx extension on one arm of an N-linked tetraantennary 
glycan. These carbohydrate structures are only present on leukocytic cell lines binding to E-
selectin and may alone be responsible for the specificity of E-selectin-dependent adhesion. In 
addition to ESL-1, E-selectin binds also independently from tyrosin sulfation to PSGL-1 and to 
carbohydrates present on L-selectin of human neutrophiles.50, 57, 60, 63, 64 
 
1.2.  The role of selectins during inflammation and human diseases 
The inflammatory response is an important mechanism of the body to defend itself against 
various pathogens like viruses, bacteria, fungi, protozoan and metazoan parasites, as well as to 
respond to the damage caused to cells and vascularised tissues. Main actors in this defense 
mechanism are leukocytes, migrating from circulation into tissues and responding to the damage 
by releasing cytotoxic and proinflammatory mediators, like chemokines or platelet-activating 
factors, and by phagocytosis. Selectins and their receptors play a predominant role among a 
multitude of signaling and adhesion molecules that control the directed migration of leukocytes 
from the circulation to the site of inflammation.65  
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1.2.1. The inflammatory cascade and its cellular mechanisms  
During acute inflammation leukocytes migrate mainly in post-capillary venules in a highly 
regulated adhesion cascade into the inflamed tissues. This adhesion cascade is usually referred 
to as the inflammatory cascade and can be divided into five major steps: Inflammatory stimulus, 
tethering and rolling, integrin activation, firm adhesion and transendothelial migration as 
exemplified in figure 4.  
 
 
 
Figure 4: Schematic representation of the inflammatory cascade.66 
 
The cascade is initiated by the release of proinflammatory mediators like chemokines or platelet 
activating factors.67, 68 These stimuli cause the expression of E- and P-selectin on vascular 
endothelial cells, which are now in a pro-adhesive state. P-selectin is stored in -granules of 
platelets and Waibel-Palade bodies of endothelial cells. After stimulation by endocytosis of 
proinflammatory mediators such as thrombin or histamine it can be transported to the cell 
surface within minutes.69, 70 Within 30-60 minutes P-selectin is subsequently removed again from 
the endothelial surface by endocytosis. Beside the transport from storage granules to the 
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plasma membrane, the synthesis of P-selectin can be transiently induced by TNF- in mouse 
and bovine endothelial cells, with slightly slower kinetics than found for E-selectin.70-72  
In contrast to P-selectin, E-selectin has to be synthesized de-novo. Its transcription is induced by 
TNF-, Interleukin-1 (IL-1) or lipopolysaccharide (LPS).73, 74 Highest level of E-selectin 
expression at cell surfaces is reached within 3-4 h after stimulation and decreases to basal 
levels again after 16-24 h.75 In the next step, endogenous ligands for E- and P-selectin like 
PSGL-1 and ESL-1 bind to the selectins in a fast association/dissociation process which leads to 
the well known tethering and rolling of leukocytes onto the endothelial surface (figure 5).76, 77 L-
selectin, which is constitutively expressed at the tips of leukocytes, serves not only as a ligand 
for E-selectin,78 but additionally plays an important role in the so-called “secondary tethering” 
process. This process describes the tethering of leukocytes on other leukocytes, which are 
already associated on the endothelium by the interaction of PSGL-1.79, 80 The “secondary 
tethering” expands the pool of leukocytes attracted to sites of inflammation. After cell activation, 
induced by a variety of chemo-attractants and activating factors, L-selectin gets rapidly cleaved 
at an extracellular cleavage site close to the cell membrane by metalloproteases.81, 82 This 
proteolytic cleavage of L-selectin happens within minutes and is supposed to facilitate the 
detachment of leukocytes from endothelial cells prior to the migration through the endothelium.38, 
83-87 
 
  
 
Figure 5:  Leukocytes adhering on the endothelium (left) and leukocyte migrating through the endothelium (right).88 
 
During the tethering and rolling phase, leukocytes are slowed from the microvascular free-
stream blood flow velocity of 1-10 mm/s down to 5 µm/s before becoming fully stationary. It was 
shown that mainly E-selectin is responsible for the slow rolling of leukocytes (5 µm/s), since 
leukocytes roll significantly faster (12 to 20 µm/s) in E-selectin-deficient mice. Hence, the E-
selectin-dependent slow-rolling drastically increases the transit time through the inflamed tissue 
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and enables the activation of leukocytes by chemo-attractants.89, 90 The exposure of leukocytes 
to chemo-attractants (e.g. fMLP, PAF, C5a, IL-8, eotaxin) progressively triggers the activation 
and upregulation of 2-integrins (CD18) on the cellular surface.91, 92 These 2-integrins (Mac-1, 
LFA-1 and x2) interact in their activated state with endothelial ligands from the immunoglobulin 
(IgG)-superfamily like ICAM-1 and VCAM-1, enabling the firm adhesion of leukocytes on the 
endothelium and leading to a flattening which further increases the contact area of leukocytes to 
endothelium.81, 92-94 Endothelial transmigration of leukocytes is finally achieved by the interaction 
of integrins located on leukocytes with endothelial PECAM-1 of the IgG superfamily.95, 96 
 
1.2.2.  The pathophysiological role of selectin-ligand interactions 
Abnormal or excessive recruitment and influx of leukocytes into inflamed tissues is a central 
component of a variety of acute or chronic inflammatory diseases. Therefore, blocking of the 
selectin-ligand interactions has a dramatic impact on the progression of these diseases, as 
shown in a number of animal models.97, 5, 98 
 
Studies on selectin-deficient mice gave first insights into the physiological and 
pathophysiological roles of these receptors. Selectin-deficient mice show no developmental 
defects nor suffer from multifocal infections.99-101  
P-selectin-deficient mice show two- to threefold higher numbers of circulating neutrophils due to 
a prolonged circulation half-life by a decreased clearance of neutrophils.99, 102 Whereas wild-type 
mice show an increase of rolling leukocytes after cremaster muscle surgery from initially 13% to 
26% within 40 to 60 minutes, the initial rolling is absent in P-selectin-deficient mice and does not 
exceed 5% later.103 In the thioglycolat-induced peritonitis model P-selectin-deficient mice have 
reduced peritoneal accumulation of neutrophils at the early stage of inflammation, but show 
normal levels later. In contrast to neutrophils, P-selectin seems to play an important role in the 
long-term recruitment for monocytes, as P-selectin-deficient mice show impaired monocyte influx 
48 h after peritoneal thioglycolat injection.102 L-selectin-deficient mice show a pronounced 
decline of rolling leukocytes during surgical dissection of the mesentery and in the thioglycolat-
induced peritonitis model a reduced peritoneal accumulation for monocytes, neutrophils as well 
as lymphocytes.100, 103, 104 This indicates that L-selectin is necessary for the recruitment of all 
types of leukocytes, whereas P-selectin is important for the long-term recruitment of monocytes. 
In contrast to P- and L-selectin, E-selectin-deficient mice displayed no significant change in the 
trafficking of neutrophils in several models of inflammation.101 
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In 1992, a rare autosomal recessive genetic disorder called “type 2 leukocyte adhesion 
deficiency” (LAD-2) was described in two patients.105 The affected individuals suffer from 
recurrent infections, persistent leukocytosis, severe mental and growth retardation and 
numerous facial and skeletal abnormalities.106, 107 Both patients exhibit the rare Bombay (hh) 
blood phenotype, show no expression of the Lewis blood group antigens, nor do they secret 
soluble blood group antigens in their saliva, which implies a global defect in fucose metabolism. 
Later it could be shown that LAD-2 results from a point mutation in the gene of a highly 
conserved GDP-fucose transporter on chromosome 11.108, 109 The deficiency in fucosylated 
glycoconjugates like sLex leads to reduced rolling of leukocytes in postcapillary venules and the 
inability of neutrophils to bind to immobilized E-selectin. Recently, it was found in one patient 
that treatment with orally administrated fucose was able to induce the expression of fucosylated 
selectin ligands on neutrophils and core fucosylation of serum glycoproteins, resulting in a 
general improvement of the patient condition.110, 111 The lack of appropriate inflammatory 
responses to external pathogens of LAD-2 patients clearly demonstrates the importance of 
selectin-ligand interactions to the inflammatory response.  
 
The tissue and organ damage resulting from ischemia and reperfusion is an important example 
of inflammatory conditions, where selectins play a key role.112, 113 Reperfusion injury occurs in a 
variety of clinical disorders like stroke, myocardial infarction and organ transplantation, leading to 
further damage to the vessel walls and surrounding tissues apart from the damage caused by 
the ischemia itself. Reperfusion of ischemic tissues results in a strong accumulation of 
neutrophils, mainly mediated by P- and E-selectin, followed by plugging of the microvasculature, 
infiltration of neutrophils into tissue and release of cell-activating and cytotoxic mediators. 
Preventing the neutrophil accumulation by antagonists is therefore an effective strategy to 
attenuate reperfusion injury. A variety of approaches to block selectins have been studied 
extensively and showed protective effects in reperfusion injury models, including monoclonal 
antibodies,114-119 carbohydrates,116, 120, 121 soluble forms of PSGL-1122 and small molecular 
antagonists.123, 124 
 
Sepsis, a state of severe systemic bacterial infection, results in peripheral hypoperfusion and 
frequently to life-threatening multiorgan dysfunction. Abnormal leukocyte activation and 
adhesion has been implicated in the pathogenesis of tissue damage and multiorgan failure 
observed under septic shock. The uncontrolled leukocyte activation results in a release of toxic 
products and leads to the hemodynamic and inflammatory derangement of the patients. Since 
selectins are involved in leukocyte adhesion, their blocking may be able to reduce vascular and 
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tissue injury during sepsis. However, the benefit of the tested anti-adhesion therapies on the 
clinical outcome is controversially discussed up to now.125-128 
 
Selectins play also a predominant role in asthma, especially E-selectin together with the integrin 
receptors ICAM-1 and VCAM-1.129-132 The increased serum concentrations of E-selectin 
observed during asthma attack probably result from an increased endothelial expression. 
Hence, E-selectin antagonism may helps to prevent the cellular infiltration during an asthma 
attack. In a primate model of allergic asthma, anti-E-selectin antibodies have been shown to 
reduce the neutrophil influx into the lung and to block the late-phase airway obstruction.133 In a 
sheep asthma model, an anti-L-selectin antibody and a small molecular selectin antagonist 
successfully prevented antigen-induced late bronchial response and airway 
hyperresponsiveness.134  
 
Rheumatoid arthritis represents one of the most prominent inflammatory rheumatic disorders 
and leads to a high percentage of disability and a significantly reduced life expectancy. Although 
the exact molecular mechanisms of rheumatoid arthritis are not yet fully elucidated, soluble E-
selectin and ICAM-1 in serum and synovial fluid were recognized as important markers for the 
severity of the disease state, allowing early differentiation between mild and severe courses of 
the disease and providing essential information for therapeutic decisions.135-138 In the adjuvant 
induced arthritis (AIA) model of Lewis rats, early treatment with mAb against E-selectin resulted 
in inhibition of antigen-dependent T cell-mediated inflammation, whereas treatment with mAb 
against P-selectin had no significant effect.139 However, recently, a small molecular antagonist of 
P-selectin showed efficacy in the same model of rheumatoid arthritis.140   
 
During the rejection of human renal,141 cardiac142, 143 and liver transplants144 increased levels of 
endothelial adhesion molecules like E-selectin, ICAM-1 and VCAM-1 have been observed, 
which imply that selectins could play an important role in the pathophysiology of organ rejection. 
Indeed, the treatment of heart-transplanted mice with either anti-E- or P-selectin mAbs, or both, 
showed significant prolongation of graft survival, which suggests that P- and E-selectins are 
involved in development of acute heart rejection.145 A recent study in a rat model revealed that a 
small molecular selectin antagonist blocked intragraft production of cyto- and chemokines and 
consequently inhibited kidney allograft rejection.146 In addition synergistic effects of the 
antagonist in combination with cyclosporine, sirolimus and FTY720 were found. The “graft vs. 
host disease” (GvHD) is a multiorgan disease caused by the immune response of donor 
leukocytes against host tissue in recipients of bone marrow transplantation. In cutaneous and 
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intestinal lesions of such patients increased E-selectin expression on the venular endothelium 
close to site of leukocyte infiltration was found.5, 147, 148 
 
Metastasis is defined as the spreading of a malignant tumor to a site different from its origin. A 
large pool of data suggests that during the tumor metastasis the malignant cells follow the 
pathway of leukocytes.149-166 The expression of selectins on the endothelium could therefore 
initiate or even be a prerequisite for the development of metastases. Colon cancer was one of 
the first where the expression of selectin ligands was correlated with its metastatic behaviour 
and received most attention in selectin studies.167-178 There is strong evidence that E-selectin 
mediates the initial rolling of colon tumor cells on the endothelium, followed by the subsequent 
firm adhesion involving other, yet unknown, adhesion molecules. However, also other cancer 
cell lines might be influenced by E-selectin-mediated adhesion as observed for several breast 
cancer cell lines.179, 180 Numerous clinical studies additionally suggest that elevated serum levels 
of E-selectin in patients with various types of cancer reflect the tumor-progression.181-185, 156, 186 
The role of P-selectin in the metastasis of tumor cells received less attention as E-selectin and is 
therefore more speculative. Generally, it is supposed that P-selectin can display an identical 
mode of action to the one of E-selectin. Additionally, it is speculated that the stimulation of the P-
selectin expression on platelets facilitates the interaction between platelets and tumor cells in 
the haematogenous metastasis.187-189 This leads to the formation of aggregates of platelets and 
tumor cells which either could embolise small vessels or facilitate the adherence to the 
endothelium, initiating the metastasis. Although the physiological role of L-selectin is well 
understood, its role in cancer metastasis still remains uncertain. It is thought that L-selectin may 
be involved in the metastasis of malignant lymphoma to distant nodes which is supported by the 
strong expression of L-selectin in T-cell hybridoma cells which metastasize extensively to 
peripheral lymph nodes.190 Yet, there is no evidence that L-selectin is a prerequisite for this 
process. 
 
In summary, a strong deregulation of the selectins has been observed in many diseases such as 
cancer metastasis and angiogenesis, atherosclerosis, asthma, COPD, organ rejection, 
hemorrhagic shock, thrombosis, rheumatoid arthritis, atopic dermatitis, psoriasis,191 diabetes-
caused microangiopathy, or myocardial and cerebral ischemia. In these diseases patients may 
benefit from the blocking of the selectin-ligand interactions by small molecular antagonists or 
antibodies.  
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1.3. Structure activity relationship of Selectins binding to their ligands 
Since the tetrasaccharide sialyl Lewisx (3) (figure 2) is the carbohydrate epitope recognized by 
all three selectins,192, 193, 21 it serves as a lead structure for the design of selectin antagonists.194-
197 In order to develop small molecular antagonists from this lead structure, a profound 
understanding of the ligand-protein complex is mandatory. In recent decades numerous 
experimental investigations by NMR-spectroscopy, X-ray crystallography, as well as 
derivatization- and in-silico studies provided growing insight into the complex interaction 
between selectins and their ligands. Despite the collected information, many aspects of this 
specific carbohydrate-protein interaction are still controversially discussed and numerous 
obscurities yet have to be clarified. 
 
1.3.1. Pharmacophores 
Preliminary insights into the interactions between selectins and sialyl Lewisx was gained by 
systematic functional group derivatization studies. By altering individual functional groups, the 
essential ones for binding could be identified, which are commonly referred to as the 
pharmacophores of sLex and are highlighted in figure 6. 
 
The fucose moiety of sLex was correctly assumed to bind to the Ca2+. This was deduced from 
the earlier solved crystal structure of an oligosaccharide bound to the C-type lectin domain of 
the mannose-binding protein A (MBP-A).198 Gaeta et al. and Hasegawa et al. observed that 
replacement of any of the fucose hydroxyls by hydrogen was completely deleterious to the 
binding to E-selectin.199, 200 However, in the case of P-selectin only the 3-hydroxyl was found to 
be necessary for binding. Replacement of the fucose by arabinose led to a 5-fold decrease in 
potency towards E-selectin binding. 
 
The importance of the galactose hydroxyls was probed by synthesizing deoxy- and fluoro-
analogues of sLex.201 The findings were that only the 4- and the 6-hydroxyl contribute to the 
binding, not the 2-hydroxyl. Yet, the replacement of any of the galactose hydroxyls is not as 
deleterious as in the case of fucose. Bänteli et al. closer investigated hypothetical interactions to 
E-selectin in the surroundings of the 6-position of galactose by synthesizing numerous ligands 
modified at this specific position. They concluded that the 6-hydroxyl is optimally suited for the 
binding to E-selectin, considering that all modified compounds were inactive.202 
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Of the functional groups of the NeuNAc moiety, only the carboxyl group was found to be crucial 
for binding to E-selectin.200, 203, 204 However, in the case of P-selectin, the crystal structure later 
revealed that the 4-hydroxyl and hydrophobic interactions additionally contribute to the binding.46  
 
The GlcNAc moiety rather serves as a spacer to optimally position the pharmacophores of 
fucose and galactose than directly contributing to the binding, as discussed in several studies.205-
207 
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Figure 6:  Structure of sialyl Lewisx. Pharmacophores involved in binding to E-selectin and assignment of torsions 
angles are highlighted.  
 
1.3.2.  Conformational aspects 
The conformational preferences of sLex in solution and bound to the selectins were elucidated 
primarily with the aid of molecular dynamics calculations and NMR spectroscopy with the labeled 
and unlabeled compound.  
 
Early work suggested sLex to adopt a single conformation in solution.208-210 However, 
subsequent NMR- and molecular dynamics studies revealed a certain degree of flexibility of the 
glycosidic linkages.211-217 A compilation of the suggested conformations is displayed in table 1. It 
is noteworthy to say, that a general agreement is found in the torsion angles (figure 6) of the 
Gal-(1-4)-GlcNAc and Fuc-(1-3)-GlcNAc linkages of the Lex moiety, commonly referred to as 
the core-structure. Substantial divergence is found in the torsion angles between Neu5Ac and 
Gal, depending on whether the NOE between Gal H-3 and Sia H-3ax was included into the 
considerations. However, the high flexibility of the Neu5Ac(2-3)Gal linkage suggests multiple 
conformations to be present in solution.212, 213 
1 1 
2 2 3 3 
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Table 1: Torsion angles of the solution conformation  
 
References Φ3/Ψ3 Φ2/Ψ2 Φ1/Ψ1 
 Neu5Ac(2-3)Gal Gal(1-4)GlcNAc Fuc(1-3)GlcNAc 
NMR/GESA/MM2  
(Ichikawa et al., 1992)218, 219 
-170°/- 18° +54°/+ 9° +48°/+24° 
NMR 
(Poppe et al., 1997)214 
--- / ---      
--- / ---   
+46°/+18° 
+46°/+18° 
+48°/+24° 
-23°/+15° 
NMR/MD 
(Rutherford et al., 1993)213 
-  70°/+ 5° +50°/+15° +48°/+22° 
MD 
(Veluraja et al., 2005)220 
-  95°/-60° 
-  70°/ 10° 
-160°/-25° 
+65°/+15° 
 
 
+65°/+40° 
 
 
 
 
Table 2: Torsion angles of the bioactive conformation.211, 221 
 
References Selectin Φ3/Ψ3 Φ2/Ψ2 Φ1/Ψ1 
  Neu5Ac(2-3)Gal Gal(1-4)GlcNAc Fuc(1-3)GlcNAc 
NMR  
(Scheffler et al., 1995)222 
E -76°/+ 16° +39°/+12° +38°/+26° 
NMR  
(Poppe et al., 1997)214 
E 
P 
-58°/-22° 
-85°/- 14° 
+24°/+34° 
+45°/+18° 
+71°/+14° 
+61°/+26° 
NMR  
(Harris et al., 1999)215 
E -43°/-12° +45°/+19° +29°/+41° 
X-ray  
(Somers et al., 2000)46 
E 
P 
[a]P[a] 
-65°/-12° 
-65°/- 18° 
-55°/-11° 
+34°/+16° 
+40°/+ 18° 
+40°/+16° 
+41°/+22° 
+40°/+16° 
+70°/+20° 
[a] Dihedral angles measured on the sLex moiety of PSGL-1 bound to P-selectin. 
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The bioactive conformation of sLex bound to E-selectin was determined in various studies based 
on a careful analysis of its NOE signals in solution and its transfer-NOE signals when bound to 
the selectins (table 2).19, 46, 212, 214, 215, 220, 223, 222 The absence of the NOE between Gal H-3 and 
Sia H-3ax in the bound state and the additional tr-NOE between Sia H-8 and Gal H-3 suggest a 
change in conformation for the Neu5Ac(2-3)Gal linkage during the binding to the selectins. In 
contrast, the core conformation seems to be rather rigid and shows only minor conformational 
changes upon binding. For the core-conformation a general agreement was found for the bound 
conformation as displayed in table 2, except for Poppe et al. who proposed a slightly modified 
conformation.214 The recently published crystal structure of E-selectin co-crystallized with sLex 
was in good agreement with the findings of Scheffler et al. (figure 7)46, 222 224 
 
 
 
Figure 7: The bioactive conformation of sLex determined by Scheffler et al.223, 222 
 
Kolb and Ernst made further use of Scheffler’s conformational data to define a bioactive window 
for selectin antagonists, a powerful tool to preliminarily evaluate potential antagonists by 
MC(JBW)/SD-simulations.216, 217 In this protocol, the hundred most favorable minima 
conformations of the compound of interest are searched by a systematic pseudo-Monte-Carlo 
method.225 These conformations are then subjected to a “Jumping between Wells” stochastic-
dynamics simulation (JBW-SD). For the calculations, a carbohydrate-adjusted AMBER force 
field in conjunction with the GB/SA continuum-water model is utilized.216, 217, 226, 227 The results 
are usually displayed in a 2D internal coordinate system with the “core-conformation” and the 
“acid-orientation” as parameters, instead of the three Φ/Ψ−plots. The definition of the two 
parameters is exemplified in figure 8.  
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Figure 8: Definition of the core- and the acid-conformation 
 
This protocol allows comparing the solution conformation of sLex, as well as the conformation of 
new antagonists with the bioactive conformation of sLex determined by NMR (figure 9).216 
Compounds having a high probability for conformations in the bioactive window were shown to 
usually have higher affinity to E-selectin, due to their increased pre-organization in the bioactive 
conformation.216, 217 
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Figure 9:  Bioactive conformation (left) determined by NMR by Scheffler et al. and solution conformation (right) 
 of sLex calculated by MC(JBW)/SD-simulation. 
 
1.3.3.  Hypothetical models for the binding of sLex to E-selectin  
Before the crystal structure of E-selectin/sLex was elucidated, several groups proposed various 
binding models for the binding of sLex to E-selectin. In a retrospective view each of the models 
was able to predict some of the interactions correctly, but none of them predicted exactly the 
binding as observed in the crystal structure. The largest discrepancy was found in the binding of 
the fucose to the Ca2+. The fucose was generally thought to bind with the equatorial 2- and the 
3-hydroxyl as observed in the crystal structure of the mannose-binding protein A (MBP-A). The 
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crystal structure of MBP-A was the only available crystal structure with a saccharide bound to a 
C-type lectin at that time and was solved in 1992 by Drickamer et al.228, 198 It shows D-mannose 
binding to the Ca2+ by its equatorial 3- and 4-hydroxyls. This led to the hypothesis that the 
fucose binds in a similar fashion with its equatorial 2- and 3-hydroxyls to the Ca2+ of E-selectin, 
whereas the axial 4-hydroxyl of fucose is interacting with protein side-chains. This hypothesis 
had great impact on all later proposed models, until the year 2000, when the crystal structure of 
E-selectin proved the binding mode to be wrong.46 
The critical region for carbohydrates binding to the lectin domain of E-selectin was firstly 
determined by mutagenesis studies of a lectin/EGF construct of E-selectin. In 1992, Erbe et al. 
hypothesized that E-selectin binds in a small shallow pocked formed by the residues Arg97, 
Lys111, Lys113, Ser47 and Tyr48.12 The three closely situated, positively charged residues 
Arg97, Lys111 and Lys113 were proposed to be involved in the binding to the carboxylate of 
Neu5Ac since substitution of any of them led to a profound loss in binding. Erbe et al. further 
superimposed these critical residues on the crystal structure of MBP-A, which was published at 
the same time. This superimposition led to the first three-dimensional model of the E-selectin 
lectin domain. 
Graves et al. were the first to solve the crystal structure of a soluble form of E-selectin containing 
the lectin/EGF domain.229 Although the overall fold was found to be similar to MBP-A, significant 
differences were found in the coordination sphere of the Ca2+ to other C-type lectins. In the 
crystal structure, Ca2+ was coordinated by the side chains of Glu80, Asn82, Asn105, Asp106, as 
well as by the backbone carbonyl of Asp106 and by two water molecules. Further mutagenesis 
studies revealed Tyr48, Asn82, Asn83, Gluc92, Tyr94, Lys111, Lys113 as critical amino acids 
for neutrophil adhesion. Additionally, Asn82 was identified to not only coordinate to the Ca2+, but 
also to bind to a ligand hydroxyl as observed from the N82D mutant.  
The first published crystal structure complexed with sLex was a selectin-like triple mutant of the 
MBP-A.230 In this mutant the residues 211-213 were replaced by the Lys111-Lys112-Lys113 
sequence found in E-selectin. To clarify the carbohydrate-binding properties, the mutant was 
crystallized as complex with sLex, 3’-sulfo-Lex and 4’-sulfo-Lex. All the structures confirmed the 
binding of the two equatorial 2- and 3-hydroxyls of fucose to the Ca2+, as expected from the 
binding of the natural MBP-A to mannose. However, the most surprising aspect in this structure 
was that the carboxylate moiety showed no direct interaction with the protein, which is in 
contrast to earlier studies with modified Neu5Ac moieties. The lack of this important interaction 
was thought to indicate that the orientation of the ligand differs from the selectin-bound one. 
Based on the bioactive conformation of sLex and the crystal structure of E-selectin solved by 
Graves et al.,229 two models for the binding of sLex to E-selectin were proposed. The first model 
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was presented by Kogan et al.231 and used the NMR-determined E-selectin bound solution 
conformation of sLex 232 together with the crystal structure of E-selectin.229 The fucose was first 
coordinated to the Ca2+ in an identical manner as mannose binds to the Ca2+ in the crystal 
structure of the MBP-A.228, 198 The E-selectin-ligand interactions of this model are summarized in 
table 3. The second model was presented by Ernst et al. and was based on the docking of sLex 
in the bioactive conformation on the crystal structure solved by Graves et al.233 The bioactive 
conformation of this model was determined by own NMR experiments. In both models the 
fucose is proposed to bind with the two equatorial 2- and 3-hydroxyls to the Ca2+ as observed for 
mannose with MBP-A.  
 
Table 3:  Proposed interactions between sLex and E-selectin by two models, and interactions found in the crystal 
structure of Camphausen et al.     
 
Functional group Kogan et al.231 Ernst et al.233 Camphausen et al.46 
Fuc O-2 Ca2+ 
Asn105 
Ca2+ 
Asn105 
H2O 
 
Fuc O-3 Ca2+ 
Glu80 
Asn82 
Ca2+ 
Glu80 
 
Ca2+ 
Asn105 
H2O 
Fuc O-4  Asn82 Ca2+ 
Glu80 
Asn82 
Gal O-4  Asn105 Tyr94 
Gal O-6 Tyr94 Tyr94 Glu92 
Neu5Ac COOH Arg97 Arg97 Arg97 
Tyr48 
Coordination sphere of the 
calcium 
Glu80 
Asn82 
 
Asn105 
Asp106 
Fuc O-2 
Fuc O-3 
Glu80 
Asn82 
 
Asn105 
Asp106 
Fuc O-2 
Fuc O-3 
Glu80 
Asn82 
Asn83 
Asn105 
Asp106 
Fuc O-3 
Fuc O-4 
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In 2000, Camphausen et al. solved the crystal structure of the lectin/EGF domains of E- and P-
selectin co-crystallized with sLex and the lectin/EGF domains of P-selectin with the N-terminal 
domain of human PSGL-1.46 Surprisingly, the fucose complexes to the Ca2+ by the 3- and 4-
hydroxyls, which is in contrast to all previously proposed models (figure 10). The 2-hydroxyl of 
fucose binds to Glu107 and Asn83 over water-mediated hydrogen-bonds. Other differences to 
earlier proposed models were the binding of the 4-hydroxyl of galactose to Tyr94 instead of the 
6-hydroxyl and the additional interaction of the Neu5Ac carboxylate to Tyr48. The detailed 
binding pattern of sLex in the crystal structure of E-selectin is shown in figure 11. 
 
  
Figure 10:  Interactions between sialyl Lewisx and E-selectin in the crystal structure with focus on Neu5Ac-Gal (left) 
and coordination of Ca2+ by the fucose (right). Coordination of Glu80 and backbone-carbonyl of Asp106 
are not shown.46 
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Figure 11:  Binding pattern found in the crystal structure of E-selectin co-crystallized with sLex. 
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1.4.  Development of sLex mimetics and small molecular weight selectin 
antagonists 
The observation that E-selectin plays a key role early in the inflammatory cascade and promotes 
the tethering and rolling of leukocytes along the endothelial surface made of E-selectin a highly 
interesting pharmaceutical target. Therefore, blocking of the E-selectin-ligand interaction may be 
useful in cases, where excess recruitment of leukocytes can contribute to acute or chronic 
diseases such as stroke, reperfusion injury, psoriasis, rheumatoid arthritis or metastasis of 
cancer cells.  
 
So far, all drug discovery approaches have been focused on blocking the lectin domain, since 
the role of the EGF and CR domains in ligand binding is still unclear.15, 18, 211, 234-238  
Early approaches utilized carbohydrate fragments of the physiological ligands as potential anti-
inflammatory therapeutics. This strategy led to the development of Cylexin, a sialyl Lewisx 
pentasaccharide, which initially showed promising biological results,239-242 but later turned out to 
be unsuccessful as a drug candidate, probably due to its low biological affinity243 and limited 
bioavailability.244 Because of its complex structure, the availability of Cylexin was initially very 
limited, as chemical synthesis provided only gram quantities.245-247 This problem, however, was 
elegantly solved by Wong et al.,209 who developed a multi-enzyme system for the large-scale 
production of sLex.211 
Despite their ultimate failure, these early studies did provide the proof-of-principle, which 
prompted intense efforts towards finding more ‘drug-like’ selectin antagonists.211 In the search of 
new E-selectin antagonists, the terminal carbohydrate epitope sialyl Lewisx was commonly taken 
as a lead structure, apart from some recent studies that were using lead structures found by 
modern HTS techniques. Main objective in the drug development process was to address and 
overcome the following problems of the lead structure sialyl Lewisx: 
• low binding affinity  
• low hydrolytical and metabolic stability 
• low bioavailability due to its high polarity and molecular weight 
• synthetical complexity and high production costs 
In numerous studies it was tried to achieve this aim by substituting or omitting unnecessary 
structural elements while retaining the important pharmacophores or even finding new protein-
ligand interactions. One of the most important and generally underestimated aspect in this lead 
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optimization process is the conformational pre-organization of the rather rigid sLex structure. 
Many of the described approaches resulted in low inhibition potencies or even failed due to an 
increase in flexibility by the replacement of sugar moieties with more flexible linkers. 
 
The following overview of different approaches is structured in a reductionist fashion, starting 
with mimics where only one carbohydrate moiety of sLex was replaced, followed by mimics with 
two carbohydrate moieties replaced and so on. In each chapter further studies addressing 
secondary binding sites or conformational pre-organization will be discussed. At the end of the 
overview the de-novo design of antagonists will be discussed either based on the spatial 
orientation of the pharmacophores or on high throughput screening. 
 
The IC50 values that are reported in the literature are difficult to compare directly, since they were 
obtained with conceptually different in vitro assays.248 Therefore, whenever available, the relative 
affinities of the test compounds compared to sLex will be quoted, which has an IC50 value for E-
selectin of approximately 1 mM. For example, a relative IC50 value (rIC50) of 0.1 corresponds to 
an IC50 value of approximately 100 µM. 
 
1.4.1.  Antagonists with three sugar moieties 
1.4.1.1.  Replacements for sialic acid 
From early pharmacophore studies it is known that, in contrast to P-selectin, only the 
carboxylate of sialic acid is important for the interaction between E-selectin and sLex. Therefore, 
replacement of sialic acid by a negatively charged functionality was the first logical step, 
especially in respect to the tremendous costs of sialic acid. Several research groups reported 
the synthesis of ligands where the Neu5Ac is successfully replaced either by sulphate,200, 243, 249 
phosphate250 or glycolate (figure 12).251 Replacement of Neu5Ac by sulphate leads to the known 
natural ‘3-sulfo-analogues of sLex and sLea (5, 6). Martin-Lomas et al. reported a more practical 
synthesis of similar ligands, where the Gal(1-4)GlcNAc moiety was replaced by the more readily 
available lactose (7).249 A phosphated lactose derivative of Lea (8) was synthesized by Kiessling 
et al.250 and was reported to show similar inhibition potency as ‘3-sulfo-Lea, which itself was 
found to be 20-fold more potent than ‘3-sulfo-Lex.  
Most commonly the sialic acid was replaced by glycolic acid as in ligand 9, which shows 
comparable affinity for E-selectin as sLex.251 Thoma et al. fixed the carboxylate in equatorial 
position of a six-membered cyclic acetal to pre-organize the acid functionality.252 However, from 
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the inactivity of the compound (10), it could be concluded that the compound was pre-organized 
in a conformation different from the bioactive one. Other more rigid sialic acid mimics like lactic 
acid and derivatives thereof were found to be highly active, as described later in combination 
with replacements for GlcNAc .    
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Figure 12: Ligands with replacement of Neu5Ac. 
 
 
1.4.1.2.  Replacements for GlcNAc 
SAR-studies and the crystal structure revealed that the GlcNAc moiety rather serves as a spacer 
to optimally position the pharmacophores of fucose and galactose than directly contributes to the 
binding. Therefore, the GlcNAc moiety is optimally suited for the replacement by spacers with 
improved pharmacodynamic or -kinetic properties, increased pre-organization or reduced 
synthetic complexity. 46, 205-207 
Hanessian et al. presented ligands where GlcNAc was replaced by a (-)-quinic acid-derived 
carbocycle (11) and by an indolizidinone-type unit, as a -turn-like scaffold (12).253, 254 Whereas 
11 was as active as sLex, 12 was found to be inactive due to the absence of any low energy 
conformer near the bioactive conformation of sLex. Töpfer et al. introduced (1R,2R)-trans-
cyclohexanediol as GlcNAc mimetic which resulted in a threefold more active compound than 
sLex.255 This GlcNAc mimetic is particularly interesting since it combines higher activity, lower 
synthetic complexity and higher lipophilicity in the same molecule, and hence found widespread 
application in the further synthesis of sLex antagonists (13, figure 13). 
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Figure 13: Ligands with replacement of GlcNAc. 
 
1.4.2.  Antagonists with two sugar moieties 
1.4.2.1.  Replacements for the N-acetyl-lactosamine disaccharide 
Several groups have been exploring suitable replacements for the central N-acetyl-lactosamine 
moiety (figure 14). However, the loss or inadequate replacement of the pharmacophores of 
galactose and the commonly increased flexibility of the linkers resulted in disappointing binding 
affinities. Töpfer et al. combined his successful GlcNAc mimetic (1R,2R)-trans-cyclohexanediol 
with various aliphatic spacers for galactose. The compounds showed only moderate or no 
affinity and good results were surprisingly only achieved by switching from - to the -sialosides 
(14-18). Attempts to mimic the galactose pharmacophores by using polyols were 
unsuccessful.255 Similar disappointing results were obtained from replacing the whole N-acetyl-
lactosamine part by aliphatic spacers as in compounds 21-24.256 Also, the less flexible 
phenylenedimethanol spacers proposed by Kaila et al.257 or the spiroketal spacer of Birkbeck et 
al.258 led to less potent antagonists.  
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Figure 14: Ligands with replacements for N-acetyl-lactosamine. 
 
 
Allanson et al. explored the possibility to link the sialic acid and the fucose by elongation from 
the fucose C-4 with suitable alkyl-chains and polyols (figure 15).259, 260 However, these 
compounds were less active than sLex or were not active at all.   
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Figure 15: Ligands with replacements for N-acetyl-lactosamine proposed by Allanson et al. 
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1.4.2.2.  Simultaneous replacement of Neu5Ac and GlcNAc 
Replacing both the sialic acid and GlcNAc at the same time by simpler mimetics is a self-evident 
approach since both of them hardly bear any pharmacophores. Sialic acid was thereby 
commonly replaced by glycolic acid or aryl- and alkyl lactic acids, whereas the range of explored 
GlcNAc mimetics was less narrow. A variety of GlcNAc mimetics in combination with glycolic 
acid as Neu5Ac replacement is shown in figure 16.261-266, 194 
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Figure 16: Ligands with glycolic acid as replacement for sialic acid. 
 
Of all the GlcNAc mimetics tested in combination with glycolic acid so far, the (1R,2R)-trans-
cyclohexanediol (40) was the most promising one, providing an optimal spatial arrangement of 
the pharmacophores, compared to the similar but inactive ortho-catechol (34).261 More flexible 
mimetics (30-33) or C-glycosides (35-37) led to a significant decrease in binding affinity due to 
the loss of pre-organization in the bioactive conformation.261-266 Surprisingly, a simple ethanediol 
linker (29) was found to be almost as effective as (1R,2R)-trans-cyclohexanediol.262 The 
previously mentioned quinic acid derivative (38) of Hanessian et al. lost in combination with 
glycolic acid its binding affinity to E-selectin.254 
 
With the help of a molecular modelling tool Ernst et al. closer investigated replacements of 
Neu5Ac by lactic acid derivatives, in combination with cyclohexanediol as GlcNAc mimetic.216, 217 
                                                                                                                                                                                                                          
                                                                26 
The (S)-cyclohexyl lactic acid (41) was thereby found as the most potent replacement, optimally 
positioning the carboxylate in the bioactive conformation (figure 17). (S)-phenyl lactic acid (42) 
and the recently investigated (S)-adamantyl lactic acid (43) were found to be less potent.267 The 
corresponding (R)-alkyl or aryl lactic acid derivatives were all inactive due to pre-organization of 
the carboxylate in the wrong conformation. In a combinatorial approach starting from (S)-isoserin 
the binding site was further explored (e.g. 44-48), however without finding any more potent 
mimetics than cyclohexyl lactic acid, which was about 10-12 times more active than sLex.268 
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Figure 17: Ligands with lactic acid derivatives in combination with cyclohexanediol as GlcNAc replacement. 
 
Starting from compound 41 the role of the cyclohexanediol as GlcNAc mimetic was further 
investigated (figure 18). Introducing more flexible linkers like ethanediol (49) or a xylal derivative 
(50) led to less active compounds.269 However, introducing equatorial substituents in 50 at the 
position close to the fucose dramatically increased potency, leading to compounds (51-55) that 
are 25-fold more active than sLex.269, 270 These findings were rationalized by the increased steric 
constrain applied to the fucose moiety, which leads to an improved pre-organization of the 
pharmacophores in the bioactive conformation. Finally, the 2-monobenzoylated antagonists 56-
58, resulting from incomplete deprotection, were up to three times more active than the 
corresponding fully deprotected antagonists.270, 271  
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Figure 18: Ligands with different GlcNAc mimetics in combination with cyclohexyl lactic acid. 
 
Various attempts were undertaken to increase the potency of antagonists either by exploring 
further binding sites or by increasing the ligands pre-organization (figure 19). Bänteli et al. 
reported a library of compounds (e.g. 59-62) with modifications at the 6-position of galactose.202 
However, the modifications were deleterious to the binding affinity and the 6-hydroxyl was 
suggested to be optimally suited for binding to E-selectin. Ernst et al. explored a hypothetical 
second binding site close to GlcNAc by using a D-(-)-quinic acid-derived GlcNAc mimetic, which 
was further acylated with numerous substituents (e.g. 63-65).233, 272 Similar work was performed 
earlier by Hayashi273 and DeFrees274 on sLex derivatives. In order to pre-organize the 
pharmacophores of the fucose, Kolb synthesized a macrocyclic sLex mimic, linking the fucose 
and the galactose directly.275 However, the macrocyclic antagonist 66 turned out to be three 
times less active than sLex. A possible reason may be that the macrocycle locks a conformation 
slightly different from the bioactive one. 
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Figure 19: Ligands addressing second binding sites or with pre-organized core-structures. 
 
1.4.3.  Antagonists with one sugar moiety 
The L-fucose moiety contains two out of five pharmacophores binding to E-selectin and is 
probably the hardest residue to substitute with a non-carbohydrate moiety. Therefore, most of 
the monosaccharide antagonists were conserving the binding to the Ca2+ either by fucose or a 
monosaccharide with the same spatial orientation of the pharmacophores, such as galactose or 
mannose. The monosaccharide moiety was linked either to established mimetics, polyaryls, 
peptides or other suitable groups for mimicking the remaining pharmacophores (figure 20). 
 
The group of Ernst et al. tried to further simplify their mimics 41 and 42 by replacing the 
galactose by aromatic spacers, whereas Neu5Ac and GlcNAc were substituted by the already 
well established lactic acid derivatives and cyclohexanediol.276 The compounds 67-72 were all 
inactive, probably due to the increased flexibility of the ether-linkage or wrong spatial orientation 
of the pharmacophores. A very similar approach was performed by Liu et al. for the compounds 
73-76.277 Interestingly, the benzyl protected compounds were found to be active, rather than the 
one with a free phenolic group. Toepfer et al. reported mimics containing piperidine carboxylic 
acid (77-80) and malonic acid derivatives (81-92).278, 279 However, none of these compounds 
was more active than sLex. Other unsuccessful approaches (93-96) were reported by other 
groups.253, 263 
 
Kogan et al. designed a library of sLex mimetics by replacing L-fucose with D-mannose.280-282 The 
carboxylic acid function, which replaces Neu5Ac was linked with the D-mannose by a biphenyl 
spacer, mimicking the Gal-(1-4)-GlcNAc disaccharide. Although these compounds lack the 
important pharmacophores of the galactose, they turned out to be slightly more potent than sLex 
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(97). The activity could further be improved by optimizing the biphenyl linker between the 
pharmacophores, leading to the compounds 98 and 99. A breakthrough was achieved with the 
dimer of 97, which was inspired by previous reports on the improved E-selectin binding of 
extended dimeric sialyl Lewisx derivatives.62, 283 
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Figure 20: Antagonists with one sugar moiety. 
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Figure 21: Biphenyl-based antagonists by Kogan et al.  
 
Wong et al. created a large library of fucose-, mannose-, or galactose-based glycopeptides.194, 
266, 284-291 Two variable design elements (figure 22) were used for replacing GlcNAc and Gal, 
whereas the Neu5Ac was commonly replaced by glutaric or a related acid. In this series some of 
the most potent compounds against E- and P-selectin were found as displayed in figure 23 (101-
108). However, the gain in affinity is commonly much more pronounced for P-selectin and 
rationalization of the source of the compounds’ activity is difficult. In addition, Wong et al. took 
advantage of the increased metabolic stability of C-glycosides compared to O-glycosides. 
Recently, the macrocyclic glycopeptide 108 was found to be approximately 1000-fold more 
active than sLex against P-selectin.291 
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Figure 22: Design elements for replacing galactose and GlcNAc.  
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Figure 23: Glycopeptide-based antagonists by Wong et al.  
 
1.4.5  Non-carbohydrate based mimetics 
Due to the unfavorable pharmacokinetic properties of carbohydrates numerous de-novo design 
approaches were undertaken, based on different means such as pharmacophore models and 
high throughput screening. Some of the discovered compounds are displayed in figure 24 and 
should illustrate the recent efforts made in order to find a small molecular weight selectin 
antagonists by de-novo design. 
Kondo et al. has used a 3D pharmacophore model to screen a commercially available database 
for lead compounds. A preliminary lead optimization resulted in compound 109 with a micro-
molar IC50 for E-selectin.248  
With a similar pharmacophore model and by structure-based design the group of Ulbrich et al. 
found the micromolar lead compound 110. The lead was evaluated in a flow-chamber assay, 
where it inhibited the rolling and adherence of cells. Its efficacy was further proofed in a in vivo 
peritonitis model of acute inflammation in mice.292 
In a ligand-based approach starting from the earlier reported biphenyl-based antagonists 97-
100,280-282 new non-glycosidic antagonists were discovered (111, 112). The novel small 
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molecules were bearing a trihydroxybenzene motif, which probably replaces the 
pharmacophores of the former fucose. The compounds showed micro- to nanomolar in vitro 
activity against E-selectin in a static assay as well as significant inhibition under dynamic 
conditions.293  
High-throughput-screening of the Wyeth chemical library led to the discovery of quinoline 
salicylic acids as lead structure for P-selectin antagonists. Iterative medicinal chemistry resulted 
in more potent compounds like e.g. 113, which was efficacious in the rat AIA model of 
rheumatoid arthritis. However, no data about E-selectin inhibition of these compounds have 
been published up to now.294 
Recently, two research groups independently reported quinic acid derivatives (114-116) as 
selectin antagonists.295, 296 In soaking experiments, the quinic acid was surprisingly found to bind 
the Ca2+ with its two equatorial 4- and 5-hydroxyls, which is in contrast to the binding of the 
fucose to the Ca2+. In addition, quinic acid was found to bind with its ring parallel to the protein’s 
surface, which leads to a significant change in the directional vectors of substituents attached to 
the 1-position of quinic acid.296  
A further group of E-selectin antagonists is formed by peptidic antagonists. However, this class 
of antagonists will not be discussed in this thesis.211 
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Figure 24: Non-carbohydrate based mimetics.  
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1.5.  Polyhydroxylated carbocycles and carbasugars as carbohydrate mimetics 
in drug discovery – Some modern synthetic approaches to carbocycles   
Carbohydrates play an important role in numerous biologically and clinically relevant events like 
intercellular adhesion, signal transduction, malignant transformation and viral and bacterial cell-
surface recognition.297-302 As more and more carbohydrate-related drug-discovery targets get 
discovered and validated, carbohydrates are emerging as potential therapeutic agents and are 
just at the very beginning of their exploitation by the pharmaceutical industry. However, the use 
of carbohydrates in drug discovery is hampered by their poor pharmacokinetic and 
pharmacodynamic properties, such as dense content of polar groups, low membrane 
permeability, low binding affinities and fast acidic and metabolic degradation after oral 
application. Numerous strategies were pursued to circumvent these carbohydrate-specific 
problems for drug discovery. One of the strategies is the replacement of the tetrahydropyran ring 
by functionalized carbocycles or carbasugars, while retaining essential pharmacophores for the 
binding. Beside the increased metabolic and chemical stability of these carbasugars, higher 
affinities can often be expected due to additional hydrophobic interactions by deletion of 
unnecessary polar groups. The loss of the anomeric center in carbasugars however, may have a 
dramatic effect on the conformational stability of the ring, and as a consequence thereof, on the 
entropic costs upon binding, and requires careful consideration in the design of antagonists. The 
following section highlights just a few of the numerous modern synthetic strategies for creating 
densely functionalized carbocycles. 
 
1.5.1. Conversion of carbohydrates into carbocycles by the use of olefin metathesis 
Carbohydrates are not obvious substrates for olefin metathesis. However, introducing two 
terminal olefins in a carbohydrate allows ring closing metathesis which results in an unsaturated 
polyhydroxylated carbocycle. The installation of the terminal olefins is usually done in two 
separate steps. The first one is the zinc-mediated fragmentation of primary iodo-glycosides, 
originally developed by Bernet and Vasella.303 The installation of the second olefin is then 
usually performed by Wittig methylenation or organometallic reactions. A major breakthrough in 
this field was achieved by Hyldtoft and Madson who described the zinc-mediated domino 
elimination-alkylation reaction, where both steps are performed at the same time.304-306 In a 
typical reaction of this type, the zinc mediates both, the fragmentation of the iodoglycoside and 
the subsequent Barbier-type alkylation of the intermediate aldehyde. The most promising 
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applications of this domino reaction have come from the use of allyl bromide or even 
functionalized allyl bromides like ethyl 4-bromocrotonate or 3-benzoyloxyallyl bromide. The 
stereochemical outcome of the reaction is determined by the proper choice of the iodoglycoside, 
except for the newly formed stereocenter, which is strongly influenced by the choice of the 
metal, e.g. indium versus zinc, and by the protecting groups.304 The ring-closing metathesis 
(RCM) easily proceeds in good yields in dichloromethane with commercial catalysts. Sometimes, 
however, protection of the hydroxyl or amine at the newly formed stereocenter is necessary prior 
to the metathesis reaction. The unsaturated bond allows further modifications like 
hydrogenation, dihydroxylation and epoxidation, enabling the synthesis of a large variety of 
functionalized carbocycles with a minimum of chemical steps. The high diversity of this synthetic 
approach for carbocycles is exemplified in scheme 1.306 
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Scheme 1: Carbohydrate carbocyclization by zinc-mediated domino reaction and ring-closing metathesis (RCM).  
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1.5.2.  3-Cyclohexene-1-carboxylic acid based approaches  
3-Cyclohexene-1-carboxylic acid (128) is a versatile starting material for the synthesis of a 
variety of carbasugars and functionalized carbocycles. Its importance for synthetic chemistry is 
reflected by the numerous publications dealing with its stereoselective synthesis or 
deracemization.307-316 Typically, the synthesis starts with iodolactonization and dehydroiodination 
affording the lactone 129, followed by reduction of the lactone. From the diol 130 further 
functional groups may be inserted via dihydroxylation, epoxidation or elimination of transient 
bromohydrins. An intelligent choice of protecting groups and reaction conditions allows to steer 
the syn-/anti-selectivities of the above mentioned reactions. Inversion of stereocenters under 
Mitsunobu conditions or by oxidation and subsequent reduction even broadens the range of 
synthetically possible carbocycles. The versatility of this approach was recently demonstrated by 
a practical synthesis of sixteen enantiopure carbasugars by Chung et al.317, 318 
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Scheme 2: General synthesis of carbasugars from 3-cyclohexene-1-carboxylic acid.  
 
1.5.3. Norbornyl based synthetic approaches 
A simple synthetic pathway to carbasugars and so-called “confused” carbasugars starts from 7-
norbornenone derivatives. The term “confused” carbasugar refers to functionalized carbocycles, 
where the hydroxymethyl and the “para”-hydroxyl of the corresponding carbasugar are 
interchanged. The 7-norbornenone derivatives and their precursor ketals are readily available 
through Diels-Alder reaction between 5,5-dimethoxy-1,2,3,4-tetrachlorocyclopentadiene and 
various vinyl alcohols, followed by reductive dehalogenation. 
Basically, 7-norbonenone derivatives like 135 and 140 are locked carbasugars, from which the 
six-membered carbasugar skeleton can be easily retrieved through m-CPBA mediated C1-C7 or 
C4-C7 bond scission. The C1-C7 bond scission leads to carbasugars, whereas the C4-C7 bond 
scission leads to the corresponding “confused” carbasugars. Further refinement by 
dihydroxylation, epoxidation or hydrogenation gives access to a variety of interesting 
carbocycles, as depicted in scheme 3. A slightly altered fragmentation process can be achieved 
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by converting the 2-hydroxyl into a leaving group, which results in functionalized 3-cyclohexene-
1-carboxylates.319-321  
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Scheme 3: Norbornyl-based approach to functionalized carbocycles.  
 
1.5.4. Approaches from substituted cyclohexadienediols 
The toluene dioxygenase of the constitutive mutant strain Pseudomonas putida UV catalyzes 
the asymmetric dihydroxylation of a wide range of monocyclic arenes. Up to date more than 50 
enantiopure cis-dihydrodiol metabolites of mono-substituted benzene substrates have been 
reported, with fluorobenzene as the only member with exceptionally low enantiomeric excess.322-
325 Despite the broad substrate tolerance, the majority of the reports are focused on metabolites 
of toluene, chloro-, bromo- and iodobenzene. Especially, the metabolite of iodobenzene found 
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particular interest due to the facile substitution of the iodine atom either by reductive 
dehalogenation or Stille coupling and due to the directing effect of the bulky iodine atom on other 
reactions.324-326 These cis-dihydrodiol metabolites found widespread application in the 
stereoselectiv synthesis of carbasugars326 (scheme 4) as well as natural products like conduritol 
C,327, 328 shikimic acid329 and many others.330, 331    
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Scheme 4: Toluene dioxygenase catalyzed reaction of substituted arenes and chemoenzymatic synthesis of 
carbasugars from iodobenzene.  
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2.  Aim of the Thesis 
The compound CGP69669 (41) was early recognized as lead for inhibiting E-selectin. However, 
this lead shows insufficient binding affinity, high synthetic complexity and is supposed to have a 
poor pharmacokinetic profile due to its susceptible O-glycosidic bonds and the high density of 
polar groups. In order to reach the profile of a development candidate, the optimization of the 
lead’s pharmacodynamic and pharmacokinetic properties is inevitable. The compound’s potency 
can be increased by different means such as installing additional interactions with the protein or 
reducing the ligands flexibility and thereby reducing the entropic costs upon binding. 
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Figure 25: Lead compound CGP69669 (41) and general target structures of the two projects.  
 
In the first part of this thesis, it was planned to occupy a hydrophobic pocket close to the 6-
position of the galactose moiety, which was identified in the recently published crystal structure 
optimization 
of enthalpy  
optimization 
of entropy  
simplification 
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of E-selectin. Since the 6-hydroxyl is crucial for binding to E-selectin, it will remain untouched, 
and the hypothetical fragments for binding to the hydrophobic pocket will alternatively be 
attached to the C-6 of the galactose. The de-novo design of the hydrophobic fragment, as well 
as its linker, will be assisted by molecular modeling tools, enabling a fragment-based design of 
novel ligands with their subsequent iterative scoring and optimization. The increase of potency, 
gained by an optimal occupation of the hydrophobic pocket, may allow drastically simplifying or 
even omitting original pharmacophores (e.g. fucose) of the ligand. This strategy would finally 
result in more drug-like E-selectin antagonists with only minor carbohydrate character.  
 
The second part of this thesis is dedicated to the optimization of the pre-organization of the 
antagonist in its bioactive conformation. Although the GlcNAc moiety of sLex displays no 
pharmacophores and mainly serves as a spacer between the fucose and the galactose, it makes 
an important contribution to the spatial pre-organization of the pharmacophores in the binding 
conformation. Replacing GlcNAc by suitable mimetics not only increases the drug-likeness of 
antagonists, but additionally helps to increase the extent of pre-organization. The aim of the 
current work is to develop novel potent antagonists by reducing the ligand’s entropic costs upon 
binding through GlcNAc mimetics that allow an optimized pre-organization. This is planned to be 
realized by different means like steric compression or conformational stabilization, while 
preserving the ligand’s drug-likeness and synthetic accessibility. The degree of pre-organization 
may be further evaluated by NMR-investigations.  
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3.  Results and Discussion 
3.1.  E-selectin antagonists containing substituted L-glycero-β-D-galacto-hepto-
pyranoses as replacement for galactose (optimization of enthalpy) 
3.1.1.  De-novo design of E-selectin antagonists 
The goal of the de-novo design of E-selectin antagonists was to identify hydrophobic pockets on 
the surface of E-selectin and target them with appropriately modified ligands. This should lead to 
antagonists with improved affinity. 
The crystal structure of E-selectin reveals several hydrophobic patches close to the galactose 
moiety.46 The first hydrophobic patch is found close to the Neu5Ac binding site (sidechains of 
Asp98 and Lys99), the second one close to the 2-hydroxyl of galactose (Pro78) and the last one 
close to the 6-hydroxyl of galactose. The accumulation of hydrophobic patches around the 
galactose moiety suggests the role of galactose to act as the scaffold to position novel 
hydrophobic substituents into these areas. Another point which argues for galactose as central 
scaffold is that the Neu5Ac and the galactose moieties make a great contribution to the binding 
affinity, whereas the fucose contributes only with the 3- and 4-hydroxyl directly to the binding, 
and the GlcNAc moiety serves mainly as spacer to optimally position the fucose. The so 
potentially gained increase in binding affinity may allow to omit the fucose and the GlcNAc 
moieties completely or to replace them by more simple Ca2+-binding fragments. This strategy 
would finally result in more drug-like E-selectin antagonists with only minor carbohydrate 
character.  
For the de-novo design of novel E-selectin antagonists we focused on a shallow hydrophobic 
pocket close to the 6-hydroxyl of the galactose moiety of sLex (figure 26). The pocket is formed 
by the residues Lys111, Lys112, Lys113, Pro46, Tyr48 and Ser47. It was previously shown by 
Bänteli and Ernst that straight derivatization of the 6-hydroxyl of the lead compound CGP69669 
(41) leads to inactive compounds, probably due to the loss of the hydrogen bond between 6-OH 
and Glu92 (figure 11).202 In addition, the region close to the 6-hydroxyl shows steric restriction 
caused by the residues Lys 111 and Tyr48 which could lead to steric clashes for hydrophobic 
extensions of the hydroxyl group in the 6-position. For our approach, we therefore decided to 
introduce substituents at the position of one of the hydrogens at C-6 of galactose in CGP69669 
(41), conserving the 6-hydroxyl for hydrogen bonding and avoiding the steric problem. 
Replacement of the hydrogen should be realized with a short linker, which passes the 
constriction and enters into the spacious binding pocket (figure 26).  
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Figure 26: sLex docked onto E-selectin. The hydrophobic pocked is highlighted. 
 
Suitable replacements for the hydrogen were investigated by using Allegrow.332, 333 CGP69669 
(41), docked on the surface of E-selectin was taken as lead. The lead and the protein were 
prepared as discussed in the thesis of Michele Porro.334 One of the hydrogens at a time was 
marked with X, indicating where the fragment-based grow-routine should start. Several 
thousands newly generated hypothetical ligands were minimized with the QXP force field and 
evaluated by a post-grow scoring function. The most potent ligands were then visually analyzed 
for hydrogen-bonding patterns and hydrophobic interactions.332, 333 Recurrent motifs were used 
for a second grow-routine and the resulting data analyzed as before. The new ligands were 
optimized by combining recurrent motifs and taking drug-likeness and feasibility of the chemical 
synthesis into consideration. As recurrent functional groups, two carbonyls were found, one 
hydrogen-bonding to Lys111 and Lys113 and the second one as H-bond acceptor of the 
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backbone NH of Lys112. The second carbonyl could also be replaced by an optimally oriented 
N-heterocycle or an ether moiety like morpholine (for examples see figure 27).  
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Figure 27: Promising fragments with optimized orientation of H-bond acceptors and hydrophobic regions. The H-
bond acceptors are highlighted in red. 
 
A 5-membered heterocyclic ring annealed to a six membered ring was found as optimal spacer 
in terms of distance and “exiting vector” for the two carbonyls. Hydrophobic interactions were 
supposed to be formed with the following residues: Pro46, Lys111, Lys112, Lys113 and Tyr48. 
As linker between the C-6 of the galactose moiety and the new carbonyl a CH2NH unit was 
found to be optimal, so that the carbonyl is part of an amide bond. The amide bond implies 
chemical and biological stability and simplifies the chemical diversification. The stereochemistry 
at the newly formed stereocenter (C-6) seems to play only a minor role as both epimers showed 
similar results in the in-silico affinity prediction. Due to easier synthetic accessibility the (6S)-
epimer was chosen as the starting point. For preliminary probing of the hydrophobic pocket a 
small library of N-acylating agents was selected (table 4). The preference was set according to 
calculated dissociation constants, drug-likeness, water solubility (piperazin-, indole moiety) and 
commercial availability or ease of synthetic access. 
 
Table 4: Calculated pKD of antagonists with different substituents 
 
compound: 195 193 197 194 
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calc. pKD: 5.7 6.0 - 7.3 8.0 - 9.0 7.6 - 8.7 
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The optimal fit of the substituents onto the hydrophobic patch and the hydrogen-bonding pattern 
is exemplified in figure 28 for compound 197, which was docked onto the surface of E-selectin 
by using the QXP force field. 
 
 
 
 
Figure 28:  Antagonist 197 docked onto the surface of E-selectin (left side) and H-bond pattern of 197 (right side). 
 
3.1.2.  Retro-synthetic considerations 
For the synthetic approach to this new class of E-selectin antagonists, a 7-amino-7-deoxy-
tetrasaccharide mimetic was chosen as scaffold allowing the subsequent derivatization and 
diversification by acylation of the primary amine. This tetrasaccharide mimic (i) was first 
dissected into a cyclohexyllactic acid electrophile (ii) and a trisaccharide mimic (iii). The 
trisaccharide mimic (iii) was further dissected into the known building block (v) and the L-
glycero-β-D-galacto-heptopyranoside (iv).335 The former is readily available by -selective 
glycosylation from a suitable fucosyl donor (166) with non-participating benzyl groups and 
cyclohexanediol (167).255 For the selective deprotection of the heptopyranoside moiety (156) and 
for the -selective glycosylation, benzoyl groups were chosen.  
From a retro-synthetic point of view, the target molecule can be synthesized from the three 
partially protected building blocks 156, 166, 171 and commercial (1R,2R)-trans-1,2-
cyclohexanediol (167), as depicted in scheme 5.  
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Scheme 5:  Retro-synthesis for E-selectin antagonist which contains L-glycero-β-D-galacto-heptopyranose as 
galactose replacement. 
 
                                                                                                                                                                                                                          
                                                                45 
3.1.3.  Synthesis of the scaffold 
3.1.3.1.  Synthesis of ethyl 7-azido-2,3,4,6-tetra-O-benzoyl-7-deoxy-1-thio-L-glycero--D-
galacto-heptopyranoside (163) 
The ethyl thioglycoside 163 was chosen as suitable glycosyl donor for the synthesis of the 
trisaccharide mimic and was easily prepared from commercial methyl galactopyranoside in 14 
steps as depicted in scheme 6.   
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Scheme 6: a) Ph3CCl, cat. DMAP, pyr, r.t., 50 h (85%); b) NaH, BnBr, DMF, 30°C, 19 h (91%); c) i. TES, cat. 
TMSOTf, CH2Cl2, r.t., 4.5 h, ii. 80% aq. AcOH, THF, r.t., 1 h (89%); d) (COCl)2, DMSO, CH2Cl2, Et3N, -78°C, 2 h 
(92%); e) Mg, (CH3)2Si(Ph)CH2Cl, THF, -78°C-r.t., 17 h (75%); f) AcOH, AcO 2H, KBr, AcONa, 0°C, 2.5 h (76%); g) 
Pd/C, 4 bar H2, EtOH, cat. AcOH, r.t., 19 h (98%); h) Ph3CCl, cat. DMAP, pyr, r.t., 36 h (79%); i) BzCl, cat. DMAP, pyr, 
r.t., 22 h (93%); j) i. TES, TMSOTf, CH2Cl2, r.t., 1 h, ii. 80% aq. AcOH, THF, r.t., 1 h (94%); k) MsCl, cat. DMAP, Et3N, 
CH2Cl2, r.t., 26 h (97%); l) NaN3, DMF, 100°C, 48 h (88%); m) AcOH, Ac 2O, H2SO4, r.t., 24 h (92%); n) ZnI2, TMSSEt, 
CH2Cl2, MS 4Å, W 50°C, 1.5 h (82%).  
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For selective protection at the 6-OH, triphenylmethyl was found to be superior to TBDPS, due to 
its increased selectivity for the 6-OH and its increased stability under the basic conditions of the 
subsequent benzylation. In case the benzylation was performed with the 6-O-TBDPS 
galactopyranoside, up to 25% of the undesired tetrabenzylated galactopyranoside were formed, 
whereas benzylation of the 6-O-triphenylmethyl galactopyranoside (150) gave 151 with a yield 
up to 91%. Detritylation of 151 was performed with cat. amounts of TMSOTf and in the presence 
of triethylsilane for quenching the trityl cation. The resulting triethylsilyl derivative of the product 
was then treated with aqueous acetic acid in THF.336 Oxidation of the primary alcohol was 
performed under Swern conditions to yield aldehyde 153 in 92% yield.337, 338 For the elongation 
of the hexose, the Grignard reagent of (phenyldimethylsilyl)methyl chloride was used, due to its 
strong preference for the L-configuration at C-6. It is assumed that for silyl Grignard reagents -
chelation (scheme 7) plays the decisive role in the stereoselective attack of the nucleophile. 
However, the outcome of the reaction also strongly depends on the protecting groups present. 
For the corresponding aldehyde protected as acetonide, the formation of a mixture of 
stereoisomers is reported. The reason is a competition of the Felkin-Anh pathway with -
chelation. The benzyl protected aldehyde 153 was in analogy to literature procedures 
stereoselectively transformed into the (R)-isomer of 154 in 75% yield. Initial starting problems of 
the reaction were easily overcome by using fresh magnesia turnings, fresh magnesia powder or 
a mixture thereof.339-341 
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Scheme 7: Effects influencing the stereoselective outcome of carbonyl reactions. 
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In the following step, the phenyldimethyl silyl group was oxidatively removed in a one-pot 
procedure by Fleming-Tamao-Oxidation yielding 155.342 Since the later -selective glycosylation 
requires participating protecting groups, the benzyl groups were removed by hydrogenation to 
yield methyl L-glycero--D-galacto-heptopyranoside 156. For the selective activation of the 
primary alcohol, various literature procedures were investigated using methyl -D-
galactopyranoside as model compound.343-345 None of the tested conditions showed sufficient 
selectivity for the primary alcohol. Therefore, the problem of regioselective activation of the 7-
position was circumvented by tritylation of the primary alcohol, benzoylation and subsequent 
detritylation of the heptopyranose (159). The primary alcohol could then easily be activated 
with mesyl chloride, Et3N and cat. DMAP. The azide functionality was introduced with sodium 
azide in DMF, followed by acetolysis to yield 162.346 The ethyl thioglycoside 163 was prepared 
according to a modified procedure of Hanessian et al. to give predominantly the -anomer as 
indicated by NMR (J1,2 = 10.0 Hz).347, 348 
 
3.1.3.2. Synthesis of the (1R,2R)-trans-1,2-cyclohexanediol derivative 168 
Synthesis of the ethyl thiofucoside 166 was done by a co-worker according to procedures 
reported in literature (scheme 8).349 The ethyl thiofucoside was transformed into the -fucosyl 
bromide by treatment with bromine in CH2Cl2 at 0°C. In situ anomerization with TEAB creates 
the more reactive -fucosyl bromide which reacts smoothly with (1R,2R)-trans-1,2-
cyclohexanediol (167) to yield the -anomer of 168 in 42% yield as observed by NMR (J1,2 = 3.6 
Hz).350, 351 
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Scheme 8: a) Ac2O, pyr, 0°C-r.t., 17 h (100%); b) EtSH, SnCl 4, DCE, 0°C, 4 h (78%); c) K 2CO3, aq. MeOH, r.t., 19 h 
(86%); d) BnBr, NaH, DMF, 0°C-r.t., 16 h (80%); e) i. Br2, CH2Cl2, 0°C, 1 h, ii. TEAB, MS 4Å, DMF, CH 2Cl2, r.t., 3 h 
(42%). 
 
3.1.3.3.  Synthesis of benzyl (R)-3-cyclohexyl-2-trifluoromethanesulfonyloxypropionate 
(171) 
The alkylating agent benzyl (R)-3-cyclohexyl-2-(trifluoromethanesulfonyloxy)propionate (171) 
was prepared from commercial (R)-phenyllactic acid.352, 353 Reduction of (R)-phenyllactic acid in 
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presence of 4 bar of H2 and rhodium on activated alumina yielded the corresponding (R)-
cyclohexyllactic acid, which was used for esterification with benzyl bromide without further 
purification. The leaving group for the later nucleophilic attack was introduced by treating the 
secondary alcohol in 170 with Tf2O in presence of a sterically hindered base (scheme 9). 
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Scheme 9: a) i. Rh/Al2O3, 4 bar H2, THF, H2O, r.t., 4 d ii. aq. Cs2CO3, MeOH, H2O, iii. BnBr, DMF, r.t., 24 h (80%); b) 
Tf2O, 2,6-DTBP, CH2Cl2, -20°C, 3 h (95%).  
 
3.1.3.4. Completion of the scaffold 175 
Thioglycosides show a wide variability in their application, can be used under mild reaction 
conditions and show improved stability compared to glycosyl halides and 
trichloroacetimidates.354-356 Their activation by DMTST is initiated by the attachement of the soft 
electrophile MeS+ to the sulfur of the donor (i) (scheme 10).357, 358 By breaking the anomeric 
carbon-sulfur bond the oxycarbenium ion (iii) is formed, which is then attacked by the acceptor 
nucleophile to form the O-glycoside. One of the most reliable ways to control stereoselectivity in 
glycosylations is achieved by neighboring group participation. Participating protecting groups like 
acetates and benzoate stabilize the oxycarbenium ion by forming the cyclic dioxolenium cation 
(iv), which is opened by nucleophilic SN2 attack. This finally leads to the 1,2-trans glycoside (v).  
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Scheme 10: DMTST-promoted -selective glycosylation with neighboring group participation. 
 
Starting from thioglycoside 163, the trisaccharide mimetic 172 was obtained by DMTST-
promoted glycosylation in 89% yield and high β-selectivity due to the participating benzoate 
(scheme 11). 
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Deprotection of the trisaccharide 172 was performed under standard Zemplén conditions to 
afford 173 in 98% yield.359 In the next step, the 3-position was regioselectively alkylated. 
Regioselectivity was achieved by forming an O-stannylene acetal with dibutyltin oxide in 
refluxing methanol. In presence of the triflate 171 and CsF as nucleophile to accelerate the 
reaction, 173 was regioselectively aklylated in 54% yield.360, 361 Although TLC control indicated 
that triflate 171 was still present, the alkylation did not go to completion and 29% starting 
material could be recovered.  
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Scheme 11: a) DMTST, MS 4Å, CH2Cl2, r.t., 67 h (89%); b) NaOMe, MeOH, r.t., 23 h (97%); c) i. Bu2SnO, MeOH, 
reflux, 3 h, ii. CsF, DME, r.t., 24 h (54%); d) i. PPh3, THF, r.t., 24 h, ii. H2O, r.t., 4h (98%). 
 
Finally, the azide was reduced to the corresponding amine under Staudinger conditions.362, 363 It 
should be noted that longer reaction times led to formation of a lactone between the acid moiety 
and the 2-position of the heptopyranoside. Prolonged storage in CDCl3 even led to full 
conversion to the lactone.  
 
3.1.4. Synthesis of indole substituents 
3.1.4.1. Synthesis of sodium 2-[(4-methyl-1-piperazinyl)carbonyl]-7-phenyl-indole-4-
carboxylate (185) 
Among the vast possibilities of building the desired indole scaffold, the Fischer indole synthesis 
promised the shortest synthetic approach and had the advantage that all starting materials were 
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commercially available.364, 365 However, n-butyl pyruvate was preferred to the commercial methyl 
or ethyl pyruvate esters due to the higher lipophilicity of the resulting hydrazone, which facilitates 
work-up and purification. Esterification of pyruvic acid with n-butanol proceeded smoothly 
without addition of any catalyst by azeotropic removal of water in refluxing benzene.366 The 
ketoester 177 was condensed with hydrazine 179, which is in situ generated from 3-amino-4-
chlorobenzoic acid, to yield the hydrazone 180 in 86% (scheme 12).  
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Scheme 12: a) nBuOH, benzene, reflux, 18 h (79%); b) i. NaNO2, conc. HCl, H2O, -10°C, 10 min, ii. SnCl 2, conc. HCl, 
-10°C, 30 min; c) n-butyl pyruvate, 90°C, 2.5 h (86% over two steps); d ) AcOH, BF3Et2O, W 90°C, 5 h (16%); e) 
CDI, THF, tBuOH, DBU, reflux, 76 h (54%); f) i. aq. NaOH, acetone, r.t., 69 h, ii. imidazole, (COCl)2, MeCN, 45°C, 1 h, 
iii. N-methylpiperazine, 55°C, 3 h (89%); g) PhB(OH) 2, Pd2(dba)3, S-Phos, Cs2CO3, toluene, W 90°C, 3 h (100%); h) 
i. TFA, TIS, CH2Cl2, H2O, r.t., 70 min, ii. Na2CO3, CH2Cl2, MeOH, H2O, r.t., 15 min (73%). 
 
The first attempts of the Fischer cyclization of 180 were performed with polyphosphoric acid in 
acetic acid, as described in the literature for similarly substituted hydrazones.367 However, under 
these conditions no product could be isolated. Therefore, the cyclization was closer investigated 
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by testing numerous Lewis or Brønsted acids and solvent systems in small scale reactions, 
which were analyzed only by TLC. However, under all tested conditions, the cyclization was 
accompanied by the fast formation of various side products. BF3Et2O in AcOH under mild 
microwave irradiation was the final choice not only due to the favorable product/side-product 
ratio, but also due to the ease of work-up and purification.365 The low yield of the cyclization 
(16%) can be explained by the unsubstituted, nucleophilic 3-position of the indole. Under the 
strongly acidic conditions, the carboxylic acid forms an activated carbocation which is attacked 
by the nucleophilic 3-position of the indole. This could be the reason for the oligo- and 
polymerization instead of the formation of the desired product.  
For the orthogonal protection of the second carboxylic acid, the t-butyl ester was formed by 
activating the acid with carbonyl diimidazole in presence of t-butanol and DBU. Despite the mild 
conditions, polymerization was observed due to the reasons mentioned above. The t-butyl ester 
was therefore obtained only in low 54% yield. In the next step, the N-methylpiperazine moiety 
was introduced by basic hydrolysis of the n-butyl ester and activation with oxalyl diimidazole.368  
The new C-C bond at the 7 position of the indole 183 was formed by Suzuki-Miyaura coupling. 
The optimization of the reaction conditions is summarized in table 5. The coupling reaction with 
S-Phos as Pd-ligand succeeded quantitatively manner using Cs2CO3 as base and toluene as 
solvent (entry 5). Reducing the reaction temperature to 90°C turned out to be crucial for the 
stability of the catalyst.369-372 Final deprotection of the carboxylic acid was performed according 
to standard procedures to yield the sodium salt 185 in 73%. 
 
Table 5: Studies on Suzuki-coupling of arylchloride 183 with Pd2(dba)3 as pre-catalyst and S-Phos as ligand 
 
Entry PhB(OH)2a) Solvent Baseb) Temp Time Yieldc) 
1 1.2 eq. THF K3PO4 W, 100°C 20 h  12.5% (66%)d) 
2 1.2 eq. THF Cs2CO3 W, 120°C 3 h  0% (96%)d), e) 
3 1.5 eq. THF/H2O K3PO4 80°C 3 h  f), g) 
4 1.5 eq. Toluene Ag2CO3 W, 90°C 6 h  h), i) 
5 1.5 eq. Toluene Cs2CO3 W, 90°C 3 h  100%h) 
 
a) equivalent to aryl chloride; b) 3 equivalents were used; c) isolated yield, number in brackets represents recovered 
starting material; d) 1 mol% Pd2(dba)3 and 3 mol% S-Phos were used; e) Pd-black formation observed; f) 3 mol% 
Pd2(dba)3 and 3 mol% S-Phos were used; g) no isolated yield, TLC-monitoring showed deactivation of catalyst before 
full conversion; h) 1 mol% Pd2(dba)3 and 5 mol% S-Phos were used; i) no isolated yield, decomposition of Ag2CO3 
before full conversion.  
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3.1.4.2.  Synthesis of 5-benzoyl-indole-3-carboxylic acid (189) 
Friedel-Crafts acylation of indole-3-carboxylic acid was achieved in presence of benzoyl chloride 
and AlCl3 as catalyst. As expected from the electron distribution in the indole ring-system, 
acylation occurred predominantly at C-5 (71%). The C-6 acylation product was only formed in 
minor amounts (27%) and from the acylation product at C-7, only traces were detectable.373, 374 
Saponification of 187, followed by acidification yielded the 5-benzoyl-indole-3-carboxylic acid 
(189) in quantitative yield (scheme 13).  
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Scheme 13: a) BzCl, AlCl3, MeNO2, r.t., 2.5 h (187: 71%, 188: 27%); b) MeCN, aq. NaOH, r.t., 10 days (100%). 
 
3.1.5.  Synthesis of the acyl-antagonists 
3.1.5.1. Synthesis of the 4-phenylbenzoyl antagonist (193) 
Acylation of a primary amino group in presence of secondary alcohols usually proceeds 
selectively due to the stronger N-nucleophilicity. Therefore, the amine 175 was reacted with 
excess of biphenyl-4-carbonyl chloride and triethyl amine as base without prior protection of the 
hydroxyls. TLC showed fast consumption of the starting material and formation of two main 
products. The more lipophilic one was identified as the desired product 190, whereas the second 
product was identified as lactone 191. During work-up, lactone 191 was partly opened by 
methanol leading to an inseperable mixture of lactone 191 and methylester 192. For the 
subsequent deprotection, a mixture of 190, 191 and 192 was subjected to hydrogenation and 
saponification with sodium hydroxide to give the final E-selectin antagonist 193 in 38% yield over 
two steps (scheme 14).  
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Scheme 14: a) biphenyl-4-carbonyl chloride, Et3N, CH2Cl2, MeCN, r.t., 30 min (190: 31%); b) i. Pd/C, H2, dioxane, 
H2O, r.t., 40 h, ii. aq. NaOH, MeOH, r.t., 50 min (38% over two steps). 
 
3.1.5.2. Synthesis of the 5-benzoyl-indole-3-carboxyl antagonist (194) 
For the coupling of non-activated carboxylic acids to the amine 175 various coupling reagents 
were tested in small-scale, starting from indole-3-carboxylic acid and methyl 6-amino-2,3,4-tri-O-
benzoyl-6-deoxy--D-galactopyranoside as a testing model. PyBoP® showed superior results 
compared to other coupling reagents (e.g. EDC, DCC, HBTU) by means of conversion rate, 
side-product formation and ease of purification of the reaction mixture.375 However, applying 
these conditions to amine 175 and indole 189 resulted in incomplete reaction and the product’s 
isolation from the remaining amine and tris-(1-pyrrolidinyl)-phosphine oxide could not be 
achieved. In order to avoid the separation problem, the use of a polymer-bound coupling reagent 
with similar or higher efficiency was considered. The monomeric reagents PyBroP® and PyCloP® 
were reported to be superior reagents to PyBoP® in coupling reaction with sterically hindered 
amino acids.376 However, these reagents are not yet commercially available in a polymer-bound 
form. Hence, a combination of polymer-bound PPh3 and CCl4 was considered to show similar 
efficiency than PyCloP®, but easier separation by simply filtering off the resin.377 Indeed, the use 
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of this system showed clean and full conversion of the amine to a mixture of the corresponding 
derivatized benzylester and 2-O-lactone. After preliminary purification, the mixture was subjected 
to hydrogenation and saponification with sodium hydroxide to give the final E-selectin antagonist 
194 in 27% yield over three steps (scheme 15). 
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Scheme 15: a) i. PPh3-polymer, NMM, CCl4, CH2Cl2, reflux, 5.5 h, ii. Pd/C, H2, dioxane, H2O, r.t., 4 d, iii. aq. NaOH, 
MeOH, r.t., 4 h (27%). 
 
3.1.5.3. Synthesis of the benzoyl antagonist (195) 
Benzoylation of the amine 175 was performed with benzoic acid in presence of PPh3/CCl4 
instead of benzoyl chloride in order to avoid the use of an excess of the acylating agent. 
Hydrogenation of the resulting lactone/benzylester mixture led to partial ring hydrogenation of 
the benzoyl moiety. Saponification yielded a 2:1 mixture (36%) of the benzoylated (195) and 
cyclohexanecarboxylated (196) E-selectine antagonists, which were not separable on LC-MS 
(scheme 16). 
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Scheme 16: a) i. BzOH, PPh3-polymer, NMM, CCl4, CH2Cl2, reflux, 4 h, ii. Pd(OH)2/C, H2, dioxane, H2O, r.t., 6 d, iii. 
aq. NaOH, MeOH, r.t., 3 h (195:196 = 2:1, 36%). 
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3.1.5.4. Synthesis of the 2-[(4-methyl-1-piperazinyl)carbonyl]-7-phenyl-indole-4-carboxyl 
antagonist (197) 
Acylation of 175 with 185 was again carried out in presence of PPh3 and CCl4. Subsequent 
deprotection and saponification resulted in a 7:3 mixture of 197 and 198 (29%) due to partial 
hydrogenation of the biphenyl moiety (scheme 17). For analytical investigations 197 was 
isolated from the mixture by preparative LC-MS. 
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Scheme 17: a) i. 185, PPh3-polymer, NMM, CCl4, CH2Cl2, reflux, 3.25 h, ii. Pd/C, H2, dioxane, H2O, r.t., 9 d, iii. aq. 
NaOH, MeOH, r.t., 6 h (197:198 = 7:3, 29%). 
 
3.1.6.  Biological evaluation of E-selectin antagonists containing substituted L-glycero-
β-D-galacto-hepto-pyranoses as replacement for galactose 
(in collaboration with Dr. John L. Magnani, Glycomimetics Inc., Rockville, USA) 
 
The synthesized antagonists containing the L-glycero-β-D-galacto-hepto-pyranose moiety were 
analyzed in a static cell free ligand binding assay that measures E-selectin inhibition under 
equilibrium conditions.378, 379 All of the synthesized antagonists were found to be inactive (rIC50 > 
10mM). The reason for this is not clear. Most probably the inactivity is caused by either an 
inappropriate linker, insufficient binding of the fragments or interference with the bioactive 
conformation. However, NMR analysis gave no clear evidence about interference with the 
bioactive conformation, which should result in a shift of the relevant protons (figure 29) or 
carbons. The suitability of the linker is more difficult to judge. To address this question, the 
biological equality of the two epimers at the 6-position should be confirmed by also synthesizing 
the (R)-epimer e.g. under Mitsunobu conditions. Besides, the rotatable bonds of the linker 
moiety result in an entropic penalty for the antagonists, which may abolish any enthalpic gain. 
For elucidating the binding properties of the fragments, they could be tested for their 
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independent binding to E-selectin in a second binding site screening with a TEMPO labelled E-
selectin antagonist.380 
 
 
 
 
 
Figure 29: Superposition of 1H-NMRs of CGP69669 (41) and 193. 
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3.2. Design and synthesis of GlcNAc mimetics for E-selectin antagonists 
(optimization of entropy) 
3.2.1.  Optimization of the synthesis of (1R,2R,3S)-3-azidocyclohexane-1,2-diols as 
GlcNAc mimetics 
Several highly active E-selectin antagonists containing (1R,2R,3S)-3-aminocyclohexane-1,2-
diols as replacement for GlcNAc have been synthesized in our group.272 As key precursor in the 
synthesis of these ligands (1R,2R,3S)-3-azido-2-hydroxycyclohexyl benzoate was used, which 
was obtained from the natural product D-(-)-quinic acid (scheme 18). 
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Scheme 18: a) i. p-TsOH, 2,2-dimethoxypropane, acetone, reflux, 5 h, ii. Ac2O, DMAP, pyr, r.t., 20 h (82%); b) LiAlH4, 
Et2O, 0°C-r.t., 24 h (81%); c) phosphate buffer pH 7, NaIO4, 0°C-r.t., 0.5 h (68%); d) BzCl, DMAP, pyr, CH 2Cl2, r.t., 18 
h (93%); e) NaBH4, MeOH, 0°C, 0.5 h (91%); f) 1-chloro- N,N,2-trimethylpropenylamine, CHCl3, reflux, 0.5 h (92%); g) 
Bu3SnH, AIBN, toluene, 90°C, 1.5 h (72%); h) 80% aq. A cOH, 80°C, 0.5 h (80%); i) TsCl, Bu 2SnO, Et3N, CH2Cl2, r.t., 
18 h (68%); j) NaN3, DMF, 80°C, 1 h (81%). 
 
Although the synthesis proceeds smoothly and the desired product is obtained stereoselectively, 
benefiting from preset stereocenters of the natural product, the synthesis was not to our entire 
satisfaction in terms of number of steps and overall yield (11%). Retrosynthetic consideration 
revealed (R)-cyclohex-2-en-1-ol (214) as key intermediate, which would allow the regio- and 
stereoselective introduction of the remaining functionalities.  
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3.2.1.1.  Synthesis of (1R,2R,3S)-3-azido-1-O-triphenylmethyl-cyclohexane-1,2-diol as 
GlcNAc mimetic (218) 
Numerous preparative methods have been reported over the last decades for the synthesis of 
enantiopure (R)-cyclohex-2-en-1-ol.381-386  
In a first approach, a direct enantioselective reduction of cyclohex-2-en-1-on to (R)-cyclohex-2-
en-1-ol (214) with chirally modified LiAlH4 was applied.384 The reducing agent with the 
hypothetical formula LiAlH(NEtPy)2(OCH(Ph)CH(Me)NMe2) was formed by treating LiAlH4 with 
2-(ethylamino)pyridine and (1R,2S)-(-)-N-methylephedrine as carrier of the stereochemical 
information. However, the low chemical and optical yields (55%, 23% ee) obtained by this 
method, made a change of strategy necessary to a less direct approach. 
Introducing a bromide in -position to the ketone as sterically demanding group followed by an 
asymmetric Corey-Bakshi-Shibata (CBS) reduction of the bromoketenone, published first by 
Corey et al.,386 was considered as most promising indirect approach (scheme 19).  
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Scheme 19: a) i. 2-cyclohexenone, Br2, CH2Cl2, 0°C, 2.5 h, ii. Et 3N, CH2Cl2, r.t., 2 h (62%); b) (S)-α,α-
diphenylprolinol, B(OMe)3, BH3N,N-diethylaniline, THF, -10°C-0°C, 3.75 h (93%, 96% e e); c) (1R)-(-)-MTPA-Cl, 
DMAP, pyr, r.t., 60 h (100%); d) i. t-BuLi, Et2O, -78°C to -20°C, 4.75 h, ii. aq. NaHCO 3, -20°C-r.t., 1 h (85%); e) 
Ph3CCl, CH2Cl2, DBU, r.t., 45 h (71%); f) NMO, OsO4, acetone, H2O, r.t., 19 h (87%); g) TsCl, n-Bu2SnO, Et3N, 
CH2Cl2, r.t., 19 h (92%); h) DMF, NaN3, 65°C, 50 h (88%); i) m-CPBA, NaHCO3, CH2Cl2, 0°C-r.t., 5 h (72%); j) CsF, 
NaN3, 15-crown-5, DMF, 65°C, 48 h then 100°C, 43 h (87% ). 
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Bromoketenone 211 was obtained by bromination of commercial cyclohexenone.387 The CBS-
reduction was performed with two different catalytic systems, in order to investigate the enantio-
selectivity of the reaction. The original procedure published by Corey et al.388-390 yielded alcohol 
212 with 89-90% ee, whereas the improved method recently published by Blechert et al.391 gave 
93% of 212 with an enantiomeric excess of 96%. Both enantiomeric excesses were determined 
by optical rotation and by calculations based on the 13C-satellites of the methyl signal of the (S)-
mosher ester 213. After halogen-metal exchange with tert-BuLi and subsequent hydrolysis, the 
secondary alcohol (R)-214 was tritylated to give tritylether 215 in 71% yield. The triphenylmethyl 
group was found to be a suitable protection for various reasons: (i) sterical control of the later 
dihydroxylation, epoxidation or tosylation, (ii) ease of cleavage under almost neutral conditions 
and (iii) increase of boiling point.392, 393  
For the regio- and stereoselective introduction of the hydroxyl-group at C-2 and the azide at C-3 
two synthetic pathways were envisaged. The first pathway leads over dihydroxylation of the 
double bond, regioselective conversion of 3-OH into a leaving group and its substitution with 
azide by a SN2 mechanism. The dihydroxylation was carried out under standard Upjohn 
conditions.394 The diastereomeric outcome was examined by 1H-NMR. The sharp peaks of H-1 
(4.04 ppm) and H-2 (3.49 ppm) and the slightly broader multiplet of H-3 suggest a distorted 4C1 
conformation of anti-216 (figure 30), but the 4C1 conformation of syn-216 could not be clearly 
excluded. However, according to the well studied reaction mechanism, the anti product should 
preferably be formed because of the sterically demanding trityl group.395 The 1C4 conformations 
of syn-216 and anti-216 could be clearly excluded due to the observed coupling constants. 
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Figure 30:  Possible configurations of syn- and anti-216. Relevant protons showing axial-axial coupling are 
highlighted in red. 
 
The cis-diol was selectively monotosylated in presence of dibutyltin oxide to afford 217 in 92% 
yield.345, 396 The downfield shift of the H-1 (4.80 ppm, former H-3) of 217 compared to H-3 (3.58 
ppm) of 216 confirmed the correct regioselectivity. The large coupling constant between H-1 
(former H-3) and H-6ax suggests a 4C1 chair conformation with an axial trityloxy group. 
Nucleophilic displacement of the tosylate with sodium azide gave 218 in 88% yield. The coupling 
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constants observed in the 1H-NMR indicate axial positions for H-1, H-2 and H-3, which confirms 
the expected 1C4 chair conformation for 218. 
In a second approach, 218 was obtained by anti-epoxidation of the cycloalkene, followed by a 
regioselective, nucleophilic attack of an azide ion. Epoxidation with m-CPBA yielded epoxide 
219 in an anti:syn ratio of 76:24 and a yield of 72% for the anti-epoxide. The anti preference is 
the consequence of a directive effect of the sterically demanding triphenylmethyl group, as 
reported earlier for the TBDMS protected cyclohex-2-enol.392, 393 For the opening of epoxide 219 
by an azide ion several conditions were tested (table 6). Although, the successful formation of 
the product could be observed (entries 1 and 3), the tedious separation from the remaining 
starting material made the reaction impracticable. Finally, addition of cesium fluoride and 15-
crown-5 resulted in complete conversion under elevated temperature to afford 218 in 87% 
yield.397, 398 Analytical data confirmed the identical regio- and stereochemical properties 
compared to 218 obtained via dihydroxylation. 
 
Table 6: Studies on the nucleophilic attack on anti-epoxide 219 
 
Entry Solvent Additives Temperature Time Yield a) 
1 MeOH NH4Cl 50°C 32.75 h 43%  b), c) 
2 THF 15-crown-5 60°C 6 ½ d 0%  d) 
3 DMF CsF 65-100°C 11 d  e) 
4 DMF 15-crown-5, CsF 65-100°C 91 h 87%  f) 
 
a) isolated yield; b) in addition 39% of an inseparable epoxide/product mixture (1:2.2) was recovered; c) TLC-
monitoring showed partial detritylation; d) TLC-monitoring showed decomposition; e) no isolated yield, but TLC-
monitoring showed almost full conversion; f) TLC-monitoring showed full conversion. 
 
In conclusion, the desired GlcNAc mimic 218 was regio- and stereoselectively synthesized in 6 
and 7 steps, respectively, with an overall yield of 22-25% from inexpensive cyclohex-2-enon. 
Compared to the original synthesis with 11 synthetic steps and an overall yield of 11%, a clear 
improvement was achieved. In addition, it could be shown that the new synthesis can easily be 
performed on a multigram-scale. 
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3.2.1.2.  Synthesis of (1R,2R,3S)-3-azido-1-O-(4-methoxybenzyl)-cyclohexane-1,2-diol 
(221) as GlcNAc mimetic  
For certain reactions it would be desirable to have a GlcNAc mimic protected with a sterically 
less demanding protecting group than triphenylmethyl. Therefore, the feasibility of a p-
methoxybenzyl (PMB)-protected GlcNAc mimic was tested. p-Methoxybenzyl was chosen due to 
its adequate stability under glycosylation conditions and to the numerous cleavage procedures, 
which are orthogonal to various protecting groups applied in carbohydrate chemistry. The 
epoxidiation of the PMB-protected allylalcohol was expected to give a low anti/syn ratio due to 
the low sterical influence of the PMB-protecting group. Therefore, the previously explored 
dihydroxylation pathway (chapter 3.2.1.1.) was applied.393  
Alkylation of 214 with PMB chloride was carried out under standard conditions, yielding the 
PMB-ether polluted with traces of an inseparable side-product. However, after the subsequent 
dihydroxylation the pure anti-220 could be easily isolated in a yield of 48% over two steps. 
Considering the long coupling constants of H-1 (3J1,2 = 8.9 Hz, 3J1,6ax = 10.4 Hz), a 1C4 
conformation can be assumed, which is in contrast to the triphenylmethyl protected compound 
216. The cis-diol was converted into the monotosylate by treatment with tosyl chloride in 
presence of Et3N and n-Bu2SnO. The monotosylate was obtained as an inseparable mixture of 
3-Ts-220 and 2-Ts-220 (9:1). The lower regioselectivity can be explained by a decrease in 
sterical restriction at the 2-position compared to 216 and by the increased reactivity of the 2-
hydroxyl, which is now in equatorial position, compared to the axial 2-hydroxyl of 216. The 
mixture of tosylates was transformed into the corresponding azides, which could be smoothly 
separated to yield the desired PMB protected GlcNAc mimic 221 in an overall yield of 19% from 
cyclohexenone (scheme 20). 
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Scheme 20: a) i. NaH, TBAB, THF, PMBCl, r.t., 7 h, ii. NMO, OsO4, acetone, H2O, r.t., 47 h (48% over two steps); b) 
i. TsCl, n-Bu2SnO, Et3N, CH2Cl2, r.t., 15.5 h, ii. DMF, NaN3, 65°C, 72 h (82% over two steps).  
 
 
                                                                                                                                                                                                                          
                                                                62 
3.2.2.  Synthesis of E-selectin antagonists with novel alkylated GlcNAc mimics 
3.2.2.1.  Synthesis of E-selectin antagonists with (1R,2R,3S)-3-alkyl-cyclohexane-1,2-diols 
as GlcNAc mimics 
In the past decade, numerous sLex analogues and related compounds were synthesized by 
various groups.221 Within the class of sLex analogues, the N-acetylglucosamine moiety is 
commonly replaced by xylal- or glucal-derived structures269, 270 or by (R,R)-cyclohexane-1,2-
diol.255 
Earlier synthetic studies revealed that in sLex analogues the 2-position of the former N-
acetylglucosamine moiety is crucial for the pre-organization of the Lex core. The glucal-derived 
antagonist 55 was reported to be five-fold more potent than its xylal-derived counterpart 50 
(figure 31).269 This increase in activity is probably due to the steric compression exercised by the 
equatorial methyl group, which leads to the pre-organization of the core structure in the 
biologically active conformation. In addition it was shown, that carbocyles show better binding 
properties than pyrans. Hence, an N-acetylglucosamine mimic without a ring-oxygen, but 
bearing a sterically demanding substituent at the 2-position should result in a compound with 
increased affinity towards the target protein. Therefore, we designed a synthesis allowing to 
stereoselectively introduce alkyl substituents at the 3-position of (R,R)-cyclohexane-1,2-diol. 
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Figure 31: E-selectin antagonist with xylal-derived GlcNAc mimic (left) and its glucal-derived counterpart (right).    
 
The synthesis for (1R,2R,3S)-3-alkyl-cyclohexane-1,2-diols 222a-d started with the nucleophilic 
opening of epoxide anti-219 (chapter 3.2.1.1.) by organocopper reagents. A preliminary 
experiment with the homocuprate Me2CuLiLiI showed low, but sufficient reactivity and the 
desired compound 222a was stereo- and regioselectively obtained after 1 week in 61% yield, 
with 2-triphenylmethoxy-cyclohexanone as minor side-product. It was supposed that taking 
advantage of the enhanced reactivity of the higher-order cyanocuprate Me2Cu(CN)Li2 in 
presence of BF3Et2O would lead to higher yields in a shorter reaction time.399, 400 Indeed, under 
optimized conditions, the nucleophilic opening took place even at low temperature and 222a was 
cleanly formed with 84% yield. 
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Under these optimized conditions, epoxide 219 was reacted with a variety of organocopper 
reagents to yield 222a-d. However, the reactions failed with the less reactive diphenylcuprate401 
and the sterically demanding and instable t-butyl cyano copper reagent (chapter 3.2.2.2.1.).399 
Fucosylation of the GlcNAc mimics 222a-d was performed under in situ anomerization 
conditions to yield predominantly the -glycoside as indicated by NMR (3JF1,F2 = 3.6 Hz).349-351 
The tedious separation of the -glycoside from traces of -glycoside was circumvented by 
detritylating the pre-purified cyclohexane derivatives in presence of ZnBr2 as mild Lewis acid and 
triethylsilane as trityl cation scavenger.402, 403 The resulting -fucosides 223a-d could then be 
readily separated from its -anomers and other side-products.  
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Scheme 21: a) R1Li, CuCN, BF3Et2O, THF, -78°C to -30°C, 22 h-51 h ( 222a: 85%, 222b: 70%, 222c: 82%, 222d: 
81%); b) i. Br2, CH2Cl2, 0°C, 30-50 min, ii. TEAB, MS 3Å, DMF, CH 2Cl2, r.t., 1-4 d, iii. ZnBr2, TES, CH2Cl2, r.t., 45 min-
8 h, (223a: 49%, 223b: 55%, 223c: 67%, 223d: 60%, yields are over two steps); c) Pd/C, H2, THF, r.t., 30 min (77%); 
d) i. methyl acrylate, Grubbs cat. 2nd gen., CH2Cl2, reflux, 9d, ii. Pd/C, H2, THF, r.t., 30 min (25% over two steps); e) 
DMTST, MS 3Å, CH2Cl2, r.t., 43 h to 65.5 h (225a: 59%, 225b: 80%, 225c: 87%, 225e: 78%, 225f: 79%); f) i. Pd/C, 
H2, EtOH, cat. AcOH, r.t., 8 d, ii. NaOMe, MeOH, r.t., 18 h, iii. Dowex (Na+), Seph.-G15 (226a: 79%); g) i. Pd(OH)2/C, 
H2, dioxane/H2O, r.t., 49 h, ii. NaOMe, MeOH, r.t., 17 h, iii. Dowex (Na+), Seph.-G15 (226b: 56%); h) i. Pd(OH)2/C, H2, 
dioxane/H2O, r.t., 24 h to 72 h, ii. NaOMe, MeOH, r.t., 16 h (226c: 72%, 226e: 77%, 226f: 73%); i) i. Pd/C, H2, EtOH, 
cat. AcOH, r.t., 6 d to 60 d, ii. LiOH, MeOH/H2O, r.t., 2 d, iii. Dowex (Na+), Seph.-G15 (226g: 74%, 226h: 30%). 
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The disaccharide mimic 223d was further transformed into the disaccharide mimics 223e and 
223f. For the synthesis of the ethyl-substituted antagonist, 223d was selectively hydrogenated in 
presence of Pd/C to yield 223e. This step was necessary prior to galactosylation since DMTST-
promoted glycosylation in presence of the vinyl group of 223d failed.  
Cross-metathesis of 223d with methyl acrylate in presence of Grubbs’ 2nd generation catalyst 
proceeded only slow- and incompletely and resulted in a remarkably low trans/cis ratio of the 
product.404 Both the slow reaction and the low trans/cis ratio are supposed to result from the 
huge sterical hindrance by the benzylated fucose. Hydrogenation of the inseparable cis/trans 
mixture yielded the 2-methoxycarbonyl-ethyl substituted disaccharide mimic 223f in a low yield 
of 25% over two steps.  
Subsequent -glycosylation with donor 224405 and dimethyl(methylthio)sulfonium triflate 
(DMTST) as promoter afforded the tetrasaccharide mimics 225a-c and 225e-f in a -selective 
manner. For the debenzylation Pd(OH)2/C was found to be a superior hydrogenation catalyst 
compared to Pd/C and markedly reduced the reaction time. The frequently observed catalyst’s 
poisoning presumably by disulfides was overcome by exchanging the catalyst after one day of 
hydrogenation. Saponification was either carried out with catalytic amounts of sodium methoxide 
in methanol to yield the 2-monobenzoylated antagonists 226a-c and 226e-f, or with lithium 
hydroxide to yield the fully deprotected antagonists 226g-h.  
 
3.2.2.2. Synthetic challenges in the synthesis of alkylated GlcNAc mimics 
3.2.2.2.1.  tert-Butyl GlcNAc mimics 227 and 229 
Steric compression of the fucose moiety by a bulky equatorial substituent could improve the pre-
organization of the core structure in the biologically active conformation and lead to increased 
biological activity. To closer investigate the influence of bulky substituents at the former 2-
position of GlcNAc, the synthesis of a t-butyl substituted GlcNAc mimic was envisaged (scheme 
22).  
The di-t-butyl cuprate reagent (tBu2CuCNLi2) is known to be instable and to decompose even at 
low temperature to isobutylene and a hydrido-copper species. This hydride species preferentially 
leads to the reduction product.399 By using the t-butyl cyano copper reagent (tBuCuCNLi) instead 
of the di-t-butyl cuprate reagent, smooth opening of epoxides by the t-butyl group can normally 
be achieved. However, in case of the triphenylmethyl protected epoxide 219, the stability of the 
t-butyl cyano copper reagent was found to be insufficient and the reagent rapidly decomposed 
when slowly warming the reaction from -78° to -30°C . Work-up of the reaction confirmed the 
absence of product formation and led to the recovery of the starting material 219. 
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To test further reaction conditions, the sterically less hindered epoxide 228 (see chapter 3.2.2.3.) 
was chosen as starting material. To avoid decomposition of the copper reagent, the reaction 
was this time kept constantly at -78°C, even during  the formation of the reagent. Addition of 228, 
followed by BF3Et2O resulted in a mixture of alcohols with a partially or fully alkylated ester 
moiety, as observed by MS. Obviously, the formation of the copper reagent at -78°C was 
incomplete, and the remaining t-BuLi preferentially attacked the methylester. However, the 
reduction of the epoxide cannot be explained, since depletion of t-BuLi renders the formation of 
a di-tert-butyl cuprate species unlikely.  
In order to favor the epoxide opening over the reduction, a reaction was started at -30°C. It was 
assumed, that the less sterically demanding epoxide 228 would react fast enough at this 
temperature, before the copper reagent is fully decomposed. However, most of the starting 
material was recovered unreacted, together with a significant amount of a compound, which 
probably is the 4-tert-butyl derivative 230 and only traces of the desired 3-tert-butyl derivative 
229. These results led to the conclusion that the preparative synthesis of a 3-tert-butyl derivative 
can not be achieved by the current synthetic strategy, due to the low reactivity of the reactants 
and the instability of the t-butyl copper reagent. 
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Scheme 22: a) t-BuLi, CuCN, BF3Et2O, THF, -78°C to -30°C, 24 h (0%), b) t-BuLi, CuCN, BF3Et2O, Et2O, -78°C, 4 h 
(0%), c) t-BuLi, CuCN, BF3Et2O, Et2O, -30°C, 4 h (traces).  
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3.2.2.2.2. Cyclopropyl GlcNAc mimic 222c 
A cyclopropyl GlcNAc mimic is supposed to exert increased steric compression on the fucose 
compared to unbranched alkyl chains, and therefore may enhance the pre-organization of the 
core structure. In addition, compared to the isopropyl functionality, cyclopropyls show enhanced 
metabolic stability and therefore attracted increasing attention in medicinal chemistry in recent 
years.406 Since the di-cyclopropyl cuprate reagent was considered as too sterically hindered to 
react with epoxide 219, an alternative route to 222c was explored. Simmons-Smith reaction is a 
simple and powerful method to generate cyclopropanes from olefins.407 Reacting one of the vinyl 
intermediates with the corresponding zinc reagent would therefore lead to a terminal 
cyclopropane in a single step. Recently, cyclopropanation reagents generated by reacting 
Zn(CH2I)2 with halogen-substituted carboxylic acids such as TFA were found to have increased 
reactivity and dramatically shorten the usually long reaction times.408 First attempts with the 
triphenylmethyl protected compound 222d failed due to the susceptibility of the triphenylmethyl 
group towards acids (scheme 23).  
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Scheme 23: a) Et2Zn, CH2I2, CF3COOH, CH2Cl2, 0°C to r.t. (0%), b) Et 2Zn, CH2I2, CH2Cl2, 0°C to r.t. (0%), c) Et 2Zn, 
CH2I2, CF3COOH, CH2Cl2, -20°C to r.t. (0%). 
 
To circumvent this problem, 222d was first fucosylated and deprotected prior to 
cyclopropanation (223d). However, the disaccharide mimic showed to be completely inert to 
various cyclopropanation conditions, probably due to steric shielding by the benzylgroups. 
Cyclopropanation with dichlorocarbene to form the geminal dichlorocyclopropane and 
subsequent reduction to the cyclopropane under various conditions resulted in low yields of 
inseparable mixtures. Finally, the cyclopropyl derivative 222c was obtained by treatment of 219 
with the dicyclopropyl cuprate reagent (see chapter 3.2.2.1.).  
 
                                                                                                                                                                                                                          
                                                                67 
3.2.2.3.  Synthesis of E-selectin antagonists (244) with methyl (1R,3R,4R,5S)-3,4-
dihydroxy-5-methyl-cyclohexane-1-carboxylate as GlcNAc mimic 
Several highly active E-selectin antagonists contain differently acylated (1R,2R,3S)-3-amino-
cyclohexane-1,2-diols as replacements for GlcNAc.272 Closer investigations on this particular 
type of GlcNAc mimetic revealed that attaching an additional methyl ester at the former ring-
oxygen position of GlcNAc leads to even superior antagonists. Ligands containing methyl 
(1R,3S,4R,5R)-N-acyl-3-amino-4,5-dihydroxy-cyclohexane carboxylates as GlcNAc mimics were 
found to be usually four- to six-fold more potent compared to the corresponding antagonists 
without the methyl ester (table 7). Since the crystal structure of E-selectin co-crystallized with 
sLex shows no close contact between the ring-oxygen position of GlcNAc and E-selectin 
(chapter 3.1.1., figure 26), the increase in binding affinity is probably due to a stabilization of the 
chair conformation. This stabilizing effect was supposed to be also present in antagonists 
containing (1R,2R,3S)-3-methyl-cyclohexane-1,2-diol as GlcNAc mimic and an additional methyl 
ester functionality in the 5-position. 
 
Table 7: Improvement of binding affinity by introducing a methylester 
 
Entry Structure: 
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R2 = H 
rIC50a), 272 
R2 = CO2Me 
rIC50a), 272 
factor 
1 R1 = acetyl 63:  0.110 231:  0.018 6.1 
2 R1 = p-phenylbenzoyl 64:  0.095 232:  0.014 6.8 
3 R1 = orotoyl 65:  0.022 233:  0.005 4.4 
 
a) Sialyl Lewisx (sLex) was taken as reference compound (IC50 = 1 mM, rIC50 = 1.0). 
 
Since the methyl ester in 244 is positioned in a non-binding region without any sterical 
restriction, it can easily be used for the synthesis of multivalent E-selectin antagonists, for linking 
to biosensor chips or for labeling of the antagonist.  
The synthesis of the novel GlcNAc mimic 240 started from commercial cis-1,2,3,6-
tetrahydrophthalic anhydride, which was transformed into the dimethyl ester 235 by acid 
catalysis in methanol (scheme 24). Deracemization was accomplished by enantioselective 
hydrolysis of the symmetrical diester by pig liver esterase (PLE).316 The optical purity of the 
resulting half-ester 236 was analyzed by optical rotation (96.4% ee) and by chiral GC (96.0% 
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ee). Subsequent Barton decarboxylation and enzymatic hydrolysis of the methyl ester yielded 
(R)-cyclohex-3-ene carboxylic acid (128) with an enantiomeric excess of 96.3% ee, determined 
by chiral GC.409, 410 Iodolactonization and DBU induced dehydroiodination afforded lactone 129, 
followed by transesterification with methanol in presence of sodium bicarbonate and protection 
of the secondary alcohol with tert-butyl-dimethylsilyl chloride (239). Epoxidation with m-CPBA 
yielded preferentially anti-epoxide 228 due to the directing effect of the sterically demanding 
TBDMS group.392, 393 
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Scheme 24: a) amberlyste 15, MeOH, CH(OCH3)3, r.t., 9d (88%); b) PLE, pH 7 buffer, aq. NaOH, 20°C, 56.5 h (90%, 
96% ee); c) i. (COCl)2, CH2Cl2, cat. DMF, r.t., 3 h, ii. 2-mercaptopyridine-1-oxide sodium salt, t-BuSH, cat. DMAP, 
THF, reflux, 3 h (83%); d)  PLE, pH 7 buffer, aq. NaOH, r.t., 11 h (84%, 96% ee); e) KI, I2, NaHCO3, H2O, r.t., 24 h 
(95%); f) DBU, THF, reflux, 20 h (94%); g) i. NaHCO3, MeOH, r.t., 12 h, ii. TBSCl, DBU, CH2Cl2, r.t., 12 h (100%); h) 
m-CPBA, CH2Cl2, 10°C to r.t., 17 h (78%); i) MeLi, CuCN, BF 3Et2O, THF, -78°C, 5 h (78%); j) TBAB, 2,6-di- t-butyl-4-
methylpyridine, MS 4Å, CuBr2, DMF, CH2Cl2, r.t., 20 h (76%); k) TBAF, THF, r.t., 13 h (78%); l) DMTST, MS 4Å, 
CH2Cl2, r.t., 63 h (66%); m) i. Pd(OH)2/C, H2, dioxane/H2O, r.t., 46 h, ii. NaOMe, MeOH, r.t., 16 h (76%). 
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Regioselective opening of epoxide 228 with Me2Cu(CN)Li2 in presence of BF3Et2O provided the 
new semi-protected GlcNAc mimic methyl (1R,3R,4R,5S)-3,4-dihydroxy-5-methyl-cyclohexane-
1-carboxylate (240).399, 400  
Selective -fucosylation of 240 was performed under the previously used in situ anomerization 
conditions (chapter 3.1.3.2.) in presence of tetraethylammonium bromide.349-351 Unlike earlier 
experiments with similar GlcNAc mimics, the desired disaccharide mimic was only isolated as 
minor product (20%). Closer investigation of the side-products revealed a significant amount of 
the difucosylated GlcNAc-mimic. Obviously, under the reaction conditions the TBDMS group, 
which is known to be sensitive to halides and acidic conditions, was cleaved. Fucosylation under 
Ogawa conditions in presence of 2,6-di-t-butyl-4-methylpyridine successfully prevented 
desilylation and yielded selectively the disaccharide mimic 241, which was then further 
deprotected according to standard procedures to yield 242.411 Subsequent glycosylation with 
donor 224405 and dimethyl(methylthio)sulfonium triflate (DMTST) as promoter afforded the 
tetrasaccharide mimic 243 in -selective manner. Debenzylation according to the previously 
described procedure (chapter 3.2.2.1) and saponification with catalytic amounts of sodium 
methoxide in methanol yielded the 2-monobenzoylated antagonist 244.  
 
3.2.2.4.  Synthesis of E-selectin antagonist (255) with (1R,2R,4R)-4-tert-butyl-
cyclohexane-1,2-diol as GlcNAc mimic  
The conformational stability of GlcNAc mimics is supposed to play a crucial role in the biological 
activity of E-selectin antagonists (see chapter 3.2.3.). Large substituents on a cyclohexane ring 
prefer to occupy equatorial positions due to unfavorable 1,3-diaxial interactions. Large 
substituents can therefore be used to lock the cyclohexane ring in one of the chair 
conformations, which may pre-organizes the antagonists and leads to higher binding affinities. 
Commonly, tert-butyl substituents are used to completely lock the chair conformation of 
cyclohexane due to the high free energy difference between the equatorial and axial orientation 
of more than 4.5 kcal/mol.412 To closer investigate the influence of the ring-stability of GlcNAc 
mimics, a novel mimic with an additional tert-butyl substituent at the former ring-oxygen position 
of GlcNAc was synthesized (scheme 25). 
The synthesis started from commercial 4-tert-butylcatechol (245) which was hydrogenated in a 
Parr-shaker under 5 bar pressure at r.t. with an alumina oxide supported rhodium catalyst. Test 
reactions with different solvent mixtures indicated that apolar solvents like cyclohexane give 
preferentially the syn-syn diol (3:1 ratio), as reported for similar tert-butylphenols.413 However, 
because of the higher catalytic activity observed with THF as co-solvent and the later possibility 
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of epimer-separation, a THF/cyclohexane mixture was chosen for the final hydrogenation (1.4:1 
ratio). The equatorial hydroxyls of the mixture of rac-246 and rac-247 were selectively mono-
benzoylated in the presence of dibutyltin oxide. Subsequently, the two diastereomers were 
separated to yield 44% of the syn-syn epimer rac-248 and 26% of the syn-anti epimer rac-249. 
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Scheme 25: a) Rh/Al2O3, H2, c-hexane/THF (8:1), 5 bar, r.t., 24 h (78%, rac-246:rac-247 = 1.4:1); b) nBu2SnO, BzCl, 
Et3N, CH2Cl2, 0°C-r.t., 3 h, ( rac-248: 44%, rac-249: 26%); c) PPh3, DEAD, 3,5-dinitrobenzoic acid, toluene, 50°C, 22. 5 
h (63%); d) MeOH, Et3N, r.t., 1 h (80%); e) i. TBAB, MS 4Å, CuBr2, DMF, CH2Cl2, r.t., 11 h, ii. MeOH/H2O, LiOH, 
50°C, 4 h ( α/β-252: 44%, α-253: 38%); f) 224, DMTST, MS 4Å, CH2Cl2, r.t., 45 h (68%); g) i. Pd(OH)2/C, H2, 
dioxane/H2O, r.t., 37 h, ii. NaOMe, MeOH, r.t., 14 h (88%). 
 
The axial hydroxyl of rac-248 was inverted under Mitsunobu conditions, using 3,5-dinitrobenzoic 
acid in 63% yield.414 3,5-dinitrobenzoic acid was preferred over p-nitrobenzoic acid because the 
subsequent hydrolysis of the p-nitrobenzoyl ester required more drastic conditions which led to 
partial cleavage of the benzoylgroup. Trichloroacetic acid (TCA) was considered as an 
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alternative to the nitrobenzoic acids by reason of its high reactivity and ease of cleavage under 
almost neutral conditions. However, treatment of rac-248 with TCA under Mitsunobu conditions 
yielded the 2,2-dichloroacetylated starting material 256 (76%) instead of the inverted 2,2,2-
trichloroacetylated diol as unexpected major product (scheme 26). Presence of the 
dichloroacetoxy group was confirmed by MS and NMR analysis (Cl2HC(O)O : δ = 6.02 ppm), 
and its axial position can be deduced from the two axial-equatorial couplings (3Jax,eq = 2.7, 4.7 
Hz) and the axial-axial coupling (3J1ax,6ax = 12.0 Hz) of the proton adjacent to the benzoyloxy 
group. As possible reaction mechanism, the formation of a mixed phosphinic anhydride as 
acylating reagent can be considered. Thereby, trichloroacetic acid forms the phosphonium salt 
similar to the commonly used carbon tetrahalogenides, resulting in the dichloroacetate which 
nucleophilically displaces the chloride on the phosphor. 
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Scheme 26: Unexpected reaction pathway of Mitsunobu reaction with TCA.  
 
Selective deprotection of the 3,5-dinitrobenzoyl group was carried out with triethylamine in 
methanol, resulting in the corresponding alcohol with 80% yield. Sodium azide in methanol 
showed similar efficiency but increased formation of a side-product, which was later identified as 
(1R,2R,4R)-4-tert-butyl-2-hydroxy-cyclohexyl benzoate.415 This implies that the benzoyl group 
tends to slowly migrate in solution.  
The racemic mixture of equatorial alcohols was reacted with ethyl thiofucoside under Ogawa 
conditions to yield a scarcely separable mixture of the two diastereomers.411 However, after 
subsequent debenzoylation with lithium hydroxide, the two diastereomers could easily be 
separated on silica to give 252 as an /-mixture (1:0.12) and 253 as pure -anomere. 
Assignment of the diastereomers was accomplished by comparing their NMR spectra with the 
reference compound 168 (figure 32 and figure 33).   
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Figure 32: Superposition of 1H-NMRs of 168 and the two diastereomers 252 & 253. 
 
 
 
 
Figure 33: Superposition of 13C-NMRs of 168 and the two diastereomers 252 & 253. 
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Subsequent glycosylation of 252 with donor 224405 and DMTST as promoter afforded the 
tetrasaccharide mimic 254 in a -selective manner. At this stage, remaining traces of the -
fucosylated mimic could be separated from the desired -fucosylated mimic. Debenzylation with 
Pd(OH)2/C and saponification with catalytic amounts of sodium methoxide in methanol yielded 
the 2-monobenzoylated antagonist 255.  
 
 
3.2.3.  Biological evaluation of antagonists with novel alkylated GlcNAc mimics  
(in collaboration with Dr. John L. Magnani, Glycomimetics Inc., Rockville, USA) 
 
All the synthesized antagonists with modified GlcNAc mimics were analyzed in a static cell free 
ligand binding assay that measures E-selectin inhibition under equilibrium conditions.378, 379 
Since IC50s may vary depending on the conditions from assay to assay, relative inhibitory 
concentrations (rIC50) were calculated by standardizing the values on CGP69669 (41), which is 
measured on the same plate and known to have a rIC50 of 0.080. All the values are expressed 
as relative IC50 to sialyl Lewisx (sLex, 3) which was taken as a reference compound with an IC50 
of 1 mM (rIC50 = 1.0). The rIC50s of the new antagonists bearing modifications on the GlcNAc 
moiety (general structure is shown in figure 34) are summarized in table 8.  
 
The antagonists 226g and 226h, bearing an alkyl modification at the former 2-position of 
GlcNAc, show increased biological activity in the ligand binding assay compared to the 
unsubstituted antagonist CGP69669 (41).216 This can be rationalized by the steric compression 
exercised by the equatorial alkyl group, which supports the pre-organization of the core 
pseudotrisaccharide in the biologically active conformation. This result is in good agreement with 
observations from glucal-derived antagonists earlier reported in literature.269  
 
Similar results were obtained for antagonists bearing an additional benzoate at the 2’-position of 
galactose. From earlier publications, it is known that an additional benzoate increases binding 
affinity approximately 3-fold.269, 416 The reason for this increase in potency is not yet fully 
elucidated. Either hydrophobic interactions with the protein, CH-π interactions to the 
cyclohexyllactic acid moiety or the influence on the core conformation through the electron 
withdrawing and steric effect of the benzoate can be considered.  
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Figure 34: General structure of antagonists with novel GlcNAc mimics. 
 
Table 8: Biological and NMR data of antagonists with novel GlcNAc mimics. 
 
Compound R1 R2 R3 R4 rIC50a) 
 
δ of Fuc H-5b) 
[ppm] 
3J1ax,2ax + 3J2ax,3ax 
[Hz] 
CGP69669 (41)202 Na H H H 0.080 4.61 17.8 
BW408-0 (257)417 H H Me H 0.013 4.89 18.6 
226g Na H Me H 0.016 4.89 18.9 
226h Na H Et H 0.009 4.84 --- 
56417 H Bz H H 0.040 4.60 17.5 
BW408-11 (258)417 H Bz Me H --- 4.97 18.4 
226a Na Bz Me H 0.004 4.96 18.5 
226e H Bz Et H 0.007 4.90 17.8 
226b (H) H Bz nBu H --- 4.90 17.8 
226b (Na) Na Bz nBu H 0.009 4.85 17.7 
226c H Bz cPr H 0.032 4.88 17.0 
226f H Bz (CH2)2CO2Me H 0.008 4.83 16.9 
244 H Bz Me CO2Me 0.002 4.99 19.2c) 
255 (H) H Bz H tBu --- 4.77 20.6 
255 (Na) Na Bz H tBu > 10 4.75 --- 
 
a) Sialyl Lewisx (sLex, 3) was taken as reference compound (IC50 = 1 mM, rIC50 = 1.0); b) all 1H-NMR were measured 
in MeOH; c) corresponds to 3J3ax,4ax + 3J4ax,5ax in this compound. 
 
Among the benzoylated antagonists (table 8), the 3-alkylated compounds show increased 
biological activity compared to the unsubstituted reference compound 56.269, 271 The most potent 
antagonist is obtained by methylation at the 3-position of the GlcNAc mimic and benzoylation of 
the 2’-position of galactose (226a), while increasing the steric bulk leads again to a slight 
decrease in activity, as e.g. observed for the cyclopropyl modification (226c).  
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The distance between the fucose and the galactose in the antagonist’s solution conformation 
can be estimated by NMR according to the chemical shift of the Fuc H-5 proton.269 The closer 
the fucose H-5 proton is located to the galactose, the stronger it is shifted downfield. In our 
series of antagonists, the observed shifts of the fucose H-5s correlate well with the biological 
activity, resulting in a pronounced downfield shift for the most potent compounds 244 and 226a 
(table 8). Therefore, these shifts can be used to preliminarily evaluate the potency of future 
antagonists.  
The controversial results from the compounds with increased steric bulk led to the hypothesis 
that with increased bulkiness the conformational stability of the cyclohexane starts to play a 
decisive role for the biological activity. The huge steric constraint around the fucose may 
destabilize the all-equatorial conformation and lead to a partial distortion from the ideal all-
equatorial chair conformation. However, even the all-axial conformation can not be fully 
excluded, as similar observations were made for trans-1,2-bis-silyloxycyclohexanes and all-
trans-polyisopropylcyclohexanes.418, 419 Despite the inherent preference of substituents for the 
equatorial conformation, the all-axial conformation gives relief from the 1,2-diequatorial steric 
repulsions and from the destabilizing interaction of carbon-oxygen bond dipoles. In addition, 
alkoxy groups have a rather small axial penalty as expressed in the the low A-value compared to 
other functional groups (table 9). 
 
Table 9: Conformational energies (A-Values).412 
 
Residue A-Value 
[kcal/mol] 
Residue A-Value 
[kcal/mol] 
-OMe 0.6 -iPr 2.2 
-Me 1.7 -tBu 4.7 
-Et 1.8 -CO2Me 1.3 
 
Our hypothesis is in agreement with the observation that an additional isolated methyl ester 
attached at the former ring oxygen position usually increases binding affinity as seen for 
antagonist 244. Since the methyl ester shows no close interaction with the protein’s surface 
(figure 35), the increased potency can only be rationalized by the additional stabilizing effect on 
the chair conformation due to the distinct equatorial preference of the isolated methyl ester.  
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Figure 35:  sLex docked onto E-selectin. Position of the 3-alkyl group and the methyl ester of the GlcNAc mimetics 
are highlighted. 
 
This theory is supported by the analysis of the chair conformation by NMR experiments. The 
sum of the two diaxial coupling constants of the axial proton (figure 34) attached to the fucose 
linkage (3J1ax,2ax + 3J2ax,3ax) can be used to estimate the portion of the ideal all-equatorial chair 
conformation. The values in table 8 show that a small substituent like methyl at the 3-position 
stabilizes the chair conformation due to its equatorial preference, whereas with larger 
substituents like cyclopropyl the 1,2-diequatorial repulsion plays a dominant role and the chair 
conformation gets destabilized. The addition of an isolated methyl ester in 244 leads to larger 
diaxial coupling constants, which implies stabilization of the all-equatorial chair-conformation and 
therefore improved potency. 
The role of the chair-stabilizing effect in the biological activity of E-selectin antagonists can be 
dissociated from the fucose-stabilizing effect in compound 255, where steric compression of the 
fucose is absent. In this compound the all-equatorial chair-conformation is completely locked by 
the isolated t-butyl functionality. This results indeed in distinctly large diaxial coupling constants. 
However, 255 was found to be inactive in a static cell free ligand binding assay. This result may 
be rationalized either by its unfavorable solvation properties like aggregate formation or by steric 
clashes of the tert-butyl group with the protein’s surface. Assuming that the new antagonists 
bind to E-selectin in a similar fashion as sLex in the crystal structure of E-selectin, renders steric 
-CO2Me 
alkyl 
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clashes of 255 with the protein’s surface unlikely. However, for this new class of antagonists we 
cannot fully exclude a binding mode different from the one observed with sLex. 
This leads to the conclusion that the activity of E-selectin antagonists with diverse GlcNAc 
mimics depends on a combination of the optimal pre-organization of the fucose by applying 
steric compression and the conformational stability of the cyclohexane ring. However, the latter 
still needs to be fully proven by further investigations. 
 
3.2.4  ROESY studies on 3-methylated antagonist 226g 
To investigate the hypothesis that the higher binding affintity of 3-alkylated antagonists is a 
consequence of the closer stacking of fucose and galactose, the solution conformations of 226g 
and CGP69669 (41) were studied by NMR experiments. This has been performed through 
selective one-dimensional ROESY measurements, according to earlier published methods.420-423 
The interglycosidic ROEs between Fuc H-5 and Gal H-2 (figure 36) were used to determine the 
proximity of fucose to galactose in CGP69669 (41) and 226g. Assuming a distance of 2.60 Å 
from Fuc H-5 to Fuc H-3, the mean distance between Fuc H-5 and Gal H-2, weighted by the 
populations of the different conformations, was quantified to be 2.98 Å for CGP69669 (41) and 
2.73 Å for 226g. The measured ROE values provide evidence for the closer stacking of the 
fucose to the galactose and therefore an increased extent of pre-organization of the core 
structure in the biologically active conformation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: Cross-relaxation rate constants which are used to determine the internuclear distance. 
Fuc H-5 to Gal H-2 in 226g 
Fuc H-5 to Fuc H-3 in CGP69669 (41) 
Fuc H-5 to Fuc H-3 in 226g 
Fuc H-5 to Gal H-2 in CGP69669 (41) 
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4.  Conclusion and Outlook 
4.1.  Summary of the thesis 
4.1.1. General background 
The interaction of E-, P- and L-selectin with their natural carbohydrate ligands has been shown 
to mediate the initial step of the recruitment of leukocytes, and to play a crucial role in many 
physiological processes and disease states.1-4 More specifically, selectins are a family of 
carbohydrate-binding proteins expressed at the site of inflammation in response to early 
precursors, liberated by the inflamed tissue. Their key role, early in the inflammatory cascade, is 
to promote the tethering and the rolling of leukocytes along the endothelial surface.1-4 These 
steps are then followed by integrin-mediated firm adhesion and final transendothelial migration.  
Therefore, control of the leukocyte-endothelial cell adhesion process may be useful in cases 
where excessive recruitment of leukocytes contributes to acute or chronic diseases such as 
stroke, reperfusion injury, psoriasis or rheumatoid arthritis.5, 6 In addition, it has been suggested 
that cancer may exploit this adhesion process after entering the bloodstream to metastasize.7, 8 
 
Tetrasaccharide sialyl Lewisx (sLex) (3, figure 37) was identified as the minimal carbohydrate 
epitope recognized by E-selectin.21, 424, 425 Important pharmacophores of sLex are the three OH 
groups of the fucose moiety, the 4- and the 6-OH of the galactose moiety and the COOH group 
of the sialic acid residue.426-429, 200, 204, 201, 252, 194-197 The N-acetylglucosamine portion of sLex (3) 
mainly serves as spacer between the fucose- and the galactose moiety, and forces the fucose 
ring to stack under the -face of galactose. Due to the flat binding site of E-selectin46 and to the 
considerable distances between the pharmacophores, their three-dimensional orientation and 
pre-organization becomes exceedingly important. 
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Figure 37: The carbohydrate epitope sLex (3) and its analogue CGP69669 (41) as a lead compound for inhibiting E-
selectin. 
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In the past decade, numerous sLex analogues and related compounds were synthesized by 
various groups.221 Within the class of sLex analogues, the N-acetylneuraminyl portion is 
commonly replaced by (S)-cyclohexyl lactic acid, whereas the N-acetylglucosamine moiety is 
substituted by xylal- or glucal-derived structures or by (R,R)-cyclohexane-1,2-diol as in 
CGP69669 (41).  
 
4.1.2. Aim of the thesis 
For this thesis, the compound CGP69669 (41) served as a lead compound for the design of E-
selectin antagonists. In order to improve the lead compound’s pharmacodynamic profile, two 
different optimization strategies were envisaged (figure 38).  
The first part of the thesis aimed at probing an unoccupied hydrophobic patch close to the 6-
position of galactose. Since the 6-hydroxyl is optimally suited for binding to E-selectin it was kept 
untouched, and the hypothetical fragments for binding to the hydrophobic pocket were 
alternatively attached to the C-6 of the galactose. The de-novo design of the hydrophobic 
fragments, as well as its linker, was supported by molecular modeling tools. 
The second part of the thesis was dedicated to the optimization of the ligand’s pre-organization 
in the bioactive conformation. Although the GlcNAc moiety of sLex displays no pharmacophores 
and mainly serves as a spacer between the fucose and the galactose, it makes an important 
contribution to the spatial pre-organization of the pharmacophores to the receptor site. The aim 
was to develop novel potent antagonists by reducing the ligand’s entropic costs upon binding 
through optimization of the GlcNAc mimetics. The new mimetics should provide a maximal 
extent of pre-organization, realized by different means like steric compression or conformational 
stabilization, while preserving the ligands drug-likeness and synthetic accessibility.  
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Figure 38: General structures for the two subprojects: Probing of a hydrophobic pocket (left) and optimization of the 
ligand’s pre-organization (right). 
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4.1.3. E-selectin antagonists containing substituted L-glycero--D-galacto-hepto-
pyranoses as replacement for galactose (optimization of enthalpy) 
Supported by molecular modeling tools, a small library of fragments were chosen for probing the 
hydrophobic patch close to the 6-position of galactose moiety of sLex. The fragments were 
attached to the C-6 position of galactose by a -CH2NH- unit as linker, so that the galactose 
became a 7-amino-7-deoxy-L-glycero--D-galacto-hepto-pyranose. The synthesis of the ligands 
started with the donor heptopyranoside, which was obtained in 14 steps. The key reaction was 
the stereoselective chain elongation with a silyl Grignard reagent resulting in the desired (6S)-
isomer of the heptopyranoside. The donor heptopyranoside was incorporated in a 
tetrasaccharide mimetic of sLex by DMTST-promoted glycosylation and regioselective alkylation 
with known building blocks. The fragments binding to the hydrophobic patch were either 
commercially available or synthesized by Friedel-Crafts acylation or by the Fischer indole 
synthesis. The fragments were then coupled to the amine group at the 7’-position of the scaffold 
by activation with PPh3/CCl4 or as acid chlorides. Subsequent deprotection yielded the new E-
selectin ligands either in pure form (193, 194) or as mixtures with the partly reduced form 
(195/196, 197/198), due to ring hydrogenation during the deprotection step (figure 39). 
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Figure 39:  E-selectin ligands with fragments which are probing the hydrophobic patch close to the 6-position of 
galactose. 
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The synthesized ligands, analyzed in a static cell free ligand binding assay, were found to be 
inactive (rIC50 > 10mM).378, 379 The inactivity of the ligands may be due to an inappropriate choice 
of the linker, insufficient binding of the fragments or interference with the bioactive conformation. 
For the full understanding of the negative results, further studies will be inevitable, like co-
crystallization of E-selectin with the lead compound 41 or testing the binding of the fragments by 
NMR. 
 
4.1.4. Design and synthesis of GlcNAc mimetics for E-selectin antagonists 
(optimization of entropy) 
The second project started with the optimization of the synthesis of the established GlcNAc 
mimic 209. The original synthesis from (D)-(-)-quinic acid yielded 209 with 11% in an 11 step 
synthesis. For the optimization, a bottom-up approach was chosen from the inexpensive 
cyclohex-2-en-1-on. The desired GlcNAc mimic was stereo- and regioselectively synthesized on 
a multi-gram scale in 6-7 steps with an overall yield of 19% for the p-methoxybenzyl- and 25% 
for the trityl-protected GlcNAc mimic (scheme 27). 
OH
COOHHOHO
HO
ROHO
N3
209: R = Bz
218: R = CPh3
221: R = PMB
O
11 steps 6-7 steps
11% 19-25%
 
 
Scheme 27:  Optimization of the synthesis of the GlcNAc mimic 209. 
 
Earlier synthetic studies with glucal- and xylal-derived antagonists269, 270 revealed that the 2-
position of the N-acetylglucosamine part of sLex analogues is crucial for the pre-organization of 
the core in the bioactive conformation. Therefore, we designed a synthesis for the regioselective 
introduction of alkyl substituents at the 3-position of (R,R)-cyclohexane-1,2-diol to yield suitably 
protected (1R,2R,3S)-3-alkyl-cyclohexane-1,2-diols as novel GlcNAc mimics. All of the 
synthesized antagonists bearing an alkyl substitutent in the 3-position (figure 40) showed 
increased potency compared to the unsubstituted cyclohexanediol.  
The increased extent of pre-organization of the alkylated antagonists was confirmed by the 
pronounced downfield shift of the fucose H-5 proton and by selective one-dimensional ROESY 
experiments. Assuming a distance of 2.60 Å from fucose H-5 to fucose H-3, the mean distance 
between fucose H-5 and galactose H-2 was quantified to be 2.98 Å for the unsubstituted 
antagonist CGP69669 (41) and 2.73 Å for the methylated antagonist 226g. The ROE values 
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provide evidence for the closer stacking of the fucose to the galactose and therefore increased 
extent of pre-organization of the core structure in the biologically active conformation. 
 
O
O
HO
OH
O
CO2-
O
HOOH
OH
O
R
HO
 
O
O
HO
O
O
CO2-
O
HOOH
OH
O
R
HO
O
 
41: R = H 80 µM  
226g: R = Me 16  µM 
226h: R = Et 9  µM 
56: R = H  40  µM 
226a: R = Me  4  µM 
226e: R = Et 7 µM 
226c: R = cPr 32 µM 
226b: R = nBu 9 µM 
226f: R = (CH2)2CO2Me 8 µM 
 
 
Figure 40: E-selectin antagonists with (1R,2R,3S)-3-alkyl-cyclohexane-1,2-diols as GlcNAc mimics. 
 
The most potent antagonist was obtained by simple methylation at the 3-position (226a), while 
increasing the steric bulk led to a slight decrease in activity, as e.g. observed for the cyclopropyl 
modification (226c). This surprising decrease may be rationalized by the conformational 
destabilization of the cyclohexane ring through 1,2-diequatorial steric repulsions. This 
explanation is supported by the slight tendency of the axial proton attached to the fucose linkage 
to lower coupling constants for compounds with increased steric bulk at the 3-position.  
 
Starting from the methylated, most potent antagonist 226a, further optimization of the pre-
organization was envisaged. Earlier studies on a similar type of GlcNAc mimetics revealed that 
attaching an additional methyl ester at the former ring-oxygen position of GlcNAc leads to a 
further improvement of affinity. Based on the assumption that these findings could be transferred 
to the new antagonist 226a, a stereoselective synthesis for antagonist 244 was designed. The 
new GlcNAc mimetic was stereoselectively synthesized from commercial cis-1,2,3,6-
tetrahydrophthalic anhydride with enzymatic deracemization as key step, and incorporated into 
the new antagonist 244 (figure 41). Biological evaluation of 244 confirmed our hypothesis, as the 
new antagonist showed a two-fold increase in potency compared to antagonist 226a. Since the 
additional methyl ester is supposed to have no contact with the protein, the increased potency 
may be rationalized by the enhanced conformational stabilization of the cyclohexane moiety. 
This theory is supported by a slight increase of the above mentioned coupling constants for 244 
compared to 226a. Since the methyl ester of the new antagonist is supposed to be positioned in 
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a non-binding region, without any sterical restriction, it can easily be used for the synthesis of 
multivalent E-selectin antagonists, for linking to biosensor chips or for labeling of the antagonist. 
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Figure 41:  E-selectin antagonist with methyl (1R,3R,4R,5S)-3,4-dihydroxy-5-methyl-cyclohexane-1-carboxylate as 
GlcNAc mimic. 
 
The newly synthesized antagonists suggest that the conformational stability of the antagonists’ 
cyclohexane moiety plays an important role for the biological activity. To closer investigate the 
influence of the conformational stability, a new antagonist was envisaged, where the GlcNAc 
mimic’s chair conformation is completely locked by an isolated equatorial tert-butyl substituent 
(figure 42). The conformational freeze would allow applying more steric compression on the 
fucose without simultaneously destabilizing the chair conformation by 1,2-diequatorial 
repulsions. 
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Figure 42: E-selectin antagonist with (1R,2R,4R)-4-tert-butyl-cyclohexane-1,2-diol as GlcNAc mimic. 
 
The position of the former ring-oxygen in GlcNAc was chosen as the position for the bulky tert-
butyl group, since earlier antagonists were already successfully substituted at this position. 
Deracemization of the tert-butyl-substituted cyclohexane moiety was performed on the level of 
diastereomers, obtained by -fucosylation and subsequent deprotection. The final antagonist 
255, however, was found to be inactive in a static cell free ligand binding assay. This result may 
be rationalized either by the unfavorable solvation properties of the molecule, like aggregate 
formation, or by steric clashes of the tert-butyl group with the protein’s surface. Assuming that 
the new antagonists bind to E-selectin in a similar fashion as sLex in the crystal structure of E-
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selectin, renders steric clashes of 255 with the protein’s surface unlikely. However, for this new 
class of antagonists, we cannot fully exclude a binding mode different from the one observed 
with sLex.  
 
4.2.  Outlook 
In order to synthesize low nanomolar E-selectin antagonists with the lead compound CGP69669 
(41) as molecular scaffold, the discovery of new hydrophobic interactions is inevitable. The 
failure of several molecular modeling-guided attempts to discover new hydrophobic interactions 
casts doubts on the predictive value of our model with CGP69669 docked on the crystal 
structure of E-selectin. Therefore, the project would immensely profit from an E-selectin crystal 
structure, co-crystallized with our lead compound CGP69669 (41). This may help to clarify the 
exact binding mode of the lead compound, as well as the inactivity of the new E-selectin 
antagonists containing substituted L-glycero--D-galacto-hepto-pyranoses as replacement for 
galactose (see figure 39) and the inactivity of the tert-butyl antagonist 255 (see figure 42). 
 
Ongoing investigations in our group are focusing on the elucidation of the influence of the 
GlcNAc mimetic’s conformational flexibility on the antagonist’s potency. For this purpose several 
new GlcNAc mimetics are being synthesized and incorporated into E-selectin antagonists (figure 
43). In order to explain the inactivity of 255, compounds 259 and 260 are being synthesized. In 
antagonist 259 steric clashes with the protein are avoided by placing the tert-butyl group at a 
position different from 255, whereas in 260 the solubility problem is addressed by using a 2-
hydroxypropan group instead of a tert-butyl group. Finding a solution for locking the GlcNAc 
mimic’s chair conformation would allow to further pre-organize the other moieties of the 
antagonists without conformationally destabilize the cyclohexane ring.  
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Figure 43: E-selectin antagonists with conformational stabilized GlcNAc mimetics. 
 
Since the methyl group of 226a simultaneously applies steric compression on the fucose and 
stabilizes the chair conformation, the synthesis of compound 261 was envisaged, where only the 
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latter effect is present. Compound 262 will finally combine the effects of the two methyl groups 
and is supposed to show a potency similar to 244, but with an increased metabolic stability 
(figure 44).  
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Figure 44: E-selectin antagonists with methyl substituents at different positions of the GlcNAc mimetic. 
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5.  Experimental Section 
5.1.  General methods 
Nuclear magnetic resonance: 
Nuclear magnetic resonance spectroscopy was performed on a Bruker Avance 500 Ultra Shield 
spectrometer at 500 MHz (1H NMR) or 125 MHz (13C NMR). Chemical shifts are given in ppm 
and were assigned in relation to the solvent signals on the -scale or to tetramethylsilane (0 
ppm) as internal standard. 1H: 7.26 ppm (CDCl3), 5.32 ppm (CD2Cl2), 3.31 ppm (CD3OD), 4.79 
ppm (D2O), 2.50 ppm ((CD3)2SO); 13C: 77.00 ppm (CDCl3), 53.50 ppm (CD2Cl2), 49.00 ppm 
(CD3OD), 39.43 ppm ((CD3)2SO). Coupling constants J are given in Hertz (Hz). Multiplicities 
were specified as follows: s (singlet), d (doublet), dd (double doublet), t (triplet), q (quartet), dq 
(double quartet), m (multiplet). Assignment of 1H and 13C NMR spectra was achieved using 2D 
methods (COSY, HSQC, HMQC, HMBC, APT).  
For assignment of resonance signals to the appropriate nuclei the following abbreviations have 
been used: Ar (aryl), Cy (cyclohexyl), Fuc (fucose), Gal (galactose), Hep (heptose), Ind (indole), 
Lac (lactic acid), Pip (piperazine), PMB (p-methoxybenzyl).  
 
Infrared spectroscopy: 
IR spectra were recorded on a Perkin Elmer Spectrum One FT-IR spectrometer as KBr pellets or 
films on NaCl plates. Most characteristic absorption bands of the spectrum were given in cm-1 
and specified as vs (very strong), s (strong), m (medium), w (weak), vw (very weak), b (broad). 
 
Optical rotation: 
Optical rotations were measured on a Perkin Elmer 341 polarimeter with a path length of 1 dm. 
The optical rotation for the Na-D-line (589 nm) can be extrapolated from the lines of a mercury 
lamp (546 nm and 579 nm) using the Drude equation:430 
     []578T  3.199 
[]DT =           100 
   4.199 - []578 T    []T =   
       []546 T         c  d 
 = measured rotation 
c = concentration in g/100 ml 
d = cell length in dm 
T = temperature in °C 
 = wavelength in nm 
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Microanalysis: 
Microanalysis was performed at the Institute of Organic Chemistry at the University of Basel, 
Switzerland. 
 
Mass spectroscopy: 
Mass spectra were recorded on a Waters micromass ZQ and HR-MS spectra were obtained on 
an ESI Bruker Daltonics micrOTOF spectrometer equipped with a TOF hexapole detector. 
 
Thin layer chromatography: 
TLC was performed using silica gel 60 coated glass plates containing fluorescence indicator 
from Merck KGaA (Darmstadt, Germany) using either UV light (254 nm) or Mostain solution [0.8 
g Cer(SO4)2, 40 g (NH4)6(Mo7O24)  4 H2O dissolved in 300 ml of 10% aq. H2SO4] followed by 
heating to 140°C for 5 minutes to visibilize the su bstances. 
 
Chromatography: 
Column chromatography was performed using silica gel 60 (40-63 µm) from Fluka. Reversed-
phase column chromatography was carried out using LiChroprep RP-18 (40-63 µm) from Merck 
KGaA, Darmstadt, Germany. 
 
Microwave reactions: 
Microwave reactions were performed in a CEM Discover microwave apparatus. 
 
Hydrogenations: 
Hydrogenation reactions were performed in a shaking apparatus from Parr Instruments 
Company (Moline, Illinois, USA) in 250 ml or 500 ml bottles under a H2 pressure of 4 bar. 
 
Solvents: 
Solvents and phosphate buffer solutions were purchased from Fluka. Solvents were dried prior 
to use. Diethylether, dioxane, toluene and tetrahydrofurane (THF) were dried by refluxing with 
sodium/benzophenone and distilled immediately before use. Pyridine was freshly distilled from 
CaH2. Dichloromethane (CH2Cl2), acetonitrile and nitromethane were dried by filtration over 
Al2O3 (Fluka, type 5016 A basic). DMF, acetic acid and DMSO were dried by stirring over 
activated MS 4Å overnight, followed by microfiltration. Methanol was dried by distillation from 
sodium methoxide.  
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LC-MS: 
LC-MS separations were carried out using sunfire C18 columns (analytical: 2.1 x 50 mm, 3.5 µm; 
preparative: 19 x 150 mm, 5.0 µm) on a Waters 2525 LC, equipped with Waters 2996 
photodiode array and Waters micromass ZQ MS for detection. 
 
GC: 
Gas chromatography was carried out on a VARIAN 3600 or CEIntruments 8000Top using a 
chiral betacyclodextrine DEtTBuSil (SE54) column from Brechbühler. 
 
MPLC: 
MPLC separations were carried out on a CombiFlash Companion from Teledyne Isco equipped 
with RediSep normal-phase flash columns. 
 
ROESY analysis: 
The ROESY measurements were performed by Dr. Brian Cutting. The samples for the ROESY 
analysis consisted of approximately 5 mg of the compounds, solvated in 99.8% D2O (Armar 
Chemicals). The samples had a pH of approximately 7.0, uncorrected for D2O and were 
measured without the addition of a buffer.  Shigemi NMR tubes were used to reduce the sample 
volume needed for measurement. Each tube was filled with 200 l of the solution to be 
analyzed. Measurements were performed at 25°C using the same NMR spectrometer that was 
used to validate the compounds synthesized. Chemical shifts were referenced with respect to 
earlier work,269 which assigned a chemical shift of 4.60 ppm to the H5F resonance of CGP69669 
(41).  
The doubly-selective homonuclear Hartmann-Hahn scheme423 was used to selectively transfer 
magnetization from H6F to H5F. This scheme allowed a highly selective transfer of magnetization 
from H6F to H5F through their scalar coupling. The selective excitation of H5F allowed an 
accurate quantitation of this resonance by avoiding the excitation of residual H2O, which has a 
similar chemical shift. To remove any remaining magnetization from H6F, a selective gradient 
echo at the frequency of H5F was applied. A 200 ms REBURP224 180° refocusing pulse was 
applied to the H5F resonance. The REBURP pulse was sandwiched by a pair of Gaussian 
shaped gradients of 1 ms each and an amplitude of 20 G/cm. This additional spectral filter 
ensured that the observed ROESY421 peaks were due to magnetization that originated from the 
H5F resonance.420 
The jump-symmetrized CW-ROESY variation of the ROESY sequence was used in all 
experiments to minimize TOCSY artifacts.422 This sub-element of the pulse sequence was 
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inserted following the selective gradient echo. During the ROESY period, the transmitter 
frequency was shifted up or downfield during the first or second half of the mixing-time, 
respectively. The high-field spin lock was applied at 4.9 ppm and the low-field at 0.9 ppm. The 
spin lock was a rectangular pulse of 2 kHz amplitude. For both compounds measured, 10 
experiments were measured to record a build-up curve of the ROE transfer. The 10 experiments 
were sampled with increasing durations of the spin lock, beginning after 50 ms, and repeated 
after each 50 ms increment, resulting in a 500 ms spin lock duration for the final experiment. 
Following the application of the spin lock, the transmitter was returned to the center of the 
spectrum, at 2.9 ppm, and the fid measured using 4096 complex points to sample a bandwidth 
of 7 ppm. To achieve a high signal-to-noise, 1024 scans were measured for mixing time. Using a 
prescan delay of 3 s, on average the experiments lasted approximately 1.2 hours each. The 
NMR data were analyzed using XWINNMR version 3.0 operating on a Silicon Graphics O2. The 
spectra were apodized with an exponential decay function with 2 Hz line broadening. An 
additional advantage of the selective experiments was the lack of signal overlap which allowed 
the possibility of integrating the signals without interference from other resonances.  
To determine the internuclear distances, the rotating-frame cross-relaxation rates were 
calculated from the build up curves. Traditionally, the cross-relaxation rate is determined from 
fitting the spectra to a bi-exponential function that depends upon both the cross- and auto-
relaxation rates.431-433 The extent to which accurate cross-relaxation rates can be determined by 
this manner depends upon how well the auto-relaxation rate can be defined. Alternatively, it is 
possible to remove the dependence on the auto-relaxation by dividing the target-peak by the 
source-peak for each value of the mixing time.434-436 The resulting function is a hyperbolic 
tangent, the arguement of which is the product of the cross-relaxation rate and the mixing time. 
For the longest mixing times performed and highest rate of cross-relaxation expected for the 
compounds studied herein, the hyperbolic tangent function is indistinguishable from a linear 
function, hence offering the potential to apply linear regression to extract the cross-relaxation 
rate. The above procedure resulted in values that were well described by linear functions. 
Removal of auto-relaxation through the conversion of bi-exponential into hyperbolic tangent 
functions has as well been recently applied to determine accurate relaxation rates in cross-
correlation measurements.437-439  
 
Biological evaluation: 
The binding assay was performed by Dr. J. L. Magnani (Glycomimetics, Rockville, USA). Wells 
in a microtiter plate (plate 1, Falcon probindTM) were coated with E-selectin/hIg chimera by 
incubation of 100 µL of the purified chimeric protein at a concentration of 200 ng/well in 50 mM 
                                                                                                                                                                                                                          
                                                                90 
Tris, 0.15 M NaCl, 2 mM CaCl2, pH 7.4 (Tris-Ca2+). After 2 h, 100 µL of a 1:1 mixture of 1% BSA 
in Tris-Ca2+ and StabilcoatTM were added to each well and incubated at 22°C to b lock 
nonspecific binding. During this incubation, inhibitory test compounds (diluted in Tris-Ca2+, 1% 
BSA) were titrated by a twofold serial dilution in a second U-shaped bottom low-bind microtiter 
plate (plate 2, Costar). An equal volume of a performed complex of a biotinylated sialyl Lewisa 
polymer and horseradish peroxidase-labeled streptavidine (KPL, Gathersburg, MD) at 1 µg/mL 
in Tris-Ca2+, 1% BSA was added to each well. After 2 h at 22°C,  plate 1 was washed with Tris-
Ca2+, and 100 µL/well was transferred from plate 2 to plate 1. The binding reaction was allowed 
to proceed for 2 h at 22 °C while rocking. Plate 1 was then washed with Tris-Ca2+ and 100 µL of 
TMB substrate reagent (KPL, Gathersburg, MD) was added to each well. After 3 min, the 
colorimetric reaction was stopped by adding 100 µL/well of 1 M H3PO4, and the optical density 
was determined at 450 nm.378, 379 
 
5.2. Experiments 
Methyl 6-O-triphenylmethyl--D-galactopyranoside (150), (DS-03-13, DS-03-16). 
Methyl -D-galactopyranoside (15.0 g, 77.3 mmol), trityl chloride (43.2 g, 155 mmol) and DMAP 
(472 mg, 3.86 mmol) were stirred in pyridine (400 mL) at r.t. for 50 h under argon. The reaction 
was quenched with brine (200 mL) and extracted with CH2Cl2 (3 x 350 mL). The organic layer 
was each time washed with brine (200 mL). The combined organic layers were dried over 
Na2SO4, filtered, concentrated under reduced pressure and co-evaporated with toluene. The 
residue was purified by silica gel chromatography (CH2Cl2/methanol, 40:1 to 13:1) to afford 150 
(28.6 g, 85%) as a yellowish foam, the NMR data of which were in accordance with Lit.440 
 
Methyl 2,3,4-tri-O-benzyl-6-O-triphenylmethyl--D-galactopyranoside (151), (DS-03-11, DS-
03-17, DS-03-26, DS-04-02, DS-04-58). 
NaH (60% in oil, 6.95 g, 174 mmol) was suspended in DMF (20 mL) and washed several times 
with pentane under argon. After cooling to 0°C, a s olution of 150 (11.4 g, 26.1 mmol) in DMF (55 
mL) was slowly added and the suspension stirred for one hour at 0°C. The mixture was warmed 
to r.t. and benzyl bromide (18.6 mL, 156 mmol) was added. The reaction was stirred at 30°C for 
19 h, then quenched with methanol (5 mL) and H2O (5 mL). The mixture was extracted with 
CH2Cl2 (150 mL) and H2O (150 mL) and, after separation, the aqueous layer was extracted with 
CH2Cl2 (2 x 50 mL). The combined organic layers were washed with H2O (100 mL) and the 
aqueous layer was again twice extracted with CH2Cl2 (2 x 50 mL). The combined organic layers 
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were dried over Na2SO4, filtered, concentrated under reduced pressure and co-evaporated with 
toluene. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate, 
1:0 to 7:1) to afford 151 (16.9 g, 91%) as a white foam, the optical rotation of which was in 
accordance with Lit.441 
 
Methyl 2,3,4-tri-O-benzyl--D-galactopyranoside (152), (DS-03-15, DS-03-17, DS-03-26, DS-
04-03, DS-04-06). 
To a stirred solution of tritylether 151 (10.6 g, 15.0 mmol) in CH2Cl2 (50 mL) was added TES 
(2.86 mL, 18.0 mmol) and TMSOTf (60 l, 0.311 mmol). After 1 h another 0.02 eq of TMSOTf 
(60 l, 0.311 mmol) was added and after 3.5 h another 0.04 eq (120 l, 0.621 mmol). After 4.5 h 
the reaction was quenched by adding H2O (1 mL) and evaporated under reduced pressure. The 
resulting syrup was dissolved in THF (25 mL) and 80% AcOH (25 mL) and stirred for 1 h at r.t.. 
The reaction was then neutralised with NaHCO3, transferred into a separation funnel with ethyl 
acetate (150 mL) and extracted with satd. aqueous NaHCO3 (2 x 150 mL). The aqueous layers 
were each extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried 
over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by 
silica gel chromatography (petroleum ether/ethyl acetate, 3:1 to 1:1) to afford 152 (6.19 g, 89%) 
as a yellowish oil, the NMR data of which were in accordance with Lit.442 
 
Methyl 2,3,4-tri-O-benzyl--D-galacto-hexodialdo-1,5-pyranoside (153), (DS-03-04, DS-03-
18, DS-03-29, DS-04-05, DS-04-10). 
CH2Cl2 (5 mL) was cooled to -78°C and oxalyl chloride (85 5 l, 9.95 mmol) was added. Then 
DMSO (1.75 mL, 24.6 mmol) was slowly added and the solution stirred for 5 min. A solution of 
alcohol 152 (2.29 g, 4.92 mmol) in CH2Cl2 (35 mL) was slowly added and the reaction stirred at -
78°C for 2 h, before Et 3N (3.42 mL, 24.6 mmol) was added. The reaction was warmed to r.t. and 
extracted with satd. aqueous NaHCO3 (40 mL). The aqueous layer was extracted with CH2Cl2 (2 
x 20 mL) and the combined organic layers were dried over Na2SO4, filtered and concentrated 
under reduced pressure. The residue was purified by silica gel chromatography (petroleum 
ether/ethyl acetate, 3:1 to 2:1) to afford 153 (2.10 g, 92%) as a yellowish oil, the NMR data of 
which were in accordance with Lit.442 
 
Methyl 7-deoxy-2,3,4-tri-O-benzyl-7-(phenyldimethylsilyl)-L-glycero--D-galacto-
heptopyranoside (154), (DS-03-06, DS-03-19, DS-03-33, DS-04-07, DS-04-13). 
Dry magnesium turnings (329 mg, 13.6 mmol) were covered with THF (7 mL) and a small 
amount of (phenyldimethylsilyl)methyl chloride (2.44 mL, 13.6 mmol) was added. After initiating 
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the reaction either by the addition of I2 in THF, crushing the turnings or local heating, the 
remaining (phenyldimethylsilyl)methyl chloride was added in such a rate as to maintain a gentle 
reflux. Upon completion of the Grignard reagent formation, the reaction was cooled to -78°C and 
the aldehyde 153 (2.09 g, 4.52 mmol) dissolved in THF (15 mL) was slowly added to the 
reaction. The mixture was then slowly brought to r.t. over 17 h. The reaction was quenched by 
addition of satd. aqueous NH4Cl (15 mL). After extraction and separation the aqueous layer was 
extracted with TBME (2 x 15 mL). The combined organic layers were washed with H2O (30 mL) 
and the aqueous layer was extracted with TBME (2 x 30 mL). The combined organic layers were 
dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified 
by silica gel chromatography (petroleum ether/ethyl acetate, 6:1 to 4:1) to afford 154 (2.07 g, 
75%) as a colourless oil, the NMR data of which were in accordance with Lit.335 
 
Methyl 2,3,4-tri-O-benzyl-L-glycero--D-galacto-heptopyranoside (155), (DS-03-12, DS-03-
22, DS-03-23, DS-03-43, DS-04-09, DS-04-15). 
To a solution of 154 (7.38 g, 12.1 mmol) in AcOH (107 mL) were added KBr (1.73 g, 14.5 mmol) 
and sodium acetate (12.3 g, 150 mmol). The solution was cooled to 0°C, stirred under argon and 
protected from light. AcOOH (50 mL, 39% solution in AcOH) was added to the mixture. After 
stirring for 2.5 h at 0°C the reaction was brought to r.t. and quenched by pouring into an ice-cold, 
aqueous solution of Na2S2O4 (20%, 300 mL). CH2Cl2 (150 mL) was added and the mixture 
transferred into a separation funnel. After extraction and separation the aqueous layer was 
extracted with CH2Cl2 (2 x 100 mL). The combined organic layers were washed with H2O (300 
mL) and the aqueous layer was extracted with CH2Cl2 (2 x 100 mL). The combined organic 
layers were dried over Na2SO4, filtered, concentrated under reduced pressure and co-
evaporated with toluene. The residue was purified by silica gel chromatography (petroleum 
ether/ethyl acetate, 1:2) to afford 155 (4.54 g, 76%) as a yellowish resin, the NMR data of which 
were in accordance with Lit.335 
 
Methyl L-glycero--D-galacto-heptopyranoside (156), (DS-03-20, DS-03-21, DS-03-25, DS-
04-11, DS-04-16). 
To Pd/C (310 mg, 10% Pd) under argon atmosphere was added a solution of 155 (930 mg, 1.88 
mmol) in ethanol (10 mL) with a catalytic amount of acetic acid (100 l). The resulting 
suspension was hydrogenated under 70 psi at r.t.. After 19 h the reaction was quenched with 
CH2Cl2, filtered over celite and washed with ethanol (30 mL). The filtrate was concentrated in 
vacuo to afford 156 (414 mg, 98%) as a white solid, the NMR data of which were in accordance 
with Lit.335 
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Methyl 7-O-triphenylmethyl-L-glycero-α-D-galacto-heptopyranoside (157), (DS-03-30, DS-
04-12, DS-04-23). 
Heptopyranoside 156 (376 mg, 1.68 mmol), trityl chloride (935 mg, 3.35 mmol) and DMAP (10.3 
mg, 84.3 mol) were stirred in pyridine (8 mL) at r.t. for 36 h under argon. The reaction was 
quenched with brine (20 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined organic 
layers were dried over Na2SO4, filtered, concentrated under reduced pressure and co-
evaporated with toluene. The residue was purified by silica gel chromatography 
(CH2Cl2/methanol, 20:1 to 10:1) to afford 157 (618 mg, 79%) as a white solid.  
[]D21 = + 67.7 (c = 0.64, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 2.12 (d, 1 H, OH), 2.72 (m, 1 
H, OH), 3.08 (d, 1 H, OH), 3.22-3.25 (dd, 3J6,7a = 6.7 Hz, 2J7a,7b = 9.5 Hz, 1 H, H-7a), 3.25 (s, 3 H, 
OCH3), 3.33 (d, 1 H, OH), 3.38 (dd, 3J6,7b = 5.5 Hz, 2J7a,7b = 9.4 Hz, 1 H, H-7b), 3.73 (m, 1 H, H-3), 
3.80 (dd, 3J1,2 = 3.6 Hz, 3J2,3 = 9.2 Hz, 1 H, H-2), 3.87 (m, 1 H, H-5), 4.03 (m, 1 H, H-4), 4.10 (m, 
1 H, H-6), 4.79 (d, 3J1,2 = 3.8 Hz, 1 H, H-1), 7.31 (m, 15 H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) 
δ: 55.47 (OCH3), 64.04 (C-7), 68.27 (C-5), 69.60 (C-2), 71.14 (C-3), 71.62 (C-4), 72.27 (C-6), 
87.06 (CPh3), 99.37 (C-1), 127.24, 127.93, 128.60, 143.63 (18 C, 3 C6H5); elemental analysis 
calcd (%) for C27H30O7 (466.53) + ½ H2O: C 68.20, H 6.57; found: C 68.47, H 6.77. 
 
Methyl 2,3,4,6-tetra-O-benzoyl-7-O-triphenylmethyl-L-glycero--D-galacto-
heptopyranoside (158), (DS-03-37, DS-04-14, DS-04-27). 
To a stirred solution of 157 (4.21 g, 9.03 mmol) and DMAP (56.3 mg, 0.461 mmol) in pyridine 
(50 mL) was slowly added benzoyl chloride (8.3 ml, 72.0 mmol). The mixture was stirred at r.t. 
for 22 h under argon, and then carefully quenched by adding MeOH (3 mL). The mixture was 
diluted with CH2Cl2 (100 mL) and transferred into a separation funnel. The organic layer was 
washed with brine (2 x 150 mL) and the aqueous layers were extracted with CH2Cl2 (4 x 60 mL). 
The combined organic layers were dried with Na2SO4, filtered and co-evaporated with toluene. 
The residue was purified by column chromatography (petroleum ether/ethyl acetate, 5:1 to 4:1) 
to yield 158 (7.41 g, 93%) as a white foam.  
[]D21 = + 144.6 (c = 0.57, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 3.30 (dd, 3J6,7a = 5.4 Hz, 2J7a,7b 
= 10.7 Hz, 1 H, H-7a), 3.42 (s, 3 H, OCH3), 3.48 (dd, 3J6,7b = 2.9 Hz, 2J7a,7b = 10.8 Hz, 1 H, H-7b), 
4.73 (m, 1 H, H-5), 5.26 (d, 3J1,2 = 3.5 Hz, 1 H, H-1), 5.60 (dd, 3J1,2 = 3.5 Hz, 3J2,3 = 10.6 Hz, 1 H, 
H-2), 5.64 (m, 1 H, H-6), 5.87 (m, 1 H, H-4), 5.94 (dd, 3J3,4 = 3.1 Hz, 3J2,3 = 10.6 Hz, 1 H, H-3), 
7.14-8.06 (m, 35 H, 7 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 55.53 (OCH3), 62.09 (C-7), 67.41 
(C-5), 68.62 (C-3), 69.12 (C-4), 69.39 (C-2), 72.18 (C-6), 86.91 (CPh3), 97.32 (C-1), 127.05, 
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127.90, 128.20, 128.36, 128.40, 128.43, 128.52, 129.17, 129.22, 129.68, 129.78, 129.87, 
129.91, 133.01, 133.06, 133.27, 133.32, 143.44 (42 C, 7 C6H5), 165.06, 165.33, 165.57, 166.01 
(4 C=O); MS (ESI) m/z: calcd for C55H46NaO11 [M+Na]+: 905.3; found: 905.3;  elemental analysis 
calcd (%) for C55H46O11 (882.96): C 74.82, H 5.25; found: C 74.52, H 5.32. 
 
Methyl 2,3,4,6-tetra-O-benzoyl-L-glycero--D-galacto-heptopyranoside (159), (DS-03-39, 
DS-04-17, DS-04-30). 
To a stirred solution of tritylether 158 (5.20 g, 5.89 mmol) in CH2Cl2 (50 mL) was added TES 
(1.13 mL, 7.08 mmol) and TMSOTf (21.0 l, 0.109 mmol). After 1 h of stirring at r.t. the reaction 
was quenched by adding a few drops of H2O and evaporated under reduced pressure. The 
resulting syrup was dissolved in THF (20 mL) and 80% AcOH (20 mL) and stirred for 1 h at r.t.. 
The reaction was then neutralised with NaHCO3, transferred into a separation funnel with ethyl 
acetate (100 mL) and successively washed with satd. aqueous NaHCO3 (100 mL) and brine 
(100 mL). The aqueous layers were each extracted with ethyl acetate (3 x 50 mL). The 
combined organic layers were dried over Na2SO4, filtered and concentrated under reduced 
pressure. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate, 
4:1 to 2:1) to afford 159 (3.56 g, 94%) as a white foam.  
[]D21 = + 209.2 (c = 0.57, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 1.93 (m, 1 H, OH), 3.44 (s, 3 
H, OCH3), 3.89 (m, 1 H, H-7a), 4.01 (m, 1 H, H-7b), 4.70 (m, 1 H, H-5), 5.30 (d, 3J1,2 = 3.6 Hz, 1 
H, H-1), 5.50 (m, 1 H, H-6), 5.66 (dd, 3J1,2 = 3.6 Hz, 3J2,3 = 10.6 Hz, 1 H, H-2), 5.99 (dd, 3J3,4 = 
3.3 Hz, 3J2,3 = 10.7 Hz, 1 H, H-3), 6.09 (m, 1 H, H-4), 7.21-8.06 (m, 20 H, 4 C6H5); 13C-NMR 
(CDCl3, 125.8 MHz) δ: 55.60 (OCH3), 61.62 (C-7), 67.50 (C-5), 68.58 (C-3), 69.30 (C-2, C-4), 
73.75 (C-6), 97.45 (C-1), 128.24, 128.41, 128.44, 128.63, 129.05, 129.14, 129.70, 129.76, 
129.87, 129.99, 133.14, 133.27, 133.35, 133.60 (24 C, 4 C6H5), 165.48, 165.74, 165.94, 166.03 
(4 C=O); MS (ESI) m/z: calcd for C36H32NaO11 [M+Na]+: 663.2; found: 663.2; elemental analysis 
calcd (%) for C36H32O11 (640.64): C 67.49, H 5.03; found: C 67.28, H 5.17. 
 
Methyl 2,3,4,6-tetra-O-benzoyl-7-O-methanesulfonyl-L-glycero--D-galacto-
heptopyranoside (160), (DS-03-42, DS-04-18, DS-04-43). 
To a stirred solution of 159 (701 mg, 1.09 mmol) and DMAP (6.8 mg, 55.7 mol) in CH2Cl2 (8 
mL) and Et3N (306 L, 2.20 mmol) was slowly added mesyl chloride (171 L, 2.20 mmol). The 
reaction was stirred at r.t. for 26 h under argon. The mixture was diluted with CH2Cl2 (20 mL) 
and transferred into a separation funnel. The organic layer was washed with brine (15 mL) and 
the aqueous layer was extracted with CH2Cl2 (2 x 20 mL). The combined organic layers were 
dried with Na2SO4, filtered and concentrated under reduced pressure. The residue was purified 
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by column chromatography (petroleum ether/ethyl acetate, 2:1) to yield 160 (761 mg, 97%) as a 
white foam.  
[]D21 = + 162.3 (c = 0.65, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 3.06 (s, 3 H, SCH3), 3.46 (s, 3 
H, OCH3), 4.42 (dd, 3J6,7a = 4.3 Hz, 2J7a,7b = 11.7 Hz, 1 H, H-7a), 4.64-4.68 (m, 2 H, H-7b, H-5), 
5.30 (d, 3J1,2 = 3.6 Hz, 1 H, H-1), 5.65 (m, 1 H, H-6), 5.67 (dd, 3J1,2 = 3.5 Hz, 3J2,3 = 10.7 Hz, 1 H, 
H-2), 5.94 (dd, 3J3,4 = 3.3 Hz, 3J2,3 = 10.7 Hz, 1 H, H-3), 6.05 (m, 1 H, H-4), 7.21-8.05 (m, 20 H, 4 
C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 37.61 (SCH3), 55.84 (OCH3), 67.04 (C-5), 67.57 (C-7), 
68.48 (C-3), 68.92 (C-4), 69.01 (C-2), 70.13 (C-6), 97.55 (C-1), 128.27, 128.45, 128.52, 128.66, 
128.75, 128.96, 129.05, 129.10, 129.68, 129.89, 130.02, 133.25, 133.43, 133.53, 133.89 (24 C, 
4 C6H5), 165.47, 165.90, 166.00 (4 C=O); IR (KBr) ν: 3439 (w), 2939 (vw), 1729 (vs, C=O), 1602 
(w), 1452 (m), 1364 (m), 1316 (m), 1268 (vs), 1179 (s), 1109 (vs), 1070 (s), 1027 (s), 937 (w), 
828 (w), 710 (s) cm-1; MS (ESI) m/z: calcd for C37H34NaO13S [M+Na]+: 741.2; found: 741.2; 
elemental analysis calcd (%) for C37H34O13S (718.72): C 61.83, H 4.77; found: C 61.79, H 4.81. 
 
Methyl 7-azido-2,3,4,6-tetra-O-benzoyl-7-deoxy-L-glycero--D-galacto-heptopyranoside 
(161), (DS-03-50, DS-03-54, DS-04-20, DS-04-45). 
Mesylate 160 (257 mg, 0.358 mmol) was dissolved in DMF (3 mL) under argon. NaN3 (69.4 mg, 
1.07 mmol) was added with stirring and the mixture was heated at 100°C for 2 d. The reaction 
was cooled to r.t., quenched with water (1 mL) and transferred into a separation funnel with ethyl 
acetate (20 mL). The organic layer was washed with H2O (20 mL) and the aqueous layer was 
extracted with ethyl acetate (2 x 15 mL). The combined organic layers were dried with Na2SO4, 
filtered and co-evaporated with toluene. The residue was purified by column chromatography 
(petroleum ether/ethyl acetate, 8:1 to 5:1) to yield 161 (209 mg, 88%) as a yellowish foam.  
[]D21 = + 109.6 (c = 0.72, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 3.44 (s, 3 H, OCH3), 3.55 (dd, 
3J6,7a = 4.4 Hz, 2J7a,7b = 13.8 Hz, 1 H, H-7a), 3.76 (dd, 3J6,7b = 3.2 Hz, 2J7a,7b = 13.8 Hz, 1 H, H-7b), 
4.62 (m, 1 H, H-5), 5.29 (d, 3J1,2 = 3.5 Hz, 1 H, H-1), 5.59 (m, 1 H, H-6), 5.65 (m, 1 H, H-2), 5.96-
5.99 (m, 2 H, H-4, H-3), 7.21-8.07 (m, 20 H, 4 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 50.74 (C-
7), 55.66 (OCH3), 67.58 (C-5), 68.42, 68.95 (C-3, C-4), 69.18 (C-2), 71.45 (C-6), 97.45 (C-1), 
128.26, 128.43, 128.52, 128.70, 128.81, 129.02, 129.13, 129.21, 129.69, 129.83, 129.87, 
130.02, 133.20, 133.39, 133.46, 133.76 (24 C, 4 C6H5), 165.40, 165.44, 165.75, 166.00 (4 C=O); 
IR (KBr) ν: 3440 (vw), 2934 (vw), 2107 (m, N3), 1728 (vs, C=O), 1602 (w), 1452 (m), 1315 (m), 
1268 (vs), 1178 (m), 1108 (s), 1070 (s), 1027 (m), 929 (vw), 709 (s) cm-1; MS (ESI) m/z: calcd 
for C36H31N3NaO10 [M+Na]+: 688.2; found: 688.2; elemental analysis calcd (%) for C36H31N3O10 
(665.65): C 64.96, H 4.69, N 6.31; found: C 64.81, H 4.72, N 6.09. 
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1-O-Acetyl-7-azido-2,3,4,6-tetra-O-benzoyl-7-deoxy-L-glycero--D-galacto-
heptopyranoside  (162), (DS-03-58, DS-03-97, DS-04-47). 
A stirred solution of 161 (210 mg, 0.315 mmol) in AcOH (1.5 mL) and acetic anhydride (1.5 mL) 
was cooled to 0°C under argon. Concentrated sulphur ic acid (30 L) was added dropwise to the 
stirred solution and the reaction warmed to r.t.. After 24 h the reaction was cooled to 0°C and 
neutralized by adding satd. aqueous NaHCO3 and pulverized NaHCO3. The mixture was 
transferred into a separation funnel with CH2Cl2 and extracted with CH2Cl2 (3 x 30 mL). The 
combined organic layers were dried over Na2SO4, filtered and concentrated under reduced 
pressure. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate, 
5:1 to 4:1) to afford 162 (201 mg, 92%) as a white foam.  
[]D21 = + 111.5 (c = 0.54, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 2.23 (s, 3 H, C(O)CH3), 3.56 
(dd, 3J6,7a = 5.0 Hz, 2J7a,7b = 13.4 Hz, 1 H, H-7a), 3.75 (dd, 3J6,7b = 4.4 Hz, 2J7a,7b = 13.4 Hz, 1 H, 
H-7b), 4.73 (m, 1 H, H-5), 5.51 (m, 1 H, H-6), 5.87 (dd, 3J1,2 = 3.7 Hz, 3J2,3 = 10.7 Hz, 1 H, H-2), 
5.97 (dd, 3J3,4 = 3.3 Hz, 3J2,3 = 10.8 Hz, 1 H, H-3), 6.06 (m, 1 H, H-4), 6.70 (d, 3J1,2 = 3.7 Hz, 1 H, 
H-1), 7.23-7.99 (m, 20 H, 4 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 20.90 (C(O)CH3), 50.43 (C-
7), 67.43 (C-2), 68.44 (C-3), 68.63 (C-4), 69.56 (C-5), 71.16 (C-6), 89.80 (C-1), 128.34, 128.37, 
128.51, 128.57, 128.65, 128.72, 128.73, 129.01, 129.72, 129.73, 129.77, 129.85, 129.94, 
130.05, 133.42, 133.57, 133.77 (24 C, 4 C6H5), 165.52 (4 C(=O)Ph), 168.74 (C(=O)CH3); IR 
(KBr) ν: 3440 (vw), 3065 (vw), 2108 (s, N3), 1760 (s, C=O), 1730 (vs, C=O), 1602 (w), 1585 
(vw), 1492 (vw), 1452 (m), 1370 (w), 1316 (m), 1267 (vs), 1218 (s), 1178 (m), 1108, (vs), 1070 
(s), 1026 (m), 935 (w), 872 (vw), 709 (s) cm-1; MS (ESI) m/z: calcd for C37H31N3NaO11 [M+Na]+: 
716.2; found: 716.2; elemental analysis calcd (%) for C37H31N3O11 (693.66): C 64.07, H 4.50, N 
6.06; found: C 63.95, H 4.54, N 5.99. 
 
Ethyl 7-azido-2,3,4,6-tetra-O-benzoyl-7-deoxy-1-thio-L-glycero--D-galacto-
heptopyranoside (163), (DS-03-62, DS-03-98, DS-03-101, DS-04-59). 
ZnI2 (186 mg, 0.581 mmol) was mixed with activated 4Å molecular sieves (800 mg) in a 
microwave tube, which was then evacuated overnight. 162 (195 mg, 0.280 mmol) was dissolved 
in CH2Cl2 (4 mL) and added to the tube via a syringe. After stirring for 20 min under argon, 
(ethylthio)trimethylsilane (90%, 105 L, 0.584 mmol) was added via a syringe and the tube was 
heated by microwave irradiation to 50°C for 1.5 h. The reaction was filtered through celite and 
the celite washed with CH2Cl2 (30 mL). The filtrate was successively washed with satd. aqueous 
NaHCO3 (30 ml) and water (30 ml). The aqueous layers were each time extracted with CH2Cl2 (3 
x 30 ml). The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The 
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crude product was purified by column chromatography (petroleum ether/ethyl acetate, 5.5:1 to 
5:1) to afford 163 (159 mg, 82%) as colourless foam.  
[]D21 = + 80.4 (c = 0.61, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 1.16 (t, 3J = 7.4 Hz, 3 H, 
SCH2CH3), 2.58-2.75 (m, 2 H, SCH2CH3), 3.55 (dd, 3J6,7a = 4.5 Hz, 2J7a,7b = 13.8 Hz, 1 H, H-7a), 
3.80 (dd, 3J6,7b = 3.3 Hz, 2J7a,7b = 13.8 Hz, 1 H, H-7b), 4.37 (m, 1 H, H-5), 4.87 (d, 3J1,2 = 10.0 Hz, 
1 H, H-1), 5.56 (m, 1 H, H-6), 5.65 (dd, 3J3,4 = 3.4 Hz, 3J2,3 = 9.9 Hz, 1 H, H-3), 5.80 (m, 1 H, H-
2), 5.99 (m, 1 H, H-4), 7.21-8.05 (m, 20 H, 4 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 14.89 
(SCH2CH3), 24.42 (SCH2CH3), 50.59 (C-7), 68.12 (C-4), 68.30 (C-2), 71.57 (C-6), 72.73 (C-3), 
75.96 (C-5), 84.22 (C-1), 128.27, 128.38, 128.42, 128.62, 128.65, 128.71, 129.13, 129.17, 
129.72, 129.79, 129.84, 130.02, 133.31, 133.43, 133.80 (24 C, 4 C6H5), 165.30, 165.38, 165.62 
(4 C, C=O); MS (ESI) m/z: calcd for C37H33N3NaO9S [M+Na]+: 718.2; found: 718.3; elemental 
analysis calcd (%) for C37H33N3O9S (695.74): C 63.88, H 4.78, N 6.04; found: C 64.02, H 4.84, N 
5.78. 
 
(1R,2R)-2-Hydroxycyclohexyl-2,3,4-tris-O-benzyl-6-deoxy--L-galactopyranoside (168), 
(DS-03-45, DS-03-51, DS-03-55).  
A solution of Br2 (380 µl, 7.49 mmol) in CH2Cl2 (12 mL) was slowly added at 0°C to a solution of 
ethyl 2,3,4-tri-O-benzyl-1-thio-L-fucopyranoside (166) (3.00 g, 6.27 mmol) in CH2Cl2 (6 mL). After 
stirring for 1 h at 0 °C, cyclohexene (1.5 mL) was added and the solution stirred for another 20 
min. The mixture was added dropwise to a solution of (1R,2R)-trans-1,2-cyclohexanediol (167) 
(610 mg, 5.25 mmol) and Et4NBr (1.31 g, 6.23 mmol) in DMF/CH2Cl2 (50 mL, 1:1) which has 
been stirred over activated 4Å molecular sieves (2.4 g) for 2 h. The mixture was stirred for 3 h at 
r.t.. The reaction was quenched with pyridine (6 mL) and filtered over celite with addition of 
CH2Cl2 (100 mL). The solution was washed with brine (100 mL) and the aqueous layer was 
extracted with CH2Cl2 (3 x 70 mL). The combined organic phases were washed with brine (150 
mL) and the aqueous layer was extracted with CH2Cl2 (3 x 70 mL). The combined organic 
phases were dried with Na2SO4, filtered and the solvent was removed azeotropically with 
toluene. The residue was purified by repeated flash chromatography (toluene/ethyl acetate, 10:1 
to 9:1) to afford 168 (1.19 g, 42%) as yellowish resin, the NMR data of which were in accordance 
with Lit.264 
 
Benzyl (R)-3-cyclohexyl-2-hydroxypropionate (170), (DS-03-49, DS-04-39, DS-04-100). 
Rh/Al2O3 (101 mg, 5% Rh) was suspended under argon in THF/H2O (10 mL, 1:1). D-(+)-3-
Phenyllactic acid (1.99 g, 12.0 mmol) was added and the resulting mixture was hydrogenated 
under 70 psi at r.t. for 4 days. The reaction was quenched with CH2Cl2 and filtered over celite. 
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The filtrate was concentrated in vacuo, suspended in methanol/water (9:1, 10 mL) and the pH 
adjusted to 8.0 by addition of an aqueous solution of Cs2CO3. The solvent was removed 
azeotropically with toluene and the residue was dried in vacuo and redissolved in DMF (35 mL). 
Benzylbromide (1.43 mL, 12.0 mmol) was slowly added and the mixture was stirred at r.t. for 24 
h. The mixture was diluted with CH2Cl2 (100 mL) and transferred into a separation funnel. The 
organic layer was washed with H2O (100 mL) and the aqueous layer was extracted with CH2Cl2 
(2 x 100 mL). The combined organic layers were dried with Na2SO4, filtered and co-evaporated 
with toluene. The residue was purified by column chromatography (petroleum ether/ethyl 
acetate, 8:1 to 6:1) to yield 170 (2.51 g, 80%) as a white solid, the NMR data of which were in 
accordance with Lit.443 
 
Benzyl (R)-3-cyclohexyl-2-trifluoromethanesulfonyloxypropionate (171), (DS-03-90, DS-03-
108, DS-04-34, DS-04-85, DS-04-92, DS-04-96). 
To a stirred solution of 170 (1.08 g, 4.12 mmol) and 2,6-di-tert-butylpyridine (1.20 mL, 5.34 
mmol) in CH2Cl2 (10 mL) was slowly added Tf2O (835 L, 4.96 mmol) at -20°C. The mixture was 
stirred for 3 h at -20°C under argon. The mixture was diluted with CH2Cl2 (20 mL) and 
transferred into a separation funnel. The organic layer was washed with satd. aqueous KH2PO4 
(20 mL) and the aqueous layer was extracted with CH2Cl2 (2 x 15 mL). The organic phases were 
combined, washed with satd. aqueous KH2PO4 (50 mL) and the aqueous layer was reextracted 
with CH2Cl2 (2 x 30 mL). The combined organic phases were dried with Na2SO4, filtered and 
concentrated under reduced pressure. The residue was purified by column chromatography 
(petroleum ether/ethyl acetate, 1:0 to 25:1) to yield 171 (1.54 g, 95%) as a colourless oil, the 
NMR data of which were in accordance with Lit.443 
 
(1R,2R)-2-[(2,3,4-tris-O-benzyl-6-deoxy--L-galactopyranosyl)oxy]cyclohexyl 7-azido-
2,3,4,6-tetra-O-benzoyl-7-deoxy-L-glycero--D-galacto-heptopyranoside (172), (DS-03-103, 
DS-03-105, DS-04-66). 
Dry CH2Cl2 (10 mL) was added to a mixture of thioglycoside 163 (224 mg, 0.322 mmol), glycosyl 
acceptor 168 (208 mg, 0.390 mmol) and activated 4Å molecular sieves (4 g) under argon. A 
suspension of DMTST (258 mg, 0.333 mmol) and activated 4Å molecular sieves (1.5 g) in 
CH2Cl2 (3 mL) was prepared in a second flask. Both suspensions were stirred at r.t. for 4 h, then 
the DMTST suspension was added in two portions to the other suspension. The reaction was 
stopped after 67 h and filtered through celite. The celite was washed with CH2Cl2 (40 mL). The 
filtrate was successively washed with satd. aqueous NaHCO3 (40 ml) and water (30 ml). The 
aqueous layers were each time extracted with DCM (3 x 40 ml). The combined organic layers 
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were dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by 
column chromatography (petroleum ether/ethyl acetate, 5:1) to afford 172 (333 mg, 89%) as a 
yellowish foam.  
[]D21 = - 20.1 (c = 0.98, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.94 (m, 1 H, Cy), 1.00-1.10 (m, 
2 H, Cy), 1.16 (m, 1 H, Cy), 1.23 (d, 3JF5,F6 = 6.3 Hz, 3 H, Fuc H-6), 1.43, 1.51, 1.77, 1.92, 3.50 
(5 m, 5 H, Cy), 3.56-3.59 (m, 2 H, Cy, Hep H-7a), 3.70 (m, 1 H, Fuc H-4), 3.77 (dd, 3JH6,H7b = 2.4 
Hz, 2JH7a,H7b = 13.8 Hz, 1 H, Hep H-7b), 4.00 (dd, 3JF1,F2 = 3.2 Hz, 3JF2,F3 = 9.8 Hz, 1 H, Fuc H-2), 
4.11 (m, 1 H, Fuc H-3), 4.28-4.29 (m, 2 H, Hep H-5, Fuc H-5), 4.60-4.74 (4 m, 4 H, 4 CH2Ph), 
4.86 (d, 3JF1,F2 = 3.4 Hz, 1 H, Fuc H-1), 4.90 (d, 1 H, Hep H-1), 4.92, 5.00 (2 m, 2 H, 2 CH2Ph), 
5.53-5.56 (m, 2 H, Hep H-3, Hep H-6), 5.72 (m, 1 H, Hep H-2), 5.92 (m, 1 H, Hep H-4), 7.21-
8.07 (m, 35 H, 7 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 16.86 (Fuc C-6), 22.35, 22.39, 28.04, 
28.08 (4 C, Cy), 50.46 (Hep C-7), 66.36 (Fuc C-5), 68.00 (Hep C-4), 69.74 (Hep C-2), 71.34, 
72.15 (3 C, Hep C-3, Hep C-5, Hep C-6), 72.85, 73.00, 74.76 (3 CH2Ph), 75.12 (Cy), 76.62 (Fuc 
C-2), 77.54 (Cy), 78.65 (Hep C-4), 79.57 (Fuc C-3), 94.71 (Fuc C-1), 98.45 (Hep C-1), 127.18, 
127.32, 127.39, 127.43, 127.78, 128.19, 128.26, 128.37, 128.61, 128.64, 128.86, 129.17, 
129.34, 129.59, 129.73, 129.83, 130.04, 133.18, 133.22, 133.29, 133.82, 138.92, 139.07, 
139.36 (42 C, 7 C6H5), 164.96, 165.31, 165.44, 165.62 (4 C=O); elemental analysis calcd (%) for 
C68H67N3O15 (1166.27): C 70.03, H 5.79, N 3.60; found: C 69.96, H 5.85, N 3.60. 
 
(1R,2R)-2-[(2,3,4-tris-O-benzyl-6-deoxy--L-galactopyranosyl)oxy]cyclohexyl 7-azido-7-
deoxy-L-glycero--D-galacto-heptopyranoside (173), (DS-03-106, DS-03-110, DS-04-72). 
172 (333 mg, 0.286 mmol) was dissolved in methanol (8 ml) and sodium methanolate (0.029 
mmol in 108 µl MeOH) was added. After stirring at r.t. under argon for 13 h additional sodium 
methanolate (0.029 mmol in 108 µl MeOH) was added. After stirring the reaction for totally 23 h 
the reaction was quenched by addition of acetic acid (15 µl). The mixture was concentrated in 
vacuo and the crude product was purified by column chromatography (CH2Cl2/methanol, 20:1) to 
afford 173 (207 mg, 97%) as a yellowish foam.  
[]D21 = - 65.3 (c = 0.54, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 1.10 (d, 3JF5,F6 = 6.5 Hz, 3 H, 
Fuc H-6), 1.12-1.38 (m, 4 H, Cy), 1.68-1.72 (m, 2 H, Cy), 1.89 (s, 1 H, OH), 2.02-2.07 (m, 2 H, 
Cy), 2.94, 2.97, 3.06 (3 s, 3 H, 3 OH), 3.29 (dd, 3JH6,H7a = 5.1 Hz, 2JH7a,H7b = 12.6 Hz, 1 H, Hep H-
7a), 3.40 (m, 1 H, Gal H-5), 3.45 (dd, 3JH6,H7b = 5.2 Hz, 2JH7a,H7b = 12.6 Hz, 1 H, Hep H-7b), 3.51-
3.58 (m, 3 H, Hep H-2, Hep H-3, Cy), 3.68-3.73 (m, 2 H, Fuc H-4, Cy), 3.91 (m, 1 H, Hep H-4), 
3.99-4.05 (m, 3 H, Hep H-6, Fuc H-3, Fuc H-2), 4.31 (d, 3JH1,H2 = 6.7 Hz, 1 H, Hep H-1), 4.35 (m, 
1 H, Fuc H-5), 4.61, 4.68, 4.76, 4.78, 4.82, 4.95 (6 m, 6 H, 3 CH2Ph), 4.97 (d, 3JF1,F2 = 3.0 Hz, 1 
H, Fuc H-1), 7.24-7.41 (m, 15 H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 16.68 (Fuc C-6), 
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23.53, 23.57, 29.51, 29.67 (4 C, Cy), 52.19 (Hep C-7), 66.31 (Fuc C-5), 69.47 (Hep C-4), 71.01, 
71.02 (Hep C-2, Hep C-6), 72.56 (CH2Ph), 73.21, 73.27 (2 C, Hep C-3, CH2Ph), 73.54 (Hep C-
5), 74.85 (CH2Ph), 76.18, 76.31 (2 C, Fuc C-3, Cy), 77.75, 78.13 (2 C, Fuc C-4, Cy), 79.52 (Fuc 
C-2), 94.38 (Fuc C-1), 100.22 (Hep C-1), 127.31, 127.47, 127.67, 128.00, 128.13, 128.28, 
128.29, 128.30, 138.43, 138.74, 139.04 (18 C, 3 C6H5); elemental analysis calcd (%) for 
C40H51N3O11 (749.85): C 64.07, H 6.86, N 5.60; found: C 64.20, H 6.85, N 5.44. 
 
(1R,2R)-2-[(2,3,4-tris-O-benzyl-6-deoxy--L-galactopyranosyl)oxy]cyclohexyl 7-azido-3-O-
[(1S)-1-benzyloxycarbonyl-2-cyclohexyl-ethyl]-7-deoxy-L-glycero--D-galacto-
heptopyranoside (174), (DS-03-109, DS-03-112, DS-04-99). 
A suspension of 173 (136 mg, 0.181 mmol) and Bu2SnO (49.6 mg, 0.199 mmol) in dry MeOH (4 
mL) was refluxed for 3 h. The solvent was removed and the resulting foam dried in vacuo 
overnight. CsF (55.0 mg, 0.362 mmol) was dried in vacuo at 200°C for 30 min and flushed with 
argon. Then the triflate 171 (144 mg, 0.365 mmol) and the tin acetal were added to the CsF in 
DME (5 mL) via syringe. The reaction was stirred for 24 h, transferred into a separation funnel 
with ethyl acetate and extracted with brine (2 x 25 mL). The aqueous layers were each extracted 
with ethyl acetate (2 x 50 mL). The combined organic layers were dried over Na2SO4, filtered 
and concentrated under reduced pressure. The residue was purified by silica gel 
chromatography (petroleum ether/ethyl acetate, 3:1) to afford 174 (97.3 mg, 54%) as yellowish 
foam.  
[]D21 = - 63.8 (c = 0.85, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.86-2.04 (m, 21 H, CyCH2, 
Cy), 1.10 (d, 3JF5,F6 = 6.5 Hz, 3 H, Fuc H-6), 2.40 (s, 1 H, OH), 3.20 (dd, 3JH6,H7a = 4.9 Hz, 2JH7a,H7b 
= 12.6 Hz, 1 H, Hep H-7a), 3.25 (dd, 3JH3,H4 = 3.1 Hz, 3JH2,H3 = 9.3 Hz, 1 H, Hep H-3), 3.32 (m, 1 
H, Hep H-5), 3.39 (dd, 3JH6,H7b = 5.3 Hz, 2JH7a,H7b = 12.6 Hz, 1 H, Hep H-7b), 3.50-3.55 (m, 2 H, 
OH, Cy), 3.65-3.70 (m, 2 H, Hep H-2, Cy), 3.72 (m, 1 H, Fuc H-4), 3.76 (m, 1 H, Hep H-4), 3.99-
4.04 (m, 4 H, Fuc H-2, Fuc H-3, Hep H-6, OH), 4.26-4.27 (m, 2 H, Hep H-1, Lac H-2), 4.44 (m, 1 
H, Fuc H-5), 4.62, 4.68, 4.77, 4.78, 4.84, 4.95 (6 m, 6 H, 3 CH2Ph), 4.92 (d, 3JF1,F2 = 2.7 Hz, 1 H, 
Fuc H-1), 5.15-5.21 (m, 2 H, CH2Ph), 7.25-7.42 (m, 20 H, 4 C6H5); 13C-NMR (CDCl3, 125.8 MHz) 
δ: 16.66 (Fuc C-6), 23.45, 29.48, 29.67, 30.50 (4 C, Cy), 25.97, 26.18, 26.37, 32.08, 33.49, 
33.84 (6C, Cy, CyCH2), 40.92 (CyCH2), 52.10 (Hep C-7), 66.17 (Fuc C-5), 67.21 (CH2Ph), 68.31 
(Hep C-4), 70.68 (Hep C-2), 71.00 (Hep C-6), 72.61 (CH2Ph), 72.96, 73.08 (2 C, Hep C-5, 
CH2Ph), 74.85 (CH2Ph), 76.14, 76.18 (2 C, Fuc C-2, Cy), 77.32 (Lac C-2), 77.94 (Fuc C-4), 
78.47 (Cy), 79.72 (Fuc C-3), 82.61 (Hep C-3), 94.75 (Fuc C-1), 100.53 (Hep C-1), 127.19, 
127.27, 127.37, 127.49, 127.91, 128.08, 128.23, 128.24, 128.29, 128.53, 128.71, 135.11, 
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138.74, 138.93, 139.31 (24 C, 4 C6H5), 174.90 (C=O); elemental analysis calcd (%) for 
C56H71N3O13 (994.18): C 67.65, H 7.20, N 4.23; found: C 67.58, H 7.32, N 4.18. 
 
(1R,2R)-2-[(2,3,4-tris-O-benzyl-6-deoxy--L-galactopyranosyl)oxy]cyclohexyl 7-amino-3-O-
[(1S)-1-benzyloxycarbonyl-2-cyclohexyl-ethyl]-7-deoxy-L-glycero--D-galacto-
heptopyranoside (175), (DS-03-111, DS-04-103). 
174 (346 mg, 0.348 mmol) was dissolved in THF (8 mL) and PPh3 (184 mg, 0.700 mmol) was 
added. After stirring under argon for 24 h, H2O (200 µL) was added and the reaction stirred for 
another 4 h. The mixture was concentrated in vacuo and the crude product was purified by 
column chromatography (petroleum ether/CH2Cl2/methanol, 20:20:1 to 0:20:1, + 0.5% Et3N) to 
afford 175 (332 mg, 98%) as a colourless foam.  
1H-NMR (MeOD, 500.1 MHz) δ: 0.86-0.97, 1.21-1.32, 1.55-1.67, 1.87-1.89, 2.08 (m, 21 H, 
CyCH2, Cy), 1.15 (m, 3 H, Fuc H-6), 2.53 (dd, 3JH6,H7a = 7.2 Hz, 2JH7a,H7b = 13.0 Hz, 1 H, Hep H-
7a), 2.71 (dd, 3JH6,H7b = 3.2 Hz, 2JH7a,H7b = 13.0 Hz, 1 H, Hep H-7b), 3.16 (m, 1 H, Gal H-5), 3.23 
(dd, 3JH3,H4 = 2.9 Hz, 3JH2,H3 = 9.3 Hz, 1 H, Hep H-3), 3.52 (m, 1 H, Cy), 3.57 (m, 1 H, Hep H-2), 
3.70 (m, 1 H, Cy), 3.79-3.83 (m, 2 H, Hep H-4, Hep H-6), 3.90 (m, 1 H, Fuc H-4), 3.96 (m, 1 H, 
Fuc H-2), 4.07 (dd, 3JF3,F4 = 2.6 Hz, 3JF2,F3 = 10.1 Hz, 1 H, Fuc H-3), 4.23 (d, 3JH1,H2 = 7.7 Hz, 1 H, 
Hep H-1), 4.49 (m, 1 H, Lac H-2), 4.59-4.62 (m, 2 H, CH2Ph), 4.68-4.74 (m, 3 H, Fuc H-5, 
CH2Ph), 4.82-4.91 (m, 2 H, CH2Ph), 4.96 (d, 3JF1,F2 = 2.9 Hz, 1 H, Fuc H-1), 5.15, 5.23 (2 m, 2 H, 
CH2Ph), 7.25-7.45 (m, 20 H, 4 C6H5); 13C-NMR (MeOD, 125.8 MHz) δ: 16.95 (Fuc C-6), 24.76, 
24.85, 27.19, 27.43, 27.65, 31.06, 31.34, 33.47, 34.65, 35.08, 42.30 84 (11 C, Cy, CyCH2), 
43.83 (Hep C-7), 65.21 (CH2Ph), 67.75 (Fuc C-5), 68.88 (Hep C-4), 72.48, 72.95 (Hep C-2, Hep 
C-6), 73.85, 74.27, 76.34 (3 CH2Ph), 76.88 (Hep C-5), 77.58 (Fuc C-2), 78.03 (1 C, Cy), 78.43 
(Lac C-2), 78.89 (1 C, Cy), 79.79 (Fuc C-4), 80.94 (Fuc C-3), 83.58 (Hep C-3), 95.78 (Fuc C-1), 
102.22 (Hep C-1), 127.97, 128.24, 128.42, 128.46, 128.58, 128.82, 129.18, 129.34, 129.37, 
129.46, 139.80, 140.22, 140.67, 142.67 (24 C, 4 C6H5), 177.30 (C=O); HR-MS (ESI) m/z: calcd 
for C56H73NNaO13 [M+Na]+: 990.4974; found: 990.4971 (0.3 ppm). 
 
n-Butyl pyruvate (177), (DS-03-65). 
Freshly destilled pyruvic acid (41.2 g, 468 mmol) was esterified with n-butanol (51.9 g, 700 
mmol) in benzene (80 mL). After refluxing for 18 h with a water separator, the reaction mixture 
was concentrated and vacuum distilled to give n-butyl pyruvate (53.3 g, 79%) as a pale green-
yellowish oil, the NMR data of which were in accordance with Lit.444 
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Butyl 2-oxopropanoate (5-carboxy-2-chlorophenyl) hydrazone (180), (DS-03-67, DS-03-74, 
DS-03-84). 
3-Amino-4-chlorobenzoic acid (6.87 g, 40.1 mmol) was suspended in H2O (30 mL) and dissolved 
with conc. HCl (32 mL). While stirring mechanically, the solution was cooled to -10°C. Sodium 
nitrite (3.31 g, 48.0 mmol) was dissolved in H2O (16 mL) and carefully added to the reaction, not 
allowing the temperature to raise above 0°C. After stirring for 10 min at -10°C, tin(II) chloride 
dihydrate (27.1 g, 120 mmol) dissolved in conc. HCl (30 mL) was slowly added and the reaction 
stirred at -10°C for another 30 min. n-Butyl pyruvate (11.5 g, 80.1 mmol) was added to the white 
suspension and the mixture heated to 90°C for 2.5 h . The reaction mixture was allowed to cool 
to r.t. and the product was extracted into ethyl acetate (3 x 100 mL). The combined organic 
layers were successively washed with HCl (3 M, 3 x 100 mL), dilute HCl (0.1 M, 150 mL) and 
brine (100 mL). The organic layer was concentrated to a syrup under reduced pressure, then ice 
was added and, after melting, the yellow pellets were filtered off and dried in vacuo at 50°C to 
give hydrazone 180 (10.7 g, 86%).  
1H-NMR (DMSO, 500.1 MHz) δ: 0.86 (t, 3J = 7.4 Hz, 3 H, nBu), 1.34 (m, 2 H, nBu), 1.59 (m, 2 H, 
nBu), 2.10 (CH3), 4.18 (m, 3J = 6.5 Hz, 2 H, nBu), 7.41 (m, 1 H, C6H3), 7.49 (m, 1 H, C6H3), 8.02 
(m, 1 H, C6H3), 12.30 (s, 1 H, NH), 13.19 (br, s, 1 H, COOH); 13C-NMR (DMSO, 125.8 MHz) δ: 
13.91 (nBu), 19.02 (nBu), 19.93 (CH3), 30.28 (nBu), 65.23 (nBu), 114.36, 121.77, 122.64, 
130.10, 130.46, 131.26 (6 C, C6H3), 139.88 (C=N), 163.52 (C=O), 166.97 (COOH); MS (ESI) 
m/z: calcd for C14H16ClN2O4 [M-H]-: 311.1; found: 311.1; elemental analysis calcd (%) for 
C14H17ClN2O4 (312.75): C 53.77, H 5.48, N 8.96; found: C 53.78, H 5.50, N 8.75. 
 
2-Butoxycarbonyl-7-chloro-indole-4-carboxylic acid (181), (DS-03-77, DS-03-83, DS-03-85). 
Hydrazone 180 (1.29 g, 4.13 mmol) was placed in a microwave tube and purged with argon. 
AcOH (5 mL) and BF3 etherate (1.04 mL, 8.25 mmol) were added and the mixture heated in the 
microwave for 5 h to 90°C. The mixture was poured i nto ice-water, filtered and dried in vacuo. 
The crude product was purified by column chromatography (toluene/THF, 5:1 to 3:1) to afford 
181 (196 mg, 16%) as a creamy solid. For the scaling-up, purification was performed by 
redissolving the crude product in THF and treatment with an equal amount of activated charcoal. 
Filtration, concentration in vacuo and recrystallization from acetone yielded the pure indole as a 
creamy solid.  
1H-NMR (DMSO, 500.1 MHz) δ: 0.89 (t, 3 H, nBu), 1.37 (m, 2 H, nBu), 1.67 (m, 2 H, nBu), 4.27 
(t, 2 H, nBu), 7.41, 7.62, 7.71 (m, 3 H, Ind), 12.43 (s, 1 H, NH), 13.05 (br, s, 1 H, COOH); 13C-
NMR (DMSO, 125.8 MHz) δ: 13.65, 18.73, 30.29, 64.59 (4 C, nBu), 109.77, 122.03, 122.48, 
123.89, 124.72, 127.50, 130.56, 135.05 (8 C, Ind), 160.81 (COOnBu), 167.23 (COOH); MS 
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(ESI) m/z: calcd for C14H13ClNO4 [M-H]-: 294.1; found: 294.0; elemental analysis calcd (%) for 
C14H14ClNO4 (295.72): C 56.86, H 4.77, N 4.74; found: C 56.77, H 4.80, N 4.72. 
 
tert-Butyl 2-butoxycarbonyl-7-chloro-indole-4-carboxylate (182), (DS-03-87). 
Carboxylic acid 181 (1.22 g, 4.13 mmol) and CDI (1.00 g, 6.19 mmol) were placed in a flask 
under argon. THF (20 mL) was slowly added and the solution heated to 50°C while stirring. After 
1.5 h tBuOH (2 mL, 21.2 mmol) and DBU (930 µL, 6.22 mmol) were added and the reaction 
heated at reflux for 76 h. The mixture was transferred into a separation funnel with ethyl acetate 
(100 mL) and washed with satd. aqueous NaHCO3 (100 mL). The aqueous layer was extracted 
with ethyl acetate (2 x 80 mL). The combined organic phases were washed with brine (150 mL) 
and the aqueous layer was extracted with ethyl acetate (2 x 100 mL). The combined organic 
phases were dried with Na2SO4, filtered and concentrated under reduced pressure. The residue 
was purified by flash chromatography (petroleum ether/ethyl acetate, 30:1 to 25:1) to afford 182 
(777 mg, 54%) as a white solid.  
1H-NMR (CDCl3, 500.1 MHz) δ: 1.00 (t, 3 H, nBu), 1.50 (m, 2 H, nBu), 1.67 (s, 9 H, tBu), 1.78 
(m, 2 H, nBu), 4.38 (t, 2 H, nBu), 7.35 (m, 1 H, Ind), 7.83 (m, 2 H, Ind), 9.14 (s, 1 H, NH); 13C-
NMR (CDCl3, 125.8 MHz) δ: 13.72, 19.19, 30.71, 65.31 (4 C, nBu), 28.31 (3 C, C(CH3)3), 81.52 
(C(CH3)3), 110.46, 121.92, 123.64, 124.13, 124.96, 127.75, 129.53, 134.54 (8 C, Ind), 161.60 
(COOnBu), 165.41 (COOtBu); MS (ESI) m/z: calcd for C18H21ClNO4 [M-H]-: 350.1; found: 350.1; 
elemental analysis calcd (%) for C18H22ClNO4 (351.82): C 61.45, H 6.30, N 3.98; found: C 61.44, 
H 6.43, N 3.92. 
 
tert-Butyl 7-chloro-2-[(4-methyl-1-piperazinyl)carbonyl]-indole-4-carboxylate (183), (DS-03-
92, DS-03-104). 
Butylester 182 (197 mg, 0.561 mmol) was dissolved in acetone (4 mL) under argon. Aqueous 
NaOH (0.5 M, 1.15 mL, 0.577 mmol) was added and the reaction stirred for 69 h under 
protection from light. The mixture was concentrated and dried in vacuo overnight. Imidazol (172 
mg, 2.53 mmol) was dissolved in acetonitrile (3 mL) under argon and cooled to 0°C. Oxalyl 
dichloride (54.0 µL, 0.619 mmol) was slowly added and the reaction warmed to r.t.. After stirring 
for 15 min the dry indole was added in acetonitrile (10 mL) and the mixture was heated to 45°C 
for 1 h. N-Methylpiperazine (70.0 L, 0.631 mmol) was added and the temperature increased to 
55°C.  After stirring for 3 h under argon the mixtu re was concentrated under reduced pressure 
and purified by flash chromatography (CH2Cl2/methanol, 20:1) to afford 183 (188 mg, 89%) as a 
white solid.  
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1H-NMR (CDCl3, 500.1 MHz) δ: 1.65 (s, 9 H, tBu), 2.36 (s, 3 H, CH3), 2.51 (s, 4 H, Pip H-3, Pip 
H-5), 3.98 (br, s, 4 H, Pip H-2, Pip H-6), 7.30, 7.47, 7.81 (3 m, 3 H, Ind), 9.39 (s, 1 H, NH); 13C-
NMR (CDCl3, 125.8 MHz) δ: 28.33 (3 C, C(CH3)3), 46.03 (CH3), 55.01 (4 C, Pip), 81.26 
(C(CH3)3), 107.16, 121.89, 122.81, 123.34, 124.81, 127.88, 131.44, 133.42 (8 C, Ind), 161.41, 
165.57 (2 C=O); MS (ESI) m/z: calcd for C19H25ClN3O3 [M+H]+: 378.2; found: 378.1; elemental 
analysis calcd (%) for C19H24ClN3O3 (377.87): C 60.39, H 6.40, N 11.12; found: C 60.27, H 6.57, 
N 11.03. 
 
tert-Butyl 2-[(4-methyl-1-piperazinyl)carbonyl]-7-phenyl-indole-4-carboxylate (184), (DS-
03-107, DS-03-113, DS-03-121). 
Pd2(dba)3 (1.7 mg, 1.64 µmol) and 2-dicyclohexylphosphino-2’,6’-dimethoxybiphenyl (S-Phos, 
3.3 mg, 8.04 µmol) were placed in a flask which was evacuated and flushed with argon several 
times. Toluene (2 mL) was added and the catalyst stirred under argon for 45 min at 50°C. 
Arylchloride 183 (60.9 mg, 0.161 mmol), phenylboronic acid (29.7 mg, 0.244 mmol) and Cs2CO3 
(161 mg, 0.493 mmol) were placed in a microwave tube and dried in vacuo at 50°C for 1 h. The 
tube was flushed with argon and the catalyst was added via syringe. After flushing for 10 min 
with argon, the solvent was degassed in ultrasonic bath for 10 min and the tube flushed with 
argon for another 10 min. The reaction was heated by microwave irradiation to 90°C for 3 h. The 
mixture was transferred into a separation funnel with ethyl acetate (10 mL) and extracted with 
satd. aqueous NaHCO3 (2 x 10 mL). The aqueous layers were each extracted with CH2Cl2 (2 x 
15 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under 
reduced pressure. The residue was purified by silica gel chromatography (CH2Cl2/methanol, 
20:1) to afford 184 (68.2 mg, 100%) as crystalline solid.  
1H-NMR (CDCl3, 500.1 MHz) δ: 1.68 (s, 9 H, tBu), 2.35 (s, 3 H, CH3), 2.50 (m, 4 H, Pip H-3, Pip 
H-5), 3.91-4.04 (b, m, 4 H, Pip H-2, Pip H-6), 7.32, 7.44, 7.50-7-53, 7.61-7.63, 7.97 (m, 8 H, Ar-
H), 9.31 (b, s, 1 H, NH); 13C-NMR (CDCl3, 125.8 MHz) δ: 28.39 (3 C, C(CH3)3), 46.04 (CH3), 
54.98 (4 C, Pip), 80.92 (C(CH3)3), 106.78, 123.26, 123.48, 124.72, 127.22, 128.27, 128.34, 
129.32, 130.70, 130.98, 134.10, 37.66 (14 C, Ar-C), 161.88, 166.17 (2 C=O); elemental analysis 
calcd (%) for C25H29N3O3 (419.52): C 71.57, H 6.97, N 10.02; found: C 71.17, H 7.07, N 9.77. 
 
Sodium 2-[(4-methyl-1-piperazinyl)carbonyl]-7-phenyl-indole-4-carboxylate (185), (DS-03-
114, DS-03-122). 
Indole 184 (89.1 mg, 0.212 mmol) was dissolved in CH2Cl2 (2 mL). The solution was treated with 
TFA (861 µL), TIS (43.5 µL, 0.212 mmol) and H2O (33.6 µL) in CH2Cl2 (500 µL) and stirred for 
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70 min. The solvent was removed azeotropically with toluene and in vacuo. The residue was 
redissolved in CH2Cl2 (1 mL) and Na2CO3 (113 mg, 1.06 mmol) dissolved in H2O-methanol (1:1, 
1 mL) was added. After stirring for 15 min the solvents were removed and the residue was 
purified by reversed-phase chromatography (methanol/H2O, 0:10 to 1:5) to afford 185 (59.8 mg, 
73%) as colourless film.  
1H-NMR (MeOD, 500.1 MHz) δ: 2.34 (s, 3 H, CH3), 2.53 (m, 4 H, Pip H-3, Pip H-5), 3.90 (b, m, 4 
H, Pip H-2, Pip H-6), 7.26, 7.41, 7.50-7.53, 7.56, 7.65-7.67, 7.79 (m, 8 H, Ar-H), 13C-NMR 
(MeOD, 125.8 MHz) δ: 46.01 (CH3), 55.92 (4 C, Pip), 108.77, 123.94, 124.46, 128.59, 128.75, 
129.46, 129.56, 130.09, 131.19, 131.77, 135.79, 139.92 (14 C, Ar-C), 164.93, 176.23 (2 C=O); 
MS (ESI) m/z: calcd for C21H22N3O3 [M+H]+: 364.2; found: 364.1. 
 
Methyl 5-benzoyl-indole-3-carboxylate (187) and Methyl 6-benzoyl-indole-3-carboxylate 
(188), (DS-04-25). 
To an ice-cold solution of methyl indole-3-carboxylate (200 mg, 1.14 mmol) in nitromethane (8 
mL) was added benzoyl chloride (380 L, 3.29 mmol) and the mixture was stirred for 15 min. 
AlCl3 (453 mg, 3.40 mmol) was rapidly added and the reaction stirred for 2.5 h at r.t.. The 
reaction was then cooled to 0°C, quenched with meth anol (10 mL) and poured into an ice-cold 
solution of NaHCO3 (70 mL). The suspension was extracted with ethyl acetate (100 mL). The 
organic layer was successively washed with satd. aqueous NaHCO3 (70 mL) and brine (70 mL). 
The aqueous layers were each extracted with ethyl acetate (2 x 70 mL). The combined organic 
layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue 
was purified by silica gel chromatography (petroleum ether/ethyl acetate, 2:1 to 5:3) to afford the 
5-benzoylated indole 187 (227 mg, 71%) and the 6-benzoylated indole 188 (84.8 mg, 27%) as 
pinkish solids. 
 
Methyl 5-benzoyl-indole-3-carboxylate (187): 
1H-NMR (DMSO, 500.1 MHz) δ: 3.79 (s, 3 H, CH3), 7.57 (m, 2 H, Bz), 7.63-7.71 (m, 3 H, H-6, H-
7, Bz), 7.73 (m, 2 H, Bz), 8.25 (m, 1 H, H-2), 8.45 (m, 1 H, H-4), 12.32 (s, 1 H, NH); 13C-NMR 
(DMSO, 125.8 MHz) δ: 50.86 (CH3), 107.57 (C-3), 112.59 (C-7), 123.96 (C-4), 124.12 (C-6), 
125.06 (C-8), 128.39 (2 C, Bz), 129.41 (2 C, Bz), 130.39 (C-5), 132.03 (Bz), 134.37 (C-2), 
138.26 (Bz), 138.80 (C-8), 164.33 (COOMe), 196.02 (CO); IR (KBr) ν: 3226 (s), 2923 (vw), 1717 
(vs), 1633 (vs), 1618 (s), 1573 (m), 1533 (m), 1449 (vs), 1370 (m), 1334 (s), 1311 (s), 1295 (s), 
1245 (m), 1193 (s), 1127 (vs), 1105 (s), 1044 (m), 882 (m), 775, (m), 713 (s), 692 (m) cm-1; 
elemental analysis calcd (%) for C17H13NO3 (279.29): C 73.11, H 4.69, N 5.02; found: C 73.06, H 
4.89, N 4.88. 
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Methyl 6-benzoyl-indole-3-carboxylate (188): 
1H-NMR (DMSO, 500.1 MHz) δ: 3.84 (s, 3 H, CH3), 7.57 (m, 2 H, Bz), 7.67 (m, 2 H, H-5, Bz), 
7.75 (m, 2 H, Bz), 7.89 (m, 1 H, H-7), 8.13 (m, 1 H, H-4), 8.34 (m, 1 H, H-2), 12.25 (s, 1 H, NH); 
13C-NMR (DMSO, 125.8 MHz) δ: 50.89 (CH3), 106.82 (C-3), 115.58 (C-7), 120.30 (C-4), 122.68 
(C-5), 128.44 (2 C, Bz), 129.06 (C-8), 129.42 (2 C, Bz), 131.06 (C-6), 132.06 (Bz), 135.57, 
135.88 (C-2, C-8), 138.12 (Bz), 164.40 (COOMe), 195.76 (CO). 
 
5-Benzoyl-indole-3-carboxylic acid (189), (DS-04-38). 
Methylester 187 (102 mg, 0.365 mmol) was dissolved in acetonitrile (5 mL) under argon. 
Aqueous NaOH (1.0 M, 10 mL) was added and the reaction stirred for 10 d. The acetonitrile was 
removed on a rotary evaporator and the aqueous solution acidified to pH 2.0 with aqueous HCl 
(6.0 M). Filtration and washing with cold H2O gave 189 (99.1 mg, 100%) as a brownish solid, the 
NMR data of which were in accordance with Lit.[RD40] 
 
(1R,2R)-2-[(2,3,4-tris-O-benzyl-6-deoxy--L-galactopyranosyl)oxy]cyclohexyl 3-O-[(1S)-1-
benzyloxycarbonyl-2-cyclohexyl-ethyl]-7-[(1,1'-biphenyl-4-yl-carbonyl)amino]-7-deoxy-L-
glycero--D-galacto-heptopyranoside (190) and lactone derivative (191) and methyl ester 
thereof (192), (DS-03-119). 
175 (34.1 mg, 35.2 mol) was dissolved in CH2Cl2 (1.5 mL) and acetonitrile (1 mL). 
Triethylamine (550 µL) and biphenyl-4-carbonyl chloride (99.6 mg, 460 mol) were added and 
the reaction stirred under argon for 30 min. The reaction was quenched with methanol (2 mL) 
and concentrated under reduced pressure. The residue was redissolved in CH2Cl2 and extracted 
with satd. aqueous Na2CO3 (2 x 30 mL). The aqueous layers were each extracted with CH2Cl2 (4 
x 30 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under 
reduced pressure. The residue was purified by silica gel chromatography (petroleum ether/ethyl 
acetate, 2:1 to 1:1) to afford 190 (12.5 mg, 31%) and a mixture of the lactone derivative 191 and 
methyl ester 192 thereof (191+192: 10.9 mg) as colourless solids, which were directly used for 
deprotection. 
 
190: 
1H-NMR (CDCl3, 500.1 MHz) δ: 0.84-2.03 (m, 21 H, CyCH2, Cy), 1.12 (d, 3JF5,F6 = 6.4 Hz, 3 H, 
Fuc H-6), 2.36 (s, 1 H, OH), 3.24 (dd, 3JH2,H3 = 9.3 Hz, 3JH3,H4 = 3.1 Hz, 1 H, Hep H-3), 3.27 (m, 1 
H, Hep H-5), 3.51-3.57 (m, 2 H, Hep H-7a, Cy), 3.61-3.73 (m, 5 H, Hep H-2, Hep H-7b, Cy, 2 
OH), 3.76 (m, 1 H, Fuc H-4), 3.94 (m, 1 H, Hep H-4), 4.03 (dd, 3JF1,F2 = 3.5 Hz, 3JF2,F3 = 10.1 Hz, 
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1 H, Fuc H-2), 4.09-4.14 (m, 2 H, Fuc H-3, Hep H-6), 4.23 (m, 1 H, Lac H-2), 4.28 (d, 3JH1,H2 = 
7.7 Hz, 1 H, Hep H-1), 4.47 (m, 1 H, Fuc H-5), 4.63, 4.68, 4.78, 4.78, 4.86, 4.96 (6 m, 6 H, 3 
CH2Ph), 4.96 (d, 3JF1,F2 = 3.6 Hz, 1 H, Fuc H-1), 5.14, 5.22 (2 m, 2 H, CH2Ph), 6.64 (t, 3J = 5.2 
Hz, 1 H, NH), 7.19-7.74 (m, 29 H, Ar-H); 13C-NMR (CDCl3, 125.8 MHz) δ: 16.70 (Fuc C-6), 
23.43, 25.98, 26.20, 26.39, 29.31, 29.68, 30.53, 32.12, 33.48, 33.84 (10 C, Cy, CyCH2), 40.90 
(Lac C-3), 42.24 (Hep C-7), 66.20 (Fuc C-5), 67.32 (CH2Ph), 67.93 (Hep C-4), 70.32 (Hep C-6), 
70.61 (Hep C-2), 72.56, 73.04 (2 C, 2 CH2Ph), 74.49 (Hep C-5), 74.89 (CH2Ph), 75.86 (1 C, Cy), 
76.24 (Fuc C-2), 77.13 (Lac C-2), 77.94 (Fuc C-4), 78.47 (1 C, Cy), 79.82 (Fuc C-3), 83.01 (Hep 
C-3), 94.42 (Fuc C-1), 100.67 (Hep C-1), 127.16, 127.27, 127.41, 127.52, 127.86, 127.92, 
128.12, 128.28, 128.56, 128.62, 128.68, 128.88, 132.90, 135.16, 138.72, 138.89, 139.15, 
140.05, 144.12 (36 C, Ar-C), 167.27, 174.98 (2 C=O); MS (ESI) m/z: calcd for C69H81NNaO14 
[M+Na]+: 1170.6; found: 1170.7. 
 
(1R,2R)-2-[(6-deoxy--L-galactopyranosyl)oxy]cyclohexyl 7-[(1,1'-biphenyl-4-yl-
carbonyl)amino]-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-7-deoxy-L-glycero--D-galacto-
heptopyranoside sodium salt (193), (DS-04-1). 
Pd/C (32 mg, 10% Pd) was suspended under argon in dioxane/H2O (5:1, 3.6 mL). Compound 
190 (12.5 mg, 10.9 µmol) and a mixture of 191 and 192 (10.9 mg) were added and the resulting 
mixture was hydrogenated under 70 psi at r.t.. After 40 h the reaction was filtered through celite, 
concentrated under reduced pressure, redissolved in methanol (1 mL) and aqueous NaOH (0.5 
M, 86.0 µL, 43.0 µmol) was added. After stirring for 50 min, the mixture was neutralized with 
Dowex 50x8 (H+) and concentrated in vacuo. The residue was purified by reversed-phase 
column chromatography (RP-18, methanol/H2O) to give 11.5 mg of 193. The residue was 
treated with 1 eq. of aqueous NaOH (0.5 M, 28.4 µL, 14.2 µmol) and purified by Sephadex G15 
column to give 193 (10.8 mg, 38% over two steps) as a colourless solid.  
[]D21 = - 58.4 (c = 0.32, MeOH); 1H-NMR (MeOD, 500.1 MHz) δ: 0.87-1.71 (m, 18 H, CyCH2, 
Cy), 1.20 (d, 3JF5,F6 = 6.6 Hz, 3 H, Fuc H-6), 1.92 (m, 1 H, CyCH2), 2.07 (m, 2 H, Cy), 3.26 (dd, 
3JH2,H3 = 9.2 Hz, 3JH3,H4 = 1.6 Hz, 1 H, Hep H-3), 3.39 (m, 1 H, Hep H-5), 3.51-3.64 (m, 3 H, Hep 
H-2, Hep H-7a, Cy), 3.69-3.75 (m, 4 H, Fuc H-2, Fuc H-4, Hep H-7b, Cy), 4.00 (dd, 1 H, 3JF2,F3 = 
10.1 Hz, 3JF3,F4 = 3.2 Hz, Fuc H-3), 4.09 (m, 1 H, Hep H-4), 4.12 (m, 1 H, Hep H-6), 4.19 (m, 1 H, 
Lac H-2), 4.30 (d, 1 H, 3JH1,H2 = 7.7 Hz, Hep H-1), 4.69 (m, 1 H, Fuc H-5), 4.87 (m, 1 H, Fuc H-
1), 7.36-7.95 (m, 9 H, Ar-H); 13C-NMR (MeOD, 125.8 MHz) δ: 16.64 (Fuc C-6), 24.62, 27.22, 
27.50, 27.75, 30.36, 31.25, 33.51, 34.66, 35.29 (10 C, CyCH2, Cy), 42.75 (Lac C-3), 43.46 (Hep 
C-7), 67.45 (Fuc C-5), 69.44 (Hep C-4), 69.96 (Fuc C-2), 71.54, 71.97, 72.29 (4 C, Hep C-2, 
Hep C-6, Fuc C-3, Fuc C-4), 73.96 (Hep C-5), 75.16 (Cy), 77.61 (Lac C-2), 79.57 (Cy), 84.49 
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(Hep C-3), 97.38 (Fuc C-1), 102.72 (Hep C-1), 128.04, 128.12, 129.05, 130.02, 134.34, 141.30, 
145.68 (12 C, Ar-C), carbonyls were beyond detection level; HR-MS (ESI) m/z: calcd for 
C41H57NNaO14 [M+H]+: 810.3671; found: 810.3668 (0.4 ppm). 
 
(1R,2R)-2-[(6-deoxy--L-galactopyranosyl)oxy]cyclohexyl 7-[(5-benzoyl-indole-3-
carbonyl)amino]-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-7-deoxy-L-glycero--D-galacto-
heptopyranoside sodium salt (194), (DS-04-111, DS-04-113). 
175 (41.5 mg, 42.9 mol), 189 (22.0 mg, 82.9 mol) and polymer-bound PPh3 (3 mmol/g, 55.9 
mg, 168 mol) were suspended in CH2Cl2 (4 mL) and CCl4 (2 mL). N-Methylmorpholine (15.0 
L, 136 mol) was added via syringe and the mixture heated to reflux for 5.5 h. The reaction 
was filtered, and the resin successively washed with THF, acetonitrile, toluene, diethyl ether and 
petroleum ether (5 mL each). The filtrate was concentrated in vacuo, redissolved in CH2Cl2 (20 
mL) and successively washed with satd. aqueous NH4Cl (20 mL), satd. aqueous NaHCO3 (40 
mL) and brine (40 mL). The aqueous layers were each extracted with CH2Cl2 (3 x 30 mL). The 
combined organic layers were dried over Na2SO4, filtered and concentrated under reduced 
pressure. The residue was purified by column chromatography (petroleum 
ether/CH2Cl2/methanol, 10:20:1 to 5:20:1) to afford 44.2 mg of a mixture of lactone and benzyl- 
and methylester, which was directly subjected to deprotection. Pd/C (40 mg, 10% Pd) was 
placed in a flask and purged with argon. A solution of lactone and benzyl- and methylester in 
dioxane/H2O (5:1, 4.8 mL) was added and the mixture was hydrogenated under 70 psi at r.t.. 
After 4 days the reaction was filtered through celite, concentrated under reduced pressure, 
redissolved in methanol (1 mL) and aqueous NaOH (0.5 M, 150 µL) was added. After stirring for 
6 h, the mixture was concentrated in vacuo. The residue was purified by column 
chromatography (CH2Cl2/methanol/H2O, 5:1:0.1 to 2.5:1:0.1) and microfiltration (0.3 m) to give 
194 (10.2 mg, 27%) as a colourless solid.  
[]D21 = - 55.5 (c = 0.11, MeOH); 1H-NMR (MeOD, 500.1 MHz) δ: 0.82-2.03 (m, 21 H, CyCH2, 
Cy), 1.19 (d, 3J = 6.5 Hz, 3 H, Fuc H-6), 3.23 (m, 1 H, Hep H-3), 3.38 (m, 1 H, Hep H-5), 3.53 (m, 
1 H, Cy), 3.61 (m, 1 H, Hep H-2), 3.65 (m, 1 H, Hep H-7a), 3.69-3.74 (m, 2 H, Fuc H-4, Cy), 3.75 
(dd, 3JF1,F2 = 3.7 Hz, 3JF2,F3 = 10.2 Hz, 1 H, Fuc H-2), 3.91 (m, 1 H, Lac H-2), 4.02 (m, 1 H, Fuc H-
3), 4.05 (m, 2 H, Hep H-4, Hep H-7b), 4.11 (m, 1 H, Hep H-6), 4.28 (d, 3JH1,H2 = 7.6 Hz, 1 H, Hep 
H-1), 4.63 (m, 1 H, Fuc H-5), 4.88 (m, 1 H, Fuc H-1), 7.02 (m, 1 H, Ar-H), 7.12 (m, 1 H, Ar-H), 
7.18-7.23 (m, 4 H, 4 Ar-H), 7.34 (m, 1 H, Ar-H), 7.96 (m, 2 H, 2 Ar-H); 13C-NMR (MeOD, 125.8 
MHz) δ: 16.67 (Fuc C-6), 24.53, 27.24, 27.52, 27.77, 30.15, 31.12, 33.60, 34.64, 35.33, 42.89 
(11 C, Cy, CyCH2), 43.22 (Hep C-7), 67.45 (Fuc C-5), 69.18 (Hep C-4), 69.98 (Fuc C-2), 71.38, 
71.59 (Hep C-2, Fuc C-3), 72.85 (Hep C-6), 73.90 (Fuc C-4), 74.75 (Hep C-5), 77.42 (Cy), 79.44 
                                                                                                                                                                                                                          
                                                                109 
(Cy), 80.81 (Lac C-2), 85.23 (Hep C-3), 97.12 (Fuc C-1), 102.69 (Hep C-1), 111.35, 112.92, 
121.49, 125.03, 126.80, 127.05, 129.31, 129.83, 130.21, 135.43, 136.80, 143.65 (14 Ar-C), 
168.73, 184.17 (3 C, C=O). 
 
(1R,2R)-2-[(6-deoxy--L-galactopyranosyl)oxy]cyclohexyl 7-benzamido-3-O-[(1S)-1-
carboxy-2-cyclohexyl-ethyl]-7-deoxy-L-glycero--D-galacto-heptopyranoside sodium salt 
(195) and (1R,2R)-2-[(6-deoxy--L-galactopyranosyl)oxy]cyclohexyl 3-O-[(1S)-1-carboxy-2-
cyclohexyl-ethyl]-7-(cyclohexyl-carbonyl)amino-7-deoxy-L-glycero--D-galacto-
heptopyranoside sodium salt (196), (DS-05-02, DS-05-39). 
175 (77.6 mg, 80.2 mol), benzoic acid (10.8 mg, 88.4 mol) and polymer-bound PPh3 (3 
mmol/g, 106.5 mg, 320 mol) were suspended in CH2Cl2 (6 mL) and CCl4 (3 mL). N-
Methylmorpholine (29.0 L, 264 mol) was added via syringe and the mixture heated to reflux 
for 4 h. The reaction was filtered, and the resin successively washed with THF, acetonitrile, 
toluene, diethyl ether and petroleum ether (5 mL each). The filtrate was concentrated in vacuo 
and purified by column chromatography (petroleum ether/ethyl acetate, 2:1 to 1:2) to afford 38.1 
mg of a mixture of lactone and benzylester, which was directly subjected to deprotection. 
Pd(OH)2/C (50 mg, 10% Pd) was placed in a flask and purged with argon. A solution of lactone 
and benzylester in dioxane/H2O (4:1, 5 mL) was added and the mixture was hydrogenated under 
70 psi at r.t.. After 6 d the reaction was filtered through celite, concentrated under reduced 
pressure, redissolved in methanol (3 mL) and aqueous NaOH (0.5 M, 142 µL) was added. After 
stirring for 3 h the mixture was concentrated in vacuo. The residue was purified by column 
chromatography (CH2Cl2/methanol/H2O, 5:1:0.1 to 2.3:1:0.1), microfiltration (0.3 m) and 
Sephadex G15 column to give a mixture of 195 and 196 (195:196 = 2:1, 21.2 mg, 36%) as a 
colourless solid. Isolation of the pure compounds by preparative reversedphase LC-MS failed. 
 
195:   
HR-MS (ESI) m/z: calcd for C35H53NNaO14 [M+H]+: 734.3358; found: 734.3360 (0.3 ppm). 
 
196:   
MS (ESI) m/z: calcd for C35H58NO14 [M-Na]-: 716.4; found: 716.6; MS (ESI): m/z : calcd for 
C35H59NNaO14 [M+H]+: 740.4; found: 740.6. 
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(1R,2R)-2-[(6-deoxy--L-galactopyranosyl)oxy]cyclohexyl 3-O-[(1S)-1-carboxy-2-
cyclohexyl-ethyl]-7-deoxy-7-{{2-[(4-methyl-1-piperazinyl)carbonyl]-7-phenyl-indole-4-
carbonyl}amino}-L-glycero--D-galacto-heptopyranoside sodium salt (197) and (1R,2R)-2-
[(6-deoxy--L-galactopyranosyl)oxy]cyclohexyl 3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-7-
deoxy-7-{{2-[(4-methyl-1-piperazinyl)carbonyl]-7-cyclohexyl-indole-4-carbonyl}amino}-L-
glycero--D-galacto-heptopyranoside sodium salt (198), (DS-04-125). 
175 (50.5 mg, 52.2 mol), 185 (22.6 mg, 58.6 mol) and polymer-bound PPh3 (3 mmol/g, 69.1 
mg, 207 mol) were suspended in CH2Cl2 (4 mL) and CCl4 (2 mL). N-Methylmorpholine (19.0 
L, 173 mol) was added via syringe and the mixture heated to reflux for 3.5 h. The reaction 
was filtered, and the resin successively washed with THF, acetonitrile, toluene, diethyl ether and 
petroleum ether (5 mL each). The filtrate was concentrated in vacuo and purified by column 
chromatography (CH2Cl2/methanol/Et3N, 25:1:0.5% to 15:1:0.5%) to afford 55.3 mg of a mixture 
of lactone and benzylester, which was directly subjected to deprotection. Pd/C (120 mg, 10% 
Pd) was placed in a flask and purged with argon. A solution of lactone and benzylester in 
dioxane/H2O (5:1, 3.6 mL) was added and the mixture was hydrogenated under 70 psi at r.t.. 
After 9 days the reaction was filtered through celite, concentrated under reduced pressure, 
redissolved in methanol (1.5 mL) and H2O (850 L), and aqueous NaOH (1.0 M, 150 µL) was 
added. After stirring for 6 h, the mixture was concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (CH2Cl2/methanol/H2O, 5:1:0.1 to 2:1:0.1) and Sephadex 
G15 to give a mixture of 197 and 198 (7:3, 15.0 mg, 29%) as a colourless solid. Of this mixture 
9.7 mg were separated by preparative LC-MC for analytical purposes to obtain 197 (6.4 mg) in 
pure form as formiate and 198 as mixture with 197. 
 
197 (formiate):  
[]D21 = - 58.6 (c = 0.55, MeOH); 1H-NMR (MeOD, 500.1 MHz) δ: 0.87-2.09 (m, 21 H, CyCH2, 
Cy), 1.21 (d, 3J = 6.6 Hz, 3 H, Fuc H-6), 2.81 (s, 3 H, CH3), 3.20 (b, s, 4 H, Pip H-3, Pip H-5), 
3.27 (dd, 3JH3,H4 = 3.2 Hz, 3JH2,H3 = 9.4 Hz, 1 H, Hep H-3), 3.46 (m, 1 H, Hep H-5), 3.53 (m, 1 H, 
Cy), 3.61-3.65 (m, 2 H, Hep H-2, Hep H-7a), 3.68-3.74 (m, 3 H, Cy, Fuc H-4, Fuc H-2), 3.76 (dd, 
3JH6,H7b = 4.4 Hz, 2JH7a,H7b = 13.5 Hz, 1 H, Hep H-7b), 4.02 (dd, 3JF3,F4 = 3.3 Hz, 3JF2,F3 = 10.2 Hz, 1 
H, Fuc H-3), 4.11-4.20 (m, 7 H, Hep H-6, Lac H-2, Hep H-4, Pip H-2, Pip H-6), 4.33 (d, 3JH1,H2 = 
7.8 Hz, 1 H, Hep H-1), 4.71 (m, 1 H, Fuc H-5), 4.85 (d, 3JF1,F2 = 3.8 Hz, 1 H, Fuc H-1), 7.24 (m, 1 
H, Ar-H), 7.32 (s, 1 H, Ar-H), 7.44 (m, 1 H, Ar-H), 7.49-7.53 (m, 3 H, Ar-H), 7.61 (m, 2 H, Ar-H), 
8.19 (s, 1 H, HCOO-); 13C-NMR (MeOD, 125.8 MHz) δ: 16.67 (Fuc C-6), 24.63, 27.25, 27.53, 
27.78, 30.42, 31.26, 33.50, 34.73, 35.40 (10 C, Cy, CyCH2), 43.02 (Lac C-3), 43.42 (Hep C-7), 
44.07 (CH3), 54.49 (4 C, Pip), 67.44 (Fuc C-5), 69.52 (Hep C-4), 69.99 (Fuc C-2), 71.52 (Fuc C-
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3), 71.96 (Hep C-2), 72.42 (Hep C-6), 74.03 (Fuc C-4), 75.24 (Hep C-5), 77.61 (Cy), 79.64 (Cy), 
79.80 (Lac C-2), 84.61 (Hep C-3), 97.37 (Fuc C-1), 102.78 (Hep C-1), 107.18, 121.86, 124.83, 
126.93, 128.39, 129.20, 129.50, 130.18, 130.86, 131.57, 135.84, 139.15 (14 Ar-C), 164.42 
(C=O), 165.90 (HCOO-), 171.06 (C=O), 181.89 (COOH); HR-MS (ESI) m/z: calcd for 
C49H69N4O15 [M+H]+: 953.4754; found: 953.4750 (0.4 ppm). 
 
198: 
HR-MS (ESI) m/z: calcd for C49H75N4O15 [M+H]+: 959.5223; found: 959.5237 (1.4 ppm). 
 
2-Bromocyclohex-2-en-1-one (211). 
2-Cyclohexenone (9.8 mL, 101 mmol) was dissolved in CH2Cl2 (250 mL) in a light protected 
flask, then the solution was cooled to 0°C. Bromine  (5.4 mL, 105 mmol) in CH2Cl2 (100 mL) was 
added dropwise over 35 min. The clear yellow solution was stirred at 0°C for 2.5 h, then Et 3N 
(23.1 mL, 166 mmol) in CH2Cl2 (20 mL) was added portion-wise, causing a colour change from 
clear yellow to brown and formation of a precipitate. The mixture was stirred at r.t. for 2 h. The 
reaction mixture was diluted with CH2Cl2 (50 mL) and washed with 3% HCl (2 x 50 mL). The 
aqueous layers were extracted with CH2Cl2 (2 x 25 mL) and the combined organic layers were 
washed with a mixture of brine (80 mL) and water (100 mL). The aqueous layer was extracted 
with CH2Cl2 (2 x 50 mL). The combined organic layers were concentrated in vacuo to afford a 
brown residue still dissolved in a few mL of CH2Cl2, which was then treated with activated 
charcoal and filtered through celite. The clear green mixture was concentrated to dryness. 
Recrystallization from hexane/ethyl acetate gave off-white crystals. The crystals were dried in a 
desiccator for 12 h affording bromide 211 (11.0 g, 62%), the NMR and IR data of which were in 
accordance with Lit.387 
 
(1R)-2-Bromocyclohex-2-en-1-ol (212):  
Application of MeO-CBS as catalyst: (S)-,-Diphenylprolinol (290 mg, 1.14 mmol) was 
dissolved in THF (20 mL) in a flame dried, light protected flask, then under stirring B(OMe)3 (153 
µL, 1.37 mmol) was added via syringe to the solution. The mixture was stirred for 1 h at r.t., 
before BH3·N,N-diethylaniline (2.00 mL, 11.2 mmol) was added and the resulting solution cooled 
to –10°C. A solution of bromide 211 (2.00 g, 11.4 mmol) in THF (15 mL) was then added over 45 
min. The clear yellow mixture was stirred for 3 h at 0°C. After complete conversion of the ketone 
the reaction was quenched with HCl (1 M, 20 mL). The resulting mixture was diluted with CH2Cl2 
(40 mL) and water (50 ml). The organic layer was washed with brine (20 mL) and the aqueous 
layers were extracted with CH2Cl2 (2 x 25 mL). The combined organic layers were dried with 
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Na2SO4, filtered and concentrated in vacuo. Chromatographic purification of the crude product 
(petroleum ether/Et2O, 2:1 to 1.5:1) gave 212 (1.89 g, 93%) as a colourless oil and with an 
optical yield of 96% ee determined by optical rotation and derivatization with (1R)-(–)-MTPA-Cl. 
The NMR data of 212 were in accordance with Lit.391  
[]D21 = + 83.0 (c = 1.01, CHCl3). 
 
Application of Me-CBS as catalyst: Bromide 211 (2.00 g, 11.45 mmol) was dissolved in THF (12 
mL) in a flame dried, light protected flask. The solution was cooled to –20°C and under stirring 
(S)-methyl-CBS-oxazaborolidine (1 M in toluene, 0.570 mL, 1.91 mmol) in THF (8 mL) and 
borane-dimethyl-sulfide complex (2 M in toluene, 3.4 mL, 6.8 mmol) were simultaneously added 
dropwise via syringe to the solution over 1 h and 10 min. The mixture was stirred for 3 h at –
20°C, then quenched with MeOH (11 mL) and warmed to  r.t.. After evaporation of the solvent, 
the yellow oily residue was redissolved in CH2Cl2 (20 mL) and washed with brine (20 mL). The 
aqueous layer was extracted with CH2Cl2 (2 x 10 mL). The combined organic layers were dried 
with Na2SO4, filtered and concentrated in vacuo. Chromatographic purification of the crude 
product (petroleum ether/Et2O, 2:1 to 3:2) gave 212 (1.70 g, 84%) as a colourless oil and with an 
optical yield of 90% ee determined by optical rotation and 89% ee determined by derivatization 
with (1R)-(–)-MTPA-Cl.  
[]D21 = + 77.8 (c = 1.89, CHCl3).  
 
(1R)-2-Bromo-2-cyclohexen-1-yl (S)--methoxy--(trifluoromethyl)-phenylacetate (213). 
212 (5.6 mg, 0.031 mmol) was dissolved in pyridine (500 µL). (1R)-(-)-MTPA-Cl (15 µL, 0.080 
mmol) and 4-dimethylaminopyridine (2-3 crystals) were added to the mixture. After stirring for 60 
h the reaction was stopped. Pyridine was removed azeotropically with toluene in vacuo to afford 
a brown residue. The residue was diluted with CH2Cl2 (5 mL) and washed with satd. aqueous 
NaHCO3 (5 mL). The aqueous layer was extracted with CH2Cl2 (2 x 5 mL). The combined 
organic layers were dried with Na2SO4, filtered and concentrated to dryness. The crude product 
was purified by column chromatography (petroleum ether/Et2O, 2:1) to afford 213 as a green 
resin in quantitative yield with an optical purity of 96% de determined by calculations based on 
13C-satellites.  
1H-NMR (CDCl3, 500.1 MHz) δ: 1.64-1.72 (m, 2 H, H-5a, H-5b), 1.97-2.11 (m, 3 H, H-4a, H-6a, H-
6b), 2.20 (m, 1 H, H-4b), 3.43 (s, (1R)-OCH3-satellite), 3.58 (s, 3 H, (1R)-OCH3), 3.64 (s, 3 H, 
(1S)-OCH3), 3.72 (s, (1R)-OCH3-satellite), 5.66 (s, 1 H, H-1), 6.38 (m, 1 H, H-3), 7.40 (m, 3 H, 
C6H5), 7.59 (m, 2 H, C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 16.91 (C-5), 27.43 (C-4), 29.93 (C-
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6), 55.48 (OCH3), 73.66 (C-1), 85.00 (C-Ph), 117.99 (C-2), 127.64, 128.29, 129.58, 131.98 (6 C, 
C6H5), 136.46 (C-3), 165.86 (C=O). 
 
(1R)-Cyclohex-2-en-1-ol (214).  
212 (7.33 g, 41.4 mmol) was dissolved in Et2O (43 mL) in a flame dried flask equipped with a 
dropping funnel. tert-BuLi (1.7 M in pentane, 133 mmol) was added dropwise at –78°C over 1 h 
and 15 min. After complete addition, the clear yellowish mixture was stirred for 1.5 h at –78 °C 
and then slowly warmed to –20 °C over 3 h and 15 mi n. The reaction was quenched by addition 
of satd. aqueous NaHCO3 (50 mL) and stirred for 1 h at r.t.. The mixture was diluted by addition 
of water (20 mL) and Et2O (20 mL). The layers were separated and the aqueous layer extracted 
with Et2O (2 x 30 mL). The combined organic layers were dried with Na2SO4, filtered and 
concentrated in vacuo (>200 mbar) to afford a yellow mixture (still presence of solvent) which 
was purified by column chromatography (petroleum ether/Et2O, 2:1 to 1:1). The product was 
concentrated to a syrup in vacuo (>200 mbar), then the rest of the solvent was removed by 
distillation under argon with vigreux column to afford alcohol 214 (3.39 g, 85%) as a clear brown 
oil. The NMR data of 214 were in accordance with Lit.391  
[]D21 = + 117.7 (c = 0.95, CHCl3).  
 
(1R)-1-O-Triphenylmethyl-cyclohex-2-en-1-ol (215).  
Alcohol 214 (1.51 g, 15.3 mmol) was stirred in CH2Cl2 (35 mL) at r.t.. Trityl chloride (9.54 g, 34.2 
mmol) was added to the mixture, then DBU (5.9 mL, 39.5 mmol) was added via syringe. The 
brown mixture was stirred for 45 h, diluted with CH2Cl2 (50 mL) and washed with satd. aqueous 
NaHCO3 (50 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 
(2 x 25 mL). The combined organic layers were dried with Na2SO4, filtered and concentrated to 
dryness. The resulting viscous brown oil was purified by column chromatography (petroleum 
ether/toluene, 11:1 to 4:1) affording tritylether 215 (3.72 g, 71%) as a yellow solid.  
[]D21 = + 74.6 (c = 1.15, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 1.31-1.41 (m, 3 H, H-5a, H-6), 
1.68-1.76 (m, 1 H, H-5b), 1.80 (m, 1 H, H-4a), 1.98 (m, 1 H, H-4b), 4.06 (s, 1 H, H-1), 5.03 (m, 1 
H, H-2), 5.61 (m, 1 H, H-3), 7.21-7.54 (m, 15 H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 19.69 
(C-5), 25.02 (C-4), 30.18 (C-6), 67.82 (C-1), 86.86 (CPh3), 129.60 (C-2), 129.97 (C-3), 126.85, 
127.68, 129.00, 145.34 (18 C, 3 C6H5); IR (KBr) ν: 3031 (vw, C=C-H), 2930 (w), 2833 (vw), 1595 
(vw), 1490 (w), 1448 (m), 1393 (vw), 1348 (vw), 1313 (vw), 1215 (w), 1150 (vw), 1043 (s), 1016 
(m), 960 (vw), 938 (vw), 900 (vw) cm-1; MS (ESI) m/z: calcd for C25H24ONa [M+Na]+: 363.2; 
found: 363.2; elemental analysis calcd (%) for C25H24O (340.46): C 88.20, H 7.10; found: C 
88.01, H 7.29.  
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(1R,2R,3R)-1-O-Triphenylmethyl-cyclohexane-1,2,3-triol (216). 
Tritylether 215 (201 mg, 0.590 mmol) and N-methylmorpholine-N-oxide monohydrate (239 mg, 
1.76 mmol) were dissolved in acetone/water (60 mL, 4:1). Osmium tetroxide (1.5 mg, 5.9 µmol) 
was added to the stirred solution. The clear colourless mixture was stirred for 19 h at r.t.. During 
the reaction additional osmium tetroxide (1 crystal, ~ 1 mol%) was added. The reaction was 
quenched with satd. aqueous sodium dithionite (10 mL) and the mixture was stirred for 
additional 30 min. Acetone was evaporated in vacuo and the aqueous layer was extracted with 
ethyl acetate (3 x 20 mL). The combined organic layers were dried with Na2SO4, filtered and 
concentrated under reduced pressure. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate, 4:1 to 3:1) affording the title compound 216 (192 
mg, 87%) as a yellowish solid.  
[]D21 = - 23.9 (c = 0.53, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 1.14 (m, 1 H, H-4a), 1.24-1.33 
(m, 1 H, H-5a), 1.42-1.50 (m, 3 H, H-4b, H-5b, H-6a), 1.59-1.65 (m, 1 H, H-6b), 1.90 (br, s, 1 H, 
OH), 2.22 (br, s, 1 H, OH), 3.49 (dd, 3J = 2.7, 6.8 Hz, 1 H, H-2), 3.58 (m, 1 H, H-3), 4.04 (m, 1 H, 
H-1), 7.23-7.31 (m, 9 H, 3 C6H5), 7.48-7.50 (m, 6 H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 
18.61 (C-4), 28.97 (2 C, C-5, C-6), 69.05 (C-1), 73.20 (2 C, C-2, C-3), 86.89 (C-Ph3), 127.18, 
127.81, 127.90, 128.70, 128.80, 144.87 (18 C, 3 C6H5); IR (KBr) ν: 3414 (m), 3057 (vw), 2936 
(w), 1597 (vw), 1490 (w), 1448 (w), 1224 (vw), 1148 (vw), 1069 (m), 1028 (m), 1000 (w), 896 
(vw), 764 (w), 746 (w), 703 (m), 632 (vw) cm-1; MS (ESI) m/z: calcd for C25H26NaO3 [M+Na]+: 
397.2; found: 397.2; elemental analysis calcd (%) for C25H26O3  ¼ H2O (378.69): C 79.23, H 
7.05; found: C 79.21, H 7.16. 
 
(1R,2S,3R)-2-Hydroxy-3-(triphenylmethoxy)cyclohexyl 4-methylbenzenesulfonate (217). 
Tritylether 216 (1.70 g, 4.54 mmol) was dissolved in CH2Cl2 (55 mL). Tosyl chloride (1.04 g, 5.45 
mmol) and dibutyltin oxide (1.13 g, 4.55 mmol) were added to the stirred solution, then Et3N 
(1.28 mL, 9.18 mmol) was added via syringe causing a change of colour from pink-orange to 
yellow. After stirring for 19 h at r.t. the reaction was quenched with MeOH (2 mL). The solvents 
were evaporated in vacuo and the crude residue was purified by column chromatography 
(toluene/ethyl acetate, 12:1 to 11:1, + 1% Et3N) affording tosylate 217 (2.20 g, 92%) as a white 
foam.  
[]D21 = + 27.2 (c = 0.58, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.88 (m, 1 H, H-4a), 1.25-1.34 
(m, 1 H, H-4b), 1.37-1.43 (m, 1 H, H-5a), 1.62-1.77 (m, 2 H, H-6a, H-5b), 1.79.1.84 (m, 1 H, H-6b), 
2.35 (s, 1 H, OH), 2.39 (s, 3 H, Ph-CH3), 3.24 (s, 1 H, H-2), 3.79 (s, 1 H, H-3), 4.80 (m, 1 H, H-
1), 7.25-7.36 (17 H, 3 C6H5, C6H4), 7.78 (m, 2 H, C6H4); 13C-NMR (CDCl3, 125.8 MHz) δ: 18.77 
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(C-5), 21.63 (Ph-CH3), 25.76 (2 C, C-6, C-4), 70.20 (C-2), 72.23 (C-3), 81.75 (C-1), 87.30 (C-
Ph3), 125.28, 127.18, 127.94, 128.74, 129.81, 133.84, 137.86, 144.46 (24 C, Ar-H); IR (KBr) ν: 
3453 (w), 3058 (vw), 2934 (w), 2867 (vw), 1598 (w), 1491 (w), 1449 (m), 1360 (m), 1189 (s), 
1177 (vs), 1148 (m), 1097 (w), 1074 (m), 1028 (m), 940 (s), 902 (m), 880 (w), 859 (w), 833 (m), 
815 (m), 765 (w), 747 (w), 703 (s), 669 (w), 632 (w), 589 (w), 556 (m) cm-1; MS (ESI) m/z: calcd 
for C32H32NaO5S [M+Na]+: 551.2; found: 551.2; elemental analysis calcd (%) for C32H32O5S 
(528.66): C 72.70, H 6.10; found: C 72.76, H 6.35. 
 
(1R,2R,3R)-2,3-Epoxy-1-O-triphenylmethyl-cyclohexan-1-ol (anti-219).  
Tritylether 215 (948 mg, 2.79 mmol) was dissolved under argon in CH2Cl2 (30 mL) and NaHCO3 
(281 mg, 3.34 mmol) was added. The mixture was cooled to 0°C and m-chloroperbenzoic acid 
(70%, 960 mg, 5.56 mmol) was added under stirring. After 1.5 h the temperature was gradually 
raised to r.t. and the mixture was stirred for another 3.5 h. The reaction was diluted with CH2Cl2 
(50 mL) and transferred to a separation funnel. The excess of m-chloroperbenzoic acid was 
destroyed by washing with satd. aqueous Na2S2O3 (2 x 150 mL). The organic layer was then 
successively washed with satd. aqueous Na2CO3 (150 mL) and brine (150 mL). The aqueous 
layers were each time extracted with CH2Cl2 (2 x 50 mL). The combined organic layers were 
dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by column 
chromatography (petroleum ether/ethyl acetate, 20:1 to 15:1) affording epoxide anti-219 (714 
mg, 72%) as colourless solid and syn-219 (230 mg, 23%) as a yellowish resin.  
 
anti-219: 
[]D21 = + 26.6 (c = 0.67, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 1.02-1.11 (m, 1 H, H-5a), 1.15-
1.22 (m, 1 H, H-6a), 1.37-1.43 (m, 1 H, H-5b), 1.53 (m, 1 H, H-6b), 1.64-1.71 (m, 1 H, H-4a), 1.90 
(m, 1 H, H-4b), 2.25 (m, 1 H, H-2). 2.97 (m, 1 H, H-3), 3.86 (m, 1 H, H-1), 7.23-7.53 (m, 15 H, 3 
C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 15.15 (C-5), 24.05 (C-4). 28.18 (C-6), 53.15 (C-3), 55.44 
(C-2), 68.56 (C-1), 87.45 (CPh3), 127.16, 127.86, 128.88, 144.68 (18 C, 3 C6H5); IR (KBr) ν: 
3060 (w), 3028 (w), 2976 (w), 2942 (m), 2859 (vw), 1597 (vw), 1490 (m), 1449 (m), 1375 (vw), 
1318 (vw), 1215 (w), 1181 (w), 1153 (w), 1055 (s), 1032 (m), 1008 (w), 990 (w) cm-1; MS (ESI) 
m/z: calcd for C25H24O2Na [M+Na]+: 379.2; found: 379.2; elemental analysis calcd (%) for 
C25H24O2 (356.46): C 84.24, H 6.79; found: C 83.86, H 6.85. 
 
 (1R,2R,3S)-3-Azido-1-O-triphenylmethyl-cyclohexane-1,2-diol (218). 
Synthesis from tosylate: 217 (2.12 g, 4.01 mmol) was dissolved in DMF (70 mL) under argon. 
NaN3 (1.04 g, 16.1 mmol) was added to the stirred solution and the mixture was heated to 65°C 
                                                                                                                                                                                                                          
                                                                116 
for 50 h. The reaction was quenched with water (10 mL), diluted with ethyl acetate (100 mL) and 
washed with H2O (100 mL). The layers were separated and the aqueous layer was extracted 
with ethyl acetate (3 x 70 mL). The combined organic layers were dried with Na2SO4, filtered and 
co-evaporated with toluene. The crude product was purified by column chromatography 
(petroleum ether/ethyl acetate, 20:1 to 15:1, + 1% Et3N) to afford azide 218 (1.40 g, 88%) as 
white solid.  
 
Synthesis from epoxide: anti-219 (111 mg, 0.312 mmol) was dissolved in DMF (10 mL) under 
argon. CsF (472 mg, 3.12 mmol) was quickly added to the stirred solution, then 15-crown-5 (690 
µL, 3.47 mmol) was added via syringe. NaN3 (225 mg, 3.47 mmol) was added and the mixture 
stirred for 48 h at 65°C then for 43 h at 100°C. Th e clear yellow reaction mixture was cooled to 
r.t., quenched with water (10 mL), diluted with ethyl acetate (20 mL) and washed with water (10 
mL). The aqueous layer was extracted with ethyl acetate (3 x 20 mL). The combined organic 
layers were dried with Na2SO4, filtered and co-evaporated with toluene to dryness. The crude 
product was purified by column chromatography (petroleum ether/ethyl acetate, 20:1 to 18:1, + 
0.5% Et3N) to afford 218 (109 mg, 87%).  
[]D21 = - 22.9 (c = 0.51, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.74-0.84 (m, 1 H, H-5), 1.17-
1.38 (m, 2 H, H-4a, H-6a), 1.44-1.52 (m, 2 H, H-5b, H-6b), 1.78 (m, 1 H, H-4b), 2.69 (s, 1 H, OH), 
2.90 (ddd, 3J = 4.1, 8.7, 11.3 Hz, 1 H, H-1), 3.04 (ddd, 3J = 4.7, 9.4, 12.1 Hz, 1 H, H-3), 3.67 (t, 
3J = 9.0, 9.2 Hz, 1 H, H-2), 7.23-7.49 (m, 15 H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 20.86 
(C-5), 29.62 (C-4), 31.42 (C-6), 63.76 (C-3), 76.94 (C-1), 77.78 (C-2), 86.90 (C-Ph3), 127.28, 
127.88, 128.71, 144.75 (18 C, 3 C6H5); IR (KBr) ν: 3554 (w, OH), 3052 (vw), 2932 (w), 2104 (vs, 
azide), 1594 (vw), 1490 (w), 1448 (w), 1362 (vw), 1309 (w), 1274 (m), 1223 (w), 1118 (vw), 1060 
(s), 1032 (m), 992 (m), 934 (w), 901 (vw), 879 (vw), 853 (vw), 776 (w), 754 (m), 699 (s), 651 
(vw), 634 (w), 559 (vw), 507 (vw) cm-1; MS (ESI) m/z: calcd for C25H25N3NaO2 [M+Na]+: 422.2; 
found: 422.2; elemental analysis calcd (%) for C25H25N3O2 (399.48): C 75.16, H 6.31, N 10.52; 
found: C 75.27, H 6.35, N 10.22. 
 
(1R,2R,3R)-1-O-(4-Methoxybenzyl)-cyclohexane-1,2,3-triol (220), (DS-04-114, DS-04-116). 
NaH (60% in oil, 1.37 g, 34.3 mmol) was suspended in THF (20 mL) under argon, and cooled to 
0°C. Alcohol  214 (1.00 g, 10.2 mmol) dissolved in THF (10 mL) was slowly added to the 
suspension and the mixture stirred at 0°C for 40 mi n. Tetrabutylammonium bromide (141 mg, 
0.437 mmol) was added in one portion to the reaction and 4-methoxybenzyl chloride (2.78 mL, 
20.5 mmol) was added dropwise to the suspension. The reaction was warmed to r.t. and stirred 
for 7 h. After cooling to 0°C, the reaction was que nched with H2O (4 mL). The mixture was 
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diluted with THF (20 mL) and washed with H2O (40 mL). The aqueous layer was extracted with 
t-butylmethyl ether (2 x 30 mL). The combined organic layers were washed with brine (100 mL) 
and the aqueous layer again extracted with t-butylmethyl ether (2 x 100 mL). The combined 
organic layers were dried with Na2SO4, filtered and concentrated to dryness. The resulting oil 
was purified by column chromatography (petroleum ether/THF, 100:1 to 70:1), affording the 
PMB-ether (1.78 g) with some inseparable impurities. The PMB-ether and N-methylmorpholine-
N-oxide monohydrate (3.31 g, 24.5 mmol) were dissolved in acetone/water (820 mL, 4:1). 
Osmium tetroxide (57.0 mg, 224 µmol) was added to the stirred solution. The mixture was stirred 
for 47 h at r.t., then quenched with satd. aqueous sodium dithionite (6 g Na2S2O4), and the 
mixture stirred for additional 30 min. Acetone was evaporated in vacuo and the aqueous layer 
was extracted with ethyl acetate (4 x 200 mL). The combined organic layers were dried with 
Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by 
column chromatography (CH2Cl2/diethyl ether, 1:1) affording pure 220 (1.24 g, 48% over two 
steps) as yellowish oil and 152 mg of unreacted PMB-ether (7%).  
[]D21 = - 71.0 (c = 0.64, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 1.22 (m, 1 H, H-6a), 1.43 (m, 1 
H, H-4a), 1.55 (m, 1 H, H-5a), 1.65 (m, 1 H, H-5b), 1.87 (m, 1 H, H-4b), 2.10 (m, 1 H, H-6b), 2.31 
(br, s, 2 H, 2 OH), 3.50 (dd, 3J2,3 = 2.8 Hz, 3J1,2 = 8.7 Hz, 1 H, H-2), 3.60 (ddd, 3J1,6eq = 4.2 Hz, 
3J1,2 = 8.9 Hz, 3J1,6ax = 10.4 Hz, 1 H, H-1), 3.81 (s, 3 H, CH3O), 4.10 (m, 1 H, H-3), 4.38, 4.62 (2 
m, 2 H, PMB), 6.88-6.90, 7.25-7.27 (m, 4 H, C6H4); 13C-NMR (CDCl3, 125.8 MHz) δ: 18.38 (C-5), 
28.50 (C-6), 29.65 (C-4), 55.27 (CH3O), 69.14 (C-3), 70.56 (PMB), 75.11 (C-2), 78.00 (C-1), 
113.92, 129.37, 130.52 (6 C, C6H4); IR (film on NaCl) ν: 3419 (vs, OH), 2938 (vs), 1614 (s), 
1587 (w), 1515 (vs), 1456 (m), 1303 (m), 1248 (vs), 1175 (m), 1080 (vs), 999 (m), 818 (m) cm-1; 
elemental analysis calcd (%) for C14H20O4 (252.31): C 66.65, H 7.99; found: C 66.54, H 8.11. 
 
(1R,2R,3S)-3-Azido-1-O-(4-methoxybenzyl)-cyclohexane-1,2-diol (221), (DS-04-118, DS-04-
119). 
PMB-ether 220 (1.24 g, 4.92 mmol) was dissolved in CH2Cl2 (60 mL). Tosyl chloride (1.13 g, 
5.91 mmol) and dibutyltin oxide (1.23 g, 4.93 mmol) were added to the stirred solution, then Et3N 
(1.38 mL, 9.90 mmol) was added via syringe. After stirring for 15.5 h at r.t. the reaction was 
quenched with MeOH (2 mL). The solvents were evaporated in vacuo and the crude residue was 
purified by column chromatography (CH2Cl2/diethyl ether, 25:1 to 20:1) affording the 
monotosylate (1.93 g, 96%) as an inseparable mixture of 3-Ts-220 and 2-Ts-220 (9:1), which 
was directly used for the next step. The tosylate mixture (1.91 g, 4.69 mmol) was dissolved in 
DMF (70 mL) under argon. NaN3 (0.917 g, 14.1 mmol) was added to the stirred solution and the 
mixture was heated to 65°C for 72 h. After 48 h add itional NaN3 (305 mg, 4.69 mmol) was 
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added. The reaction was quenched with water (10 mL), diluted with ethyl acetate (100 mL) and 
washed with H2O (100 mL). The aqueous layer was extracted with ethyl acetate (3 x 70 mL). 
The combined organic layers were dried with Na2SO4, filtered and co-evaporated with toluene to 
dryness. The crude product was purified by column chromatography (petroleum ether/diethyl 
ether, 3:1 to 2:1) to afford azide 221 (1.13 g, 82% over two steps) as yellowish oil.  
[]D21 = - 35.7 (c = 0.56, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 1.17-1.34 (m, 3 H, H-4a, H-5a, 
H-6a), 1.78 (m, 1 H, H-5b), 1.95 (m, 1 H, H-4b), 2.01 (m, 1 H, H-6b), 2.80 (s, 1 H, OH), 3.21-3.30 
(m, 2 H, H-1, H-3), 3.41 (t, 3J = 9.2 Hz, 1 H, H-2), 3.81 (s, 3 H, OCH3), 4.44, 4.63 (2 m, 2 H, 
PMB), 6.88-6.90, 7.25-7.27 (2 m, 4 H, C6H4); 13C-NMR (CDCl3, 125.8 MHz) δ: 20.79 (C-5), 28.63 
(C-6), 29.73 (C-4), 55.26 (OCH3), 63.69 (C-3), 71.07 (PMB), 77.69 (C-2), 80.79 (C-1), 113.93, 
129.38, 130.17, 159.33 (6 C, C6H4); IR (film on NaCl) ν: 3445 (w, OH), 2941 (m), 2868 (m), 2097 
(vs, N3), 1613 (m), 1586 (vw), 1514 (s), 1463 (w), 1361 (w), 1303 (m), 1249 (vs), 1174 (w), 1079 
(s), 1035 (m) cm-1; elemental analysis calcd (%) for C14H19N3O3 (277.32): C 60.63, H 6.91, N 
15.15; found: C 60.91, H 7.19, N 14.74. 
 
General procedure A for nucleophilic opening of epoxides with cuprate reagents (222a-d).  
CuCN (3.81 mmol) was dried in vacuo at 150ºC for 30 min, suspended in dry THF (10 mL) and 
cooled to -78ºC. A solution of the appropriate organo lithium compound (7.63 mmol) was slowly 
added via syringe and the temperature was raised over a period of 30 min to -20ºC and the 
mixture stirred at this temperature for 10 min. The mixture was cooled to -78ºC followed by the 
addition of freshly distilled BF3 etherate (1.53 mmol) in THF (2 mL). After stirring for 20 min, 
epoxide 219 (0.761 mmol) dissolved in THF (8 mL) was added. The reaction was slowly warmed 
to -50°C over 5 h and then stirred at this temperat ure for 24 h. After slowly warming the reaction 
to -30°C over another 21 h the reaction was quenche d with a 25% aq. NH3/satd. NH4Cl (1:9, 20 
mL) solution. The mixture was transferred with Et2O (30 mL) into a separation funnel and 
extracted with additional 25% aq. NH3/satd. NH4Cl (1:9, 30 mL) solution. The layers were 
separated and the organic layer was washed with brine (50 mL). The aqueous layers were 
extracted with Et2O (2 x 30 mL). The combined organic layers were dried over Na2SO4, filtered 
and concentrated in vacuo. The crude product was purified by column chromatography 
(petroleum ether/Et2O, 20:1 to 13:1, + 1% Et3N) to afford the corresponding GlcNAc mimic. 
 
(1R,2R,3S)-3-Methyl-1-O-triphenylmethyl-cyclohexane-1,2-diol (222a), (DS-04-147, DS-05-
05). 
CuCN (935 mg, 10.4 mmol) in THF (50 mL) was treated with MeLi (1.6 M in Et2O, 13 mL, 20.8 
mmol) and BF3 etherate (875 µL, 6.95 mmol) in THF (10 mL) according to the general procedure 
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A. Epoxide 219 (1.23 g, 3.45 mmol) in THF (20 mL) was slowly added and the reaction slowly 
warmed to -30°C (-78°C: 2 h; -78°C to -50°C: 1 h; - 50°: 24 h; -50°C to -30°C: 2 h). Work-up and 
purification according to the general procedure A yielded 222a (1.09 g, 85%) as a yellowish 
resin.  
[]D21 = - 57.6 (c = 0.52, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.78 (m, 1 H, H-5a), 0.94 (m, 1 
H, H-4a), 1.00 (d, 3J = 6.4 Hz, 3 H, CH3), 1.17 (m, 1 H, H-3), 1.32 (m, 1 H, H-6a), 1.40 (m, 1 H, H-
5b), 1.46-1.49 (m, 2 H, H-4b, H-6b), 2.67 (s, 1 H, OH), 2.83 (ddd, 3J = 4.1, 8.6, 11.1 Hz, 1 H, H-1), 
3.32 (t, 3J =  9.2 Hz, 1 H, H-2), 7.21-7.30, 7.49-7.50 (2 m, 15 H, 3 C6H5); 13C-NMR (CDCl3, 125.8 
MHz) δ: 18.61 (CH3), 23.44 (C-5), 32.43, 32.86 (C-4, C-6), 37.53 (C-3), 78.81 (C-1), 79.21 (C-2), 
86.45 (OCPh3), 127.07, 127.75, 128.71, 145.13 (18 C, 3 C6H5); IR (KBr) ν: 3577 (w), 3057 (w), 
2929 (s), 2856 (m), 1596 (vw), 1490 (m), 1448 (s), 1371 (vw), 1288 (w), 1226 (w), 1064 (vs), 
1001 (m), 967 (w), 762 (m), 746 (m), 707 (vs) cm-1; elemental analysis calcd (%) for C26H28O2 
(372.51): C 83.83, H 7.58; found: C 83.51, H 7.56. 
 
(1R,2R,3S)-3-Butyl-1-O-triphenylmethyl-cyclohexane-1,2-diol (222b), (DS-05-34). 
CuCN (342 mg, 3.81 mmol) in THF (10 mL) was treated with nBuLi (2.5 M in hexane, 3.05 mL, 
7.63 mmol) and BF3 etherate (192 µL, 1.53 mmol) in THF (2 mL) according to the general 
procedure A. Epoxide 219 (271 mg, 0.761 mmol) in THF (8 mL) was slowly added and the 
reaction slowly warmed to -30°C (-78°C: 1 h; -78°C to -50°C: 4 h; -50°: 24 h; -50°C to -30°C: 21 
h). Work-up and purification according to the general procedure A yielded 222b (220 mg, 70%). 
[]D21 = - 37.8 (c = 0.66, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.73 (m, 1 H, H-5a), 0.85 (m, 1 
H, H-4a), 0.86 (t, 3J = 7.2 Hz, 3 H, H-10), 1.03-1.16 (m, 3 H, H-3, H-7a, H-8a), 1.21-1.35 (m, 4 H, 
H-6a, H-8b, H-9a, H-9b), 1.38-1.49 (m, 2 H, H-5b, H-6b), 1.61 (m, 1 H, H-4b), 1.75 (m, 1 H, H-7b), 
2.70 (s, 1 H, OH), 2.82 (ddd, 3J = 4.0, 8.6, 11.2 Hz, 1 H, H-1), 3.40 (t, 3J = 9.0 Hz, 1 H, H-2), 
7.21-7.30, 7.48-7.50 (2 m, 15 H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 14.11 (C-10), 23.10 
(C-9), 23.37 (C-5), 28.73 (C-8), 29.38 (C-4), 32.05 (C-7), 32.30 (C-6), 42.45 (C-3), 77.62 (C-2), 
79.05 (C-1), 86.43 (CPh3), 127.05, 127.74, 128.70, 145.12 (18 C, 3 C6H5); elemental analysis 
calcd (%) for C29H34O2 (414.58): C 84.02, H 8.27; found: C 84.05, H 8.27. 
 
(1R,2R,3R)-3-Cyclopropyl-1-O-triphenylmethyl-cyclohexane-1,2-diol (222c), (DS-04-147, 
DS-05-62). 
A cPrLi solution was generated in situ by treating a solution of bromocyclopropane (370 µL, 4.63 
mmol) in THF (4 mL) with tBuLi (1.7 M in pentane, 5.45 mL, 9.27 mmol) during 80 min at -78°C. 
CuCN (210 mg, 2.34 mmol) in THF (5 mL) was treated with the cPrLi solution and BF3 etherate 
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(115 µL, 0.914 mmol) in THF (1 mL) according to the general procedure A. Epoxide 219 (165 
mg, 0.463 mmol) in THF (5 mL) was slowly added and the reaction slowly warmed to -30°C (-
78°C: 1.5 h; -78°C to -50°C: 1.5 h; -50°: 24 h; -50 °C to -30°C: 40 min). Work-up and purification 
according to the general procedure A yielded 222c (150.7 mg, 82%).  
[]D21 = - 38.8 (c = 0.50, CH2Cl2); 1H-NMR (CD2Cl2, 500.1 MHz) δ: -0.16 (m, 1 H, cPr), 0.13-0.23 
(m, 2 H, cPr), 0.34-0.43 (m, 2 H, cPr, H-3), 0.54-0.67 (m, 2 H, cPr, H-5a), 0.91 (m, 1 H, H-4a), 
1.18 (m, 1 H, H-6a), 1.27-1.35 (m, 2 H, H-5b, H-6b), 1.44 (m 1 H, H-4b), 2.52 (s, 1 H, OH), 2.71 
(ddd, 3J = 4.1, 8.6, 11.0 Hz, 1 H, H-1), 3.47 (t, 3J = 9.1 Hz, 1 H, H-2), 7.15-7.23, 7.42-7.43 (2 m, 
15 H, 3 C6H5); 13C-NMR (CD2Cl2, 125.8 MHz) δ: 0.85, 4.26, 14.56 (3 C, cPr), 23.11 (C-5), 29.50 
(C-4), 32.15 (C-6), 46.68 (C-3), 78.55 (C-2), 78.92 (C-1), 86.37 (OCPh3), 127.07, 127.73, 
128.82, 145.37 (18 C, 3 C6H5); IR (KBr) ν: 3571 (m, OH), 3058 (w), 2930 (m), 2858 (m), 1596 
(vw), 1490 (m), 1448 (s), 1284 (w), 1225 (w), 1152 (w), 1063 (vs), 926 (w), 844 (vw), 824 (vw), 
761 (m), 746 (m), 707 (vs) cm-1; elemental analysis calcd (%) for C28H30O2 (398.54): C 84.38, H 
7.59; found: C 84.16, H 7.78.  
 
(1R,2R,3R)-3-Ethenyl-1-O-triphenylmethyl-cyclohexane-1,2-diol (222d), (DS-04-143, DS-05-
03). 
A vinyl lithium solution was generated in situ by treating a solution of tetravinyltin (409 µL, 2.25 
mmol) in THF (3 mL) with nBuLi (2.5 M in hexane, 3.35 mL, 8.38 mmol) during 30 min at 0°C. 
CuCN (373 mg, 4.16 mmol) in THF (8 mL) was treated with the vinyl lithium solution and BF3 
etherate (209 µL, 1.66 mmol) in THF (1.5 mL) according to the general procedure A. Epoxide 
219 (296 mg, 0.830 mmol) in THF (8 mL) was slowly added and the reaction slowly warmed to -
30°C (-78°C: 15 min; -78°C to -50°C: 1.5 h; -50°: 1 3 h; -50°C to -30°C: 1.5 h; -30°C: 24 h). 
Work-up and purification according to the general procedure A yielded 222d (258 mg, 81%) as a 
yellowish resin.  
[]D21 = - 33.7 (c = 0.53, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.84 (m, 1 H, H-5a), 1.15 (m, 1 
H, H-4a), 1.32 (m, 1 H, H-6a), 1.43-1.55 (m, 3 H, H-5b, H-6b, H-4b), 1.81 (m, 1 H, H-3), 2.66 (s, 1 
H, OH), 2.91 (ddd, 3J = 3.9, 8.6, 11.3 Hz, 1 H, H-1), 3.51 (t, 3J = 9.3 Hz, 1 H, H-2), 5.02 (A of 
ABX, 3JA,X = 10.4 Hz, 2JA,B = 1.7 Hz, 3JA,3 = 0.7 Hz, 1 H, vinyl HA), 5.04 (B of ABX, 3JB,X = 17.2 Hz, 
2JA,B = 1.7 Hz, 3JB,3 = 1.1 Hz, 1 H, vinyl HB), 5.83 (X of ABX, 3JA,X = 10.4 Hz, 3JB,X = 17.2 Hz, 3JX,3 
= 7.6 Hz, 1 H, vinyl HX), 7.21-7.31, 7.48-7.50 (2 m, 15 H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) 
δ: 23.18 (C-5), 30.39 (C-4), 32.21 (C-6), 47.30 (C-3), 76.74 (C-2), 78.53 (C-1), 114.77 (vinyl C), 
127.11, 127.77, 128.75, 145.07 (18 C, 3 C6H5), 140.57 (vinyl C); IR (film on NaCl) ν: 3577 (m, 
OH), 3059 (m), 2932 (vs), 2860 (s), 1641 (vw), 1597 (vw), 1489 (s), 1448 (s), 1278 (m), 1225 
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(m), 1152 (w), 1064 (vs), 991 (s), 915 (m) cm-1; elemental analysis calcd (%) for C27H28O2 
(384.51): C 84.34, H 7.34; found: C 84.15, H 7.33.  
 
General procedure B for -fucosylation and detritylation (223a-d).  
A solution of Br2 (0.837 mmol) in CH2Cl2 (1 mL) was added dropwise at 0°C to a solution of ethyl 
2,3,4-tri-O-benzyl-1-thio-L-fucopyranoside (0.729 mmol) in CH2Cl2 (2 mL). After stirring for 50 
min at 0°C, cyclohexene (100 µL) was added and the solution stirred for another 20 min. The 
mixture was added dropwise to a solution of 222a-d (0.558 mmol) and Et4NBr (0.733 mmol) in 
DMF/CH2Cl2 (10 mL, 1:1), which has been stirred with activated 3Å molecular sieves (850 mg) 
for 2 h. The mixture was stirred for 14 h at r.t.. The reaction was quenched with pyridine (1 mL) 
and filtered over celite with addition of CH2Cl2 (20 mL). The solution was washed with brine (40 
mL) and the aqueous layer was extracted with CH2Cl2 (3 x 30 mL). The combined organic 
phases were dried with Na2SO4, filtered and the solvents were removed azeotropically with 
toluene. The residue was purified by flash chromatography (petroleum ether/diethyl ether, 12:1 
to 7:1, + 1% Et3N) to afford the fucosylated tritylether. To a stirred solution of the tritylether 
(0.305 mmol) in CH2Cl2 (4 mL), ZnBr2 (0.924 mmol) and triethylsilane (0.344 mmol) were added. 
The reaction was quenched after 8 h by adding water (100 µL). CH2Cl2 (10 mL) was added and 
the reaction mixture extracted with satd. aqueous NaHCO3 (30 mL). The aqueous layer was 
extracted with DCM (2 x 20 mL). The combined organic layers were washed with satd. aqueous 
NaHCO3 (50 mL) and the aqueous layer was extracted with DCM (2 x 50 mL). The combined 
organic layers were dried with Na2SO4, filtered and concentrated in vacuo. Chromatographic 
purification of the crude product (petroleum ether/toluene/ethyl acetate, 7:7:1 to 4:4:1) afforded 
223a-d. 
 
[(1R,2R,3S)-1-Hydroxy-3-methyl-cyclohex-2-yl] 2,3,4-tris-O-benzyl-6-deoxy--L-
galactopyranoside (223a), (DS-04-101, DS-04-106). 
According to the general procedure B, ethyl 2,3,4-tri-O-benzyl-1-thio-L-fucopyranoside (349 mg, 
0.729 mmol) in CH2Cl2 (2 mL) was treated with a solution of Br2 (43 µL, 0.837 mmol) in CH2Cl2 
(1 mL) for 50 min at 0°C. After destroying the exce ss of bromine, the fucosyl bromide solution 
was added to a solution of 222a (208 mg, 0.558 mmol) and Et4NBr (154 mg, 0.733 mmol) in 
DMF/CH2Cl2 (10 mL, 1:1), which has been stirred with activated 3Å molecular sieves (850 mg) 
for 2 h. The reaction was stirred for 28 h at r.t. and then quenched with pyridine (1 mL). Work-up 
was performed according to the general procedure B and the resulting residue was purified by 
flash chromatography (petroleum ether/toluene/ethyl acetate, 20:5:1, + 1% Et3N) yielding the 
pure tritylether (254 mg, 58%) as a colorless foam. To a stirred solution of the tritylether (241 
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mg, 0.305 mmol) in CH2Cl2 (4 mL), ZnBr2 (208 mg, 0.924 mmol) and triethylsilane (55 µL, 0.344 
mmol) were added. The reaction was quenched after 8 h by adding H2O (100 µL). Work-up and 
purification according to the general procedure B yielded 223a (140 mg, 84%) as a yellowish 
solid.  
[]D21 = - 35.0 (c = 0.45, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.98 (m, 1 H, H-4a), 1.08 (d, 3J 
= 6.4 Hz, 3 H, CH3), 1.16 (d, 3J = 6.5 Hz, 3 H, Fuc H-6), 1.22-1.30 (m, 2 H, H-5a, H-6a), 1.51 (m, 
1 H, H-3), 1.61-1.67 (m, 2 H, H-4b, H-5b), 2.00 (m, 1 H, H-6b), 2.87 (t, 3J = 9.3 Hz, 1 H, H-2), 3.37 
(m, 1 H, H-1), 3.70 (m, 1 H, Fuc H-4), 3.97 (dd, 3J = 2.7, 10.2 Hz, 1 H, Fuc H-3), 4.10-4.14 (m, 2 
H, Fuc H-2, Fuc H-5), 4.65, 4.70, 4.76, 4.77, 4.86, 4.99 (6 m, 6 H, 3 CH2Ph), 5.00 (d, 1 H, Fuc 
H-1), 7.25-7.39 (m, 15 H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 16.61 (Fuc C-6), 18.67 
(CH3), 23.20 (C-5), 32.73 (C-6), 33.70 (C-4), 36.57 (C-3), 67.47 (Fuc C-5), 72.99, 73.02, 73.41 
(C-1, 2 CH2Ph), 74.85 (CH2Ph), 76.45 (Fuc C-2), 77.50 (Fuc C-4), 78.95 (Fuc C-3), 93.13 (C-2), 
98.50 (Fuc C-1), 127.36, 127.44, 127.55, 127.62, 127.89, 128.20, 128.23, 128.33, 128.37, 
138.32, 138.42, 138.78 (18 C, 3 C6H5); IR (KBr) ν: 3434 (s, OH), 3030 (w), 2929 (s), 2866 (s), 
1496 (w), 1454 (m), 1368 (w), 1347 (w), 1306 (w), 1245 (vw), 1208 (vw), 1161 (m), 1138 (s), 
1106 (vs), 1059 (vs), 1028 (vs), 735 (s), 696 (s) cm-1; elemental analysis calcd (%) for C34H42O6 
(546.69): C 74.70, H 7.74; found: C 74.68, H 7.80. 
 
[(1R,2R,3S)-3-Butyl-1-hydroxy-cyclohex-2-yl] 2,3,4-tris-O-benzyl-6-deoxy--L-
galactopyranoside (223b), (DS-05-32, DS-05-42). 
According to the general procedure B, ethyl 2,3,4-tri-O-benzyl-1-thio-L-fucopyranoside (308 mg, 
0.644 mmol) in CH2Cl2 (3 mL) was treated with a solution of Br2 (38 µL, 0.740 mmol) in CH2Cl2 
(1 mL) for 30 min at 0°C. After destroying the exce ss of bromine, the fucosyl bromide solution 
was added to a solution of 222b (205 mg, 0.495 mmol) and Et4NBr (137 mg, 0.650 mmol) in 
DMF/CH2Cl2 (10 mL, 1:1), which has been stirred with activated 3Å molecular sieves (700 mg) 
for 3.5 h. The reaction was stirred for 67 h at r.t. and then quenched with pyridine (1 mL). Work-
up and purification according to the general procedure B yielded the tritylether (283 mg) as a 
yellowish resin. To a stirred solution of the tritylether in CH2Cl2 (4 mL), ZnBr2 (229 mg, 1.02 
mmol) and triethylsilane (81 µL, 0.510 mmol) were added. The reaction was quenched after 1.25 
h by adding H2O (100 µL). Work-up and purification according to the general procedure yielded 
223b (161 mg, 55% over two steps) as a colourless solid.  
[]D21 = - 21.3 (c = 0.56, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.82 (t, 3J = 7.0 Hz, 3 H, H-10), 
0.86 (m, 1 H, H-4a), 0.98 (m, 1 H, H-7a), 1.15 (d, 3JF5,F6 = 6.5 Hz, 3 H, Fuc H-6), 1.09-1.37 (m, 7 
H, H-3, H-5a, H-6a, H-8a, H-8b, H-9a, H-9b), 1.66 (m, 1 H, H-5b), 1.81 (m, 1 H, H-4b), 1.98 (m, 1 H, 
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H-6b), 2.10 (m, 1 H, H-7b), 2.94 (t, 3J = 9.3 Hz, 1 H, H-2), 3.36 (m, 1 H, H-1), 3.68 (m, 1 H, Fuc 
H-4), 3.98 (dd, 3JF3,F4 = 2.6 Hz, 3JF2,F3 = 10.2 Hz, 1 H, Fuc H-3), 4.09-4.14 (m, 2 H, Fuc H-2, Fuc 
H-5), 4.65, 4.70, 4.75, 4.78, 4.85 (5 m, 5 H, 3 CH2Ph), 4.98-5.00 (m, 2 H, Fuc H-1, 1 CH2Ph), 
7.25-7.39 (m, 15 H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 14.11 (C-10), 16.57 (Fuc C-6), 
22.72 (C-9), 23.19 (C-5), 29.03 (C-8), 30.26 (C-4), 31.24 (C-7), 32.55 (C-6), 41.18 (C-3), 67.54 
(Fuc C-5), 72.97 (CH2Ph), 73.26 (C-1), 73.39 (CH2Ph), 74.84 (CH2Ph), 76.38 (Fuc C-2), 77.60 
(Fuc C-4), 78.80 (Fuc C-3), 91.47 (C-2), 98.31 (Fuc C-1), 127.40, 127.45, 127.52, 127.61, 
127.86, 128.20, 128.21, 128.33, 128.38, 138.32, 138.44, 138.79 (18 C, 3 C6H5); elemental 
analysis calcd (%) for C37H48O6 (588.77): C 75.48, H 8.22; found: C 75.55, H 8.28. 
 
[(1R,2R,3R)-3-Cyclopropyl-1-hydroxy-cyclohex-2-yl] 2,3,4-tris-O-benzyl-6-deoxy--L-
galactopyranoside (223c), (DS-05-63). 
According to the general procedure B, ethyl 2,3,4-tri-O-benzyl-1-thio-L-fucopyranoside (223 mg, 
0.466 mmol) in CH2Cl2 (1.5 mL) was treated with a solution of Br2 (27.5 µL, 0.535 mmol) in 
CH2Cl2 (1 mL) for 30 min at 0°C. After destroying the exc ess of bromine, the fucosyl bromide 
solution was added to a solution of 222c (142 mg, 0.356 mmol) and Et4NBr (98.9 mg, 0.471 
mmol) in DMF/CH2Cl2 (6 mL, 1:1), which has been stirred with activated 3Å molecular sieves (1 
g) for 4 h. The reaction was stirred for 67 h at r.t. and then quenched with pyridine (1 mL). Work-
up and purification according to the general procedure B yielded the tritylether (237 mg). To a 
stirred solution of the tritylether in CH2Cl2 (4 mL), ZnBr2 (193 mg, 0.859 mmol) and triethylsilane 
(70 µL, 0.441 mmol) were added. The reaction was quenched after 1.75 h by adding H2O (100 
µL). Work-up and purification according to the general procedure B yielded 223c (136 mg, 67% 
over two steps) as a colourless solid.  
[]D21 = - 29.0 (c = 0.65, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: -0.06 (m, 1 H, cPr), 0.08 (m, 1 
H, cPr), 0.22 (m, 1 H, cPr), 0.33 (m, 1 H, cPr), 0.87 (m, 1 H, H-4a), 0.96 (m, 1 H, cPr), 1.05-1.27 
(m, 6 H, Fuc H-6, H-3, H-5a, H-6a), 1.54 (m, 1 H, H-4b), 1.64 (m, 1 H, H-5b), 1.96 (m, 1 H, H-6b), 
3.11 (t, 3J = 9.1 Hz, 1 H, H-2), 3.35 (m, 1 H, H-1), 3.69 (m, 1 H, Fuc H-4), 3.98 (dd, 3JF3,F4 = 2.5 
Hz, 3JF2,F3 = 10.1 Hz, 1 H, Fuc H-3), 4.11-4.16 (m, 2 H, Fuc H-2, Fuc H-5), 4.66-4.68 (m, 2 H, 
CH2Ph), 4.76, 4.77, 4.90, 5.01 (4 m, 4 H, CH2Ph), 5.14 (d, 3JF1,F2 = 3.4 Hz, 1 H, Fuc H-1), 7.26-
7.41 (m, 15 H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 0.76, 4.93, 13.58 (3 C, cPr), 16.56 (Fuc 
C-6), 22.86 (C-5), 28.32 (C-4), 32.56 (C-6), 44.14 (C-3), 67.64 (Fuc C-5), 73.14, 73.19 (2 
CH2Ph), 73.95 (C-1), 74.85 (CH2Ph), 76.74 (Fuc C-2), 77.68 (Fuc C-4), 78.63 (Fuc C-3), 92.33 
(C-2), 99.20 (Fuc C-1), 127.42, 127.45, 127.50, 127.64, 128.18, 128.22, 128.35, 128.44, 138.44, 
138.58, 138.90 (18 C, 3 C6H5); IR (KBr) ν: 3426 (s, OH), 3031 (vw), 3004 (vw), 2933 (s), 1497 
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(vw), 1453 (m), 1348 (w), 1247 (vw), 1212 (vw), 1161 (m), 1136 (s), 1103 (vs), 1064 (vs), 1026 
(vs), 957 (w), 911 (vw), 843 (vw), 736 (s), 696 (s) cm-1; elemental analysis calcd (%) for 
C36H44O6 (572.73): C 75.50, H 7.74; found: C 75.38, H 7.75. 
 
[(1R,2R,3R)-3-Ethenyl-1-hydroxy-cyclohex-2-yl] 2,3,4-tris-O-benzyl-6-deoxy--L-
galactopyranoside (223d), (DS-04-148, DS-04-149, DS-05-06, DS-05-09). 
According to the general procedure B, ethyl 2,3,4-tri-O-benzyl-1-thio-L-fucopyranoside (205 mg, 
0.428 mmol) in CH2Cl2 (1.5 mL) was treated with a solution of Br2 (25.5 µL, 0.496 mmol) in 
CH2Cl2 (1 mL) for 40 min at 0°C. After destroying the exc ess of bromine, the fucosyl bromide 
solution was added to a solution of 222d (126 mg, 0.329 mmol) and Et4NBr (90.8 mg, 0.432 
mmol) in DMF/CH2Cl2 (6 mL, 1:1), which has been stirred with activated 3Å molecular sieves 
(500 mg) for 4 h. The reaction was stirred for 67 h at r.t. and then quenched with pyridine (1 mL). 
Work-up and purification according to the general procedure B yielded the tritylether (213 mg). 
To a stirred solution of the tritylether in CH2Cl2 (4 mL), ZnBr2 (179 mg, 0.793 mmol) and 
triethylsilane (63 µL, 0.397 mmol) were added. The reaction was quenched after 2 h by adding 
H2O (100 µL). Work-up and purification according to the general procedure B yielded 223d (110 
mg, 60% over two steps) as a colourless solid.  
[]D21 = - 22.1 (c = 0.52, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 1.15 (d, 3JF6,F5 = 6.5 Hz, 3 H, 
Fuc H-6), 1.17 (m, 1 H, H-4a), 1.26-1.30 (m, 2 H, H-5a, H-6a), 1.72 (m, 1 H, H-5b), 1.78 (m, 1 H, 
H-4b), 2.02 (m, 1 H, H-6b), 2.13 (m, 1 H, H-3), 3.04 (t, 3J = 9.5 Hz, 1 H, H-2), 3.45 (m, 1 H, H-1), 
3.69 (m, 1 H, Fuc H-4), 3.98 (dd, 3JF3,F4 = 2.6 Hz, 3JF2,F3 = 10.1 Hz, 1 H, Fuc H-3), 4.10 (dd, 
3JF1,F2 = 3.6 Hz, 3JF2,F3 = 10.1 Hz, 1 H, Fuc H-2), 4.12 (m, 1 H, Fuc H-5), 4.65, 4.70, 4.76, 4.78,  
(4 m, 4 H, 2 CH2Ph), 4.85 (m, 2 H, CH2Ph, vinyl H), 4.98 (m, 1 H, vinyl H), 4.99 (m, 1 H, CH2Ph), 
5.03 (d, 3JF1,F2 = 3.6 Hz, 1 H, Fuc H-1), 6.25 (m, 1 H, vinyl H), 7.27-7.40 (m, 15 H, 3 C6H5); 13C-
NMR (CDCl3, 125.8 MHz) δ: 16.55 (Fuc C-6), 22.81 (C-5), 29.67 (C-4), 32.39 (C-6), 44.33 (C-3), 
67.56 (Fuc C-5), 72.97, 73.01 (CH2Ph, C-1), 73.38, 74.85 (2 CH2Ph), 76.41 (Fuc C-2), 77.54 
(Fuc C-4), 78.86 (Fuc C-3), 90.26 (C-2), 97.98 (Fuc C-1), 113.46 (vinyl C), 127.43, 127.48, 
127.53, 127.63, 127.82, 128.23, 128.36 (18 C, 3 C6H5), 140.43 (vinyl C), IR (KBr) ν: 3429 (s, 
OH), 3065 (w), 3031 (w), 2932 (s), 2866 (s), 1636 (vw), 1497 (w), 1454 (m), 1348 (m), 1308 (w), 
1246 (vw), 1212 (w), 1161 (s), 1138 (s), 1101 (vs), 1064 (vs), 1027 (vs), 953 (m), 911 (w) cm-1; 
elemental analysis calcd (%) for C35H42O6 (558.70): C 75.24, H 7.58; found: C 74.91, H 7.55. 
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[(1R,2R,3S)-3-Ethyl-1-hydroxy-cyclohex-2-yl] 2,3,4-tris-O-benzyl-6-deoxy--L-
galactopyranoside (223e), (DS-05-14). 
A solution of 223d (90.0 mg, 0.161 mmol) in THF (4 mL) was added to Pd/C (45.2 mg, 10% Pd) 
under argon. The mixture was hydrogenated under atmospheric pressure at r.t.. After 30 min the 
reaction was filtered through celite, concentrated under reduced pressure and purified by 
column chromatography (toluene/petroleum ether/ethyl acetate, 7:7:1 to 5:5:1) to yield 223e 
(69.8 mg, 77%) as a colourless solid.  
[]D21 = - 37.2 (c = 0.50, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.78 (t, 3J = 7.5 Hz, 3 H, 
CH2CH3), 0.88 (m, 1 H, H-4a), 1.06-1.26 (m, 3 H, CH2CH3, H-5a, H-6a), 1.16 (d, 3JF5,F6 = 6.5 Hz, 3 
H, Fuc H-6), 1.30 (m, 1 H, H-3), 1.67 (m, 1 H, H-5b), 1.79 (m, 1 H, H-4b), 1.99-2.07 (m, 2 H, H-6b, 
CH2CH3), 2.96 (dd, 3J = 8.6, 10.2 Hz, 1 H, H-2), 3.38 (ddd, 3J = 4.8, 8.5, 10.6 Hz, 1 H, H-1), 3.70 
(m, 1 H, Fuc H-4), 3.98 (dd, 3JF3,F4 = 2.7 Hz, 3JF3,F2 = 10.2 Hz, 1 H, Fuc H-5), 4.10-4.14 (m, 2 H, 
Fuc H-2, Fuc H-5), 4.66, 4.70, 4.77, 4.80, 4.84 (5 m, 5 H, CH2Ph), 4.89-5.00 (m, 2 H, Fuc H-1, 
CH2Ph), 7.27-7.40 (m, 15 H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 10.99 (CH2CH3), 16.60 
(Fuc C-6), 23.09 (C-5), 24.17 (CH2CH3), 29.50 (C-4), 32.60 (C-6), 42.64 (C-3), 67.48 (Fuc C-5), 
72.83, 73.13, 73.47 (C-1, 2 CH2Ph), 74.84 (CH2Ph), 76.32 (Fuc C-2), 77.37 (Fuc C-4), 78.86 
(Fuc C-3), 91.07 (C-2), 98.31 (Fuc C-1), 127.40, 127.46, 127.50, 127.64, 127.80, 128.21, 
128.33, 128.39, 138.31, 138.39, 138.70 (18 C, 3 C6H5); HR-MS (ESI) m/z: calcd for C35H44NaO6 
[M+Na]+: 583.3030; found: 583.3018 (2.1 ppm). 
 
[(1R,2R,3R)-1-Hydroxy-3-(2-methoxycarbonyl-ethyl)-cyclohex-2-yl] 2,3,4-tris-O-benzyl-6-
deoxy--L-galactopyranoside (223f), (DS-05-35). 
223d (106 mg, 0.189 mmol) was dissolved in CH2Cl2 (5 mL) and Grubbs cat. 2nd gen. (16.0 mg 
18.8 µmol) and methyl acrylate (171 µL, 1.90 mmol) were added. The reaction was heated 
under reflux for 9 d. After 1 d, 2 d and 7 d additional Grubbs cat. 2nd gen. (each 16.0 mg, 18.8 
µmol) and methyl acrylate (each 171 µL, 1.90 mmol) were added. The mixture was concentrated 
under reduced pressure and purified by column chromatography (petroleum ether/ethyl acetate, 
5:1 to 4:1) to yield an E/Z mixture (53.9 mg), which was directly used for hydrogenation. A 
solution of the E/Z-mixture in THF (4 mL) was added to Pd/C (28.0 mg, 10% Pd) under argon. 
The mixture was hydrogenated under atmospheric pressure at r.t.. After 30 min the reaction was 
filtered through celite, concentrated under reduced pressure and purified by column 
chromatography (petroleum ether/ethyl acetate, 3:1 to 2:1) to yield 223f (29.1 mg, 25%) as a 
brownish oil.  
[]D21 = - 21.2 (c = 1.46, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.94 (m, 1 H), 1.14 (d, 3JF6,F5 = 
6.5 Hz, 3 H, Fuc H-6), 1.19-1.28 (m, 2 H), 1.35-1.47 (m, 2 H), 1.67 (m, 1 H), 1.74 (m, 1 H), 1.99 
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(m, 1 H), 2.29-2.36 (m, 3 H), 2.97 (t, 3J = 9.2 Hz, 1 H, H-2), 3.36 (m, 1 H, H-1), 3.57 (s, 3 H, Me), 
3.67 (m, 1 H, Fuc H-4), 3.98 (dd, 3JF3,F4 = 2.4 Hz, 3JF2,F3 = 10.2 Hz, 1 H, Fuc H-3), 4.09-4.13 (m, 
2 H, Fuc H-2, Fuc H-5), 4.65, 4.71, 4.76, 4.78, 4.85 (5 m, 5 H, CH2Ph), 4.96 (d, 3JF1,F2 = 3.4 Hz, 
1 H, Fuc H-1), 4.99 (1 m, 1 H, CH2Ph), 7.25-7.41 (m, 15 H, 3 C6H5); 13C-NMR (CDCl3, 125.8 
MHz) δ: 16.50 (Fuc C-6), 23.03, 27.48, 30.37, 32.02, 32.33 (5 C), 40.72 (C-3), 51.30 (Me), 67.64 
(Fuc C-5), 72.97, 73.00 (CH2Ph, C-1), 73.48, 74.82 (2 CH2Ph), 76.01 (Fuc C-2), 77.50 (Fuc C-
4), 78.84 (Fuc C-3), 91.25 (C-2), 98.33 (Fuc C-1), 127.43, 127.47, 127.58, 127.62, 127.92, 
128.19, 128.28, 128.34, 128.36, 138.23, 138.36, 138.73 (18 C, 3 C6H5), 174.33 (COOMe); HR-
MS (ESI) m/z: calcd for C37H46NaO8 [M+Na]+: 641.3085; found: 641.3080 (0.8 ppm). 
 
General procedure C for DMTST promoted glycosylations (225a-225c, 225e-225f). 
A solution of the thioglycoside 224 (0.292 mmol) and the appropriate glycosyl acceptor 223 
(0.225 mmol) in dry CH2Cl2 (8 mL) was added via syringe to activated 3Å molecular sieves (2 g) 
under argon. A suspension of dimethyl(methylthio)sulfonium triflate (DMTST) (0.685 mmol) and 
activated 3Å molecular sieves (1 g) in CH2Cl2 (4 mL) was prepared in a second flask. Both 
suspensions were stirred at r.t. for 4 h, then the DMTST suspension was added via syringe to 
the other suspension with some additional CH2Cl2 (2 ml). The reaction was stopped after 2 d, 
filtered through celite and the celite washed with CH2Cl2 (10 mL). The filtrate was successively 
washed with satd. aqueous NaHCO3 (25 mL) and water (40 mL). The aqueous layers were 
extracted with CH2Cl2 (3 x 25 mL). The combined organic layers were dried with Na2SO4, filtered 
and concentrated in vacuo. The crude product was purified by column chromatography 
(petroleum ether/toluene/ethyl acetate, 10:10:1 to 5:5:1) to afford the tetrasaccharide mimic 225 
as a colourless foam.  
 
{(1R,2R,3S)-2-[(2,3,4-tris-O-benzyl-6-deoxy--L-galactopyranosyl)oxy]-3-methyl-cyclohex-
1-yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexyl-ethyl]--D-
galactopyranoside (225a), (DS-04-107). 
Thioglycoside 224 (254 mg, 0.326 mmol) and glycosyl acceptor 223a (137 mg, 0.250 mmol) in 
dry CH2Cl2 (8 mL) were added via syringe to activated 4Å molecular sieves (2 g). A suspension 
of DMTST (206 mg, 0.797 mmol) and activated 4Å molecular sieves (1 g) in CH2Cl2 (4 mL) was 
prepared in a second flask. Both suspensions were stirred at r.t. for 4 h, then the DMTST 
suspension was added via syringe to the other suspension. The reaction was stopped after 43 h 
and work-up and purification according to the general procedure C afforded 225a (187 mg, 59%) 
as a colourless foam.  
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[]D21 = - 51.0 (c = 0.51, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.45-1.46 (m, 19 H, CyCH2, 
MeCy), 1.04 (d, 3J = 6.3 Hz, 3 H, CH3), 1.44 (d, 3JF5,F6 = 6.4 Hz, 3 H, Fuc H-6), 1.86 (m, 1 H, 
MeCy), 3.21 (t, 3J = 9.1 Hz, 1 H, H-2), 3.48 (m, 1 H, H-1), 3.51 (s. 1 H, Fuc H-4), 3.82 (dd, 3JG3,G4 
= 3.3 Hz, 3JG2,G3 = 9.9 Hz, 1 H, Gal H-3), 3.91 (m, 1 H, Gal H-5), 4.02 (dd, 3JF1,F2 = 3.3 Hz, 3JF2,F3 
= 10.3 Hz, 1 H, Fuc H-2), 4.05 (dd, 3JF3,F4 = 2.3 Hz, 3JF2,F3 = 10.3 Hz, 1 H, Fuc H-3), 4.12 (dd, 3J 
= 4.6, 7.9 Hz, 1 H, Lac H-2), 4.24 (dd, 3JG5,G6a = 7.2 Hz, 2JG6a,G6b = 11.4 Hz, 1 H, Gal H-6a), 4.26 
(m, 1 H, CH2Ph), 4.38 (dd, 3JG5,G6b = 5.7 Hz, 2JG6a,G6b = 11.4 Hz, 1 H, Gal H-6b), 4.51 (m, 1 H, 
CH2Ph), 4.54 (d, 3JG1,G2 = 8.2 Hz, 1 H, Gal H-1), 4.63, 4.67, 4.74, 4.77 (4 m, 4 H, CH2Ph), 4.88 
(m, 1 H, Fuc H-5), 5.05 (m, 1 H, CH2Ph), 5.06 (d, 3JF1,F2 = 3.5 Hz, 1 H, Fuc H-1), 5.11 (m, 1 H, 
CH2Ph), 5.60 (m, 1 H, Gal H-2), 5.84 (m, 1 H, Gal H-4), 7.17-7.34, 7.42-7.46, 7.52-7.58, 8.03-
8.12 (4 m, 35 H, 7 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 16.80 (Fuc C-6), 18.68 (CH3), 22.65, 
25.46, 25.72, 26.08, 30.73, 32.63, 33.03, 33.21, 33.40, 38.97, 40.48 (11 C, MeCy, CyCH2), 
62.47 (Gal C-6), 66.31 (Fuc C-5), 66.63 (CH2Ph), 70.20 (Gal C-4), 71.43 (Gal C-5), 72.10 
(CH2Ph), 72.18 (Gal C-2), 74.19, 74.92 (2 CH2Ph), 76.38 (Fuc C-2), 78.10 (Gal C-3), 78.43 (Lac 
C-2), 79.46 (Fuc C-4), 79.74 (Fuc C-3), 80.97, 81.20 (2 C, MeCy), 97.88 (Fuc C-1), 100.07 (Gal 
C-1), 126.91, 127.01, 127.17, 127.37, 127.72, 128.03, 128.07, 128.40, 128.45, 128.49, 128.55, 
129.66, 129.74, 129.94, 129.98, 133.04, 133.16, 133.26, 135.43, 138.63, 139.05, 139.25 (42 C, 
7 C6H5), 164.54, 166.11, 166.22, 172.45 (4 C=O); IR (KBr) ν: 3064, 3032, 2926, 1730 (C=O), 
1602, 1497, 1452, 1315, 1267, 1175, 1069, 1098 cm-1; elemental analysis calcd (%) for 
C77H84O16 (1265.48): C 73.08, H 6.69; found: C 73.16, H 6.76. 
 
{(1R,2R,3S)-2-[(2,3,4-tris-O-benzyl-6-deoxy--L-galactopyranosyl)oxy]-3-butyl-cyclohex-1-
yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexyl-ethyl]--D-
galactopyranoside (225b), (DS-05-45). 
Thioglycoside 224 (218 mg, 0.279 mmol) and glycosyl acceptor 223b (126 mg, 0.215 mmol) in 
dry CH2Cl2 (8 mL) were added via syringe to activated 3Å molecular sieves (2 g). A suspension 
of DMTST (166 mg, 0.644 mmol) and activated 3Å molecular sieves (1 g) in CH2Cl2 (4 mL) was 
prepared in a second flask. Both suspensions were stirred at r.t. for 4.5 h, then the DMTST 
suspension was added via syringe to the other suspension with some additional CH2Cl2 (2 ml). 
The reaction was stopped after 65.5 h and work-up and purification according to the general 
procedure C afforded 225b (224 mg, 80%) as a colourless foam.  
[]D21 = - 46.7 (c = 0.49, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.45-1.84 (m, 26 H, CyCH2, 
nBuCy), 0.80 (d, 3J = 6.8 Hz, 3 H, nBu), 1.40 (d, 3J = 6.5 Hz, 3 H, Fuc H-6), 3.36 (t, 3J = 8.5 Hz, 1 
H, H-2), 3.52 (s, 1 H, Fuc H-4), 3.54 (m, 1 H, H-1), 3.83 (dd, 3JG3,G4 = 3.0 Hz, 3JG2,G3 = 9.8 Hz, 1 
H, Gal H-3), 3.92 (m, 1 H, Gal H-5), 4.01 (dd, 3JF1,F2 = 3.2 Hz, 3JF2,F3 = 10.3 Hz, 1 H, Fuc H-2), 
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4.04 (dd, 3JF3,F4 = 2.0 Hz, 3JF2,F3 = 10.4 Hz, 1 H, Fuc H-3), 4.13 (dd, 3J = 4.6, 7.8 Hz, 1 H, Lac H-
2), 4.28 (dd, 3JG5,G6a = 6.7 Hz, 2JG6a,G6b = 11.4 Hz, 1 H, Gal H-6a), 4.28 (m, 1 H, CH2Ph), 4.39 (dd, 
3JG5,G6b = 5.8 Hz, 2JG6a,G6b = 11.4 Hz, 1 H, Gal H-6b), 4.52 (m, 1 H, CH2Ph), 4.56 (d, 3JG1,G2 = 8.1 
Hz, 1 H, Gal H-1), 4.65, 4.68, 4.74, 4.76 (4 m, 4 H, CH2Ph), 4.79 (m, 1 H, Fuc H-5), 5.01 (d, 
3JF1,F2 = 3.0 Hz, 1 H, Fuc H-1), 5.05, 5.11 (2 m, 2 H, CH2Ph), 5.61 (m, 1 H, Gal H-2), 5.85 (m, 1 
H, Gal H-4), 7.20-7.36, 7.42-7.46, 7.52-7.59, 8.04-8.13 (4 m, 35 H, 7 C6H5); 13C-NMR (CDCl3, 
125.8 MHz) δ: 14.26 (CH2CH2CH2CH3), 16.81 (Fuc C-6), 21.84, 22.95, 25.46, 25.71, 26.07, 
28.34, 28.55, 30.20, 30.39, 32.61, 33.19, 33.39, 40.48, 42.80 (14 C, CyCH2, nBuCy), 62.52 (Gal 
C-6), 66.37 (Fuc C-5), 66.63 (CH2Ph), 70.15 (Gal C-4), 71.45 (Gal C-5), 72.11 (CH2Ph), 72.21 
(Gal C-2), 73.89, 74.92 (2 CH2Ph), 76.17 (Fuc C-2), 78.05 (Gal C-3), 78.38 (Lac C-2), 78.76 (C-
2), 79.23 (Fuc C-4), 79.75 (Fuc C-3), 80.79 (C-1), 97.71 (Fuc C-1), 100.03 (Gal C-1), 126.95, 
127.04, 127.21, 127.30, 127.80, 128.04, 128.09, 128.15, 128.39, 128.44, 128.48, 128.49, 
128.54, 129.66, 129.71, 129.75, 129.92, 129.94, 133.03, 133.16, 133.25, 135.42, 138.70, 
138.99, 139.16 (42 C, 7 C6H5), 164.56, 166.09, 166.21, 172.47 (4 C=O); elemental analysis 
calcd (%) for C80H90O16 (1307.58): C 73.49, H 6.94; found: C 73.16, H 6.93. 
 
{(1R,2R,3R)-2-[(2,3,4-tris-O-benzyl-6-deoxy--L-galactopyranosyl)oxy]-3-cyclopropyl-
cyclohex-1-yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexyl-ethyl]--D-
galactopyranoside (225c), (DS-05-64). 
Thioglycoside 224 (228 mg, 0.292 mmol) and glycosyl acceptor 223c (129 mg, 0.225 mmol) in 
dry CH2Cl2 (8 mL) were added via syringe to activated 3Å molecular sieves (2 g). A suspension 
of DMTST (177 mg, 0.685 mmol) and activated 3Å molecular sieves (1 g) in CH2Cl2 (4 mL) was 
prepared in a second flask. Both suspensions were stirred at r.t. for 4 h, then the DMTST 
suspension was added via syringe to the other suspension with some additional CH2Cl2 (2 ml). 
The reaction was stopped after 48 h and work-up and purification according to the general 
procedure C afforded 225c (253 mg, 87%) as a colourless foam.  
[]D21 = - 43.1 (c = 0.61, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: -0.11 (m, 1 H, cPr), 0.16  (m, 1 
H, cPr), 0.32-0.35 (m, 2 H, cPr), 0.46-0.53 (m, 2 H, CyCH2), 0.64-1.46 (m, 18 H, CyCH2, Cy, 
cPr), 1.38 (d, 3JF5,F6 = 6.4 Hz, 3 H, Fuc H-6), 1.80 (m, 1 H, H-6b), 3.52 (t, 3J = 7.3 Hz, 1 H, H-2), 
3.57 (s, 1 H, Fuc H-4), 3.62 (m, 1 H, H-1), 3.84 (dd, 3JG3,G4 = 2.8 Hz, 3JG2,G3 = 9.8 Hz, 1 H, Gal H-
3), 3.93 (m, 1 H, Gal H-5), 4.03 (dd, 3JF1,F2 = 3.2 Hz, 3JF2,F3 = 10.2 Hz, 1 H, Fuc H-2), 4.07 (dd, 
3JF3,F4 = 1.7 Hz, 3JF2,F3 = 10.4 Hz, 1 H, Fuc H-3), 4.13 (dd, 3J = 4.5, 7.8 Hz, 1 H, Lac H-2), 4.32-
4.40 (m, 3 H, Gal H-6, CH2Ph), 4.53 (m, 1 H, CH2Ph), 4.58 (d, 3JG1, G2 = 8.1 Hz, 1 H, Gal H-1), 
4.62, 4.68 (2 m, 2 H, CH2Ph), 4.74-4.76 (m, 2 H, Fuc H-5, CH2Ph), 4.78 (m, 1 H, CH2Ph), 5.05, 
5.11 (2 m, 2 H, CH2Ph), 5.35 (d, 3JF1,F2 = 2.8 Hz, 1 H, Fuc H-1), 5.61 (m, 1 H, Gal H-2), 5.87 (m, 
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1 H, Gal H-4), 7.20-7.36, 7.42-7.44, 7.52-7.59, 8.03-8.14 (4 m, 35 H, 7 C6H5); 13C-NMR (CDCl3, 
125.8 MHz) δ: 3.06 (cPr), 5.26 (cPr), 13.55 (cPr), 16.81 (Fuc C-6), 20.97, 25.46, 25.72, 26.07, 
27.71, 29.44, 32.62, 33.21, 33.40 (9 C, CyCH2, Cy), 40.46 (Lac C-3), 45.35 (C-3), 62.50 (Gal C-
6), 66.34 (Fuc C-5), 66.61 (CH2Ph), 70.10 (Gal C-4), 71.49 (Gal C-5), 72.13 (CH2Ph), 72.32 (Gal 
C-2), 74.22 (CH2Ph), 74.87 (CH2Ph), 76.15 (Fuc C-2), 77.97 (Gal C-3), 78.38 (Lac C-2), 78.82 
(C-2), 79.13 (Fuc C-4), 79.66 (C-1), 79.83 (Fuc C-3), 97.02 (Fuc C-1), 99.60 (Gal C-1), 126.96, 
127.05, 127.20, 127.38, 127.78, 128.05, 128.09, 128.37, 128.43, 128.47, 128.53, 129.61, 
129.73, 129.89, 129.93, 129.96, 133.03, 133.16, 133.23, 135.44, 138.51, 138.95, 139.21 (42 C, 
7 C6H5), 164.57, 165.98, 166.16, 172.43 (4 C=O); IR (KBr) ν: 3064 (vw), 3032 (vw), 2927 (s), 
2854 (w), 1731 (vs, C=O), 1602 (vw), 1497 (vw), 1452 (m), 1315 (m), 1267 (vs), 1176 (s), 1097 
(vs), 1027 (vs), 840 (vw), 713 (vs) cm-1; elemental analysis calcd (%) for C79H86O16 (1291.52): C 
73.47, H 6.71; found: C 73.32, H 6.81. 
 
{(1R,2R,3S)-2-[(2,3,4-tris-O-benzyl-6-deoxy--L-galactopyranosyl)oxy]-3-ethyl-cyclohex-1-
yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexyl-ethyl]--D-
galactopyranoside (225e), (DS-05-17). 
Thioglycoside 224 (112 mg, 0.144 mmol) and glycosyl acceptor 223e (61.6 mg, 0.110 mmol) in 
dry CH2Cl2 (4 mL) were added via syringe to activated 3Å molecular sieves (1 g). A suspension 
of DMTST (87.0 mg, 0.337 mmol) and activated 3Å molecular sieves (500 mg) in CH2Cl2 (2 mL) 
was prepared in a second flask. Both suspensions were stirred at r.t. for 4 h, then the DMTST 
suspension was added via syringe to the other suspension with some additional CH2Cl2 (1 ml). 
The reaction was stopped after 49.5 h and work-up and purification according to the general 
procedure C afforded 225e (110 mg, 78%) as a colourless foam.  
[]D21 = - 51.5 (c = 0.42, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ : 0.45-1.61 (m, 20 H, CyCH2, 
EtCy), 0.75 (t, 3J = 7.3 Hz, 3 H, CH2CH3), 1.41 (d, 3JF5,F6 = 6.4 Hz, 3 H, Fuc H-6), 1.84 (m, 1 H, 
H-6b), 1.92 (m, 1 H, CH2CH3), 3.31 (t, 3J = 8.7 Hz, 1 H, H-2), 3.49-3.52 (m, 2 H, H-1, Fuc H-4), 
3.82 (dd, 3JG3,G4 = 3.2 Hz, 3JG2,G3 = 9.8 Hz, 1 H, Gal H-3), 3.92 (m, 1 H, Gal H-5), 3.99-4.05 (m, 2 
H, Fuc H-2, Fuc H-3), 4.12 (dd, 3J = 4.6, 7.9 Hz, 1 H, Lac H-2), 4.25 (dd, 3JG5,G6a = 7.2 Hz, 
3JG6a,G6b = 11.4 Hz, 1 H, Gal H-6a), 4.28 (m, 1 H, CH2Ph), 4.39 (dd, 3JG5,G6b = 5.7 Hz, 3JG6a,G6b = 
11.4 Hz, 1 H, Gal H-6b), 4.51-4.55 (m, 2 H, CH2Ph, Gal H-1), 4.63, 4.65, 4.75, 4.78 (4 m, 4 H, 
CH2Ph), 4.81 (m, 1 H, Fuc H-5), 4.98 (d, 3JF1,F2 = 2.8 Hz, 1 H, Fuc H-1), 5.04, 5.11 (2 m, 2 H, 
CH2Ph), 5.60 (m, 1 H, Gal H-2), 5.84 (m, 1 H, Gal H-4), 7.17-7.33, 7.42-7.46, 7.52-7.58, 8.04-
8.12 (4 m, 35 H, 7 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 10.94 (CH2CH3), 16.82 (Fuc C-6), 
23.18 (CH2CH3), 22.11, 25.45, 25.71, 26.07, 27.89, 30.41, 32.60, 33.19, 33.40, 40.49 (10 C, 
EtCy, CyCH2), 44.71 (C-3), 62.50 (Gal C-6), 66.35 (Fuc C-5), 66.64 (CH2Ph), 70.17 (Gal C-4), 
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71.40 (Gal C-5), 72.07 (CH2Ph), 72.17 (Gal C-2), 74.29, 74.91 (2 CH2Ph), 76.42 (Fuc C-2), 
78.06 (Gal C-3), 78.38 (Lac C-2), 79.22, 79.27 (Fuc C-4, C-2), 79.77 (Fuc C-3), 80.95 (C-1), 
97.96 (Fuc C-1), 100.05 (Gal C-1), 126.94, 127.06, 127.21, 127.39, 127.77, 128.05, 128.10, 
128.38, 128.44, 128.50, 128.54, 129.66, 129.93, 133.03, 133.17, 133.27, 135.40, 138.64, 
139.01, 139.17 (42 C, 7 C6H5), 164.58, 166.11, 166.22, 172.48 (4 C=O); elemental analysis 
calcd (%) for C78H86O16 (1279.51) + ½ H2O: C 72.20, H 6.84; found: C 72.37, H 6.82; HR-MS 
(ESI) m/z: calcd for C78H86NaO16 [M+Na]+: 1301.5808; found: 1301.5855 (3.6 ppm). 
 
{(1R,2R,3R)-2-[(2,3,4-tris-O-benzyl-6-deoxy--L-galactopyranosyl)oxy]-3-(2-
methoxycarbonyl-ethyl)-cyclohex-1-yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-
2-cyclohexyl-ethyl]--D-galactopyranoside (225f), (DS-05-47). 
Thioglycoside 224 (47.9 mg, 61.3 µmol) and glycosyl acceptor 223f (29.1 mg, 47.0 µmol) in dry 
CH2Cl2 (4 mL) were added via syringe to activated 3Å molecular sieves (500 mg). A suspension 
of DMTST (37.6 mg, 146 µmol) and activated 3Å molecular sieves (250 mg) in CH2Cl2 (2 mL) 
was prepared in a second flask. Both suspensions were stirred at r.t. for 4 h, then the DMTST 
suspension was added via syringe to the other suspension with some additional CH2Cl2 (1 ml). 
The reaction was stopped after 65.5 h and work-up according to the general procedure C and 
purification by column chromatography (petroleum ether/ethyl acetate, 4:1 to 3:1) afforded 225f 
(49.5 mg, 79%) as a colourless foam.  
[]D21 = - 38.1 (c = 0.59, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ : 0.45-1.57 (m, 19 H, CyCH2, 
Cy), 1.37 (d, 3J = 6.4 Hz, 3 H, Fuc H-6), 1.61 (m, 1 H, (CH2)2CO2Me), 1.82 (m, 1 H, H-6b), 2.13-
2.26 (m, 3 H, (CH2)2CO2Me), 3.39 (t, 3J = 8.1 Hz, 1 H, H-2), 3.51 (s, 1 H, Fuc H-4), 3.53-3.56 (m, 
4 H, H-1, Me), 3.84 (dd, 3JG3,G4 = 3.3 Hz, 3JG2,G3 = 9.9 Hz, 1 H, Gal H-3), 3.93 (m, 1 H, Gal H-5), 
3.98-4.03 (m, 2 H, Fuc H-2, Fuc H-3), 4.13 (dd, 3J = 4.5, 8.0 Hz, 1 H, Lac H-2), 4.28 (dd, 3JG5,G6a 
= 7.2 Hz, 2JG6a,G6b = 11.4 Hz, 1 H, Gal H-6a), 4.31 (m, 1 H, CH2Ph), 4.38 (dd, 3JG5,G6b = 5.6 Hz, 
2JG6a,G6b = 11.4 Hz, 1 H, Gal H-6b), 4.54 (m, 1 H, CH2Ph), 4.55 (d, 3JG1,G2 = 8.0 Hz, 1 H, Gal H-1), 
4.66-4.71 (m, 3 H, CH2Ph, Fuc H-5), 4.73, 4.77 (2 m, 2 H, CH2Ph), 5.02 (d, 3JF1,F2 = 2.3 Hz, 1 H, 
Fuc H-1), 5.05, 5.12 (2 m, 2 H, CH2Ph), 5.60 (m, 1 H, Gal H-2), 5.85 (m, 1 H, Gal H-4), 7.19-
7.34, 7.42-7.47, 7.53-7.59, 8.03-8.13 (4 m, 35 H, 7 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 16.78 
(Fuc C-6), 21.18, 25.44, 25.66, 25.70, 26.05, 27.84, 31.26, 32.57, 33.19, 33.38, 40.45 (12 C, 
CyCH2, Cy, (CH2)2CO2Me), 41.94 (C-3), 51.42 (CO2Me), 62.54 (Gal C-6), 66.50 (Fuc C-5), 66.62 
(CH2Ph), 70.09 (Gal C-4), 71.48 (Gal C-5), 72.24 (2 C, CH2Ph, Gal C-2), 73.79, 74.90 (2 
CH2Ph), 76.26 (Fuc C-2), 77.91 (Gal C-3), 78.34, 78.38 (Lac C-2, C-2), 79.09 (Fuc C-4), 79.53 
(Fuc C-3), 80.22 (C-1), 97.70 (Fuc C-1) 99.93 (Gal C-1), 126.96, 127.06, 127.23, 127.29, 
127.83, 128.04, 128.06, 128.08, 128.15, 128.38, 128.44, 128.48, 128.53, 128.57, 129.62, 
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129.65, 129.69, 129.74, 129.86, 129.88, 129.94, 129.99, 133.05, 133.19, 133.24, 135.39, 
138.64, 138.99, 139.07 (42 C, 7 C6H5), 164.55, 166.06, 166.17, 172.45, 174.02 (5 C=O); 
elemental analysis calcd (%) for C80H88O18 (1337.54): C 71.84, H 6.63; found: C 71.70, H 6.73. 
 
{(1R,2R,3S)-2-[(6-deoxy--L-galactopyranosyl)oxy]-3-methyl-cyclohex-1-yl} 2-O-benzoyl-3-
O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]--D-galactopyranoside sodium salt (226a), (DS-04-
139). 
Pd/C (20.2 mg, 10% Pd) was suspended under argon in ethanol (3.5 mL) with a catalytic 
amount of acetic acid. Compound 225a (68.0 mg, 53.7 µmol) was added and the mixture was 
hydrogenated under 70 psi at r.t.. After 18 h additional Pd/C (23.1 mg) was added and the 
hydrogenation continued. After 4 d the mixture was filtered through celite and reacted with fresh 
Pd/C (23 mg) for another 4 d, until TLC control indicated completion of the reaction. The reaction 
mixture was filtered through celite and evaporated to dryness. The residue was redissolved in 
methanol (4 mL) and sodium methoxide (0.161 mmol in 618 µl MeOH) was added. After stirring 
at r.t. for 18 h the reaction was quenched by addition of acetic acid (15.3 µL). The mixture was 
concentrated in vacuo and purified by column chromatography (CH2Cl2/methanol/water, 
3.4:1:0.1 to 2:1:0.1), followed by Dowex 50 (Na+ form) ion exchange column, Sephadex G15 
column, microfiltration and lyophilization from tert.-butanol/H2O to give 226a (30.3 mg, 79%) as a 
colourless foam.  
[]D21 = - 91.5 (c = 0.46, MeOH); 1H-NMR (MeOD, 500.1 MHz) δ: 0.49-1.65 (m, 19 H, CyCH2, 
MeCy), 1.07 (d, 3J = 6.4 Hz, 3 H, CH3), 1.33 (d, 3J = 6.5 Hz, 3 H, Fuc H-6), 2.02 (m, 1 H, MeCy), 
3.11 (t, 3J = 9.2 Hz, 1 H, H-2), 3.55-3.63 (m, 3 H, H-1, Gal H-3, Gal H-5), 3.71-3.81 (m, 5 H, Gal 
H-6, Fuc H-2, Fuc H-4, Lac H-2), 3.89 (dd, 3JF3,F4 = 3.0 Hz, 3JF2,F3 = 10.2 Hz, 1 H, Fuc H-3), 3.94 
(m, 1 H, Gal H-4), 4.67 (d, 3JG1,G2 = 8.1 Hz, 1 H, Gal H-1), 4.94-4.98 (m, 2 H, Fuc H-1, Fuc H-5), 
5.41 (t, 3J = 8.8 Hz, 1 H, Gal H-2), 7.48-7.51, 7.60-7.62, 8.07-8.08 (3 m, 5 H, C6H5); 13C-NMR 
(MeOD, 125.8 MHz) δ: 16.69 (Fuc C-6), 19.44 (CH3), 23.94, 26.58, 26.84, 27.42, 32.24, 33.08, 
34.47, 34.59, 35.41, 40.23, 43.55 (11 C, MeCy, CH2Cy), 63.17 (Gal C-6), 67.72 (2 C, Gal C-4, 
Fuc C-5), 70.32 (Fuc C-2), 71.37 (Fuc C-3), 73.16 (Gal C-2), 73.95 (Fuc C-4), 75.97 (Gal C-5), 
80.68 (Lac C-2), 80.75 (C-1), 83.54 (C-2), 83.73 (Gal C-3), 100.15 (Fuc C-1), 100.73 (Gal C-1), 
129.59, 130.83, 131.85, 134.17 (6 C, C6H5), 166.83 (C=O), 183.26 (CO2Na); IR (KBr) ν: 3412 
(vs, OH), 2927 (vs), 2852 (m), 1723 (m, C=O), 1591 (s), 1450 (m), 1412 (m), 1365 (m), 1316 
(w), 1273 (s), 1168 (m), 1079 (vs), 1031 (s), 1000 (w), 970 (vw) cm-1; elemental analysis calcd 
(%) for C35H51NaO14 (718.76) + 3 H2O: C 54.40, H 7.43; found: C 54.41, H 7.33; HR-MS (ESI) 
m/z: calcd for C35H52NaO14 [M+H]+: 719.3249; found: 719.3247 (0.3 ppm). 
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General procedure D for deprotection with Pd(OH)2/C and sodium methoxide (226c, 226e-
226f). 
Pd(OH)2/C (50 mg, 10% Pd) was suspended under argon in dioxane/H2O (4:1, 3.75 mL). The 
appropriate compound 225 (77.7 µmol) was added and the resulting mixture was hydrogenated 
under 70 psi at r.t.. After 24 h the mixture was filtered through celite and reacted with fresh 
Pd(OH)2/C (50 mg) for additional 48 h, until TLC control indicated completion of the reaction. 
The reaction mixture was filtered through celite and evaporated to dryness. The residue was 
redissolved in methanol (5 mL) and sodium methoxide (0.194 mmol in 190 µl MeOH) was 
added. After stirring at r.t. for 16 h the reaction was quenched by addition of acetic acid (22 µL). 
The mixture was concentrated in vacuo and purified by preparative, reversed-phase HPLC to 
afford the antagonists 226 as colourless solids. 
 
{(1R,2R,3S)-3-butyl-2-[(6-deoxy--L-galactopyranosyl)oxy]-cyclohex-1-yl} 2-O-benzoyl-3-
O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]--D-galactopyranoside sodium salt (226b), (DS-05-
46). 
225b (100 mg, 76.5 µmol) was hydrogenated with Pd(OH)2/C (50 mg, 10% Pd) in dioxane/H2O 
(4:1, 3.75 mL) according the to general procedure D. After 19 h the mixture was filtered through 
celite and hydrogenated with fresh Pd(OH)2/C (50 mg) for another 30 h. The reaction mixture 
was filtered through celite and evaporated to dryness. The residue was redissolved in methanol 
(5 mL) and sodium methoxide (0.191 mmol) was added. After stirring at r.t. for 17 h the reaction 
was quenched by addition of acetic acid (22 µL). The mixture was concentrated in vacuo and 
purified by column chromatography (CH2Cl2/methanol/water, 3.4:1:0.1 to 2:1:0.1), followed by 
Dowex 50 (Na+ form) ion exchange column, Sephadex G15 column, microfiltration and 
lyophilization from dioxane to give 226b (32.3 mg, 56%) as a colourless foam. For biological 
testing a small amount was purified by preparative, reversed-phase HPLC to afford the free acid 
of 226b as colourless needles. 
 
226b sodium salt:  
[]D21 = - 77.9 (c = 0.61, MeOH); 1H-NMR (MeOD, 500.1 MHz) δ : 0.47-1.89 (m, 25 H, CyCH2, 
nBu, Cy), 0.88 (t, 3J = 7.1 Hz, 3 H, nBu), 1.31 (d, 3J = 6.5 Hz, 3 H, Fuc H-6), 2.00 (m, 1 H, H-6b), 
3.24 (t, 3J = 8.9 Hz, 1 H, H-2), 3.56-3.60 (m, 2 H, Gal H-5, Gal H-3), 3.65 (m, 1 H, H-1), 3.72-
3.77 (m, 4 H, Gal H-6a, Fuc H-2, Fuc H-4, Lac H-2), 3.80 (dd, 3JG5,G6b = 6.9 Hz, 2JG6a,G6b = 11.5 
Hz, 1 H, Gal H-6b), 3.88 (dd, 3JF3,F4 = 3.3 Hz, 3JF2,F3 = 10.3 Hz, 1 H, Fuc H-3), 3.95 (m, 1 H, Gal 
H-4), 4.68 (d, 3JG1,G2 = 8.1 Hz, 1 H, Gal H-1), 4.85 (m, 1 H, Fuc H-5), 4.94 (d, 3JF1,F2 = 4.0 Hz, 1 
H, Fuc H-1), 5.41 (dd, 3JG1,G2 = 8.5 Hz, 3JG2,G3 = 9.2 Hz, 1 H, Gal H-2), 7.48-7.51, 7.60-7.63, 
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8.07-8.09 (3 m, 5 H, C6H5); 13C-NMR (MeOD, 125.8 MHz) δ: 14.48 (nBu), 16.72 (Fuc C-6), 
23.27, 23.92, 26.57, 26.82, 27.41, 29.83, 30.04, 31.69, 31.86, 33.06, 34.44, 35.41, 43.54, 44.30 
(14 C, nBu, Cy, CH2Cy), 63.06 (Gal C-6), 67.70 (Gal C-4), 67.84 (Fuc C-5), 70.21 (Fuc C-2), 
71.34 (Fuc C-3), 73.08 (Gal C-2), 73.90 (Fuc C-4), 75.92 (Gal C-5), 80.69 (Lac C-2), 80.41 (C-
1), 81.37 (C-2), 83.69 (Gal C-3), 99.91 (Fuc C-1), 100.53 (Gal C-1), 129.60, 130.84, 131.76, 
134.23 (6 C, C6H5), 166.87 (C=O), 183.26 (COOH); HR-MS (ESI) m/z: calcd for C38H58NaO14 
[M+H]+: 761.3719; found: 761.3710 (1.2 ppm). 
 
226b free acid: 
1H-NMR (MeOD, 500.1 MHz) δ: 0.54-1.91 (m, 25 H, CyCH2, nBu, Cy), 0.89 (t, 3J = 7.1 Hz, 3 H, 
nBu), 1.32 (d, 3J = 6.6 Hz, 3 H, Fuc H-6), 1.98 (m, 1 H, H-6b), 3.23 (t, 3J = 8.9 Hz, 1 H, H-2), 3.56 
(m, 1 H, Gal H-5), 3.62 (m, 1 H, H-1), 3.66 (dd, 3JG3,G4 = 3.0 Hz, 3JG2,G3 = 9.8 Hz, 1 H, Gal H-3), 
3.70-3.75 (m, 3 H, Gal H-6a, Fuc H-2, Fuc H-4), 3.79 (dd, 3JG6b,G5 = 6.9 Hz, 2JG6a,G6b = 11.3 Hz, 1 
H, Gal H-6b), 3.85 (dd, 3JF3,F4 = 3.3 Hz, 3JF2,F3 = 10.3 Hz, 1 H, Fuc H-3), 3.97 (m, 1 H, Gal H-4), 
4.06 (dd, 3J = 2.9, 9.9 Hz, 1 H, Lac H-2), 4.67 (d, 3JG1,G2 = 8.1 Hz, 1 H, Gal H-1), 4.88-4.92 (m, 2 
H, Fuc H-1, Fuc H-5), 5.43 (dd, 3JG1,G2 = 8.2 Hz, 3JG2,G3 = 9.6 Hz, 1 H, Gal H-2), 7.49-7.52, 7.62-
7.64, 8.07-8.09 (3 m, 5 H, C6H5); 13C-NMR (MeOD, 125.8 MHz) δ: 14.48 (nBu), 16.74 (Fuc C-6), 
23.38, 23.90, 26.54, 26.72, 27.28, 29.83, 29.99, 31.71, 31.81, 33.12, 34.19, 35.07, 42.78, 44.51 
(14 C, nBu, Cy, CH2Cy), 62.69 (Gal C-6), 67.79 (2 C, Fuc C-5, Gal C-4), 70.27 (Fuc C-2), 71.43 
(Fuc C-3), 73.10 (Gal C-2), 73.94 (Fuc C-4), 75.90 (Gal C-5), 77.93 (Lac C-2), 80.71 (C-1), 
81.45 (C-2), 83.57 (Gal C-3), 100.29 (Fuc C-1), 100.52 (Gal C-1), 129.67, 130.85, 131.63, 
134.37 (6 C, C6H5), 166.77 (C=O), 178.84 (CO2H). 
 
{(1R,2R,3R)-3-cyclopropyl-2-[(6-deoxy--L-galactopyranosyl)oxy]-cyclohex-1-yl} 2-O-
benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]--D-galactopyranoside (226c), (DS-05-65). 
225c (100 mg, 77.7 µmol) was hydrogenated with Pd(OH)2/C (52 mg, 10% Pd) in dioxane/H2O 
(4:1, 3.75 mL) according to the general procedure D. After 24 h the mixture was filtered through 
celite and hydrogenated with fresh Pd(OH)2/C (50 mg) for another 48 h. The reaction mixture 
was filtered through celite and evaporated to dryness. The residue was redissolved in methanol 
(5 mL) and sodium methoxide (194 µmol in 190 µl MeOH) was added. After stirring at r.t. for 16 
h the reaction was quenched by addition of acetic acid (22 µL). The mixture was concentrated in 
vacuo and purified by preparative, reversed-phase HPLC to afford 226c (40.5 mg, 72%) as a 
colourless solid.  
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[]D21 = - 85.4 (c = 0.75, MeOH); 1H-NMR (MeOD, 500.1 MHz) δ: -0.04 (m, 1 H, cPr), 0.33 (m, 1 
H, cPr), 0.45-0.52  (m, 2 H, cPr), 0.56-1.65 (m, 20 H, CyCH2, cPrCy), 1.30 (d, 3JF5,F6 = 6.6 Hz, 3 
H, Fuc H-6), 1.94 (m, 1 H, H-6b), 3.45 (t, 3J = 8.5 Hz, 1 H, H-2), 3.56 (m, 1 H, Gal H-5), 3.62 (m, 
1 H, H-1), 3.66 (dd, 3JG3,G4 = 3.1 Hz, 3JG2,G3 = 9.8 Hz, 1 H, Gal H-3), 3.71-3.74 (m, 2 H, Gal H-6a, 
Fuc H-2), 3.78 (m, 1 H, Fuc H-4), 3.83 (dd, 3JG5,G6b = 7.1 Hz, 2JG6a,G6b = 11.4 Hz, 1 H, Gal H-6b), 
3.95 (dd, 3JF3,F4 = 3.3 Hz, 3JF2,F3 = 10.2 Hz, 1 H, Fuc H-3), 3.97 (m, 1 H, Gal H-4), 4.06 (dd, 3J = 
2.9, 9.8 Hz, 1 H, Lac H-2), 4.66 (d, 3JG1,G2 = 8.0 Hz, 1 H, Gal H-1), 4.88 (m, 1 H, Fuc H-5), 5.37 
(d, 3JF1,F2 = 3.9 Hz, 1 H, Fuc H-1), 5.39 (dd, 3JG1,G2 = 8.1 Hz, 3JG2,G3 = 9.6 Hz, 1 H, Gal H-2), 7.49-
7.52, 7.61-7.65, 8.07-8.09 (3 m, 5 H, C6H5); 13C-NMR (MeOD, 125.8 MHz) δ: 3.96, 7.18, 15.53 
(3 C, cPr), 16.72 (Fuc C-6), 22.94, 26.54, 26.73, 27.27, 30.78, 31.45 (6 C, CyCH2, Cy), 33.13, 
34.20, 35.07, 42.76 (4 C, CyCH2), 48.49 (C-3), 62.72 (Gal C-6), 67.61 (Fuc C-5), 67.88 (Gal C-
4), 70.24 (Fuc C-2), 71.34 (Fuc C-3), 73.16 (Gal C-2), 73.97 (Fuc C-4), 76.02 (Gal C-5), 78.01 
(Lac C-2), 80.29 (C-1), 80.52 (C-2), 83.45 (Gal C-3), 98.97 (Fuc C-1), 100.41 (Gal C-1), 129.66, 
130.82, 131.63, 134.36 (6 C, C6H5), 166.76 (C=O), 178.83 (CO2H); HR-MS (ESI) m/z: calcd for 
C37H54NaO14 [M+Na]+: 745.3406; found: 745.3407 (0.1 ppm). 
 
{(1R,2R,3S)-2-[(6-deoxy--L-galactopyranosyl)oxy]-3-ethyl-cyclohex-1-yl} 2-O-benzoyl-3-O-
[(1S)-1-carboxy-2-cyclohexyl-ethyl]--D-galactopyranoside (226e), (DS-05-67). 
225e (38.2 mg, 29.9 µmol) was hydrogenated with Pd(OH)2/C (50 mg, 10% Pd) in dioxane/H2O 
(4:1, 3.75 mL) according to the general procedure D. After 24 h the reaction mixture was filtered 
through celite and evaporated to dryness. The residue was redissolved in methanol (5 mL) and 
sodium methoxide (74.6 µmol in 73 µl MeOH) was added. After stirring at r.t. for 16 h the 
reaction was quenched by addition of acetic acid (8.5 µL). The mixture was concentrated in 
vacuo and purified by preparative, reversed-phase HPLC to afford 226e (16.3 mg, 77%) as a 
colourless solid.  
[]D21 = - 89.3 (c = 0.47, MeOH); 1H-NMR (MeOD, 500.1 MHz) δ: 0.55-1.69 (m, 20 H, CyCH2, 
EtCy), 0.83 (t, 3J = 7.3 Hz, 3 H, CH2CH3), 1.32 (d, 3J = 6.6 Hz, 3 H, Fuc H-6), 1.90 (m, 1 H, 
CH2CH3), 1.99 (m, 1 H, H-6b), 3.24 (t, 3J = 8.9 Hz, 1 H, H-2), 3.57 (m, 1 H, Gal H-5), 3.62 (m, 1 
H, H-1), 3.67 (dd, 3JG3,G4 = 3.0 Hz, 3JG2,G3 = 9.8 Hz, 1 H, Gal H-3), 3.70-3.75 (m, 3 H, Gal H-6a, 
Fuc H-2, Fuc H-4), 3.79 (dd, 3JG5,G6b = 6.9 Hz, 2JG6a,G6b = 11.3 Hz, 1 H, Gal H-6b), 3.86 (dd, 3JF3,F4 
= 3.3 Hz, 3JF2,F3 = 10.3 Hz, 1 H, Fuc H-3), 3.97 (m, 1 H, Gal H-4), 4.07 (dd, 3J = 3.0, 9.8 Hz, 1 H, 
Lac H-2), 4.67 (d, 3JG1,G2 = 8.1 Hz, 1 H, Gal H-1), 4.90 (m, 1 H, Fuc H-5), 4.91 (m, 1 H,  Fuc H-
1), 5.43 (dd, 3JG1,G2 = 8.3 Hz, 3JG2,G3 = 9.4 Hz, 1 H, Gal H-2), 7.49-7.52, 7.61-7.64, 8.08-8.09 (3 
m, 5 H, C6H5); 13C-NMR (MeOD, 125.8 MHz) δ: 11.12 (CH2CH3), 16.72 (Fuc C-6), 23.39, 24.59, 
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26.54, 26.72, 27.27, 29.47, 31.86, 33.14, 34.20, 35.06, 42.76 (11 C, EtCy, CH2Cy), 45.96 (C-3), 
62.68 (Gal C-6), 67.77 (Fuc C-5), 67.83 (Gal C-4), 70.30 (Fuc C-2), 71.38 (Fuc C-3), 73.12 (Gal 
C-2), 73.92 (Fuc C-4), 75.90 (Gal C-5), 77.94 (Lac C-2), 80.77 (C-1), 81.11 (C-2), 83.55 (Gal C-
3), 100.20 (Fuc C-1), 100.52 (Gal C-1), 129.67, 130.84, 131.63, 134.37 (6 C, C6H5), 166.79 
(C=O), 178.76 (CO2H); HR-MS (ESI) m/z: calcd for C36H54NaO14 [M+Na]+: 733.3406; found: 
733.3409 (0.4 ppm). 
 
{(1R,2R,3R)-2-[(6-deoxy--L-galactopyranosyl)oxy]-3-(2-methoxycarbonyl-ethyl)-cyclohex-
1-yl} 2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]--D-galactopyranoside (226f), 
(DS-05-48). 
225f (46.0 mg, 34.4 µmol) was hydrogenated with Pd(OH)2/C (25 mg, 10% Pd) in dioxane/H2O 
(4:1, 3.75 mL) according to the general procedure D. After 42 h the mixture was filtered through 
celite and hydrogenated with fresh Pd(OH)2/C (27 mg) for additional 24 h. The reaction mixture 
was filtered through celite and evaporated to dryness. The residue was redissolved in methanol 
(3 mL) and sodium methoxide (51.6 µmol in 55 µl MeOH) was added. After stirring at r.t. for 16 h 
the reaction was quenched by addition of acetic acid (6 µL). The mixture was concentrated in 
vacuo and purified by preparative, reversed-phase HPLC to afford 226f (19.2 mg, 73%) as a 
colourless solid.  
[]D21 = - 78.3 (c = 0.63, MeOH); 1H-NMR (MeOD, 500.1 MHz) δ: 0.55-0.75 (m, 4 H, CyCH2), 
0.84-0.96 (m, 2 H, CyCH2, H-4a), 1.04 (m, 1 H, H-6a), 1.14 (m, 1 H, H-5a), 1.21-1.36 (m, 5 H, 
CyCH2), 1.32 (d, 3J = 6.6 Hz, 3 H, Fuc H-6), 1.39-1.60 (m, 6 H, CyCH2, H-3, H-5b, 
(CH2)2CO2Me), 1.66 (m, 1 H, H-4b), 1.97 (m, 1 H, H-6b), 2.18-2.38 (m, 3 H, CyCH2, 
(CH2)2CO2Me), 3.27 (t, 3J = 8.4 Hz, 1 H, H-2), 3.57 (m, 1 H, Gal H-5), 3.63-3.68 (m, 5 H, CH3, 
Gal H-3, H-1), 3.71-3.75 (m, 3 H, Gal H-6a, Fuc H-2, Fuc H-4), 3.79 (dd, 3JG5,G6b = 6.8 Hz, 
2JG6a,G6b = 11.3 Hz, 1 H, Gal H-6b), 3.84 (dd, 3JF3,F4 = 3.3 Hz, 3JF2,F3 = 10.2 Hz, 1 H, Fuc H-3), 
3.98 (m, 1 H, Gal H-4), 4.07 (dd, 3J = 3.0, 9.9 Hz, 1 H, Lac H-2), 4.67 (d, 3JG1,G2 = 8.1 Hz, 1 H, 
Gal H-1), 4.83 (m, 1 H, Fuc H-5), 4.92 (m, 1 H, Fuc H-1), 5.43 (dd, 3JG1,G2 = 8.2 Hz, 3JG2,G3 = 9.6 
Hz, 1 H, Gal H-2), 7.49-7.52, 7.62-7.65, 8.08-8.09 (3 m, 5 H, C6H5); 13C-NMR (MeOD, 125.8 
MHz) δ: 16.73 (Fuc C-6), 22.77 (C-5), 26.55, 26.73, 27.28, 27.34 (4 C, CyCH2), 29.49 (C-4), 
31.34 (C-6), 32.16 ((CH2)2CO2Me), 33.13, 34.20, 35.07 (3 C, CyCH2), 42.78 ((CH2)2CO2Me), 
43.52 (C-3), 52.03 (Me), 62.62 (Gal C-6), 67.81 (Gal C-4), 67.89 (Fuc C-5), 70.25 (Fuc C-2), 
71.41 (Fuc C-3), 73.09 (Gal C-2), 73.90 (Fuc C-4), 75.92 (Gal C-5), 77.98 (Lac C-2), 80.36 (C-
1), 80.96 (C-2), 83.50 (Gal C-3), 100.34 (Fuc C-1), 100.50 (Gal C-1), 129.68, 130.85, 131.62, 
134.39 (6 C, C6H5), 166.77, 176.09, 178.86 (3 C=O); elemental analysis calcd (%) for C38H56O16 
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(768.84) + 1½ H2O: C 57.35, H 7.47; found: C 57.57, H 7.36; HR-MS (ESI) m/z: calcd for 
C38H56NaO16 [M+Na]+: 791.3461; found: 791.3463 (0.3 ppm). 
 
{(1R,2R,3S)-2-[(6-deoxy--L-galactopyranosyl)oxy]-3-methyl-cyclohex-1-yl} 3-O-[(1S)-1-
carboxy-2-cyclohexyl-ethyl]--D-galactopyranoside sodium salt (226g), (DS-04-115). 
Pd/C (49.6 mg, 10% Pd) was suspended under argon in ethanol (3 mL) containing a catalytic 
amount of acetic acid. Compound 225a (101 mg, 79.8 µmol) was added and the mixture was 
hydrogenated under 70 psi at r.t.. After 24 h additional Pd/C (50.0 mg) was added and the 
hydrogenation was continued for another 5 d. The reaction was quenched with CH2Cl2, filtered 
through celite and the celite washed with methanol. The filtrate was concentrated under vacuo, 
redissolved in methanol/water (3:1, 4 mL) and lithium hydroxide (100 mg, 4.18 mmol) was 
added. After stirring for 2 d, the mixture was neutralized with Dowex 50x8 (H+), filtered through a 
Dowex 50 (Na+ form) ion exchange column and concentrated in vacuo. The residue was purified 
by column chromatography (CH2Cl2/methanol/water, 5:1:0.1 to 2:1:0.1), followed by Sephadex 
G15 column and lyophilization from dioxane to give 226g (36.5 mg, 74%) as colourless foam.  
[]D21 = - 84.8 (c = 0.32, MeOH); 1H-NMR (MeOD, 500.1 MHz) δ: 0.87-1.00 (m, 2 H, CyCH2, 
MeCy), 1.04-1.38 (m, 6 H, CyCH2, MeCy), 1.13 (d, 3J = 6.3 Hz, 3 H, CH3), 1.20 (d, 3J = 6.5 Hz, 3 
H, Fuc H-6), 1.55-1.74 (m, 10 H, CyCH2, MeCy), 1.92 (m, 1 H), 2.13 (m, 1 H, MeCy), 3.20 (t, 3J 
= 9.3 Hz, 1 H, H-2), 3.24 (dd, 3JG3,G4 = 2.8 Hz, 3JG2,G3 = 9.3 Hz, 1 H, Gal H-3), 3.42 (m, 1 H, Gal 
H-5), 3.62-3.68 (m, 3 H, Gal H-2, Gal H-6a, H-1), 3.70-3.75 (m, 3 H, Fuc H-2, Fuc H-4, Gal H-6b), 
3.85 (dd, 3JF3,F4 = 3.3 Hz, 3JF2,F3 = 10.3 Hz, 1 H, Fuc H-3), 3.88 (m, 1 H, Gal H-4), 4.07 (dd, 3J = 
3.1, 9.3 Hz, 1 H, Lac H-2), 4.29 (d, 3JG1,G2 = 7.8 Hz, 1 H, Gal H-1), 4.89 (m, 1 H, Fuc H-5), 5.00 
(d, 3JF1,F2 = 3.9 Hz, 1 H, Fuc H-1); 13C-NMR (MeOD, 125.8 MHz) δ: 16.84 (Fuc C-6), 19.65 
(CH3), 24.28, 27.31, 27.58, 27.83, 31.92, 33.62, 34.79, 35.00, 35.41, 40.45, 42.95 (11 C, MeCy, 
CH2Cy), 63.14 (Gal C-6), 67.60 (Fuc C-5), 67.94 (Gal C-4), 70.37 (Fuc C-2), 71.41 (Fuc C-3), 
71.62 (Gal C-2), 73.88 (Fuc C-4), 75.80 (Gal C-5), 79.90 (2 C, Lac C-2, MeCy), 84.60 (1 C, 
MeCy), 85.00 (Gal C-3), 100.41 (Fuc C-1), 102.36 (Gal C-1), 182.16 (CO2Na); IR (KBr) ν: 3413 
(OH), 2926, 2852, 1716 (C=O), 1587, 1449, 1413, 1376, 1164, 1078, 1034, 972 cm-1; elemental 
analysis calcd (%) for C28H47NaO13 + 1 H2O (614.65): C 53.16, H 7.81; found: C 53.22, H 7.91; 
HR-MS (ESI) m/z: calcd for C28H48NaO13 [M+H]+: 615.2987; found: 615.2991 (0.7 ppm). 
 
{(1R,2R,3S)-2-[(6-deoxy--L-galactopyranosyl)oxy]-3-ethyl-cyclohex-1-yl} 3-O-[(1S)-1-
carboxy-2-cyclohexyl-ethyl]--D-galactopyranoside sodium salt (226h), (DS-05-18). 
Pd/C (20 mg, 10% Pd) was suspended under argon in ethanol (3 mL) containing a catalytic 
amount of acetic acid. Compound 225e (65.5 mg, 51.2 µmol) was added and the mixture was 
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hydrogenated under 70 psi at r.t.. The mixture was several times filtered through celite and set 
up with fresh Pd/C (20 mg). After 50 d the catalyst was exchanged with Pd(OH)2/C (100 mg, 
10% Pd) in dioxane/H2O (4:1, 4.8 mL) and the mixture was hydrogenated under 70 psi at r.t. for 
additional 10 d. The reaction mixture was filtered through celite and evaporated to dryness. The 
residue was redissolved in methanol/H2O (4:1, 5 mL) and lithium hydroxide (65.0 mg, 2.71 
mmol) was added. After stirring for 32 h, the mixture was neutralized with Dowex 50x8 (H+), 
filtered through a Dowex 50 (Na+ form) ion exchange column and concentrated in vacuo. The 
residue was purified by column chromatography (CH2Cl2/methanol/water, 3.4:1:0.1 to 2:1:0.1), 
followed by Sephadex G15 column, microfiltration and lyophilization from dioxane to give 226h 
(9.8 mg, 30%) as a colourless foam.  
[]D21 = - 73.9 (c = 0.39, MeOH); 1H-NMR (MeOD, 500.1 MHz) δ: 0.82-2.03 (m, 21 H, CyCH2, 
EtCy), 0.89 (t, 3J = 7.4 Hz, 3 H, CH2CH3), 1.20 (d, 3J = 6.6 Hz, 3 H, Fuc H-6), 2.13 (m, 1 H, H-
6b), 3.18 (dd, 3JG3,G4 = 2.8 Hz, 3JG2,G3 = 9.4 Hz, 1 H, Gal H-3), 3.33 (m, 1 H, H-2), 3.43 (m, 1 H, 
Gal H-5), 3.60-3.76 (m, 6 H, Gal H-6, Gal H-2, H-1, Fuc H-4, Fuc H-2), 3.84-3.87 (m, 3 H, Gal H-
4, Fuc H-3, Lac H-2), 4.30 (d, 3JG1,G2 = 7.9 Hz, 1 H, Gal H-1), 4.84 (m, 1 H, Fuc H-5), 4.98 (d, 
3JF1,F2 = 3.9 Hz, 1 H, Fuc H-1); 13C-NMR (MeOD, 125.8 MHz) δ: 11.13 (CH2CH3), 16.79 (Fuc C-
6), 23.91, 24.87, 27.28, 27.58, 27.84, 30.05, 31.69, 33.51, 34.77, 35.50, 43.32 (11 C, EtCy, 
CH2Cy), 46.24 (C-3), 63.27 (Gal C-6), 67.68 (Fuc C-5, Gal C-4), 70.24 (Fuc C-2), 71.25 (Fuc C-
3), 71.32 (Gal C-2), 73.79 (Fuc C-4), 75.83 (Gal C-5), 79.84 (C-1), 80.73 (Lac C-2), 82.00 (C-2), 
85.57 (Gal C-3), 100.07 (Fuc C-1), 102.23 (Gal C-1), 183.44 (COONa); HR-MS (ESI) m/z: calcd 
for C29H50NaO13 [M+H]+: 629.3144; found: 629.3144 (0.0 ppm). 
 
Dimethyl cis-4-cyclohexene-1,2-dicarboxylate (235).  
Amberlyste 15 (50.0 g) was placed in a flask and dried in vacuo for 1 h. Methanol (1 L) was 
added, followed by cis-1,2,3,6-tetrahydrophthalic anhydride (50.0 g, 328 mmol) and 
trimethylorthoformate (100 mL, 914 mmol). The reaction mixture was then vigorously stirred. 
After 5 d, additional trimethylorthoformate (50 mL, 457 mmol) was added. The reaction was 
stopped after 9 d, filtered through celite and the celite washed with methanol. The solvent was 
removed in vacuo (20 mbar). The brown residue was dissolved in CH2Cl2 (150 mL) and washed 
with satd. aqueous NaHCO3 and brine (each 150 mL). The aqueous layers were extracted with 
CH2Cl2 (3 x 150 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated in vacuo (20 mbar) to afford diester 235 (57.5 g, 88%) as a brownish oil, the NMR 
data of which were in accordance with Lit.445 
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cis-2-(Methoxycarbonyl)-cyclohex-4-ene-1-carboxylic acid (236). 
To a stirred suspension of diester 235 (2.00 g, 10.1 mmol) in phosphate buffer (pH 7.00, 103 
mL, 0.07 M), PLE (8.00 mg, 216 units) was added. The pH was kept at 7 by adding continuously 
NaOH solution (1.0 M) via syringe pump. The reaction was stirred at 20ºC until one equivalent of 
NaOH (10 mL) was consumed (56.5 h). The reaction mixture was transferred into a separation 
funnel with ethyl acetate (100 mL). The layers were separated and the organic layer was 
extracted with phosphate buffer (pH 7.00, 2 x 60 mL). The combined aqueous layers were 
acidified to pH 2 with 1 M HCl solution and extracted with ethyl acetate (4 x 150 mL). To 
separate the layers NaCl was added. The combined organic layers were dried over Na2SO4, 
filtered and concentrated in vacuo to afford the monoester 236 (1.67 g, 90%) as a yellowish oil, 
the NMR data of which were in accordance with Lit.E14 236 showed an optical yield of 96.4% ee 
determined by optical rotation and 96.0% ee determined by chiral GC.  
[]D21 = + 15.2 (c = 0.20, EtOH), (Lit. + 15.8, c = 0.2, EtOH).446 
 
Methyl (R)-cyclohex-3-ene-carboxylate (237). 
A solution of monoester 236 (0.992 g, 5.38 mmol) in dry CH2Cl2 (18 mL) was treated with 
(COCl)2 (0.7 mL, 8.15 mmol) and DMF (14 µL), stirred for 3 h at r.t. and evaporated. A solution 
of the residue in dry THF (20 mL) was added dropwise over a period of 20 min to a boiling 
suspension of 2-mercaptopyridine-1-oxide sodium salt (975 mg, 6.49 mmol), t-BuSH (3.1 mL, 
27.5 mmol), and 4-DMAP (26.3 mg, 0.216 mmol) in dry THF (50 mL). The solution was stirred at 
reflux for 3 h. The reaction mixture was then cooled to r.t., transferred into a separation funnel 
with ethyl acetate (50 mL) and washed with water (100 mL). The aqueous layer was extracted 
with ethyl acetate (2 x 100 mL). The combined organic layers were dried over Na2SO4, filtered 
and concentrated in vacuo (200 mbar). The crude product was purified by column 
chromatography (petroleum ether/Et2O, 30:1 to 15:1) to afford methylester 237 (585 mg, 83%) 
as a yellowish oil, the NMR data of which were in accordance with Lit.307  
[]D21 = + 78.2 (c = 1.01, CHCl3). 
 
(R)-Cyclohex-3-ene-carboxylic acid (128). 
To a stirred suspension of methylester 237 (5.19 g, 37.0 mmol) in phosphate buffer (pH 7.00, 
520 mL, 0.07 M), PLE (51.2 mg, 1382 units) was added. The pH was kept at 7 by adding NaOH 
solution (1.0 M) via syringe pump. The reaction was stirred at r.t. until one equivalent of NaOH 
(37 mL) was consumed (11 h). The reaction mixture was washed with ethyl acetate (2 x 300 
mL). The organic layers were extracted with phosphate buffer (pH 7.00, 2 x 300 mL). The 
combined aqueous layers were acidified to pH 2 with aqueous HCl (30 mL, 4 M) and extracted 
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with ethyl acetate (3 x 400 mL). The combined organic layers were dried over Na2SO4, filtered 
and concentrated in vacuo (100 mbar). The crude product was filtered through a pad of silica 
affording acid 128 (3.92 g, 84%) as a pale yellowish oil, the NMR data of which were in 
accordance with Lit.309 128 showed an optical yield of 94.3% ee determined by optical rotation 
and 96.3% ee determined by chiral GC.  
[]D21 = + 89.1 (c = 6.73, MeOH), (Lit. + 94.5, c = 7, MeOH).447 
 
(1R,2R,5R)-2-Iodo-7-oxabicyclo[3.2.1]octan-6-one (238). 
Acid 128 (8.30 g, 65.7 mmol) was suspended in water (180 mL) under argon. The reaction 
mixture was cooled to 0°C and NaHCO 3 (16.6 g, 197 mmol) was added, followed by a solution of 
KI (65.4 g, 394 mmol) and iodine (17.5 g, 68.9 mmol) in water (150 mL). The reaction was stirred 
at r.t. for 24 h and then extracted with CH2Cl2 (3 x 60 mL). The combined organic layers were 
washed with a solution of Na2S2O3 (50 g) in water (250 mL). The aqueous layer was extracted 
with CH2Cl2 (2 x 60 mL). The combined organic layers were protected from light, dried over 
Na2SO4, filtered and concentrated in vacuo (20 mbar) and quickly in vacuo to afford iodolactone 
238 (15.8 g, 95%) as an off-white solid, the NMR data of which were in accordance with Lit.309  
[]D21 = + 36.0 (c = 0.57, CHCl3). 
 
(1R,5R)-7-Oxabicyclo[3.2.1]oct-2-ene-6-one (129). 
Iodolactone 238 (15.7 g, 62.2 mmol) was dissolved in dry THF (340 mL). Then, DBU (14 mL, 
93.3 mmol) was added and the mixture was refluxed for 20 h. The reaction mixture was cooled 
to r.t., diluted with Et2O (200 mL) and extracted with aqueous HCl (400 mL, 0.5 M) and brine 
(400 mL). The aqueous layers were extracted with Et2O (3 x 200 mL). The combined organic 
layers were dried over Na2SO4, filtered and concentrated in vacuo (350 mbar). The crude 
product was purified by column chromatography (petroleum ether/CH2Cl2/Et2O, 20:5:1 to 8:5:1) 
to afford lactone 129 (7.28 g, 94%) as a yellowish oil, the NMR data of which were in 
accordance with Lit.309  
[]D21 = + 187.3 (c = 1.08, CHCl3). 
 
Methyl (1R,3R)-3-O-(tert-butyldimethylsilyl)-3-hydroxy-cyclohex-4-ene-1-carboxylate (239).  
NaHCO3 (4.36 g, 51.8 mmol) was dried in vacuo for 2 h. Then, freshly distilled methanol (268 
mL) was added, followed by lactone 129 (6.38 g, 51.4 mmol). The reaction mixture was stirred 
under argon for 12 h. The solvent was evaporated, the residue transferred into a separation 
funnel with CH2Cl2 (60 mL), and extracted with water (60 mL) and brine (60 mL). The aqueous 
layers were extracted with CH2Cl2 (2 x 60 mL). The combined organic layers were dried over 
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Na2SO4, filtered and concentrated in vacuo (50 mbar) to obtain the alcohol as yellowish oil. To a 
solution of the alcohol in dry CH2Cl2 (150 mL), tert-butyldimethylsilyl chloride (14.93 g, 99.1 
mmol) was added in small portions, followed by DBU (18.4 mL, 123 mmol). The reaction was 
stirred at r.t. for 12 h and then quenched with methanol (20 mL).  The mixture was diluted with 
CH2Cl2 (100 mL) and washed with satd. aqueous NaHCO3 (100 mL) and brine (100 mL). The 
aqueous layers were extracted with CH2Cl2 (2 x 100 mL). The combined organic layers were 
dried over Na2SO4, filtered and evaporated (200 mbar). The crude product was purified by 
column chromatography (petroleum ether/Et2O, 40:1 to 20:1) to afford silylether 239 (14.0 g, 
quant.) as colourless oil.  
[]D21 = + 2.0 (c = 1.05, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.08 (2 s, 6 H, 2 SiCH3), 0.89 (s, 
9 H, SiC(CH3)3), 1.64 (m, 1 H, H-2a), 2.02-2.24 (m, 3 H, H-6a, H-6b, H-2b), 2.64 (m, 1 H, H-1), 
3.69 (s, 3 H, Me), 4.35 (m, 1 H, H-3), 5.60 (m, 1 H, H-4), 5.70 (m, 1 H, H-5); 13C-NMR (CDCl3, 
125.8 MHz) δ: -4.72 (SiCH3), -4.57 (SiCH3), 18.19 (SiC(CH3)3), 25.84 (C(CH3)3), 27.37 (C-6), 
34.87 (C-2), 38.58 (C-1), 51.78 (Me), 67.73 (C-3), 126.24 (C-4), 131.90 (C-5), 175.10 (C=O); IR 
(film on NaCl) ν: 2954 (s), 2857 (s), 1740 (vs, C=O), 1436 (w), 1389 (w), 1251 (m), 1200 (m), 
1170 (m) cm-1; elemental analysis calcd (%) for C14H26O3Si (270.44): C 62.18, H 9.69; found: C 
62.38, H 9.62. 
 
Methyl (1R,3R,4R,5R)-3,4-epoxy-5-(tert-butyldimethylsilyloxy)-cyclohexane-1-carboxylate 
(228). 
To a solution of silylether 239 (1.21 g, 4.47 mmol) in CH2Cl2 (36 mL), m-CPBA (1.92 g, 11.1 
mmol) was added in one portion at 10°C. The reactio n mixture was stirred at 10°C for 15 h. The 
temperature was then slowly raised to r.t. (2 h) and the reaction stopped. The mixture was 
diluted with CH2Cl2 (150 mL) and washed with satd. aqueous Na2S2O3 (2 x 150 mL), satd. 
aqueous NaHCO3 (150 mL) and brine (150 mL). The aqueous layers were each extracted with 
CH2Cl2 (2 x 100 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by column chromatography (petroleum 
ether/Et2O, 12:1 to 10:1) to obtain epoxide 228 (1.00 g, 78%) as yellowish oil.  
[]D21 = - 25.6 (c = 0.99, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.10 (s, 3 H, SiCH3), 0.12 (s, 3 
H, SiCH3), 0.91 (s, 9 H, SiC(CH3)3), 1.33 (m, 1 H, H-6a), 1.92 (m, 1 H, H-2a), 2.08 (m, 1 H, H-6b), 
2.31-2.41 (m, 2 H, H-2b, H-1), 3.05 (m, 1 H, H-4), 3.32 (m, 1 H, H-3), 3.68 (s, 3 H, Me) 3.95 (m, 1 
H, H-5); 13C-NMR (CDCl3, 125.8 MHz) δ: -4.95 (SiCH3), -4.76 (SiCH3), 18.11 (SiC(CH3)3), 25.76 
(C(CH3)3), 27.33 (C-2), 32.88 (C-1), 33.72 (C-6), 51.90 (Me), 53.44 (C-3), 56.89 (C-4), 6.65 (C-
5), 175.23 (C=O); IR (film on NaCl) ν: 2954 (vs), 2858 (vs), 1740 (vs, C=O), 1463 (s), 1436 (s), 
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1369 (s), 1307 (s), 1259 (vs), 1174 (vs), 1095 (vs), 1053 (s), 1006 (s), 986 (m), 902 (s), 838 (vs), 
778 (vs), 669 (m), 636 (w) cm-1; elemental analysis calcd (%) for C14H26O4Si (286.44): C 58.70, 
H 9.15; found: C 58.92, H 9.12. 
 
Methyl (1R,3R,4R,5S)-3-(tert-butyldimethylsilyloxy)-4-hydroxy-5-methyl-cyclohexane-1-
carboxylate (240). 
CuCN (635 mg, 7.09 mmol) was dried in vacuo at 150ºC for 30 min, suspended in dry THF (10 
mL) and cooled to -78ºC. MeLi (1.6 M in Et2O, 8.90 mL, 14.2 mmol) was slowly added via 
syringe and the temperature was raised over a period of 30 min to -10ºC. The mixture was again 
cooled to -78ºC and freshly distilled BF3 etherate (360 µL, 2.86 mmol) in THF (2 mL) was added. 
After stirring for 20 min, epoxide 228 (408 mg, 1.42 mmol) in THF (10 mL) was added. The 
reaction was stopped after stirring for 5 h at -78ºC. The excess of MeLi was quenched with a 
mixture of methanol (4 mL) and triethylamine (4 mL). The mixture was diluted with Et2O (100 
mL) and extracted with 25% aq. NH3/satd. NH4Cl (1:9). The organic layer was then successively 
washed with brine (60 mL), 5% aqueous acetic acid (60 mL), satd. aqueous NaHCO3 (60 mL) 
and brine (60 mL). The aqueous layers were extracted with Et2O (2 x 100 mL). The combined 
organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The crude product 
was purified by column chromatography (petroleum ether/Et2O, 10:1 to 8:1) to afford 240 (337 
mg, 78%) as a reddish oil.  
[]D21 = - 28.3 (c = 1.02, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.09 (s, 3 H, SiCH3), 0.10 (s, 3 
H, SiCH3), 0.89 (s, 9 H, SiC(CH3)3), 1.07 (d, 3JMe,5 = 6.4 Hz, 3 H, Me), 1.25 (m, 1 H, H-6a), 1.47-
1.57 (m, 2 H, H-5, H-2a), 1.90 (m, 1 H, H-6a), 2.07 (m, 1 H, H-2a), 2.43 (m, 1 H, H-1), 2.98 (t, 3J = 
9.3 Hz, 1 H, H-4), 3.41 (ddd, 3J2eq,3 = 4.5 Hz, 3J3,4 = 8.5 Hz, 3J2a,3 = 11.3 Hz, 1 H, H-3), 3.67 (s, 3 
H, Me); 13C-NMR (CDCl3, 125.8 MHz) δ: -4.75 (SiCH3), -4.10 (SiCH3), 17.95 (C(CH3)3), 18.09 
(Me), 25.74 (C(CH3)3), 35.46 (C-6), 35.64, 35.69 (C-2, C-5), 40.62 (C-1), 51.80 (Me), 75.51 (C-
3), 80.12 (C-4), 174.85 (C=O); IR (film on NaCl) ν: 3584 (w, OH), 2954 (vs), 2858 (s), 1738 (vs, 
C=O), 1462 (m), 1378 (w), 1257 (m), 1173 (m), 1123 (m), 1100 (s), 1075 (vs), 1052 (w), 973 
(vw), 924 (vw), 873 (m), 836 (vs), 778 (s), 667 (vw) cm-1; elemental analysis calcd (%) for 
C15H30O4Si (302.48): C 59.56, H 10.00; found: C 59.75, H 9.93. 
 
Methyl (1R,3R,4R,5S)-4-O-(2,3,4-tris-O-benzyl-6-deoxy--L-galactopyranosyl)-3-O-(tert-
butyldimethylsilyl)-3,4-dihydroxy-5-methyl-cyclohexane-1-carboxylate (241), (DS-05-57). 
A mixture of 240 (348 mg, 1.15 mmol), ethyl 2,3,4-tri-O-benzyl-L-fucothiopyranoside (166) (1.11 
g, 2.32 mmol), (Bu)4NBr (1.12 g, 3.48 mmol), 2,6-di-tert-butyl-4-methylpyridine (713 mg, 3.47 
mmol), and powdered 4Å molecular sieves (3 g) in CH2Cl2 (12 mL) and DMF (3 mL) was stirred 
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at r.t. under argon for 4 h. Then, CuBr2 (776 mg, 3.47 mmol) was added and the reaction mixture 
was stirred at r.t. for 20 h. The reaction mixture was filtered through celite, the filtrate was diluted 
with CH2Cl2 (20 mL) and successively washed with satd. aqueous NaHCO3 and brine (each 40 
mL). The aqueous layers were extracted with CH2Cl2 (3 x 40 mL). The combined organic layers 
were dried with Na2SO4, filtered and co-evaporated with toluene to dryness. The residue was 
purified by column chromatography (petroleum ether/Et2O, 7:1 to 5:1) to yield compound 241 
(631 mg, 76%) as a yellowish oil.  
[]D21 = - 40.7 (c = 0.79, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.01 (s, 3 H, SiCH3), 0.07 (s, 3 
H, SiCH3), 0.86 (s, 9 H, SiC(CH3)3), 1.07 (d, 3JMe,5 = 6.4 Hz, 3 H, Me), 1.09 (d, 3JF5,F6 = 6.4 Hz, 3 
H, Fuc H-6), 1.25 (m, 1 H, H-6a), 1.55 (m, 1 H, H-2a), 1.64 (m, 1 H, H-5), 1.79 (m, 1 H, H-6b), 
2.05 (m, 1 H, H-2b), 2.38 (m, 1 H, H-1), 3.29 (t, 3J = 9.2 Hz, 1 H, H-4), 3.63 (m, 1 H, Fuc H-4), 
3.65-3.68 (m, 4 H, H-3, Me), 4.02-4.07 (m, 2 H, Fuc H-2, Fuc H-3), 4.37 (m, 1 H, Fuc H-5), 4.63, 
4.73, 4.74, 4.82, 4.84, 4.98 (6 m, 6 H, 3 CH2Ph), 5.22 (m, 1 H, Fuc H-1), 7.27-7.39 (m, 15 H, 3 
C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: -5.03 (SiCH3), -3.32 (SiCH3), 16.94 (Fuc C-6), 18.12 
(C(CH3)3), 19.45 (Me), 26.12 (C(CH3)3), 36.30 (C-6), 37.41 (C-2), 37.64 (C-5), 40.60 (C-1), 51.75 
(Me), 66.26 (Fuc C-5), 72.78 (CH2Ph), 74.12 (CH2Ph), 74.25 (C-3), 74.88 (CH2Ph), 76.49 (Fuc 
C-2), 78.28 (Fuc C-4), 79.17 (Fuc C-3), 82.34 (C-4), 97.13 (Fuc C-1), 127.41, 127.60, 128.13, 
128.17, 128.25, 128.32, 128.35, 138.47, 138.84, 138.89 (18 C, 3 C6H5 ), 174.87 (C=O); IR (film 
on NaCl) ν: 3031 (vs), 2929 (vs), 1732 (vs, C=O), 1497 (m), 1455 (s), 1361 (m), 1103 (br), 836 
(w), 696 (w), 667 (vw) cm-1; MS (ESI) m/z: calcd for C42H58NaO8Si [M+Na]+: 741.4; found: 741.5; 
elemental analysis calcd (%) for C42H58O8Si (718.99): C 70.16, H 8.13; found: C 70.18, H 8.20. 
 
Methyl (1R,3R,4R,5S)-4-O-(2,3,4-tris-O-benzyl-6-deoxy--L-galactopyranosyl)-3,4-
dihydroxy-5-methyl-cyclohexane-1-carboxylate (242), (DS-05-58). 
To a solution of 241 (606 mg, 0.842 mmol) in THF (5 mL), TBAF (1 M, in THF, 4.21 mL, 4.21 
mmol) was added. The reaction was stirred for 13 h and concentrated in vacuo. The crude 
product was purified by column chromatography (petroleum ether/ethyl acetate, 3:1) to afford 
242 (399 mg, 78%) as a white solid.  
[]D21 = - 43.0 (c = 1.09, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 1.11 (d, 3JF5,F6 = 6.4 Hz, 3 H, 
Fuc H-6), 1.15 (d, 3JMe,5 = 6.5 Hz, 3 H, Me), 1.23 (m, 1 H, H-6a), 1.48 (m, 1 H, H-2a), 1.59 (m, 1 
H, H-5), 1.92 (m, 1 H, H-6b), 2.24 (m, 1 H, H-2b), 2.39 (m, 1 H, H-1), 2.89 (dd, 3J = 8.6, 10.0 Hz, 
1 H, H-4), 3.43 (ddd, 3J = 4.7, 8.4, 11.5 Hz, 1 H, H-3), 3.67 (s, 3 H, Me), 3.70 (m, 1 H, Fuc H-4), 
3.96 (dd, 3JF3,F4 = 2.7 Hz, 3JF2,F3 = 10.2 Hz, 1 H, Fuc H-3), 4.08-4.12 (m, 2 H, Fuc H-2, Fuc H-5), 
4.65, 4.69, 4.67, 4.78, 4.85, 4.99 (6 m, 6 H, 3 CH2Ph), 4.97 (d, 3JF1,F2 = 3.8 Hz, 1 H, Fuc H-1), 
7.26-7.39 (m, 15 H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 16.61 (Fuc C-6), 18.35 (Me), 34.77 
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(C-2), 35.44 (C-5), 35.84 (C-6), 40.33 (C-1), 51.77 (Me), 67.63 (Fuc C-5), 71.99 (C-3), 72.97 
(CH2Ph), 73.52 (CH2Ph), 74.86 (CH2Ph), 76.32 (Fuc C-2), 77.38 (Fuc C-4), 78.87 (Fuc C-3), 
92.12 (C-4), 98.74 (Fuc C-1), 127.36, 127.49, 127.63, 127.66, 127.91, 128.23, 128.27, 128.35, 
128.38, 138.23, 138.35, 138.70 (18 C, 3 C6H5), 174.89 (C=O); IR (KBr) ν: 3424 (s, OH), 3031 
(vw), 2998 (w), 2952 (s), 2904 (s), 1737 (vs, C=O), 1497 (w), 1454 (m), 1384 (w), 1344 (s), 1305 
(m), 1273 (w), 1248 (w), 1191 (s), 1138 (s), 1157 (s), 1102 (vs), 1037  (vs), 973 (w), 957 (w), 
909 (w), 823 (vw), 802 (vw), 743 (s), 720 (w), 697 (m) cm-1; elemental analysis calcd (%) for 
C36H44O8 (604.73): C 71.50, H 7.33; found: C 71.51, H 7.36. 
 
{(1R,3R,4R,5S)-4-[(2,3,4-tris-O-benzyl-6-deoxy--L-galactopyranosyl)oxy]-1-
methoxycarbonyl-5-methyl-cyclohex-3-yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-
benzyloxycarbonyl-2-cyclohexyl-ethyl]--D-galactopyranoside (243). 
Dry CH2Cl2 (16 mL) was added to a mixture of thioglycoside 224 (562 mg, 0.719 mmol), glycosyl 
acceptor 242 (336 mg, 0.555 mmol) and activated 4Å molecular sieves (4 g) under argon. A 
suspension of DMTST (441 mg, 1.71 mmol) and activated 4Å molecular sieves (2 g) in CH2Cl2 
(8 mL) was prepared in a second flask. Both suspensions were stirred at r.t. for 4 h, then the 
DMTST suspension was added via syringe to the other suspension with some additional CH2Cl2 
(1 mL). The reaction was stopped after 63 h, filtered through celite and the celite washed with 
CH2Cl2. The filtrate was successively washed with satd. aqueous NaHCO3 (40 mL) and water 
(100 mL). The aqueous layers were extracted with DCM (3 x 60 mL). The combined organic 
layers were dried with Na2SO4, filtered and concentrated in vacuo. The crude product was 
purified by column chromatography (petroleum ether/Et2O, 1:1) to afford 243 (485 mg, 66%) as 
a white foam.  
[]D21 = - 52.8 (c = 1.05, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.45-2.23 (m, 18 H, CyCH2, 
Cy), 1.07 (d, 3JMe,5 = 6.4 Hz, 3 H, Me), 1.43 (d, 3JF5,F6 = 6.4 Hz, 3 H, Fuc H-6), 1.51 (m, 1 H, H-5), 
3.21 (t, 3J = 9.5 Hz, 1 H, H-4), 3.53-3.56 (m, 5 H, H-3, Fuc H-4, Me), 3.81 (dd, 3JG3,G4 = 3.2 Hz, 
3JG2,G3 = 9.9 Hz, 1 H, Gal H-3), 3.91 (m, 1 H, Gal H-5), 4.00-4.05 (m, 2 H, Fuc H-2, Fuc H-3), 
4.12 (dd, 3J = 4.5, 7.9 Hz, 1 H, Lac H-2), 4.24-4.28 (m, 2 H, Gal H-6a, CH2Ph), 4.36 (dd, 3JG5,G6b 
= 5.6 Hz, 2JG6a,G6b = 11.4 Hz, 1 H, Gal H-6b), 4.51, 4.62, 4.67, 4.74, 4.79 (5 m, 5 H, 3 CH2Ph), 
4.56 (d, 3JG1,G2 = 8.2 Hz, 1 H, Gal H-1), 4.89 (m, 1 H, Fuc H-5), 5.04 (m, 1 H, CH2Ph), 5.04 (m, 1 
H, Fuc H-1), 5.12 (m, 1 H, CH2Ph), 5.61 (m, 1 H, Gal H-2), 5.85 (m, 1 H, Gal H-4), 7.19-7.33, 
7.42-7.48, 7.53-7.58, 8.04-8.12 (4 m, 35 H, 7 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 16.77 (Fuc 
C-6), 18.51 (Me), 25.46, 25.71, 26.07, 32.60, 33.19, 33.40, 35.37, 38.04, 40.21, 40.46 (11 C, Cy, 
CH2Cy), 51.68 (Me), 62.50 (Gal C-6), 66.38 (Fuc C-5), 66.65 (CH2Ph), 70.20 (Gal C-4), 71.60 
(Gal C-5), 71.99 (Gal C-2), 72.05 (CH2Ph), 74.39 (CH2Ph), 74.90 (CH2Ph), 76.18 (Fuc C-2), 
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78.02 (Gal C-3), 78.41 (Lac C-2), 79.23 (Fuc C-4), 79.84 (Fuc C-3), 80.08 (C-3), 80.64 (C-4), 
98.11 (Fuc C-1), 100.13 (Gal C-1), 126.91, 127.05, 127.20, 127.45, 127.71, 128.04, 128.09, 
128.12, 128,42, 128.45, 128.52, 128.56,129.56, 129.65, 129.75, 129.93, 133.09, 133.21, 
133.30, 135.40, 138.49, 138.95, 139.15 (42 C, 7 C6H5 ), 164.60, 166.08, 166.15, 172.43, 174.09 
(5 C=O); IR (KBr) ν: 4925 (s), 1731 (vs, C=O), 1602 (w), 1497 (w), 1452 (m), 1267 (vs), 1176 
(m), 1097 (vs), 712 (s) cm-1; elemental analysis calcd (%) for C79H86O18 (1323.53): C 71.69, H 
6.55; found: C 71.73, H 6.65. 
 
{(1R,3R,4R,5S)-4-[(6-deoxy--L-galactopyranosyl)oxy]-1-methoxycarbonyl-5-methyl-
cyclohex-3-yl} 2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]--D-galactopyranoside 
(244), (DS-05-60). 
A mixture of 243 (133 mg, 0.100 mmol), Pd(OH)2/C (50.5 mg), dioxane (3 mL) and water (0.75 
mL) was hydrogenated under 70 psi at r.t.. After 20 h the mixture was filtered through celite and 
set up with fresh Pd(OH)2/C (50.7 mg) for additional 26 h. The reaction mixture was filtered 
through celite and evaporated to dryness. The residue was redissolved in methanol (4 mL) and 
sodium methoxide (0.150 mmol in 160 µL MeOH) was added. After stirring at r.t. for 16 h the 
reaction was quenched by addition of acetic acid (17 µL). The mixture was concentrated in 
vacuo and purified by preparative, reversed-phase HPLC to afford compound 244 (57.1 mg, 
76%) as a white solid.  
[]D21 = - 85.0 (c = 0.57, MeOH); 1H-NMR (MeOD, 500.1 MHz) δ: 0.55-0.75 (m, 4 H, Cy), 0.92 
(m, 1 H, Cy), 1.04-1.15 (m, 2 H, H-6a, H-2a), 1.10 (d, 3J = 6.5 Hz, 3 H, CH3), 1.21-1.36 (m, 5 H, 
Cy), 1.33 (d, 3J = 6.5 Hz, 3 H, Fuc H-6), 1.43 (ddd, 3JL2,L3a = 3.0 Hz, 3JL3a,L4 = 9.6 Hz, 2JL3a,L3b = 
13.9 Hz, 1 H, Lac H-3a), 1.52 (ddd, 3JL3b,L4 = 4.0 Hz, 3JL2,L3b = 10.0 Hz, 2JL3a,L3b = 14.0 Hz, 1 H, 
Lac H-3b), 1.60 (m, 1 H, Cy), 1.64 (m, 1 H, H-5), 1.76 (m, 1 H, H-6b), 2.28 (m, 1 H, H-2b), 2.40 
(m, 1 H, H-1), 3.10 (t, 3J = 9.6 Hz, 1 H, H-4), 3.56-3.58 (m, 4 H, Gal H-5, Me), 3.63-3.68 (m, 2 H, 
Gal H-3, H-3), 3.71-3.79 (m, 4 H, Gal H-6, Fuc H-2, Fuc H-4), 3.85 (dd, 3JF3,F4 = 3.3 Hz, 3JF2,F3 = 
10.3 Hz, 1 H, Fuc H-3), 3.97 (m, 1 H, Gal H-4), 4.07 (dd, 3JL2,L3a = 3.0 Hz, 3JL2,L3b = 9.9 Hz, 1 H, 
Lac H-2), 4.69 (d, 3JG1,G2 = 8.1 Hz, 1 H, Gal H-1), 4.94 (d, 3JF1,F2 = 4.0 Hz, 1 H, Fuc H-1), 4.99 
(m, 1 H, Fuc H-5), 5.43 (dd, 3JG1,G2 = 8.2 Hz, 3JG2,G3 = 9.7 Hz, 1 H, Gal H-2), 7.49-7.52, 7.62-
7.65, 8.07-8.09 (3 m, 5 H, C6H5); 13C-NMR (MeOD, 125.8 MHz) δ: 16.72 (Fuc C-6), 19.18 (Me), 
26.59, 26.78, 27.32, 33.13, 34.23 (5 C, Cy), 34.95 (C-2), 35.12 (Cy), 36.98 (C-6), 39.17 (C-5), 
41.40 (C-1), 42.80 (Lac C-3), 52.27 (Me), 62.68 (Gal C-6), 67.72 (Fuc C-5), 67.78 (Gal C-4), 
70.35 (Fuc C-2), 71.47 (Fuc C-3), 73.11 (Gal C-2), 74.00 (Fuc C-4), 75.92 (Gal C-5), 77.91 (Lac 
C-2), 79.97 (C-3), 83.06 (C-4), 83.60 (Gal C-3), 100.53 (Fuc C-1), 100.76 (Gal C-1), 129.71, 
130.96, 131.60, 134.40 (6 C, C6H5), 166.88 (O(C=O)Ph), 176.18 (COOMe), 178.81 (COOH); 
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elemental analysis calcd (%) for C37H54O16 ⋅ 1 H2O (754.82): C 57.50, H 7.30; found: C 57.53, H 
7.16; HR-MS (ESI) m/z: calcd for C37H53O16 [M-H]-: 753.3339; found: 753.3331 (1.1 ppm).  
 
rac-(1S,2R,5S)-5-tert-Butyl-2-hydroxycyclohexyl benzoate (rac-248) and  
rac-(1S,2R,4S)-4-tert-Butyl-2-hydroxycyclohexyl benzoate (rac-249), (DS-05-91/92). 
4-tert-Butylcatechol (2.02 g, 12.2 mmol), Rh/Al2O3 (98.9 mg), cyclohexane (4 mL) and THF (0.5 
mL) were hydrogenated under 5 bar at r.t.. After 24 h the mixture was filtered through celite and 
evaporated to dryness. The residue was purified by MPLC on silica (CH2Cl2/ethyl acetate, 3:1 to 
1:3) to afford a mixture of syn-diols (1.64 g, 78%, rac-246:rac-247, 1.4:1) as a white solid. The 
mixture (1.64 g, 9.55 mmol) and dibutyltin oxide (2.37 g, 9.52 mmol) were dissolved in CH2Cl2 
(50 mL) and cooled to 0°C. Et 3N (2.68 mL, 19.2 mmol) and benzoyl chloride (1.32 mL, 11.45 
mmol) were slowly added via syringe. The mixture was warmed to r.t. during 3 h and then 
quenched with MeOH (2 mL). The solvents were evaporated in vacuo and the crude residue was 
purified by MPLC on silica (toluene/ethyl acetate, 10:0 to 10:1) affording rac-248 (1.15 g, 44%) 
and rac-249 (688 mg, 26%) as white solids. 
 
rac-248: 
1H-NMR (CDCl3, 500.1 MHz) δ: 0.90 (s, 9 H, tBu), 1.23 (m, 1 H, H-5), 1.42 (m, 1 H, H-4a), 1.50-
1.57 (m, 2 H, H-3a, H-4b), 1.68 (m, 1 H, H-6a), 1.85 (m, 1 H, H-6b), 2.04 (m, 1 H, H-3b), 4.17 (m, 1 
H, H-2), 5.05 (ddd, 3J = 2.7, 4.7, 11.9 Hz, 1 H, H-1), 7.44-7.47, 7.56-7.59, 8.05-8.07 (3 m, 5 H, 
C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 19.59 (C-4), 26.42 (C-6), 27.51 (3 C, tBu), 30.57 (C-3), 
32.49 (tBu), 46.35 (C-5), 67.10 (C-2), 76.47 (C-1), 128.39, 129.58, 130.27, 133.07 (6 C, C6H5), 
165.62 (C=O); HR-MS (ESI) m/z: calcd for C17H24NaO3 [M+Na]+: 299.1618; found: 299.1621 (1.0 
ppm). 
 
rac-249: 
1H-NMR (CDCl3, 500.1 MHz) δ: 0.89 (s, 9 H, tBu), 1.18 (m, 1 H, H-5a), 1.34 (m, 1 H, H-3a), 1.56 
(m, 1 H, H-4), 1.83-1.98 (m, 3 H, H-5b, H-6), 2.04 (m, 1 H, H-3b), 4.25 (m, 1 H, H-2), 4.98 (ddd, 
3J = 2.8, 4.9, 11.7 Hz, 1 H, H-1), 7.44-7.47, 7.56-7.59, 8.04-8.06 (3 m, 5 H, C6H5); 13C-NMR 
(CDCl3, 125.8 MHz) δ: 25.07 (C-5), 25.27 (C-6), 27.48 (3 C, tBu), 31.91 (tBu), 31.98 (C-3), 39.43 
(C-4), 68.14 (C-2), 75.87 (C-1), 128.39, 129.58, 130.28, 133.06 (6 C, C6H5), 165.72 (C=O); HR-
MS (ESI) m/z: calcd for C17H24NaO3 [M+Na]+: 299.1618; found: 299.1621 (1.0 ppm). 
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rac-(1R,2R,4R)-2-(Benzoyloxy)-4-tert-butylcyclohexyl 3,5-dinitrobenzoate (rac-250), (DS-05-
94). 
rac-248 (400 mg, 1.45 mmol), triphenylphosphine (1.14 g, 4.33 mmol) and 3,5-dinitrobenzoic 
acid (921 mg, 4.34 mmol) were dissolved in toluene (25 mL). Diethyl azodicarboxylate (680 µL, 
4.32 mmol) was slowly added to the reaction via syringe. The mixture was warmed to 50°C and 
stirred for 1 d. The solvent was evaporated in vacuo and the residue, redissolved in a small 
amount of CH2Cl2, was purified by MPLC on silica (petroleum ether/ethyl acetate, 10:0 to 10:1) 
affording rac-250 (428 mg, 63%) and recovered starting material rac-248 (103 mg, 26%) as 
white solids.  
1H-NMR (CDCl3, 500.1 MHz) δ: 0.93 (s, 9 H, tBu), 1.25-1.47 (m, 3 H, H-3a, H-4, H-5a), 1.68 (m, 1 
H, H-6a), 1.94 (m, 1 H, H-5b), 2.29-2.35 (m, 2 H, H-3b, H-6b), 5.27 (ddd, 3J = 4.9, 9.7, 11.4 Hz, 1 
H, H-1), 5.35 (ddd, 3J = 4.7, 9.9, 10.5 Hz, 1 H, H-2), 7.36-7.39, 7.48-7.52, 7.96-7.98 (3 m, 5 H, 
C6H5), 9.06, 9.14-9.15 (2 m, 3 H, C6H3); 13C-NMR (CDCl3, 125.8 MHz) δ: 24.79 (C-5), 27.52 (3 
C, tBu), 29.76 (C-6), 31.79 (C-3), 32.36 (tBu), 45.73 (C-4), 74.80 (C-2), 77.55(C-1), 122.31, 
128.39, 129.44, 129.58, 129.74, 133.17, 133.81, 148.54 (12 C, C6H5, C6H3), 162.16, 165.89 (2 
C=O); HR-MS (ESI) m/z: calcd for C24H26N2NaO8 [M+Na]+: 493.1581; found: 493.1582 (0.2 
ppm). 
 
rac-(1R,2R,5R)-5-tert-Butyl-2-hydroxycyclohexyl benzoate (rac-251), (DS-05-96). 
rac-250 (135 mg, 0.287 mmol) was suspended in methanol (5 mL). Et3N (1 mL) was added and 
the reaction stirred for 1 h. The solvents were evaporated in vacuo and the residue was purified 
by MPLC on silica (toluene/ethyl acetate, 6:0 to 6:1) affording rac-251 (63.2 mg, 80%) as a white 
solid.  
1H-NMR (CDCl3, 500.1 MHz) δ : 0.88 (s, 9 H, tBu), 1.12 (m, 1 H, H-4a), 1.19-1.32 (m, 2 H, H-5, 
H-6a), 1.41 (m, 1 H, H-3a), 1.80 (m, 1 H, H-4b), 2.12-2.18 (m, 2 H, H-3b, H-6b), 3.69 (ddd, 3J = 
4.9, 9.3, 11.3 Hz, 1 H, H-2), 4.88 (ddd, 3J = 4.7, 9.4, 10.7 Hz, 1 H, H-1), 7.43-7.46, 7.55-7.58, 
8.06-8.07 (3 m, 5 H, C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 24.89 (C-4), 27.54(3 C, tBu), 31.44 
(C-6), 32.28 (tBu), 32.61 (C-3), 46.01 (C-5), 73.33 (C-2), 79.47 (C-1), 128.34, 129.64, 130.23, 
133.05 (6 C, C6H5), 166.82 (C=O); HR-MS (ESI) m/z: calcd for C17H24NaO3 [M+Na]+: 299.1618; 
found: 299.1619 (0.3 ppm). 
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[(1R,2R,5R)-5-tert-Butyl-1-hydroxy-cyclohex-2-yl] 2,3,4-tris-O-benzyl-6-deoxy-L-
galactopyranoside (252) and [(1S,2S,5S)-5-tert-Butyl-1-hydroxy-cyclohex-2-yl] 2,3,4-tris-O-
benzyl-6-deoxy--L-galactopyranoside (253), (DS-05-100). 
A mixture of rac-251 (76.9 mg, 0.278 mmol), ethyl 2,3,4-tri-O-benzyl-L-fucothiopyranoside (166) 
(202 mg, 0.421 mmol), (Bu)4NBr (274 mg, 0.850 mmol) and powdered 4Å molecular sieves (1 g) 
in CH2Cl2 (4 mL) and DMF (1 mL) was stirred at r.t. under argon for 3.5 h. Then, CuBr2 (188 mg, 
0.844 mmol) was added and the reaction mixture was stirred at r.t. for 11 h. The reaction mixture 
was filtered through celite and the filtrate was diluted with CH2Cl2 (30 mL). The organic layer was 
successively washed with satd. aqueous NaHCO3 and brine (each 30 mL) and the aqueous 
layers were extracted with CH2Cl2 (3 x 40 mL). The combined organic layers were dried with 
Na2SO4, filtered and co-evaporated with toluene to dryness. The residue was purified by MPLC 
on silica (petroleum ether/CH2Cl2/diethyl ether, 2:1:0 to 2:1:1) to afford the fucosylated 
diastereomers. To a stirred solution of these diastereomers in methanol/water (5:1, 6 mL), 
lithium hydroxide (200 mg) was added and the mixture warmed to 50°C. After stirring for 4 h the 
reaction mixture was diluted with CH2Cl2 (30 mL) and the organic layer was washed with brine 
(50 mL). The aqueous layer was extracted with CH2Cl2 (3 x 30 mL), and the combined organic 
layers were dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified by 
MPLC on silica (petroleum ether/ethyl acetate, 4:0 to 4:1) to yield 252 (72.1 mg, 44%, : = 
1:0.12, yield over two steps) as an anomeric mixture and 253 (63.0 mg, 38%, yield over two 
steps) as pure -anomer. 
 
-252:  
[]D21 = - 41.3 (c = 0.31, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.86 (s, 9 H, tBu), 0.97-1.38 (m, 
7 H, Fuc H-6, H-3a, H-4a, H-5, H-6a), 1.74 (m, 1 H, H-4b), 1.99-2.06 (m, 2 H, H-3b, H-6b), 3.22 (m, 
1 H, H-2), 3.47 (m, 1 H, H-1), 3.70 (m, 1 H, Fuc H-4), 3.94 (dd, 3JF3,F4 = 2.4 Hz, 3JF2,F3 = 10.1 Hz, 
1 H, Fuc H-3), 4.05-4.09 (m, 2 H, Fuc H-2, Fuc H-5), 4.65, 4.66, 4.75, 4.82, 4.87 (5 m, 5 H, 
CH2Ph), 4.97-5.00 (m, 2 H, Fuc H-1, CH2Ph), 7.26-7.41 (m, 15 H, 3 C6H5); 13C-NMR (CDCl3, 
125.8 MHz) δ: 16.65 (Fuc C-6), 25.17 (C-4), 27.55 (3 C, tBu), 29.54 (C-3), 32.19 (tBu), 33.63 (C-
6), 45.82 (C-5), 66.97 (Fuc C-5), 73.15, 73.33 (2 CH2Ph), 73.52 (C-1), 74.86 (CH2Ph), 76.16 
(Fuc C-2), 77.41 (Fuc C-4), 79.21 (Fuc C-3), 84.09 (C-2), 96.33 (Fuc C-1), 127.40, 127.48, 
127.64, 127.69, 127.90, 128.21, 128.35, 128.44, 138.41, 138.50, 138.81 (18 C, 3 C6H5); HR-MS 
(ESI) m/z: calcd for C37H48NaO6 [M+Na]+: 611.3343; found: 611.3346 (0.5 ppm). 
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253:  
[]D21 = - 40.7 (c = 0.38, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.85 (s, 9 H, tBu), 1.01-1.17 (m, 
6 H, Fuc H-6, H-4a, H-5, H-6a), 1.29 (m, 1 H, H-3a), 1.70 (m, 1 H, H-4b), 1.97-2.04 (m, 2 H, H-3b, 
H-6b), 3.17 (m, 1 H, H-2), 3.45 (m, 1 H, H-1), 3.69 (m, 1 H, Fuc H-4), 3.96-4.05 (m, 3 H, Fuc H-2, 
Fuc H-3, Fuc H-5), 4.66, 4.73, 4.76, 4.81, 4.87, 4.97 (6 m, 6 H, CH2Ph), 4.98 (m, 1 H, Fuc H-1), 
7.26-7.41 (m, 15 H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 16.69 (Fuc C-6), 25.32 (C-4), 
27.58 (3 C, tBu), 31.26 (C-3), 32.25 (tBu), 32.88 (C-6), 45.78 (C-5), 66.57 (Fuc C-5), 72.63, 
74.19 (2 CH2Ph), 74.66 (C-1), 74.80 (CH2Ph), 76.33 (Fuc C-2), 77.40 (Fuc C-4), 80.01 (Fuc C-
3), 87.22 (C-2), 101.01 (Fuc C-1), 127.34, 127.52, 127.58, 127.84, 128.18, 128.22, 128.34, 
128.39, 128.47, 137.95, 138.53, 138.65 (18 C, 3 C6H5). 
 
{(1R,2R,5R)-2-[(2,3,4-tris-O-benzyl-6-deoxy--L-galactopyranosyl)oxy]-5-tert-butyl-
cyclohex-1-yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexyl-ethyl]--D-
galactopyranoside (254), (DS-05-101). 
Thioglycoside 224 (125 mg, 0.161 mmol) and glycosyl acceptor 252 (71.4 mg, 0.121 mmol) in 
dry CH2Cl2 (4 mL) were added via syringe to activated 4Å molecular sieves (1 g). A suspension 
of DMTST (120 mg, 0.465 mmol) and activated 4Å molecular sieves (500 mg) in CH2Cl2 (2 mL) 
was prepared in a second flask. Both suspensions were stirred at r.t. for 2 h, before adding the 
DMTST suspension via syringe to the other suspension with some additional CH2Cl2 (1 mL). The 
reaction was stopped after 45 h and worked-up according to the general procedure C. The crude 
product was purified by MPLC on silica (toluene/ethyl acetate, 11.5:0 to 11.5:1) to yield 254 (107 
mg, 68%) as a colourless foam.  
[]D21 = - 57.9 (c = 0.50, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.46-1.43 (3 m, 17 H, CyCH2, 
Cy), 0.58 (s, 9 H, tBu), 1.36 (d, 3J = 6.0 Hz, 3 H, Fuc H-6), 1.60 (m, 1 H, H-4b), 1.81 (m, 1 H, H-
6b), 1.99 (m, 1 H, H-3b), 3.45 (m, 1 H, H-2), 3.55 (m, 1 H, H-1), 3.58 (s, 1 H, Fuc H-4), 3.87-3.90 
(m, 2 H, Gal H-3, Gal H-5), 3.97-4.04 (m, 2 H, Fuc H-2, Fuc H-3), 4.16 (m, 1 H, Lac H-2), 4.29 
(m, 2 H, Gal H-6), 4.39 (m, 1 H, CH2Ph), 4.55-4.57 (m, 2 H, Gal H-1, CH2Ph), 4.63 (m, 1 H, 
CH2Ph), 4.69-4.74 (m, 2 H, CH2Ph), 4.79-4.83 (m, 2 H, Fuc H-5, CH2Ph), 4.88 (d, 3JF1,F2 = 2.1 
Hz, 1 H, Fuc H-1), 5.04, 5.13 (2 m, 2 H, CH2Ph), 5.56 (m, 1 H, Gal H-2), 5.91 (m, 1 H, Gal H-4), 
7.17-7.35, 7.39-7.48, 7.54-7.55, 8.04-8.11 (m, 35 H, 7 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 
16.62 (Fuc C-6), 24.43 (C-4), 25.40, 25.71, 26.06 (3 C, CyCH2), 27.19 (3 C, tBu), 28.97 (C-3), 
31.95 (tBu), 32.23 (C-6), 32.49, 33.17, 33.44 (3 C, CyCH2), 40.44 (CyCH2), 45.50 (C-5), 62.21 
(Gal C-6), 65.98 (Fuc C-5), 66.58 (CH2Ph), 69.86 (Gal C-4), 71.19 (Gal C-5), 72.53, 72.56 (Gal 
C-2, CH2Ph), 73.02 (CH2Ph), 74.90 (CH2Ph), 75.25 (C-2), 76.44 (Fuc C-2), 77.51 (Gal C-3), 
78.08 (Lac C-2), 79.24 (Fuc C-4), 79.64 (Fuc C-3), 81.37 (C-1), 94.16 (Fuc C-1), 100.24 (Gal C-
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1), 126.87, 126.95, 127.22, 127.38, 127.93, 127.95, 128.03, 128.15, 128.34, 128.42, 128.47, 
128.50, 129.64, 129.74, 129.83, 129.88, 129.91, 133.04, 133.16, 133.21, 135.43, 138.86, 
139.08, 139.14 (42 C, 7 C6H5), 164.56, 165.65, 166.11, 172.47 (4 C=O); elemental analysis 
calcd (%) for C80H90O16 (1307.56): C 73.48, H 6.94; found: C 73.50, H 6.95. 
  
{(1R,2R,5R)-5-tert-Butyl-2-[(6-deoxy--L-galactopyranosyl)oxy]-cyclohex-1-yl} 2-O-
benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]--D-galactopyranoside (255), (DS-05-102). 
A mixture of 254 (102 mg, 77.9 µmol), Pd(OH)2/C (49.4 mg), dioxane (3 mL) and water (0.75 
mL) was hydrogenated under 4 bar at r.t.. After 37 h TLC control indicated completion of the 
reaction and the mixture was filtered through celite and evaporated to dryness. The residue was 
redissolved in methanol (5 mL) and sodium methoxide (0.195 mmol in 255 µL MeOH) was 
added. After stirring at r.t. for 14 h the reaction was quenched by addition of acetic acid (23 µL). 
The mixture was concentrated in vacuo and purified by preparative, reversed-phase HPLC to 
afford compound 255 (50.9 mg, 88%) as a white solid.  
[]D21 = - 93.2 (c = 0.91, MeOH); 1H-NMR (MeOD, 500.1 MHz) δ: 0.60-0.77 (m, 5 H, H-6a, 
CyCH2), 0.65 (s, 9 H, tBu), 0.84 (m, 1 H, H-4a), 0.93 (m, 1 H, CyCH2), 1.01 (m, 1 H, H-5), 1.15 
(m, 1 H, H-3a), 1.26 (d, 3JF5,F6 = 6.6 Hz, 3 H, Fuc H-6), 1.29-1.39 (m, 5 H, CyCH2), 1.43 (m, 1 H, 
CyCH2), 1.53 (m, 1 H, CyCH2), 1.60-1.66 (m, 2 H, H-4b, CyCH2), 1.95 (m, 1 H, H-6b), 2.05 (m, 1 
H, H-3b), 3.33 (m, 1 H, H-2), 3.56-3.61 (m, 2 H, H-1, Gal H-5), 3.69-3.74 (m, 4 H, Fuc H-2, Fuc 
H-4, Gal H-3, Gal H-6a), 3.79 (m, 3JG6b,G5 = 6.9 Hz, 2JG6a,G6b = 11.3 Hz, 1 H, Gal H-6b), 3.91 (dd, 
3JF3,F4 = 3.4 Hz, 3JF2,F3 = 10.1 Hz, 1 H, Fuc H-3), 4.00 (m, 1 H, Gal H-4), 4.10 (dd, 3J = 2.9, 10.0 
Hz, 1 H, Lac H-2), 4.67 (d, 3JG1,G2 = 8.0 Hz, 1 H, Gal H-1), 4.77 (m, 1 H, Fuc H-5), 4.82 (d, 3JF1,F2 
= 3.8 Hz, 1 H, Fuc H-1), 5.36 (dd, 3JG1,G2 = 8.0 Hz, 3JG2,G3 = 9.8 Hz, 1 H, Gal H-2), 7.49-7.52 (m, 
2 H, C6H5), 7.61-7.64 (m, 1 H, C6H5), 8.10-8.12 (m, 2 H, C6H5); 13C-NMR (MeOD, 125.8 MHz) δ: 
16.53 (Fuc C-6), 25.74 (C-4), 26.60, 26.82, 27.30 (3 C, CyCH2), 27.78 (3 C, tBu), 29.73 (C-3), 
32.83 (tBu), 33.11 (CyCH2), 33.74 (C-6), 34.26 (Lac C-4), 35.12 (CyCH2), 42.76 (Lac C-3), 47.02 
(C-5), 62.69 (Gal C-6), 67.38 (Fuc C-5), 67.99 (Gal C-4), 70.03 (Fuc C-2), 71.57 (Fuc C-3), 
73.63 (Gal C-2), 73.96 (Fuc C-4), 76.02 (Gal C-5), 76.90 (C-2), 78.03 (Lac C-2), 81.57 (C-1), 
83.17 (Gal C-3), 96.51 (Fuc C-1), 101.13 (Gal C-1), 129.74, 130.90, 131.70, 134.40 (6 C, C6H5), 
166.83 (C=O), 178.78 (COOH); HR-MS (ESI) m/z: calcd for C38H58NaO14 [M+H]+: 761.3719; 
found: 761.3723 (0.5 ppm). 
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6.  Formula Overview of E-Selectin Antagonists 
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